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Life is based on the properties of carbon, which leads to the importance of organic molecules for 
the various species of living organisms as well as individuals.[1] Most organic molecules have a 
carbon backbone, whose versatility provides the key skeleton to biomolecule structures. 
Understanding the chemical structures of organic molecules allows us to understand better the 
action of life and modification of them. The range of applications of organic molecules is enormous, 
which are widely found in pharmaceuticals, agrochemicals, materials, fuels and a vast number of 
other areas.[2] As a consequence, methods to synthesize these complex molecules are highly 
desired not only in fundamental research but also in pharmaceutical and fine chemical industries. In 
modern synthetic chemistry, the main challenges are how to seek efficient, green and economic 
ways to construct chemical bonds from simple precursors.  
Hydrocarbons are organic compounds consisting of hydrogen and carbon, which could be found in 
crude oil and natural gas. The efficiency of the transformation process of hydrocarbons into other 
more useful and high value organic molecules, such as alcohols, ketones and acids, is of high 
importance in chemical industies.[3] C─H bonds are ubiquitous in organic molecules. Thus, from an 
atom- and step-economic point of view, the direct functionalization of C─H bonds to C─C and C─Het 
(Het = N, O, P, S, Si, etc.) bonds has emerged as one of the most straightforward and valuable 
approaches in organic synthesis. 
Catalysis is one of the foundations of the chemical industry. Significant successes in this field of 
chemistry have already been achieved on solving numerous economic, environmental and 
technological problems during the last century.[4] Furthermore, catalysis is also one of the twelve 
principles of green chemistry, as defined by Warner and Anastas in 1998.[5] Therefore, the 
combination of direct C─H activation and catalysis could provide a more effective, atom- and 




1.1 Transition Metal-Catalyzed C–H Functionalizations 
1.1.1 The Advantages of Transition Metal-Catalyzed C─H Activation 
The direct catalyzed C─H functionalization is a highly important method, as it allows the conversion 
of C─H bonds into valuable C─C and C─Het bonds. However, the main question is how to directly 
activate the C─H bond. It is well known that the dissociation energy of C─H bond is generally very 
high (≈ 110 kcal mol-1 for C(aryl)─H and ≈ 105 kcal mol-1 for alkanes).[6] In early studies the cleavage 
of C─H bonds often required harsh reaction condition.[7] Therefore, a strategy in which the 
transition metal catalyst directly reacts with a C─H bond to generate a C─TM bond under mild 
reaction conditions is an ideal option to achieve C─H functionalization (Scheme 1.1.1a). The 
resulting C─TM bonds are more reactive than the C─H bonds, and can thus be easily converted to 
other valuable functional groups. Indeed, the last few decades have witnessed explosive progress in 
the field of transition metal-catalyzed C─H functionalization.[8]  
 
Scheme 1.1.1 Transition metal-catalyzed C─H functionalization. 
 
It is well known that traditional cross-coupling reactions have been one of the most useful synthetic 
methods for the formation of carbon-carbon bonds, such as Suzuki-Miyaura, Negishi and Heck 
reactions, which led to the 2010 Nobel Prize in chemistry.[9] In these transformations, one of the key 
steps is the generation of the organometallic C─TM species (Scheme 1.1.1b). However, cross 
coupling reactions heavily rely on the transformations of various functional groups, thus requiring 
the pre-functionalized substrates, such as organic halides and organometallic compounds, such as 




and the generation of stoichiometric amounts of salt wastes, significantly decreases the atom- and 
step-economy. In sharp contrast, the direct transition metal-catalyzed C─H activation could reduce 
the steps of those procedures, thus making the reaction cost-effective and environmentally-friendly. 
As a result, over the last 20 years creative applications of metal-catalyzed C─H functionalizations 
have been made in the synthesis of natural products, pharmaceuticals, and functional materials, 
among others.[8] For example, Stoltz and co-workers in 2002 completed the synthesis of 
dragmacidin D (1) in 25 steps,[10] while Yamaguchi and Itami in 2011 achieved it in only 15 steps 
based on three-fold C─H arylation (Scheme 1.1.2).[11] Therefore, the traditional synthetic methods 
could be revised by using C─H functionalizations. 
 
Scheme 1.1.2 Example of C─H functionalizations in the total synthesis of natural product. 
 
Meanwhile, experimental and computational mechanistic studies for transition metal-catalyzed C─H 
functionalization have also provided detailed insights into those reactions.[12] In many cases, the 
great achievements of C─H activation have resulted from the good understanding of the reaction 
mechanism. Even though the details of reaction mechanism may change from in select cases, the 
catalytic cycle can be often devided into three main steps (Scheme 1.1.3): (i) the C─H activation; (ii) 
functionalization of the organometallic intermediate; and finally, (iii) regeneration of the active 





1.1.2 Mechanistic Manifolds 
 
Scheme 1.1.3 General catalytic cycle for transition metal-catalyzed C─H activation reactions. 
 
In general terms, the C─H cleavage event is a key step of the mechanism. It is very important to 
understand how the C─H bond can be cleaved by transition metals. Recent mechanistic studies 
indicated that several distinct transition states could be involved in the C─H metalation step 
(Scheme 1.1.4).[13] The possible mechanistic modes of action include: oxidative addition (OA);[14] 
σ-bond metathesis (σ-BM);[15] electrophilic substitution (ES);[16] 1,2-addition;[17] concerted 
metalation-deprotonation (CMD),[18] also called ambiphilic metal ligand activation (AMLA);[19] 
internal electrophilic substitution (IES) based on a four-membered transition state;[20] and 
base-assisted internal electrophilic substitution (BIES) via a six-membered transition state.[21] For 
example, a cobalt(III)-catalyzed C─H alkylation provided the branched products based on a BIES-type 






Scheme 1.1.4 Possible transition states for C─H metalation. 
 
1.1.3 Selectivity Control in Transition Metal-Catalyzed C─H Functionalizations 
Although the strategy of direct C─H functionalization has enormous potential in synthetic chemistry, 
there are still some fundamental challenges which have to be addressed. The C─H bonds are 
ubiquitous in organic molecules and often exhibit similar dissociation energies. Therefore, selective 
and efficient functionalization of one specific C─H bond is highly challenging. This goal has been 
identified as the “Holy Grail” of organic synthesis,[23] and several different strategies have been 
employed to address this issue (Scheme 1.1.5).   
 
 
Scheme 1.1.5 Strategies to achieve site-selectivity in C─H activation. 
 
The site-selectivity can be controlled by (a) enhancing the acidity of specific C─H bonds,[24] (b) using 




groups.[26] However, due to the dependency on the substrate substitution patten, the first two 
strategies are difficult to be widely used in this field. In contrast, a variety of catalytic 
transformations have been achieved by using directing groups to control the site-selectivities. The 
directing group can be the part of various different substrates, and in many cases it also can be 
easily removed after the transformation.[27] Generally, Lewis basic directing atom can coordinate to 
the metal center and bring the catalyst to a proximal C─H bond. Then, the transition metal can 
directly activate this C─H bond. Many different transition metals, such as palladium, rhodium, 
ruthenium and iridium, can undergo this cyclometalation step.[28]   
In contrast, the rise of green chemistry has increased the emphasis on low-waste transformations.[29] 
The same strategy generally could reduce the cost and toxicity of the reaction by employing 3d 
metals, such as cobalt and manganese.  
1.2 Cobalt(III)-Catalyzed C─H Activation 
Although transition metal-catalyzed C─H functionalization has been considered as one of the most 
powerful and reliable tools for constructing C─C and C─Het bonds over the last decades, precious 
metals, such as palladium,[30] rhodium,[31] platinum,[32] ruthenium[33] and iridium[34] have been thus 
far dominant in this field. However, there are some problems associated with their continuous use 
in catalytic processes, such as their low natural abundance,[35] high cost and toxicity.[36] In contrast, 
the inexpensive, Earth-abundant, and low toxic base metals could serve as a suitable alternative to 
precious metals for C─H activation. As a result, various inexpensive early transition metals have 
recently attracted much attention in the area of C─H activations. In this regard, cobalt is an 
attractive candidate because of its unique properties.[37] Compared with 4d transition metals, for 
example rhodium, cobalt exhibits a lower electronegativity leading to the formation of more 
nucleophilic intermediates, which could set the stage for unexpected reaction outcomes.  
1.2.1 Early Examples of Cobalt-Catalyzed C─H Activations 
In 1955, the first example of chelation-assisted cobalt-catalyzed C─H functionalization was disclosed 
by Murahashi, providing access to phthalimidine 3 or indazolone 5 through the 





further applications were limited because of the harsh reaction conditions. Until recent years, only 
few examples have been sporadically reported for cobalt-catalyzed C─H activation. For example, in 
1973, Kochi and co-workers reported the first example of high-valent cobalt(III)-mediated 
trifluoroacetylation of aromatic compounds operating via a proposed SET mechanism (Scheme 
1.2.1b).[39] And in 1994, Kisch and coworkers developed the alkenylation of alkynes by well-defined 
cobalt(I) catalysts [Co(H)(N2)(PPh3)3] or [CoH3(PPh3)3] (Scheme 1.2.1c).
[40] Subsequently, Brookhart 
and coworkers developed various Cp*Co(I)-catalyzed C─H functionalizations (Scheme 1.2.1d), 
including C─H hydroacylation of olefins,[41] synthesis of enamines by C(sp3)─H bond activation,[42] 
and C─H activation of simple benzene.[43]   
 
Scheme 1.2.1 Early examples of cobalt-catalyzed/mediated C─H activation. 
 
It is noteworthy that a cyclometalated cobalt complex is often the key intermediate in C─H 
activation catalytic cycles. Thus, the isolation and characterization of such cyclocobaltated 
complexes are essential to understand the mechanism of these reactions. In 1993, Klein and 
co-workers isolated the cyclometalated cobalt complex of azobenzene (4a) and phenyl phosphites 
(14) with stoichiometric [Co(CH3)(PMe3)4].
[44] Later, the cyclometalation could be achieved with 




phosphorus[48] (Scheme 1.2.2). 
 
Scheme 1.2.2 Cyclocobaltated complexes prepared by C─H activation using stoichiometric 
[Co(CH3)(PMe3)4]. 
 
In 2008, Li and Wang also reported a cyclocobaltated complex of azobenzene (4) with hydroxyl as 
an additional donor group using stoichiometric Co(PMe3)3Cl, along with the complete cleavage of 
the N=N bond (Scheme 1.2.3).[49]  
 
Scheme 1.2.3 Reaction of Co(PMe3)3Cl with 2-(arylazo)phenols for C─H activation. 
 




low-valent cobalt-catalyzed hydroarylation of internal alkynes 8 in 2010.[50] The electron-rich cobalt 
species could be generated in situ from the simple cobalt(II) salts, phosphine ligands and Grignard 
reagents. The role of the Grignard reagent was proposed to serve as a base and a reductant in the 
reaction (Scheme 1.2.4). Thereafter, the low-valent cobalt-catalyzed C─H functionalizations have 
been rapidly developed by the groups of Yoshikai,[8a, 51] Nakamura,[52] Ackermann,[53] among 
others[54] over the last 10 years. However, a disadvantage of this manifold is the requirement of 
large amount of Grignard reagents, which could make undesired coupling reactions, generate lots 
of metal wastes, and limit the functional group tolerance. Therefore, the development of new 
cobalt-catalyzed C─H functionalizations without Grignard reagents under mild reaction conditions 
was in high demand.  
 
Scheme 1.2.4 Low-valent cobalt-catalyzed hydroarylation of internal alkynes.  
1.2.2 High-Valent Cobalt(III)-Catalyzed C─H Activations 
Based on the earlier work of Brookhart,[55] in 2013, a significant advance in high-valent 
cobalt(III)-catalyzed C─H activation was made by Matsunaga/Kanai and coworkers, which employed 
a Cp*Co(III)-type complexes as catalysts (Scheme 1.2.5a).[56] This work showed the high catalytic 
activity of [Cp*Co(C6H6)](PF6)2 (37) in addition reactions of 2-phenylpyridine (20a) to sulfonyl imines 
(36) and α,β-unsaturated ketones (39). Afterwards, the same auther successfully extended this 
approach with catalytic amounts of cobalt complex 37 and KOAc to the N-(2-pyrimidyl)-indole 






Scheme 1.2.5 Cobalt(III)-catalyzed hydroarylation of electrophiles via C─H activation. 
 
The following year, the same group further developed a more general catalytic system using 
Cp*Co(CO)I2 in combination with a silver salt, which displayed a superior activity for C-2 selective 
C─H amidation of indoles 41a with sulfonyl azides (43) (Scheme 1.2.6).[59] They also disclosed a 
procedure for preparing the catalyst of Cp*Co(CO)I2 with slight modification of reported 
methods.[60]  
 
Scheme 1.2.6 Cobalt(III)-catalyzed C─H amidation. 
 
In 2014, Daugulis and coworkers also developed a new method for the Co(III)-catalyzed C─H 
alkenylation with alkynes with the aid of aminoquinolines 45 as the directing groups (Scheme 
1.2.7).[61] This reaction employed Co(OAc)2·4H2O as the precatalyst, which then was oxidized in situ 
to the activated CoIII species by adding an external chemical oxidant of Mn(OAc)2. This reaction 




with the coupling.    
 
Scheme 1.2.7 Cobalt(III)-catalyzed, aminoquinoline-directed C─H bond alkenylation with alkynes.  
 
Since then, the recent years witnessed a rapid growth in high-valent cobalt(III)-catalyzed C─H 
functionalizations. The next chapter will discuss some typical examples of the high-valent 
Cp*Co(III)-catalyzed C─H activation reactions.  
1.2.2.1 Cp*Co(III)-Catalyzed Cyanation and Halogenation 
In 2015, Ackermann and coworkers developed the first example of Cp*Co(III)-catalyzed C─H 
cyanation of 2-phenylpyridines (20) and (hetero)arenes with N-cyano-N-phenyl-p- 
toluenesulfonamide (NCTS) (47a) as the cyanating reagent (Scheme 1.2.8)[62]. This reaction showed 
high functional group tolerance, as well as high site-selectivity and ample scope. The pyrimidyl 
group could be easily removed in a traceless fashion.  
 
Scheme 1.2.8 Cobalt(III)-catalyzed C─H cyanation.  
 
A plausible catalytic cycle was proposed for this cobalt(III)-catalyzed cyanation protocol. After 




thus generated the cobalt intermediate 51 undergoes coordination and insertion with NCTS (47a), 
and then affords the complex 53. The desired cyanation product 48 is obtained by β-elimination 
and the active cobalt(III) catalyst 50 is regenerated by proto-demetalation (Scheme 1.2.9). 
 
Scheme 1.2.9 Plausible catalytic cycle for cobalt(III)-catalyzed C─H cyanation. 
 
Thereafter, Glorius and coworkers reported a similar work on cobalt(III)-catalyzed C─H cyanation 
using NaOAc as the base (Scheme 1.2.10).[63] At the same time, a selective C─H halogenation in the 
presence of Cp*Co(CO)I2, AgSbF6, and PivOH was also developed.  
 





Moreover, a similar approach of C─H cyanation was developed by Chang and coworkers using 
N-cyanosuccinimide (51) as a more efficient cyanating reagent (Scheme 1.2.11).[64]. 6-Arylpurines 
50 were found to be suitable substrates and furnished the desired products 52 in moderate to good 
yields  
 
Scheme 1.2.11 Cobalt(III)-catalyzed C─H cyanation of arylpurines. 
1.2.2.2 Cp*Co(III)-Catalyzed Allylations 
The allyl group can be easily manipulated to access a wide variety of functionalized building 
blocks,[65] making allylation reactions very important in organic synthesis. However, metal-catalyzed 
C─H allylation reactions have been dominated by precious metals over the last decade.[66] Recently, 
efforts toward cobalt(III)-catalyzed C─H allylation have been made by Glorius,[63] Ackermann,[67] 
Matsunaga/Kanai,[68] and Li.[69] Glorius and coworkers developed the cobalt(III)-catalyzed C─H 
allylation reactions of N-pyrimidylindoles 41 with allyl carbonates (53a) in the presence of 
Cp*Co(CO)I2, AgSbF6 and PivOH (Scheme 1.2.12).
[63] A remarkable feature of this reaction was that 
when even lowering the Cp*Co(CO)I2 catalyst loading to 0.5 mol %, the desired C-2 allylated indole 





Scheme 1.2.12 Cp*Co(III)-catalyzed C─H allylation with allyl methyl carbonate 53a.  
 
Matsunaga and Kanai developed the dehydrative allylation of indoles 41 with allylic alcohols 
(Scheme 1.2.13).[68a] The desired products could be more efficiently obtained with Cp*Co(CO)I2 
compared with the analogous [Cp*RhCl2]2 catalyst. Various functional groups were tolerated under 
the optimized conditions. The Cp*Co(III) catalysis was successfully applied to 6-arylpurines 50, 
benzamides 55, and aromatic Weinreb amide substrates.[68b]  
 
Scheme 1.2.13 Cp*Co(III)-catalyzed C─H allylation with prop-2-en-1-ol. [a] TFE as the solvent. [b] 






Scheme 1.2.14 Cp*Co(III)-catalyzed C─H allylation via C─H/C─C activation. 
 
In 2015, Ackermann and coworkers disclosed a versatile cobalt(III)-catalyzed C─H allylation reaction 
on arenes 20, indoles 41, and pyrroles 20e with allyl acetates 53c (Scheme 1.2.14a).[67] The 
following year, the same group also reported the Z-selective allylation via C─H/C─C activation by 
cobalt(III) catalysis under mild conditions (Scheme 1.2.14b).[70] Remarkably, this reaction showed a 
broad reaction scope and delivered the thermodynamically less stable (Z)-alkenes with excellent 
diastereoselectivity. Thereafter, Li developed a C─H/C─O allylation reaction of N-pyrimidinylindoles 
with strained rings such as 7-oxabenzonorbornadienes and 2-vinyloxirane under mild conditions.[69]    
A plausible catalytic cycle of these cobalt(III)-catalyzed allylations is proposed to be initiated by the 
formation of an active cobalt species 61 from the precatalyst Cp*Co(CO)I2 and silver salts (Scheme 
1.2.15). The following C─H metalation resulting in the formation of complex 62 involves a BIES 
pathway. Subsequent coordination and olefin insertion give the intermediate 63, which then 
undergoes β-oxygen elimination to afford the desired product 54a. The active cobalt catalyst 61 is 





Scheme 1.2.15 Plausible catalytic cycle for cobalt(III)-catalyzed C─H allylation. 
1.2.2.3 Cp*Co(III)-Catalyzed Annulation 
Annulation reactions are among the most fundamental and useful transformation in organic 
synthesis.[71] They provide a straightforward and step-economical method for the synthesis of 
heterocycles, which are important motifs in pharmaceuticals, natural products and 
agrochemicals.[72] During the last years, a broad range of examples using Cp*Co(III)-type catalysts 
for annulation reactions have been developed.[37a, 37b, 73] Here, only selected examples of 
cobalt(III)-catalyzed annulation reactions will be discussed in this context. 
Matsunaga and Kanai developed a Cp*Co(III)-catalyzed redox-neutral C-2 selective C─H 
alkenylation/annulation of N-carbamoyl indoles 65 with internal alkynes 8 (Scheme 1.2.16).[74] The 
intramolecular addition of an alkenyl-Cp*Co species 67 to a carbamoyl moiety provided 
pyrroloindolones 66 in moderate to good yields. A variety of unsymmetrical alkynes underwent this 
reaction smoothly and afforded the desired products in high yields and regioselectivities. In 
addition, when the reaction temperature was decreased to 80 °C, only simple C─H alkenylated 
products were obtained. In contrast, the analogous Cp*Rh(III) catalysis failed to achieve the 





Scheme 1.2.16 Pyrroloindolone 66 synthesis via Cp*Co(III)-catalyzed C─H alkenylation/annulation. 
 
Ellman and Hummel disclosed a cobalt(III)-catalyzed C─H addition reaction to aldehydes (Scheme 
1.2.17).[75] The air-stable cationic cobalt catalyst [Cp*Co(C6H6)][B(C6H5)4]2 was developed to achieve 
the cyclization and aromatization with a catalytic amount of AcOH, affording N-aryl-2H-indazoles 70 
and furans 69 in good yield. A wide range of aryl, heteroaryl, and alkyl aldehydes were found to be 
suitable substrates, efficiently delivering the desired substituted heterocycles.  
 






Recently, Ackermann and coworkers reported a C─H/N─H bond functionalization for the synthesis 
of 1-aminoisoquinolines 73 from aryl benzimidamide 71 and diazo compounds 72 under mild 
conditions by cobalt(III) catalysis (Scheme 1.2.18).[76] This reaction showed a broad substrate scope 
and functional groups tolerance. Moreover, H2O and N2 were the sole byproducts of the 
transformation, making the process environmentally-benign.   
 
 
Scheme 1.2.18 Cobalt(III)-catalyzed C─H/N─H functionalization for the synthesis of isoquinolines 73. 
1.2.2.4 Cp*Co(III)-Catalyzed Hydroarylation  
 





The Cp*Co(III)-catalyzed direct addition of unactivated arenes and 6-arylpurines to terminal alkynes 
under mild conditions was described by Yu and Chen in 2016 (Scheme 1.2.19).[77] This process 
selectively provided only the (E)-stereoisomer in very high yield and also showed high functional 
group compatibility.  
Recently, Ackermann and coworkers reported a cobalt(III)-catalyzed C─H alkylations with 
unactivated alkenes, in which the excellent regio-selectivities (linear- and branched-products) could 
be controlled by tunning the reaction conditions (Scheme 1.2.20).[22] A combination of Cp*Co(CO)I2 
and AgSbF6 was employed (under additive free conditions) to provide the linear anti-Markovnikov 
products 76. In contrast, when using sterically hindered 1-AdCO2H as the additive and decreasing 
the reaction temperature to 50 °C, the unexpected branched-selective C─H alkylation products 77 
and 78 were obtained. Detailed mechanistic studies showed that the selectivity was obtained by a 
change of mechanism from a linear-selective ligand-to-ligand hydrogen transfer (LLHT) to a 
branched-selective base-assisted internal electrophilic-type substitution (BIES).  
 
Scheme 1.2.20 Full selectivity control in cobalt(III)-catalyzed C─H alkylations. 
1.2.2.5 Cp*Co(III)-Catalyzed C(sp3)─H activation 




reported in recent years, significantly less efforts have been devoted to C(sp3)─H bond activation in 
this field. Thus, Sundararaju and coworkers reported the C(sp3)─H alkenylation of 
8-methylquinolines 79 in the presence of catalytic amounts of Cp*Co(CO)I2, AdCO2H, and AgOTf 
(Scheme 1.2.21).[78] Compared to Cp*Rh(III) catalysis, stoichiometric amount of copper salts were 
not necessary in this Cp*Co(III) catalysis. However, a low reactivity of aryl alkynes under the 
optimized conditions was observed. A Cp*Co(III)-catalyzed C(sp3)─H amidation of 8-methylquinoline 
with dioxazolones was also developed.[79]  
 
Scheme 1.2.21 Cp*Co(III)-catalyzed C(sp3)─H alkenylation and amidation. 
1.2.2.6 Asymmetric Cp*Co(III)-Catalyzed C─H Functionalization 
Ackermann and coworkers disclosed the first enantioselective Cp*Co(III)-catalyzed C─H alkylation of 
indoles 81 with alkenes 11 using a novel chiral acid as ligand 83 (Scheme 1.2.22).[80] A variety of 
substituted indoles and alkenes were successfully converted, yielding the corresponding products in 
moderate to good yields with high regio- and enantio-selectivities. A combination of experimental 
and computational studies in a chiral setting demonstrated that the C─H activation step is 
reversible and the formation of the (R)-enantiomer could be rationalized by DFT studies. Moreover, 
the 5-methylpyridine could be easily removed, yielding the free indole 83 in 86% yield without loss 





Scheme 1.2.22 First example of Cp*Co(III)-catalyzed asymmetric reaction by C─H activation. 
1.3 Manganese(I)-Catalyzed C─H Activation 
Although transition metal catalysis has revolutionized the hydrocarbon chemistry compared to 
traditional synthetic strategies, the field of C─H functionalization to date was still dominated by 
precious metals.[81] Recent developments have changed the potential of catalytic reactions using 
Earth-abundant 3d metals, such as iron, cobalt, and manganese.[35b] In this regard, manganese is an 
attractive alternative for the C─H activation catalysis due to its natural abundancy, low toxicity, and 
unique reactivity. The low toxicity is reflected by its key importance as an essential trace element 
for several organisms on Earth.[82] The range of oxidation states of manganese is from -3 to +7, 
which bears great potential of exhibiting extraordinary activity. The recent years have witnessed 
many advances in manganese-catalyzed C─H functionalizations.[83]  
Only representative examples of manganese(I)-catalyzed C─H functionalizations developed in 
recent years are summarized herein. The high-valent manganese species catalyzed C─H 
oxygenations,[84] halogenations,[85] and nitrogenations[86] via outer-sphere radical mechanisms are 




1.3.1 Early Examples of Manganese-Catalyzed C─H Functionalizations 
An early example of stoichiometric manganese-mediated C─H activation of azobenzene (4a) was 
reported by Stone/Bruce and coworkers in 1970 (Scheme 1.3.1).[87] The cyclometalated manganese 
complex 85 could be isolated in 93% yield from the MnMe(CO)5 precursor under thermal 
conditions.    
 
Scheme 1.3.1 The first synthesis of five-membered manganaycle 85 via C─H activation. 
 
Based on the pioneering work of Stone and Bruce, a wide range of well-defined manganacycles 
were successfully prepared according to a similar strategy using stoichiometric amounts of 
MnR(CO)5 (with R= Me, Bn, or Ph). Notably, the directing groups were necessary for manganese to 
achieve the C─H metalation. Representative directing groups include imidazole,[88] azo,[89] imino,[90] 
amido,[91] keton,[92] and formyl,[93] among others.[94] The directing atom can bind to the manganese 
center of MnR(CO)5 and bring it to the proximal C─H bond, which is followed by C─H activation 
along with the release of CO and RH.   
 
 
Scheme 1.3.2 Selected manganese complexes synthesized by C─H activation from MnR(CO)5. 
 




via C─H activation, no directed manganese-catalyzed C─H activation was developed until a reported 
by Kuninobu/Takai and coworkers in 2007.[95] Here, the authors described the 
manganese(I)-catalyzed C─H addition to aldehydes using imidazole as the directing group. In the 
course of their optimization studies, the stoichiometric reaction of 2-phenylimidazoles with 
MnBr(CO)5 was accomplished, followed by the addition to the C=O bond of the aldehyde leading to 
the formation of alcohol. It was found that the catalytic reaction could only be achieved with the 
assistance of Et3SiH. Remarkably, the authors demonstrated that stereoselective reactions of chiral 
imidazolines 94 with aldehydes 10 gave the desired products 95 in moderate to good yields with 
varying diastereomeric excesses of de: 30-95% (Scheme 1.3.3). 
 
Scheme 1.3.3 Manganese(I)-catalyzed hydroarylation of aldehydes by Kuninobu and Takai et al. 
 
Moreover, a plausible mechanism was proposed by Kuninobu and Takai. First, the MnBr(CO)5 
undergoes C─H activation by oxidative addition, furnishing the Mn(III)-hydride species 96. Then, a 
migratory insertion of the aldehyde into the manganese-carbon bond forms the intermediate 97. 






Scheme 1.3.4 Proposed mechanism for the hydroarylation of aldehydes. 
1.3.2 Examples of Manganese(I)-Catalyzed C─H Functionalizations 
1.3.2.1 Manganese(I)-Catalyzed C─H Hydroarylations 
In 2013, Wang and coworkers reported the manganese-catalyzed C─H alkenylation of 
2-phenylpyridines 20 with terminal alkynes 8 in the presence of Cy2NH as the base (Scheme 
1.3.5a).[96] From the optimized conditions, weak organic bases showed better performance than 
strong bases. Moreover, this hydroarylation process exhibited high (E)-diastereo, regio-, and 
mono-selectivities. Various functional groups, such as fluoro, chloro, bromo, iodo, ester, and nitro 
groups were well tolerated under the optimized conditions.  
Furthermore, Li and coworkers also reported in 2015 a similar manganese-catalyzed C─H 
alkenylation reaction of indoles 41a using benzoic acid as the additive instead of the Cy2NH base.
[97] 
The authors proposed that the benzoic acid serves as the selectivity controlling element via a 
H-transfer process (Scheme 1.3.5b). Very recently, Fairlamb/Lynam and coworkers described a 
highly reactive seven-membered Mn(I) intermediate 100, which was shown to be effective for 
H-transfer to provide alkenylated products 101 (Scheme 1.3.5c).[98] The detailed computational 






Scheme 1.3.5 Manganese(I)-catalyzed C─H hydroarylations with alkynes. [a]100 °C. 
 
The manganese-catalyzed hydroarylation-type C─H activation strategy was further extended to the 
C=C double bond. In 2014, Wang and coworkers developed the manganese-catalyzed direct 
aromatic C─H addition reaction to α,β-unsaturated carbonyls 11 as well (Scheme 1.3.6).[99] This 
reaction featured a simple catalyst system, high chemo- and mono-selectivity, and a broad 





Scheme 1.3.6 Manganese(I)-catalyzed C─H alkylation with alkenes.  
 
Furthermore, the manganese-catalyzed C─H hydroarylation was not limited to carbon-carbon 
multiple bonds, but electrophilic C─Het multiple bonds, such as C=O, and C=N bonds, also proved to 
be viable. Wang and coworkers reported the manganese-catalyzed Grignard-type nucleophilic 
addition to aldehydes 10, affording various alcohol products 103. The reaction showed a broad 
substrate scope. Various aliphatic aldehydes, including primary, secondary, and tertiary ones and 
olefinic C─H bonds all underwent the reaction smoothly, delivering the desired alcohols in good 
yields (Scheme 1.3.7a).[100] In 2016, Ackermann and coworkers reported an unprecedented 
hydroarylation of C=O double bonds by manganese catalysis under additive-free conditions 
(Scheme 1.3.7b).[101] Challenging aldehydes and ketones were also successfully employed, 
delivering the corresponding products in good yields with high C-2 selectivities. Moreover, it is 
noteworthy that the first manganese-catalyzed C─H hydroarylation with imines 106 was achieved 
(Scheme 1.3.7c). Thereafter, the similar works of manganese(I)-catalyzed C─H hydroarylation of 





Scheme 1.3.7 Manganese(I)-catalyzed C─H addition onto C=Het double bonds. [a] 80 °C. 
1.3.2.2 Manganese(I)-Catalyzed C─H Allylation 
In 2016, Ackermann and coworkers reported the first example of manganese(I)-catalyzed C─H 
allylations of arenes 34 with allyl carbonates 53 (Scheme 1.3.8).[104] Both electron-rich and 
electron-withdrawing heterocycles, including various functional groups such as fluoro, chloro, 
bromide, iodo, cyano, aldehyde, and amine, could be employed in the reaction. The α-substituted 
allyl carbonates 53c were also found to be suitable substrates and provided linear allylation 




higher reactivity, and a significant H/D-scrambling in C-2 position of ketimines was observed as well. 
Both observations were in accordance with a base-assisted intramolecular electrophilic-type 
substitution (BIES) for manganese-catalyzed C─H activation.    
 
Scheme 1.3.8 Manganese(I)-catalyzed C─H allylation. [a]120 °C. 
 
Afterwards, Glorius and coworkers also developed a similar manganese(I)-catalyzed C─H allylation 
reaction (Scheme 1.3.9a).[105] New types of allyl coupling partners were employed in this reaction, 
affording allylic alcohols 111, allylated arenes 59 and functionalized cyclopentenes 112 in moderate 
to good yields and acceptable E/Z ratios. In the same year, Zhang and coworkers also reported a 
manganese(I)-catalyzed C─H 3,3-difluoroallylation using 3-bromo-3,3-difluoroprop-1-ene (114) as 
the allylating reagent (Scheme 1.3.9b).[106] The reaction featured a broad substrate scope, and high 
functional group compatibility. Nevertheless the industrial applicability of such reaction was 





Scheme 1.3.9 Manganese(I)-catalyzed C─H allylation with different coupling partners. 
 
Moreover, Glorius and coworkers also reported manganese(I)-catalyzed allylation-type C─H 
activation providing a direct access to 2-allenylindoles 117 (Scheme 1.3.10).[107] The protocol 
provided an alternative method for the synthesis of fully substituted allenes 117 with high 
enantioselecties via chirality transfer (Scheme 1.3.10a and b). It is noteworthy that the ketone 
products 118 could be obtained in good yields when indole substrates bearing a 3-formyl group 






Scheme 1.3.10 Manganese(I)-catalyzed C─H allylation for the synthesis of 2-allenylindoles. 
1.3.2.3 Manganese(I)-Catalyzed C─H Annulations 
Isoquinolines are among the most abundant and important classes of heterocycles found in natural 
products, agrochemicals, and pharmaceuticals.[108] Many routes for the assembly of this 
heterocyclic skeleton have been developed during the last century.[109] Recent advances in C─H 
activation/annulation to access certain substituted isoquinolines have been developed by 
manganese(I) catalysis in this context. In 2014, Wang and coworkers disclosed a 
manganese(I)-catalyzed dehydrogenative [4+2] annulation of N─H imines 16 and alkynes 8, which 




isoquinoline synthesis processes,[111] this manganese-catalyzed C─H annulation does not require 
any oxidants, external ligands, and additives, highlighting a unique and robust manganese catalyst. 
Detailed mechanistic studies suggested that the isolated five-membered manganacycle 120 is a key 
reaction intermediate in the catalytic cycle (Scheme 1.3.11a). Moreover, Glorius and coworkers also 
reported a manganese(I)-catalyzed C─H annulation to the synthesis of isoquinolines using alkyne 
coupling partners with a traceless directing group very recently (Scheme 1.3.11b).[112] Indeed, 
aliphatic, terminal, dialkyl- and monoalkyl-substitued alkynes were all compatible in this C─H 
annulation and delivered the desired products 119. 
 
Scheme 1.3.11 Manganese(I)-catalyzed C─H annulations with alkynes. [a]BPh3 (10 mol %) and 
1,2-dimethoxyethane (DME) were employed. 
 
Manganese exhibits a lower electronegativity in comparison to 4d transition metals such as 
rhodium, ruthenium, and iridium, which could form more nucleophilic intermediates leading to 
more significant reactions. Indeed, in 2015, Ackermann and coworkers developed the first 
manganese-catalyzed C─H annulation of ketimines 34 with acrylates 11, providing expedient access 




catalytic efficacy, good functional group tolerance, and an unusual cis stereo-selectivity. The 
catalytic cycle include a manganese nucleophilic intermediate which undergoes the intramolecular 
nucleophilic addition to the carbon atom of the imine moiety and then delivers the desired product 
120.    
 
Scheme 1.3.12 Manganese(I)-catalyzed synthesis of cis-β-amino acid esters via C─H activation. [a] In 
PhMe. [b] With Mn2(CO)10 (10 mol %). 
 
Thereafter, Rueping[114] and Wang/Li[115] independently developed the unprecedented C─H/C─N 
functionalization of pyrimidinyl-indoles 41 with allenes 121. The optimized reactions showed that a 
high yield could be obtained when NaOAc was used as the additive. The use of disubstituted allenes 
121b resulted in the selectively alkenylated C-2 indoles 124 under mild reaction conditions. 
However, when trisubstituted allenes were employed under similar reaction conditions, the 
unexpected annulation products 122 were obtained (Scheme 1.3.13a). In Wang/Li’s system, the 
reaction proceeded under simple reaction conditions with no additives or even solvent-free 
conditions, but a high reaction temperature of 100 °C was necessary, providing the 
hydroarylation/cyclization products 122 in moderate to good yields with high stereo- and 
regio-selectivity. The decarboxylative ring-opening of the products 122 offered a series of vicinal 





Scheme 1.3.13 Manganese(I)-catalyzed C─H/C─N functionalization. 
1.3.2.4 Manganese(I)-Catalyzed C─H Cyanations 
In 2016, Ackermann and coworkers reported a manganese-catalyzed C─H cyanation of 
heteroarenes with NTCS (47a) as the cyanating reagent.[116] A combination of MnBr(CO)5 and Cy2NH 
gave the highest efficiency to provide cyanated products 49 with the assistance of ZnCl2. The 
intermolecular competition experiments showed that electron-rich substrates reacted 
preferentially. Moreover, this catalyst enabled C─H cyanations on heterocycles, including pyrroles 
and thiophenes, with high mono- and C-2 selectivities (Scheme 1.3.14a). It is noteworthy that this 
cyanation strategy could be applied to tryptophan derivatives 125 and the authors showed that 
electron-deficient cyanating reagents could provide the desired products 126 in higher yields, 





Scheme 1.3.14 Manganese(I)-catalyzed C─H cyanation. 
 
Very recently, Bao and coworkers also described a manganese-catalyzed C─H cyanation reaction of 
arenes by using N-cyano-N-(4-methoxy)phenyl-p-toluenesulfonamide (NMTS) (47b) as the 
cyanating reagent.[117] The aromatic nitriles were obtained in 27-79% yields in the presence of 20 
mol % of MnBr(CO)5 catalyst (Scheme 1.3.15).  
 




1.3.2.5 Manganese(I)-Catalyzed C─H Alkynylation 
 
Scheme 1.3.16 Manganese(I)-catalyzed C─H alkynylation. 
 
In 2017, Ackermann and coworkers described the first manganese(I)-catalyzed substitutive 
alkynylation with bromoalkynes 127 (Scheme 1.3.16).[118] The unique robustness of manganese 
catalyst was reflected by the unparalleled substrate scope, and valuable electrophilic functional 




further extended to aryl, alkenyl, and alkyl alkynes using a combination of MnBr(CO)5 and 
triphenylborane as the key cocatalytic additive. It is worth noting that high efficiency was achieved, 
even with cocatalyst loadings as low as 0.05 mol %. More important, various acyclic peptides could 
also be employed as suitable substrates in this remarkable C─H alkynylation approach, delivering 
the corresponding products 128 in 53-82% yields without any racemization (Scheme 1.3.16a). In 
addition, a highly challenging macrocyclization was accomplished to provide the 21-membered 
cyclic peptide 130 under high-dilution conditions (Scheme 1.3.16b). At last, the pyridine group 
could also be removed in a traceless fashion under mild conditions. 
The detailed mechanistic studies, including H/D exchange, KIE, and kinetic experiments revealed a 
fast and reversible C─Mn bond formation. Thereafter, a plausible catalytic cycle was proposed to be 
initiated by a facile organometallic C─H activation. Subsequently, the alkyne migratory insertion 
gives the seven-membered intermediate 133. The final alkynylation product 128 was most likely 
generated through β-elimination, although a mechanism involving oxidative addition and reductive 
elimination could not be ruled out (Scheme 1.3.17).  
 




1.4 Transition Metal-Catalyzed C–C Functionalizations 
Selective transition metal-catalyzed carbon−carbon single bond functionalizations have recently 
been shown to be increasingly versatile tools for organic synthesis. Although numerous examples in 
this field have been disclosed in the past decade,[119] the reported examples are still much fewer 
than the reports of transition metal-catalyzed C─H functionalizations due to the intrinsic difficulties 
in activating C─C bonds versus C─H bonds in terms of thermodynamics and kinetics. The 
dissociation energy of C─C bond is rather high of up to 375 kcal mol-1,[120] which results in a higher 
inertness of C─C bond. Moreover, C─C σ-bond has a less favorable orbital directionality than C─H 
bond, which makes the orbital interaction with transition metals more difficult.[121] Therefore, 
selective C─C activations often needed harsh reaction conditions. However, applying more forcing 
conditions may end up the reactions in side products. To date, many different strategies have been 
developed to solve these problems in order to achieve the C─C bond cleaving transformations. The 
currently main methods for C─C bond activation are restricted to the highly strained systems such 
as three- and four-membered rings, or more polarized C─C bonds, for example, towards C─CN bond 
activation (Scheme 1.4.1). The strain-release energy (cyclopropane is 29.0 kcal mol-1)[122] facilitates 
the transition metal insertion leading to the formation of organometallic intermediate, which 
provides access to other organic molecules.[123] In addition, the strong electron-withdrawing cyano 
group could weaken the C─CN bond and coordinate to the transition metals that achieve the C─C 
bond activation.[124] 
 





Besides these two transformations, other strategies have also been devised to enforce C─C 
cleavages (Scheme 1.4.2), including: a) forming stable metallacycles via a chelation-assisted 
oxidative addition step;[125] b) forming metallic aromatics;[126] c) decarbonylation of unstrained 
ketones;[127] d) forming the stable metal─carbon bond via a β-carbon elimination step;[128] e) 
retro-allylation base on a 6-membered transition state.[119a, 129] 
 
Scheme 1.4.2 Other promising strategies for C─C bond activations. 
1.4.1 Transition Metal-Catalyzed C─C Functionalizations 
The fist example of C─C activation by transition metal insertion was reported by Tipper in 1955 
(Scheme 1.4.3).[130] The C─C bond of cyclopropane (135) was activated by [H2PtCl6] generating a 
platinacyclobutane intermediate 141 (structure was corrected by Chatt in 1961, Tipper thought it 
reacted with“PtCl2”)





Scheme 1.4.3 Stoichiometric C–C cleavage cyclopropane via oxidative addition. 
 
Inspired by the pioneering work of Tipper and Chatt, strained ring systems have thus emerged as 
role models for a number of C─C cleaving transformations.[123] For example, in 2013, Bower and 
coworkers developed rhodium-catalyzed multicomponent synthesis of N-heterobicyclic enones 144 
and 145 by carbonylative C─C bond activation of aminocyclopropanes 143 (Scheme 1.4.4).[132] A 
plausible pathway was postulated. Firstly, the rhodium catalyst activates the proximal C─C bond of 
cyclopropane with the aid of N-protecting group, and then undergoes CO insertion generating the 
rhodacyclopentanone intermediate 146. Finally, the desired product was obtained by the alkyne 
insertion and C─C bond reductive elimination.  
 
Scheme 1.4.4 Rhodium-catalyzed carbonylative C─C activation of aminocyclopropanes. 
 
Meanwhile, other unstained substrates were also successfully employed for C─C activations, such 
as C─C bond cleavage assisted by chelation. Recently, Ackermann and coworkers reported an 
unprecedented ruthenium-catalyzed C─C arylations as well as C─C alkylations on decorated 
pyrazoles 148.[133] The robust and unique ruthenium catalyst was reflected by fully tolerating 
valuable functional groups, including nitriles, cyano, free NH2, halides, alkenes, esters, and ketones. 
The leaving group for C─C bond cleavage is not limited to the amide. Indeed, the decarboxylative 




Detailed mechanistic studies indicated a facile and reversible C─C metalation step (Scheme 1.4.5a). 
Moreover, the pyrazole group could be easily removed by ozonolysis,[134] providing the arylated 
anilides 151 in moderate yields (Scheme 1.4.5b).  
 
Scheme 1.4.5 Ruthenium(II)-catalyzed C─C functionalizations by Ackermann and coworkers. 
 
In 2011, Shi and coworkers developed a rhodium-catalyzed selective C─C bond activation of 
secondary alcohols 152 with the aid of a pyridinyl group via β-carbon elimination.[135] This C─C 
alkenylation features a broad reaction scope and highly functional group tolerance. Inter- and 
intra-molecular competition experiments both supported that C─C bond activation was much faster 
than the direct C─H activation under the optimal conditions. This strategy offered a mild and 
efficient process for C─C cleavage (Scheme 1.4.6a). Thereafter, the same group also reported the 
rhodium-catalyzed C─C arylation under an oxidative condition, and reductive cleavage of the 






Scheme 1.4.6 C─C bond activation via β-carbon elimination. 
 
Compared to the noble metals, such as rhodium, cobalt is an alternative candidate for C─C bond 
activation due to its benefits of Earth-abundant, nontoxic. In 2015, Morandi and coworkers 
developed the C─C cleavage by using inexpensive cobalt as catalyst through a β-carbon elimination 
step.[137] The electronic and steric effects of the substrates both had little influence on the 
transformation of C─C cleavage. The secondary and tertiary alcohols underwent the reaction 
smoothly, but the primary alcohol could not achieve the C─C bond activation (Scheme 1.4.7a). 
Moreover, when the cyanating reagent NCTS (47a) was selected as the reaction partner, the 
desired product was obtained in 91% yield (Scheme 1.4.7b). Two possible pathways were proposed 
for the cobalt(III)-catalyzed C─C cyanation reaction. The cobalt intermediate 157 was firstly 
generated by the initial β-carbon elimination, and then underwent the cyanation directly, delivering 
the final product (Path A, direct C─C activation). Alternatively, the intermediate 157 could be 
trapped by proton providing the phenylpyridine firstly, then underwent the C─H functionalization 



















Transition metal-catalyzed C─H functionalizations have emerged as increasingly powerful tools for 
sustainable organic syntheses.[81b, 138] Remarkable advances in this area have been achieved by Prof. 
Dr. Lutz Ackermann and coworkers, which is mainly focused on the development of chemo- and 
site-selective syntheses of valuable organic molecules, with applications to pharmaceutical 
chemistry, materials sciences and peptide assembly.[80, 139] Within this context, major efforts were 
made to develop novel C─H or C─C activation reactions by environmentally-benign, less expensive 
and Earth-abundant versatile cobalt(III)/manganese(I) catalysts. 
In the past few years, alkyne annulations by C─H/N─O functionalizations have proven to be 
instrumental for the step-economical assembly of various heterocycles with activities of relevance 
to medicinal chemistry and biology.[109c, 140] In addition, in light of the beneficial features of naturally 
abundant 3d transition metals, focus has shifted in recent years to the use of 
environmentally-benign, less expensive base metal catalysts for the C─H activation processes, such 
as cobalt catalyst. Therefore, it was of great interest to establish a novel approach for 
cobalt(III)-catalyzed C─H/N─O functionalization for the redox-neutral preparation of isoquinolines 
(Scheme 2.1).[141]  
 
Scheme 2.1 Cobalt(III)-catalyzed C─H/N─O functionalization of O-acyl oximes 158. 
 
Substituted indoles are important structural motifs widely found in compounds of relevance to 
medicinal chemistry, crop protection, and drug discovery, among others.[142] Although the recent 
years have witnessed the emergence of C─H functionalization as increasingly powerful tools for the 
direct synthesis of indoles, these protocols largely required precious 4d and 5d transition metals.[143] 
In this regard, an Earth-abundant and environmentally-benign cobalt catalyst would be desired to 





Scheme 2.2 Selective synthesis of indoles by cobalt(III)-catalyzed C–H/N–O functionalization with 
nitrones 159. 
 
Biologically relevant N-heterocycles, such as pyrazoles, oxazolines, pyrimidines, or pyridines, can 
strongly coordinate to the active transition metals, in some cases, resulting in C─H activation at 
undesired position or catalyst poisoning,[145] which severely limits the application of these reactions 
in material sciences or drug discovery. In 2014, Yu reported the palladium-catalyzed 
position-selective C─H functionalizations of the substrates containing two different directing groups, 
which the N-heterocycles, such as pyridine, quinolone, pyrazine, pyrimidine, pyrazole, thiazole, and 
oxazoline, are fully tolerant.[146] Although major advances in cobalt(III)-catalyzed C─H 
functionalizations have been accomplished in recent years, no example was reported for 
cobalt(III)-catalyzed C─H activation fully tolerating strongly coordinating N-heterocycles. Herein, we 
would plan to establish cobalt(III)-catalyzed C─H amidation by the assistance of imidate that 
tolerated strongly coordinating N-heterocycles (Scheme 2.3).[147]  
 
Scheme 2.3 Strongly coordinating N-heterocycles were fully tolerated in cobalt-catalyzed C─H 
amidations. 
 
Despite significant progress of Cp*Co(III)-catalyzed C─H activation has been accomplished recently, 




from their analogous Cp*Rh(III) counterparts. Herein, a first cobalt(III)-catalyzed domino reaction 
comprising C─H/N─H allylation for the direct synthesis of isoquinolines has been developed, which 
notably could not be achieved by Rh(III) catalysis (Scheme 2.4).[148]  
 
Scheme 2.4 Cobalt-catalyzed domino C─H/N─H allylations of imidates 161. 
 
In 2016, Ackermann and coworkers reported an unprecedented manganese(I)-catalyzed substitutive 
C─H allylation with allyl carbontates 53.[104] Based on this work, further expansion for 
manganese-catalyzed C─H allylation in water using dioxolanones 110 as the allyl source was 
investigated (Scheme 2.5).[149]  
 
Scheme 2.5 Manganese(I)-catalyzed C─H activation for decarboxylative C─H/C─O cleavages. 
 
Flow chemistry bears huge potential to address the needs of sustainable synthesis, facilitating 
challenging synthetic transformations and providing additional advantages, such as safer and faster 
reactions, clean products, and easy scale-up.[150] In addition, remarkable advances have been 
achieved with the aid of less toxic manganese catalysis over the last decade.[83] Nevertheless, all 
manganese(I)-catalyzed functionalization of substrates, bearing leaving groups in proximity to the 
C─C multiple bond, thus far resulted in β-heteroatom eliminations.[104-107, 151] Therefore, it is of great 
significance to develop a new versatile protocol, combining with continuous flow for 






Scheme 2.6 Manganese(I)-catalyzed synergistic C─H activation for chemoselective hydroarylation in 
flow. 
 
Recent years have witnessed great sucssess in transition-metal-catalyzed C─C bond activations, 
offering new opportunities to the synthesis of valuable and novel organic moleculars.[119] However, 
precious metals, such as rhodium, ruthenium and palladium, have always played a predominant role 
in this field, which limites their further application in synthetic chemistry due to the high cost and 
toxicity of these metals. In this regard, catalysts based on Earth-abundant metals, for example 
manganese, are highly desirable for C─C bond functionalization. In addition, organic synthesis 
reactions catalyzed in water is consistent with the requirements of green chemistry.[29] However, to 
date, transition-metal-catalyzed C─C functionalizations in water have proven elusive. Within our 
program on sustainable C–C functionalizations,[153] herein, we disclosed the first versatile C–C 
activation by inexpensive and less toxic manganese catalyst in water (Scheme 2.7).[154]  
 
Scheme 2.7 Chelation-assisted manganese-catalyzed C─C activations in H2O. 
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3 Results and Discussion 
3.1 Cobalt(III)-Catalyzed C–H/N–O Functionalizations: Isohypsic Access to 
Isoquinolines 
Isoquinolines are versatile heterocycles that are widely used as a key structural moiety present in 
integrate molecules with medicinal benefits, natural products and diverse bioactivities.[108] As a 
consequence, the development of efficient methods for the synthesis of isoquinolines continues to 
be of great interest. Over the past years, with advances in transition metal-catalyzed C─H bond 
functionalizations, many effective methods have been developed to synthesize isoquinolines mainly 
using second- and third-row transition metals.[109c, 140b-d, 155] Since the pioneering work of Matsunaga 
and Kanai,[56] Cp*Co(III) catalysts have been shown as an inexpensive alternative to Cp*Rh(III) 
catalysts for directed C─H activation. Within our research program on cobalt(III)-catalyzed C─H 
activation,[156] we developed a novel cobalt(III)-catalyzed C─H/N─O functionalizations for the 
redox-neutral preparation of isoquinolines. 
3.1.1 Optimization Studies for the Synthesis of Isoquinoline  
The cobalt(III)-catalyzed C─H annulation was initiated using (E)-acetophenone O-acetyl oxime (158a) 
and 1,2-diphenylethyne (8a) in the presence of Cp*Co(CO)I2 as the catalyst (Table 3.1.1). Preliminary 
experiments indicated DCE to be the solvent of choice, while low yields of the product 119aa were 
obtained in MeOH, H2O, 1,4-dioxane, and toluene (entries 1-5). Attempts to decrease the catalyst 
loading or reaction temperature of this annulation reaction resulted in a significant decrease in the 
product yields (entries 6-7). The desired product was isolated in only 48% yield when HOPiv was 
introduced as the additive (entry 8). It is worth noting that the cobalt(III)-catalyzed alkyne 
annulation proceeded efficiently under an atmosphere of air (entry 9). A significant decrease in 
reaction efficacy was observed when the [Cp*Co(C6H6)](PF6)2 catalyst was employed for this 
reaction (entry 10). As anticipated, other cobalt catalysts did not afford the desired product 119aa 
under the otherwise identical conditions (entries 11-13). 
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Table 3.1.1 Optimization studies for the synthesis of isoquinoline 119aa[a] 
 
Entry [Co] Additive Solvent Yield 
1 Cp*Co(CO)I2 NaOAc MeOH trace
[b] 
2 Cp*Co(CO)I2 NaOAc H2O trace
[b] 
3 Cp*Co(CO)I2 NaOAc 1,4-dioxane 18%
[b] 
4 Cp*Co(CO)I2 NaOAc toluene 11%
[b] 
5 Cp*Co(CO)I2 NaOAc DCE 86%
[b] 
6 Cp*Co(CO)I2 NaOAc DCE 63%
[c] 
7 Cp*Co(CO)I2 NaOAc DCE 60%
[d] 
8 Cp*Co(CO)I2 HOPiv DCE 48% 
9 Cp*Co(CO)I2 NaOAc DCE 87% 
10 [Cp*Co(C6H6)](PF6)2 NaOAc DCE 45%
[e] 
11 CoCl2 NaOAc DCE --- 
12 Co(OAc)2 NaOAc DCE --- 
13 Co(acac)2 NaOAc DCE --- 
[a] Reaction conditions: 158a (0.50 mmol), 8a (0.75 mmol), [Co] (10 mol %), AgSbF6 (20 mol %), 
additive (20 mol %), solvent (2.0 mL), under air, 120 °C, 16 h, isolated yield. [b] Under N2. 
[c] 
Cp*Co(CO)I2 (5.0 mol %) was used. 
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3.1.2 Scope of Cobalt(III)-Catalyzed C–H/N–O Functionalization 
3.1.2.1 Cobalt(III)-Catalyzed C–H/N–O Functionalization with Substituted Arenes 158 
With the optimized catalytic conditions in hand (Table 3.1.1, entry 9), we evaluated the reaction 
versatility by utilizing various substituted arenes 158 (Scheme 3.1.1). 
 
Scheme 3.1.1 Scope of cobalt(III)-catalyzed C─H/N─O functionalization with substituted arenes 158. 
[a] 15 min reaction time. [b] In HFIP. 
 
Both electron-donating and -withdrawing groups at the para-position, such as alky, methoxy, fluoro, 
trifluoromethyl, chloro, bromo, nitro, and cyano, were all well tolerated and afforded the desired 
products 119 in moderate to excellent yields. When O-acetyl oximes 158l-158m bearing methyl, 
chloro and bromo groups at the meta-positions were chosen as the substrates, the C─H activation 
occurred at the least hindered site and afforded the desired product in good yields with excellent 
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selectivities, due to the small size of the cobalt. However, while the secondary interactions 
dominated in oxime derivatives, the totally opposite positions were selectively functionalized 
(119oa and 119pa). The C─H/N─O annulation with substituted arene 158q set the stage for the 
assembly of the tricyclic product 119qa. In addition, the heterocyclic product 119ta was obtained in 
85% yield with good regioselectivity when HFIP was employed as the reaction solvent. It is 
noteworthy that high catalytic activity of this cobalt(III) catalyst was showcased by obtaining the 
annulation products in high yields within only 15 min. 
3.1.2.2 Isohypsic Annulation of Alkynes 8 
 
Scheme 3.1.2 Isohypsic annulation of alkynes 8. [a] 15 min reaction time. 
 
Subsequently, we further explored the scope of this cobalt(III)-catalyzed C─H/N─O functionalization 
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by testing different alkynes 8 (Scheme 3.1.2). Various aryl- and alkyl-substituted alkynes were viable 
substrates, delivering the desired products in moderate to good yields (8b-8m). Unsymmetrical 
alkyne 8n underwent the reaction smoothly and provided the single products 119an with the 
phenyl substituent next to nitrogen in 68% yield. Terminal alkynes were also successfully applied for 
this annulation reaction, generating the desired products in good yields with excellent 
regio-selctivity (119go-119gp). 
3.1.3 Mechanistic Studies 
3.1.3.1 Competition Experiments 
 
Scheme 3.1.3 Intermolecular and intramolecular competition experiments. 
 
Furthermore, intermolecular and intramolecular competition experiments between electron-rich 
158c and electron-deficient arenes 158e under the optimized conditions were carried out (Scheme 
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3.1.3a and b). As a result, the electron-rich arenes react preferentially, which possibly supports a 
base-assisted internal electrophilic-type substitution (BIES) C–H activation by the cationic cobalt 
catalyst. It is noteworthy that the diastereomeric mixture of substrate 158u afforded the annulation 
product in high yield (63% + 12%). This result indicated that a Z-configuration of the O-acetyl oximes 
is not a prerequisite for this alkyne annulation reaction.[157] Further, a competition experiment 
between different alkynes showed that aromatic substituents increased the inherent reaction rate 
(Scheme 3.1.3c). 
3.1.3.2 H/D-Exchange Experiments 
Moreover, in order to understand the mechanism of this C–H activation reaction, the H/D-exchange 
experiment using substrate (E)-1-(4-methoxyphenyl)ethanone O-acetyl oxime (158c) with D2O as 
the co-solvent was conducted. Here, significant deuterium incorporation was observed in the 
ortho-position of reisolated substrate [D]n-158c as well as the product [D]n-119ca (Scheme 3.1.4a), 
revealing the C–H cobaltation process is reversible. Moreover, a 74% D incorporation was observed 
at the C(sp3)–H bond of the product [D]n-119ca, suggesting that the cationic cobalt catalyst could 
enolize the product (Scheme 3.1.4b). 
 
Scheme 3.1.4 H/D exchange experiments.    
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3.1.3.3 Kinetic Isotope Effect 
The kinetic isotope effect (KIE) of the cobalt(III)-catalyzed C–H activation was determined by 
independent experiments of substrates 158a and [D]5-158a to be kH/kD ≈ 1.5 (Scheme 3.1.5). The 
result suggested that the reversible C–H metalation is not the rate-determining step. 
 
 
Scheme 3.1.5 Kinetic isotope effect experiment. 
3.1.3.4 Attempted Cyclization of ortho-Alkenylated Arene 169 
Additionally, the ortho-alkenylated intermediate 169 was separately prepared and subjected to the 
reaction conditions (Scheme 3.1.6). Notably, the cyclic product 119aa as not observed when the 
reaction was performed without Cp*Co(III) catalyst. Likewise, the attempted transformation of 
substrate 169 in the presence of Cp*Co(III) catalyst gave the isohypsic alkyne annulation product in 
only 15% yield, suggesting a hydroarylation/electrocyclization sequence unlikely to be operative. 
 
y = 0.9919x - 1.2703 

















t / min 
[D]5-119aa 
119aa 




Scheme 3.1.6 Attempted cyclization of ortho-alkenylated arene 169. 
3.1.4 Proposed Catalytic Cycle 
In summary, based on the mechanistic findings, a catalytic cycle was proposed for the 
cobalt(III)-catalyzed C–H/N–O functionalization (Scheme 3.1.7). The catalytically active species 
might be a cationic cobalt(III)-acetate complex 50 formed by reaction of cobalt(III) precursor and 
AgSbF6. The reaction is initiated by reversible C–H cobaltation of O-acetyl oxime 158, assisted by the 
acetate additive and presumably proceeds via a BIES-type pathway to furnish the intermediate 170. 
Then the key alkenyl intermediate 171 is generated by the alkyne migratory insertion, which 
subsequently undergoes the intramolecular cyclization by a C–N bond formation. Finally, the desired 
product 119 was obtained along with the regeneration of the catalytic cobalt(III) complex 50 by a 
concerted acetate transfer process. 
 




Scheme 3.1.7 Proposed catalytic cycle. 
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3.2 Selective Synthesis of Indoles by Cobalt(III)-Catalyzed C–H/N–O 
Functionalization with Nitrones 
Substituted indoles are important building blocks abundantly found in natural products and 
pharmaceutically active compounds.[142b] Since Fischer and coworkers developed the new method 
for the synthesis of indole in 1883 from an arylhydrazine with a ketone or an aldehyde via the 
acid-mediated arylhydrazone formation, following by [3,3]-sigmatropic rearrangement (Scheme 
3.2.1),[158] indole synthese have become one of the most important topics in modern synthetic 
chemistry. Among those methods, C–H activation has recently rapidly emerged as a robust tool for 
the synthesis of indole derivatives, avoiding the use of pre-functionalized substrates.[8, 13b] In the 
past few years, significant progress has been achieved in C–H activation using Earth-abundant and 
inexpensive first-row transition metals.[35b] While many routes for the synthesis of indoles have 
been reported, developing mild, environmentally-benign and atom-economical methods remains an 
important area. Herein, we became attracted to devise a protocol for cobalt(III)-catalyzed indole 
synthesis. 
 
Scheme 3.2.1 Fischer indole synthesis. 
3.2.1 Optimization of Cobalt(III)-Catalyzed C–H/N–O Alkyne Annulation  
We initiated our studies by testing the feasibility of the envisioned cobalt(III)-catalyzed C─H/N─O 
functionalization with nitrone 159a and 1,2-diphenylethyne (8a) (Table 3.2.1). Preliminary 
experiments highlighted Cp*Co(CO)I2 to be the catalyst of choice and indicated that TFE and HFIP 
were most suitable solvents (entries 1-7). A significant decrease in the product yields was observed 
when lower catalyst loadings or shorter reaction time were tested (entries 8-11). The isohypsic 
alkyne annulation proceeded at lower reaction temperatures, yet the best yield of the indole 
product 160aa was accomplished at 100 °C (entries 12-15). Moreover, the desired product was 
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formed in 92% yield by a cationic single-component catalyst, thus avoiding the use of any silver salts 
(entry 16). It is noteworthy that only 13% yield of the annulation product 160aa was observed in the 
presence of [Cp*RhCl2]2 as the catalyst (entry 17). 
 
Table 3.2.1 Optimization of alkyne annulation[a] 
 
Entry [Co] / mol % Solvent T / °C Yield[b] 
1 Cp*CoI2(CO) / 10 TFE 120 88% 
2 Cp*CoI2(CO) / 10 TFE 120 75% 
3 Cp*CoI2(CO) / 10 DCE 120 21% 
4 Cp*CoI2(CO) / 10 1,4-dioxane 120 trace 
5 Cp*CoI2(CO) / 10 MeOH 120 -- 
6 Cp*CoI2(CO) / 10 HFIP 120 6%
 [c] 
7 Cp*CoI2(CO) / 5.0 HFIP 120 90% 
8 Cp*CoI2(CO) / 2.5 HFIP 120 64% 
9 Cp*CoI2(CO) / 1.0 HFIP 120 5% 
10 Cp*CoI2(CO) / 5.0 HFIP 120 49%
 [d] 
11 Cp*CoI2(CO) / 5.0 HFIP 120 67%
 [e] 
12 Cp*CoI2(CO) / 5.0 HFIP 100 92% 
13 Cp*CoI2(CO) / 5.0 HFIP 80 77% 
14 Cp*CoI2(CO) / 5.0 HFIP 50 46% 
15 Cp*CoI2(CO) / 5.0 HFIP 23 9% 
16 [Cp*Co(CH3CN)3](SbF6)2 / 5.0 HFIP 120 92%
 [f] 
17 [Cp*RhCl2]2 / 2.5 HFIP 120 13% 
[a] Reaction conditions: 159a (0.50 mmol), 8a (0.75 mmol), AgSbF6 (20 mol %), NaOAc (20 mol %), 
solvent (2.0 mL), under air, 100 °C, 16h. [b] Yield of isolated product. [c] Cu(OAc)2 (1.0 equiv) was 
used. [d] 1 h. [e] 3 h. [f] Without Ag salts. 
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Table 3.2.2 Effect of additives[a] 
 
Entry Additive 1 Additive 2 Yield[b] 
1 AgSbF6 NaOAc 92% 
2 AgPF6 NaOAc 82% 
3 AgBF4 NaOAc 80% 
4 AgOTs NaOAc 82% 
5 AgOTf NaOAc 86% 
6 -- K2CO3 10% 
7 AgSbF6 KOAc 86% 
8 AgSbF6 CsOAc 88% 
9 AgSbF6 -- 7% 
10 AgSbF6 NaOAc --
[c] 
[a] Reaction conditions: 159a (0.50 mmol), 8a (0.75 mmol), Cp*CoI2(CO) (5.0 mol %), additive 1 (20 
mol %), additive 2 (20 mol %), HFIP (2.0 mL), under air, 120 °C, 16h. [b] Yield of isolated product. [c] 
Without Cp*CoI2(CO). 
 
Furthermore, various additives were tested for the cobalt(III)-catalyzed C–H/N–O functionalization 
(Table 3.2.2). Different silver salts were firstly employed for the reaction, delivering the desired 
product 160aa in satisfactory yields. AgSbF6 was optimal, presumably because 
hexafluoroantimonate is a weakly-coordinating and non-nucleophilic anion which stabilizes the 
cationic cobalt species (entries 1-5). Subsequently, the reactions with different bases or without 
base were examined, and these results suggested that NaOAc is the most effective (entries 6-9). A 
control experiment showed that there was no reaction in the absence of the cobalt(III) catalyst 
(entry 10). 
The last few years have witnessed the significant progress of N-acyl amino acids as powerful ligands 
in transition metal-catalyzed C–H activation, as reported by Yu[159] and Ackermann group.[160] 
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Therefore, with the previous optimization results in hand, we tested a series of amino acid ligands 
instead of NaOAc for the cobalt(III)-catalyzed C–H/N–O functionalization with nitrone 159a (Table 
3.2.3). Notably, Piv-Leu-OH proved to be a powerful ligand, delivering the desired indole 160aa in 
88% yield (entry 4). 
 
Table 3.2.3 Effect of different amino acid ligands[a] 
 
Entry Additive  Yield[b] 
1 Piv-Ile-COONa 73% 
2 Ac-Ile-COONa 83% 
3 Piv-Phe-OH 71% 
4 Piv-Leu-OH 88% 
5 Piv-Ile-OH 78% 
6 MeCO2-Ile-OH 74% 
7 Piv-Pro-OH 74% 
8 Fmoc-Met-OH 6% 
9 Ac-Tyr-OH 68% 
10 Piv-Ala-OH 72% 
11 Ac-Ile-OH 77% 
12 Piv-Asn-OH 73% 
13 Ac-Leu-COONa 87% 
Reaction conditions: 159a (0.50 mmol), 8a (0.75 mmol), Cp*CoI2(CO) (5.0 mol %), AgSbF6 (20 mol %), 
additive (20 mol %), HFIP (2.0 mL), under air, 100 °C, 16h. [b] Yield of isolated product. 
3.2.2 Influence of the C–Substitution Pattern 
Moreover, we also tested the dependence of the catalytic efficacy on the C─substitution pattern of 
the nitrones 159 (Scheme 3.2.2). These test reactions under the optimized reaction conditions 
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verified the importance of the C─substitution pattern. Notably, the electron-donating PMP 
substituent afforded the desired product 160aa in the highest yield of 92%, presumably due to the 
fine tunning of electronic and steric factors. 
 
Scheme 3.2.2 Influence of the C─substitution pattern on nitrones. 
3.2.3 Scope of Cobat-Catalyzed C–H/N–O Functionalization 
3.2.3.1 C–H/N–O Functionalization with Nitrones 159 
With the optimized catalytst in hand (Table 3.2.1, entry 12 and Table 3.2.3, entry 4), the scope of 
the cobalt(III)-catalyzed C─H/N-O annulation with various substituted nitrones 159 was examined 
(Scheme 3.2.3). A variation of substituents in para-position of the nitrones led to overall good to 
excellent yields. Moreover, valuable functional groups, such as fluoro, chloro, and bromo, were well 
tolerated under the optimal reaction conditions (160ca-160ea). The intramolecular competition 
experiment with meta-substituted nitrone 159f bearing two different ortho-C─H bonds delivered 
site-selectively indole 160fa as the sole product. Moreover, there are no significant differences in 
the product yields between Piv-Leu-OH and NaOAc as the additives. 
 




Scheme 3.2.3 C–H/N–O functionalization with nitrones 159. 
 
3.2.3.2 Cobalt(III)-Catalyzed Annulation of Tolanes  
Furthermore, the reaction was explored with differently substituted tolane derivatives 8, which also 
proved to be viable for the C─H annulation reaction and afforded the 2,3-diaryl indoles 160 in 
moderate to good yields (Scheme 3.2.4). Notably, this cobalt(III)-catalyzed annulation reaction was 
shown tolerant for both electron-donating and electron-withdrawing groups, including Me (8b), 
OMe (8c), Cl (8g, 8h) and CF3 (8e). 




Scheme 3.2.4 Cobalt(III)-catalyzed annulation of tolanes 8. 
 
3.2.3.3 Cobalt(III)-Catalyzed Annulation of Unsymmetrical Alkynes  
Particularly, when unsymmetrically substituted alkynes 8 were applied to this reaction using 
Piv-Leu-OH as the additive, the corresponding products 160ap-160ar was obtained in good yields 
and excellent regio-selectivities (Scheme 3.2.5). By comparison with a related rhodium(III)-catalyzed 
indole synthesis,[161] higher regio-selectivities (E/Z >15) were obtained, highlighting a more effective 
cobalt catalysis for this annulation reaction. 




Scheme 3.2.5 Cobalt(III)-catalyzed annulation of unsymmetrical alkynes 8. 
3.2.4 Formation of 3H-Indole and Cationic Cobalt(III) as the Catalyst 
 
Scheme 3.2.6 Formation of 3H-indole 161 and cationic cobalt(III) as the catalyst. 
 
Interestingly, when the dialkyl-substituted alkyne 8 was employed under the optimal reaction 
conditions, the unexpected 3,3-disubstituted 3H-indole 161 was obtained, which was in agreement 
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with Chang’s work[162] reported on rhodium(III)-catalyzed C─H activation for the synthesis of 
indolines (Scheme 3.2.6a) Moreover, the user-friendly nature of this C─H activation strategy was 
reflected by using a cationic single-component cobalt catalyst, thus avoiding the use of additional 
silver salts (Scheme 3.2.6b). 
3.2.5 Mechanistic Studies 
3.2.5.1 Competition Experiments 
Subsequently, an intermolecular competition experiment between electron-rich and 
electron-deficient para-substituted nitrones under the optimized conditions was carried out 
(Scheme 3.2.7a). As a result, the electron-rich nitrones 159a reacted preferentially, which supports 
a base (acetate)-assisted electrophilic-type (BIES) C–H activation. Further competition experiments 
between electronically distinct alkynes 8c and 8e showed that electron-rich alkynes were found to 
be preferentially converted (Scheme 3.2.7b). 
 
 
Scheme 3.2.7 Competition experiments. 
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3.2.5.2 H/D Exchange and Kinetic Isotope Effect Study 
When the reaction was performed in the presence of isotopically labelled CD3OD as co-solvent, we 
did not observe any H/D scrambling on both the reisolated starting material 159a and the desired 
product 160aa (Scheme 3.2.8a). Moreover, the KIE of the cobalt(III)-catalyzed C─H/N─O annulation 
was determined by comparison of independent reaction rates of substrates 159b and [D]5-159b, 
resulting in a value of kH/kD ≈ 2.7 (Scheme 3.2.8b). These results suggested that the C─H metalation 
is the rate-determining step. 
 
 
Scheme 3.2.8 H/D exchange and kinetic isotope effect study. 
3.2.6 Plausible Catalytic Cycle 
At last, a catalytic cycle for this cobalt(III)-catalyzed C─H functionalization is proposed based on our 
mechanistic findings (Scheme 3.2.9). The BIES C─H activation is likely assisted by the carboxylate, 
which in situ forms the cationic cobalt(III)-carboxylate complex 50. After the metallacyle 176 is 
generated, coordination and insertion of alkyne 8 furnishes the key intermediate 177, then the 
following N─O bond cleavage and C─O bond formation generates the intermediate 178. Afterwards, 
the active cationic catalyst 50 is regenerated by a proto-demetalation, while the protected 
ortho-amino ketone 179 is also formed, which upon hydrolysis and subsequent intramolecular 
condensation provides the desired product 160. 




Scheme 3.2.9 Plausible catalytic cycle. 
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3.3 Overcoming the Limitations of C–H Activation with Strongly Coordinating 
N-Heterocycles by Cobalt Catalysis 
The synthesis of heterocycles has always attracted great attention in organic chemistry, because 
they widely exist in various pharmaceutical molecules and natural products.[163] Over the past few 
decades, transition metal-catalyzed C─H functionalization has emerged as one of the most powerful 
approaches for the synthesis and diversification of novel heterocycles.[164] However, in direct C─H 
activation, all nitrogen atoms present in heterocyclic substrates will strongly coordinate with metal 
catalysts, which in some cases could either activate an undesired C─H bond or poison the catalyst. 
Thus, the solution to achieving the control of positional selectivity in C─H activation will be a very 
meaningful topic in organic synthesis. But only one example was reported in 2014 by Yu and 
coworkers to achieve the position-selective C─H activation on heterocycles with different 
N-atoms.[146] Despite great success in cobalt(III)-catalyzed C─H functionalizations in recent years,[37a-c, 
37e, 37f] there is no example for cobalt catalysis which achieves the control of positional selectivity on 
substrates with strongly coordinating N-atoms. Therefore, the demand for a robust C─H activation 
achieving the positional selectivity on heterocycles by cobalt catalysis is highly desirable. 
3.3.1 Optimization of the Cobalt(III)-Catalyzed C–H Amidation of Imidates  
We initiated our studies by testing a variety of reaction conditions for cobalt(III)-catalyzed C─H 
amidation of ethyl benzimidate (161a) with 3-phenyl-1,4,2-dioxazol-5-one (162a) (Table 3.3.1). 
Firstly, the desired amidation product 163aa could be obtained in good yields with Cu(OAc)2 and 
NaOAc as the additives (entries 1, 2). However, a quantitative yield of the product could be 
obtained without any additives (entry 3). The catalyst loading and reaction temperature could be 
significantly decreased, which still furnished the desired product 163aa in excellent yields (entries 
3-6). Among a set of representative silver salts, AgSbF6 and AgBF4 provided the optimal results 
(entries 7-12). Moreover, the C─H amidation was achieved with Cp*Co(CO)I2 as the sole component 
catalyst in the absence of silver salts, albeit delivering the desired product 163aa in a lower yield 
(entry 13). Notably, no reactivity was observed using other typical cobalt catalysts or omitting the 
Cp*Co(Co)I2 catalyst (entries 14-16). It is noteworthy that the well-defined complex 
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[Cp*Co(CH3CN)3](SbF6)2 (180) was identified as a user-friendly single component catalyst, which 
also provided the desired product 163aa with high efficiency (entries 17 and 18). 
 
Table 3.3.1 Optimization of the Cobalt(III)-Catalyzed C–H Amidation of Imidate 
 
Entry [Co] / mol % Ag salt / mol % T / oC Yield[a] 
1 Cp*CoI2(CO) / 10 AgSbF6 / 20 120 81%
 [b, c, d] 
2 Cp*CoI2(CO) / 10 AgSbF6 / 20 120 85%
 [c, d] 
3 Cp*CoI2(CO) / 10 AgSbF6 / 20 120 99%
 [d] 
4 Cp*CoI2(CO) / 5 AgSbF6 / 10 120 99%
 [d] 
5 Cp*CoI2(CO) / 5 AgSbF6 / 10 100 99%
 [d] 
6 Cp*CoI2(CO) / 5 AgSbF6 / 10 80 83%
 [d] 
7 Cp*CoI2(CO) / 5 AgSbF6 / 10 100 99% 
8 Cp*CoI2(CO) / 5 AgBF4 / 10 100 96% 
9 Cp*CoI2(CO) / 5 AgPF6 / 10 100 99% 
10 Cp*CoI2(CO) / 5 AgOTf / 10 100 80% 
11 Cp*CoI2(CO) / 5 AgN(OTf)2 (10) 100 88% 
12 Cp*CoI2(CO) / 5 AgOTs / 10 100 19% 
13 Cp*CoI2(CO) / 5 -- 100 56% 
14 Co(OAc)2 / 5 AgSbF6 / 10 100 -- 
15 Co(acac)3 / 5 AgSbF6 / 10 100 -- 
16 -- AgSbF6 / 10 120 -- 
17 [Cp*Co(CH3CN)3] (SbF6)2 / 5 -- 100 94%
 [e] 
18 [Cp*Co(CH3CN)3] (SbF6)2 / 5 -- 100 96% 
[a] Reaction conditions: 161a (0.25 mmol), 162a (0.375 mmol), DCE (1.0 mL), T, 13 h, yields of 
isolated products are given. [b] Cu(OAc)2 (2.0 equiv). 
[c] NaOAc (20 mol %). [d] 180 (2.0 equiv). [e] 




3.3.2 Cobalt-Catalyzed C–H Amidation of Imidates 
 
Scheme 3.3.1 Cobalt-catalyzed C─H amidation of imidates 161. 
 
The scope of substrates was surveyed using the single component catalyst 180 (Scheme 3.3.1). A 
variety of substituents on the aryl ring of benzimidates 161 could directly couple with 162 in 
moderate to good yields. Various valuable functional groups, such as trifluoromethyl, fluoro, chloro, 
ester, ketone, and nitro, were also well tolerated under the optimized conditions (163ea-163ja). The 
meta-substituted benzimidates delivered the corresponding products at the less hindered C─H bond 
(163ka-163ma). It is worth mentioning that thiophene imidate 161n was also shown to be a suitable 
substrate and the desired product was obtained in 60% yield with high regioselectivity (163na). 
Next, we explored the generality of this cobalt(III)-catalyzed C─H amidation reaction with respect to 
dioxazolones 162. High yields were obtained with different alkyl- as well as heteroaryl-substituted 
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dioxazolones (162c-162e). Likewise, both electron-donating and electron-withdrawing groups, such 
as methoxy, methyl, chloro, fluoro, and nitro, were all compatible to react with benzimidate 161a, 
delivering the desired products in good to excellent yields (163af-163ak). 
3.3.3 Overriding the Conventional Selectivity Dictated by Strongly Coordinating Heterocycles 
Encouraged by the success of above results, more challenging benzimidate substrates 161 
containing strongly coordinating N-heterocyclic directing groups, were further investigated (Scheme 
3.3.2). To our delight, various strongly coordinating heterocycles, such as pyrazole, pyrimidine, 
pyrazine, and even pyridine, were fully tolerated for the cobalt(III)-catalyzed C─H amidation by 
imidate assistance, delivering the quinazolines 163 as the sole products. Moderate to good yields of 
the desired C─H annulation products were obtained with excellent positional and regioselectivity 
when meta- and para-pyrazole substituted benzimidates were applied to react with different 
dioxazolones. Benzimidate bearing a meta-pyrazole group showed good reactivity towards the less 
sterically hindered C─H bond (163la). Furthermore, we subsequently replaced the pyrazole by other 
groups, including the heterocylics adjacent to an O-atom, amide and pyridines, and moderate to 
good yields of the desired products were obtained with excellent positional selectivity 
(163na-163te). Remarkably, the competition experiments were performed by Dr. M. M. Lorion with 
various directing groups for this cobalt(III)-catalyzed C─H functionalization. The relative directing 
capabilities of N-heterocycles were found to decrease in the order: imidate ≥ pyridine ≈ pyrazole > 
oxazoline > pyrimidine. 
 
 




Scheme 3.3.2 Overriding the conventional selectivity dictated by strongly coordinating heterocycles. 
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3.3.4 Mechanistic Studies 
3.3.4.1 Positional Selectivity in Stoichiometric C–H Cobaltation 
Subsequently, the H/D exchange studies as to the positional selectivity of the key C─H activation 
step were carried out using the stoichiometric single-component catalyst 180 and then quenched 
with CD3CO2D (Scheme 3.3.3). Similar amounts of deuterium incorporation at ortho-position of 
both directing groups were detected after the treatment with CD3CO2D, when para-pyrazole, 
pyrimidine or pyridine substituted benzimidates were employed. These findings indicate that the 
positional selectivity is not determined in the C─H metalation, but the C─N bond-forming step is. 
 
Scheme 3.3.3 Positional selectivity in stoichiometric C─H cobaltation. 
3.3.4.2 Intermolecular Competition Experiments 
Additionally, intermolecular competition experiments showed that the electron-rich imidate 161d 
and dioxazolone 162g both were preferred for this cobalt(III)-catalyzed C─H amidation (Scheme 
3.3.4).  
 




Scheme 3.3.4 Intermolecular competition experiments. 
3.3.4.3 Kinetic Isotope Effect 
To gain deeper insight into the C─H activation mechanism, a KIE study by comparison of initial rates 
of independent reactions with substrates 161a and [D]5-161a was carried out (Scheme 3.3.5). A KIE 
of kH/kD ≈ 2.4 suggested a rate-limiting step of the C─H metalation likely to be operative. 
 
 
Scheme 3.3.5 Kinetic isotope effect. 
3.3.5 Proposed Catalytic Cycle 
Based on our mechanistic findings and literature precedestes on cobalt(III)-catalyzed C─H 
activation,[37b] a catalytic cycle of this reaction is proposed (Scheme 3.3.6). Presumably, the reaction 
involves a reversible and feasible C─H activation step which is indicated by the significant H/D 
exchange studies of positional selectivity. The elementary step of C─H activation possibly proceeds 
by BIES mechanism based on the competition experiment, showing a preference for electron-rich 
substrates. Subsequently, the intermediate 182 is generated by the coordination and migratory 
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insertion with dioxazolones 162, resulting in the C─N bond formation and CO2 extrusion. Finally, the 
desired product 163 is obtained through the intramolecular condensation following the amination 
product generation, along with the regeneration of the active cobalt(III) complex 181.  
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3.4 Domino C–H/N–H Allylation of Imidates by Cobalt Catalysis 
In modern synthetic chemistry, a green reaction is an increasingly attractive option to all chemists, 
which aims to provide the products with efficiency, while minimizing the generation of waste and 
avoiding the use of toxic reagents or solvents.[165] During the last few decades, the transition 
metal-catalyzed C─H functionalization has made great success in such transformations, because of 
its practicality and high atom economy.[8b, 166] With the increasing attention to environmental issues, 
we have to face the question of how to synthesize the desired products in a green manner. In this 
regard, domino reactions have the potential to simplify reactions by forming several bonds in a 
one-pot fashion, which allows for minimization of waste compared to the stepwise reactions.[167] 
Recent advances indicated that the direct C─H activation in combination with domino reactions 
showed great promises in sustainable chemistry.[168] However, precious metals such as palladium, 
rhodium, and iridium, have overwhelmingly dominated this field, which was inconsistent with the 
principles of green chemistry. With the advantages of Earth abundant metals, for example low price 
and low toxicity, we became interested in developing direct C─H domino reactions with 3d 
transition metals. Moreover, we had great success in cobalt(III)-catalyzed C─H annulation reactions 
recently.[37e] Therefore, we started to explore the possibility of developing direct cobalt(III)-catalyzed 
C─H domino reactions.  
3.4.1 Optimization of the Domino C–H/N–H Allylation of Imidate  
The optimization studies for the direct domino C─H/N─H allylation reaction were initiated by testing 
various solvents, which delivered the desired vinyl-substituted heteroarene 164aa. Initially, no 
reactivity or unsatisfactory yields of the desired product 164aa were observed (Table 3.4.1, entries 
1-5). In contrast, HFIP turned out to be the solvent of choice, resulting in the formation of the 
desired product in moderate yield (entry 6). Control experiments revealed that the C─H 
functionalization did not occur without the cationic cobalt(III)-catalyst or with other typical cobalt 
complexes (entries 7-9). Only trace amounts of the desired product were obtained in the absence of 
NaOAc (entry 10). By investigating different additives, we found that NaOAc was the optimal 
additive for this domino C─H/N─H allylation (entries 6, 10-16). To our delight, the reaction efficacy 
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could be improved by adding cocatalytic amounts of the Lewis acid BPh3 (entries 17, 18). 
Subsequently, several different cobalt(III) catalysts were tested for this domino reaction (entries 
19-22), and it turned out that the new single-component complex [Cp*Co(CH3CN)3](PF6)2 provided 
the highest catalytic efficacy. The complex [Cp*Rh(CH3CN)3](SbF6)2 failed in this domino C−H/N−H 
allylation reaction (entries 23, 24). 
 
Table 3.4.1 Optimization of the Domino C–H/N–H Allylation of Imidate 161a[a] 
 
Entry Catalyst Additive Solvent Yield[b] 
1 [Cp*Co(CH3CN)3](SbF6)2 NaOAc MeOH -- 
2 [Cp*Co(CH3CN)3](SbF6)2 NaOAc GVL -- 
3 [Cp*Co(CH3CN)3](SbF6)2 NaOAc TFE 13% 
4 [Cp*Co(CH3CN)3](SbF6)2 NaOAc PhCl 16% 
5 [Cp*Co(CH3CN)3](SbF6)2 NaOAc DCE 34% 
6 [Cp*Co(CH3CN)3](SbF6)2 NaOAc HFIP 50% 
7 -- NaOAc HFIP -- 
8 Co(OAc)2 NaOAc HFIP -- 
9 CoC2O4 NaOAc HFIP -- 
10 [Cp*Co(CH3CN)3](SbF6)2 -- HFIP < 2% 
11 [Cp*Co(CH3CN)3](SbF6)2 NaOPiv HFIP 34%
c 
12 [Cp*Co(CH3CN)3](SbF6)2 NaO2CAd HFIP 30% 
13 [Cp*Co(CH3CN)3](SbF6)2 CsOAc HFIP trace 
14 [Cp*Co(CH3CN)3](SbF6)2 Cu(OAc)2 HFIP 26% 
15 [Cp*Co(CH3CN)3](SbF6)2 HOPiv HFIP 22% 
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16 [Cp*Co(CH3CN)3](SbF6)2 HO2CAd HFIP 43% 
17 [Cp*Co(CH3CN)3](SbF6)2 NaOAc HFIP 36%
[c] 
18 [Cp*Co(CH3CN)3](SbF6)2 NaOAc HFIP 62%
[d] 
19 Cp*Co(CO)I2 NaOAc HFIP < 2%
[d,e] 
20 [Cp*Co(CH3CN)3](BF4)2 NaOAc HFIP 50%
[d] 
21 [Cp*Co(CH3CN)3](PF6)2 NaOAc HFIP 64% 
22 [Cp*Co(CH3CN)3](PF6)2 NaOAc HFIP 72%
[d] 
23 [Cp*Rh(CH3CN)3](SbF6)2 NaOAc DCE < 2% 
24 [Cp*Rh(CH3CN)3](SbF6)2 NaOAc HFIP < 2%
[d] 
[a] Reaction conditions: 161a (0.25 mmol), 110a (0.75 mmol), catalyst (5.0 mol %), additive (40 
mol %), solvent (1.0 mL), 55 °C, 16 h. [b] Yields of isolated products. [c] In(OTf)3 (40 mol %). 
[d] BPh3 
(40 mol %). [e] AgSbF6 (15 mol %). 
3.4.2 Scope of Cobalt(III)-Catalyzed Domino C–H/N–H Allylation 
3.4.2.1 Scope of Cobalt(III)-Catalyzed C–H Allylation 
With the optimized catalytic reaction conditions being identified, we tested the versatility of the 
cationic Cp*Co(III)-catalyzed C─H allylation towards the synthesis of vinyl-substituted 
3,4-dihydroisoquinolines 164 with various imidates 161 (Scheme 3.4.1). Thus, aryl-substituted 
imidates bearing various electron-donating and electron-withdrawing groups at different positions 
reacted smoothly with 110a, affording the corresponding products in moderate to good yields. 
Moreover, the catalytic system also tolerated various functional groups on the arene part such as 
halides, ester, ketone and amide substituents, which can be easily transformed into other 
functionalities. Notably, an increased level of catalytic efficacy was achieved with the Lewis acid 
BPh3. The alkoxy-substituted benzimidates 110b and 110w were also well tolerated under the 
optimized conditions, delivering the allylation products in good yields. Likewise, the reaction system 
displayed a good reactivity when different substituted dioxolanones were examined (164ab-164ad). 
 




Scheme 3.4.1 Scope of the domino C─H/N─H allylation. [a] Without BPh3. 
3.4.2.2 Scope of Cobalt(III)-Catalyzed C–H Allylation with meta-Substituted Imidates 
 
Scheme 3.4.2 Scope of cobalt(III)-catalyzed C–H allylation with meta-substituted imidates. [a] 
Without BPh3. 
 
The intramolecular competition experiments with meta-substituted arylimidates 161m, 161x and 
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161l bearing two different ortho-C─H bonds showed excellent selectivity for the sterically less 
hindered position and delivered the products 164ma, 164xa and 164la in moderate yields. In 
contrast, the meta-fluoro substituted imidate 161y reacted preferentially at the more sterically 
hindered position, providing compound 164ya as the sole product in 67% yield (Scheme 3.4.2). 
3.4.3 Key Mechanistic Findings 
3.4.3.1 Intermolecular Competition Experiments 
Intermolecular competition experiments were performed between electron-rich and 
electron-deficient benzimidates under the optimal conditions (Scheme 3.4.3). As a result, the 
electron-rich substrates 161d and 161c reacted preferrentally in this C─H/N─H allylation reaction, 
which is in good agreement with a BIES-type C─H activation. 
 
Scheme 3.4.3 Intermolecular competition experiments. 
3.4.3.2 H/D Exchange and KIE Studies 
In order to further investigate the reaction mechanism of the C─H activation step, a series of 
important test reactions was thereafter conducted, including H/D exchange, inter- and 
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intra-molecular KIE experiments (Scheme 3.4.4). 
 
Scheme 3.4.4 H/D exchange and KIE studies. 
 
The H/D exchange experiment was performed in CF3CHOD as the reaction solvent under the 
optimal conditions. As a result, a minor H/D exchange in ortho-position of product 164aa was 
observed (a). The kinetic isotope effect of the cobalt(III)-catalyzed C─H/N─H annulation was studied 
with labeled substrate [D]5-161a by independent experiment, resulting in a value of kH/kD ≈ 2.9 (b). 
In addition, a one-pot intermolecular KIE experiment showed a similar result of kH/kD ≈ 2.7 (c). 
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Furthermore, an intramolecular KIE of kH/kD ≈ 2.6 was observed, which is in good agreement with 
the above mentioned results of the intermolecular KIE experiments (d). The mechanistic studies 
indicated that the C─H activation step is the rate-limiting step of the catalytic cycle. 
3.4.4 Proposed Catalytic Cycle 
Based on the mechanistic observations, a plausible mechanism was proposed for the 
cobalt(III)-catalyzed C─H functionalization (Scheme 3.4.5). Initially, benzimdate 161 undergoes the 
C─H metalation with single-component cationic cobalt(III) catalyst, forming intermediate 187. Then, 
coordination of 4-vinyl-1,3-dioxolan-2-one 110a and migratory insertion into the cobalt─carbon 
bond generates complex 188, which undergoes extrusion of CO2 to form intermediate 189. 
Subsequently, the desired product 164 is obtained through an intramolecular cyclization by 
nucleophilic attack of the N-atom with the help of cobalt(III) catalyst and BPh3. Finally, the active 
cationic cobalt(III) catalyst is regenerated by the reaction with acetic acid, which was formed in the 
initial C─H metalation step. 
 
Scheme 3.4.5 Proposed catalytic cycle. 
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3.4.5 Diversification of Vinylated Heteroarenes 
Finally, the utility of the obtained vinyl-substituted heteroarenes 164 was investigated (Scheme 
3.4.6). Hydrolysis of product 164aa provided access to vinyl-substituted dihydroisoquinolone 
derivatives 191. Furthemore, acetylated isoquinoline 192 was obtained in 76% yield through Wacker 
oxidation conditions.[169]  
 
Scheme 3.4.6 Diversification of vinylated heteroarenes 164. 
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3.5 Air-Stable Manganese(I)-Catalyzed C–H Activation for Decarboxylative C–H/C–O 
Cleavages in Water 
The allyl structural unit has proven to be a very useful building block in organic synthesis, which is 
widely found in natural products, pharmaceuticals and agrochemicals.[65] Recent developments in 
transition metal-catalyzed C─H allylation provided attractive approaches that streamlined the 
synthesis of allylic compounds without the need for pre-functionalizations.[170] However, in most of 
these methods, expensive and rare 4d or 5d transition metals, such as rhodium, palladium, iridium, 
and ruthenium, are necessary. In contrast, 3d metals, such as cobalt, manganese, nickel, and iron 
are typically cheap and Earth-abundant.[35b] In this regard, developing an alternative allylation 
reaction by replacing these noble metal catalysts by inexpensive ones is highly desirable. With the 
emergence of the concept of green chemistry, a mild and environmentally-benign reaction is 
considerably attractive.[29] Consequently, a reaction explored in water, under air, and by using 3d 
metal would be an ideal option. Based on our great achievement in manganese-catalyzed 
substitutive C─H allylation of arenes,[83] we now are interested in exploring the possibility of 
air-stable manganese-catalyzed decarboxylative C─H/C─O cleavages in water. 
3.5.1 Optimization of Decarboxylative C–H/C–O Activation 
We initiated our studies with 1-(pyridin-2-yl)-1H-indole (41a) and 4-vinyl-1,3-dioxolan-2-one (110a) 
as model substrates and optimized the reaction conditions (Table 3.5.1). Initially, we probed various 
solvents for the envisioned manganese(I)-catalyzed C─H activation. We found that the solvent plays 
a significant role in promoting the reaction efficiency. As a result, the polar solvents TFE and H2O 
displayed highest reactivities with good diastereoselectivities (entries 1-9). No reaction was 
observed in the absence of the manganese catalyst (entry 10). Moreover, other manganese sources, 
such as MnCl2, MnBr2, and Mn2(CO)10, were also not applicable to this C─H/C─O allylation reaction 
(entries 10-13). It should be noted that this manganese(I)-catalyzed C─H activation was not only 
tolerant towards water, but also delivered good results under an atmosphere of air (entry 14). Next, 
the effect of different bases was explored for the reaction. Trace amounts of the product 111aa 
were observed when the strong base K2CO3 was used (entry 15). Organic bases like Cy2NH or 
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monoprotected amino acid only provided the desired product in low yields (entries 16, 17). A lower 
catalyst loading (2.5 mol %) was tested for this reaction, affording the allylated product 111aa in 79% 
yield (entry 18). Importantly, a slight decrease of the catalytic activity was observed when the 
reaction temperature was decreased to 80 °C. Even at 60 °C, we could still obtain the desired 
product in 80% yield, reflecting the robustness of the manganese(I) catalysis system for this C─H 
transformation (entries 19, 20). 
 
Table 3.5.1 Optimization of decarboxylative C–H/C–O activation. 
 
Entry Catalyst Additive Solvent Yield[a] E/Z 
1 MnBr(CO)5 NaOAc Et2O 92%
[b] 5.5 
2 MnBr(CO)5  NaOAc nBu2O 85%
[b] 1.8 
3 MnBr(CO)5  --- nBu2O 21%
[b] 3.5 
4 MnBr(CO)5  NaOAc MeCN 21%
[b] 1.9 
5 MnBr(CO)5  NaOAc CH2Cl2 77%
[b] 2.4 
6 MnBr(CO)5 NaOAc 1,4-dioxane 90%
[b] 1.4 
7 MnBr(CO)5 NaOAc TFE 92%
[b] 5.1 
8 MnBr(CO)5 NaOAc DCE 84%
[b] 2.8 
9 MnBr(CO)5 NaOAc H2O 93%
[b] 6.4 
10 -- NaOAc H2O --
[b] -- 
11 MnCl2 NaOAc H2O --
[b] -- 
12 MnBr2 NaOAc H2O --
[b] -- 
13 Mn2(CO)10 NaOAc H2O <5%
[b,c,d] -- 
14 MnBr(CO)5 NaOAc H2O 94% 5.9 
15 MnBr(CO)5 K2CO3 H2O <10%
[d] -- 
16 MnBr(CO)5 Cy2NH H2O 24% 6.4 
17 MnBr(CO)5 Piv-Val-OH H2O 46% 5.7 
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18 MnBr(CO)5 NaOAc H2O 79%
[c,e] 5.7 
19 MnBr(CO)5 NaOAc H2O 84%
[f] 5.9 
20 MnBr(CO)5 NaOAc H2O 80%
[g] 5.9 
[a] Reaction conditions: 41a (0.25 mmol), 110a (0.75 mmol), catalyst (10 mol %), additive (20 mol %), 
solvent (1.0 mL), under air, 100 °C, 16 h, isolated yield. [b] Under N2. 
[c] NaOAc (10 mol %). [d] GC 
conversation. [e] MnBr(CO)5 (5 mol %). 
[f] 80 °C. [g] 60 °C.  
 
3.5.2 Scope of Manganese(I)-Catalyzed C–H/C–O Activation  
3.5.2.1 Scope of Manganese(I)-Catalyzed Allylation of Indoles  
With the optimized reaction conditions in hand, we explored the scope of the 
manganese(I)-catalyzed C─H/C─O activation on differently substituted indoles 41 in H2O or TFE 
(Scheme 3.5.1). Notably, various functional groups, such as halogens, hydroxyl, ester and ketone, 
were fully tolerated in the reaction conditions. Aryl-substituted indoles bearing electron-donating 
and electron-withdrawing groups at different positions all reacted smoothly with 
4-vinyl-1,3-dioxolan-2-one 110a, delivering the allylated products in moderate to good yields with 
good E/Z ratio. Moreover, sterically demanding substituents in C-3 position were investigated. When 
TFE was chosen as the reaction solvent, the desired products were obtained in good yields 
(111la-111na, 111pa). However, the allylation of 3-methyl-substituted indole 41m gave a lower 
yield of the desired product 111ma in H2O, probably due to the low solubility of the substrate 41m 
in H2O. In addition, 2-phenylpyridine was also shown to be a viable substrate and the desired 
product 111qa was obtained in 64% yield. 




Scheme 3.5.1 Scope of manganese(I)-catalyzed allylation of indoles. E/Z ratio in parentheses. [a] TFE 
as the solvent.  
3.5.2.2 Scope of Manganese(I)-Catalyzed Allylation with Dioxolanones 110 
Subsequently, we also examined the applicability towards a representative set of vinylated 
dioxolanones 110 (Scheme 3.5.2). Notably, our method was compatible with different substitution 
pattern on dioxolanones and provided secondary and tertiary allylic alcohol products 111 in good 
yields with high diastereoselectivities. A variety of functional groups was also well tolerated, such as 
halogens, and even in case of the challenging nitro-substituent, a 79% yield of the desired product 
111ae was obtained. 




Scheme 3.5.2 Scope of manganese(I)-catalyzed C–H/C–O allylation with dioxolanones 110. 
3.5.3 Manganese(I)-Catalyzed C–H/C–O Functionalization of Tryptophan and Ketimines  
Furthermore, the synthetic utility of the manganese(I)-catalyzed C–H activation strategy was 
reflected by the direct modification of tryptophan 41r and 41s, delivering the desired products 
111ra and 111sa in good yields without racemization (Scheme 3.5.3a). Motivated by the range of 
tolerated indoles and tryptophan derivatives, the applicability was further investigated by testing a 
variety of synthetically useful ketimines 34 (Scheme 3.5.3b). Remarkably, electron-rich as well as 
electron-deficient ketimines reacted smoothly and furnished the ketone products 165 in good yields 
with excellent diastereoselectivities. The position-selectivity of meta-substituted ketimines 34i and 
34k was controlled by steric interactions, delivering the ketones 165ia and 165ka as sole products in 
60%, and 85% yields, respectively. These results highlighted a broad applicability and excellent 
functional group tolerance of this manganese(I) catalytic system. 
 




Scheme 3.5.3 Manganese(I)-catalyzed C–H/C–O functionalization of tryptophan 41 and ketimines 34. 
[a] In H2O. 
3.5.4 Key Mechanistic Findings 
3.5.4.1 H/D Exchange Experiment 
In order to delineate the manganese catalyst’s mode of action, a series of mechanistic studies was 
performed. Firstly, a H/D exchange experiment in the presence of isotopically labeled D2O was 
conducted (Scheme 3.5.4). A significant H/D exchange was observed in C-2 position of the 
re-isolated starting material [D]n-41a, indicating a reversible C─H activation elementary step to be 
operative.  
 




Scheme 3.5.4 H/D exchange experiment. 
3.5.4.2 Intermolecular Competition Experiment 
Then, an intermolecular competition experiment was carried out by comparing the reaction rates 
between electronically differentiated ketimines 34a and 34d (Scheme 3.5.5). This result showed a 
minor preference for the electron-deficient substrate under the optimized conditions.  
 
Scheme 3.5.5 Intermolecular competition experiment. 
3.5.4.3 Decarboxylative C–H/C–O Activation with Cyclometalated Complex 193 
The organometallic complex 193 was independently prepared by the C–H activation of 
stoichiometric amounts of MnBr(CO)5 with substrate 41a. Remarkably, complex 193 showed a high 
reaction efficiency to afford the allylic alcohol products 111 not only in a catalytic reaction, but also 
in a stoichiometric experiment (Scheme 3.5.6). Overall, these results showed that this manganese 
cyclometalated complex probably is a key intermedate in the catalytic cycle. 
 




Scheme 3.5.6 Decarboxylative C─H/C─O activation with cyclometalated complex 193. 
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3.6 Synergistic Manganese(I) C–H Activation Catalysis in Continuous Flow: 
Chemoselective Hydroarylation 
In recent years, the number and types of reactions performed in continuous flow have grown 
substantially, which were already widely applied to many fields, such as catalytic reactions, green 
chemistry, pharmaceutical and fine chemical industries due to the number of benefits, including: 1) 
improved process safety, 2) increased product quality and yield, 3) decreased reaction time, and 4) 
easy scale-up of chemical reactions.[150] In addition, significant processes in transition 
metal-catalyzed C─H activation also have been achieved during last few decades.[8, 13b] However, 
metal-catalyzed C─H activation in combination with continuous flow technology thus far has proven 
elusive. Only a few examples in this field have been very recently reported by Ackermann[171] and 
Noël[172]. In addition, from a sustainable perspective, Earth abundant 3d metals as the catalyst for 
C─H activation would be highly desirable. Based on our previous studies on C─H 
functionalizations,[160, 173] we hence became interested in developing a chemoselective 
manganese(I)-catalyzed C─H hydroarylation in continuous flow.  
3.6.1 Optimization of Synergistic Hydroarylation in Flow 
The optimization studies were commenced by probing the feasibility of the manganese(I)-catalyzed 
C─H hydroarylation of substrate 41b with 4-ethynyl-4-methyl-1,3-dioxolan-2-one (166a) in 
continuous flow. Efforts towards the chemo-selective hydroarylation product 167ba, being fully 
tolerant of β-O leaving groups, were optimized (Table 3.6.1). No reaction took place at 60 °C in the 
presence of NaOAc (entry 1). However, when we increased the reaction temperature to 100 °C, 56% 
of the allene product was obtained (entry 2). Similar results were observed with Cy2NH as organic 
base or without additives (entries 3-4). When we chose (nBu)4NOAc as the additive, the desired 
product 167ba was obtained in 26% yield (entry 5). A significant breakthrough was made by using 
acidic conditions. The use of pivalic acid furnished the desired hydroarylation product in good yield 
without formation of the allene product (194) (entry 6). Subsequently, we tried to optimize the flow 
rate with HOPiv as the additive. As a result, a longer residence time of the reaction in flow resulted 
in a slightly higher performance (entries 7-10). Notably, the reaction temperature played a major 
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role in the reaction (entry 11). Moreover, the high yields of the hydroarylation product were 
obtained with HOAc as the additive (entries 12-15). Switching to toluene or DCE as the reaction 
solvent, reducing the catalyst loading or decreasing the reaction temperature resulted in a 
significant decrease in the yield of the desired product 167ba (entries 16-19). At last, the product 
was not observed in the absence of the manganese catalyst (entry 20). 
 
Table 3.6.1 Optimization of synergistic hydroarylation of 41b in flow 
 
Entry Additive Solvent Rate / (µL/min) T / °C 
Yield[a] 
167ba 194 
1 NaOAc 1,4-dioxane 100 60 -- -- 
2 NaOAc 1,4-dioxane 500 100 trace 56% 
3 Cy2NH 1,4-dioxane 500 100 -- 32% 
4 -- 1,4-dioxane 500 100 -- 63% 
5 (nBu)4NOAc 1,4-dioxane 500 100 26% 40% 
6 HOPiv 1,4-dioxane 500 100 71% -- 
7 HOPiv 1,4-dioxane 150 100 85% -- 
8 HOPiv 1,4-dioxane 200 100 87% -- 
9 HOPiv 1,4-dioxane 250 100 80% -- 
10 HOPiv 1,4-dioxane 300 100 75% -- 
11 HOPiv 1,4-dioxane 500 80 trace -- 
12 HOAc 1,4-dioxane 200 100 93% - 
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13 HOAc 1,4-dioxane 300 100 92% -- 
14 HOAc 1,4-dioxane 500 100 95% -- 
15 HOAc 1,4-dioxane 1000 100 82% -- 
16 HOAc toluene 500 100 25% -- 
17 HOAc DCE 500 100 24% -- 
18 HOAc 1,4-dioxane 500 80 57% -- 
19[b] HOAc 1,4-dioxane 500 100 61% -- 
20[c] HOAc 1,4-dioxane 500 100 -- -- 
[a] Reaction conditions: 41b (0.25 mmol), 166a (0.50 mmol), MnBr(CO)5 (10.0 mol %), additive (20.0 
mol %), solvent (1.0 mL), under air, T, isolated yield. [b] MnBr(CO)5 (5.0 mol %) was used. 
[c] Without 
MnBr(CO)5. 
3.6.2 Scope of Synergistic C–H Activation in Flow 
3.6.2.1 Scope of C–H Activation of the Heteroarenes 41 in Flow 
Having established the optimized catalytic system, we explored the generality and scope of various 
indoles 41 for the manganese(I)-catalyzed C─H hydroarylation in continuous flow (Scheme 3.6.1). 
Notably, these results showed a broad substrate applicability and excellent tolerance towards 
various functional groups, such as halogens, cyano, ester and carboxylic acid, which delivered the 
corresponding products in moderate to good yields. It should be noted that the C-3 substituted 
sterically hindered substrates 41m, 41n, and 41t were found to be suitable for this flow C─H 
alkenylation and furnished the desired products 167ma, 167na, and 167ta in good yields. Moreover, 
the heterocyclic substrate 41d’ also underwent this process smoothly, affording the desired product 
167d’a in good yield with high chemo- and regio-selectivity. Remarkably, this flow C─H 
hydroarylation reaction could be conducted within only one minute at 150 °C, which demonstrated 
the major advantage of flow chemistry, avoiding the use of high-pressure sealed-tube equipment. 




Scheme 3.6.1 Synergistic C─H activation of the heteroarenes 41 in flow. [a] 150 °C, 1 min. 
 
3.6.2.2 Scope of C–H Hydroarylation with Propargylic Alkynes 166 in Flow 
 
Scheme 3.6.2 C─H activation/hydroarylation with the propargylic alkynes 166 in flow. 
 
Motivated by the success in the synergistic C─H activation with a wide range of heteroarenes 41, we 
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next tested the effect of propargylic alkynes 166 on the reaction process (Scheme 3.6.2). As 
expected, substituted propargylic alkynes 166 were also viable in this flow reaction, delivering the 
desired products in good yields with excellent levels of chemo-selectivity. Additional dioxolanone 
alkynes were tested by Dr. Pesciaioli.[152] 
3.6.3 Key Mechanistic Findings 
3.6.3.1 Intermolecular Competition Experiment 
To further understand the mechanism of this unique manganese(I)-catalyzed C─H hydroarylation, a 
set of experiments was carried out to delineate its mode of action. Firstly, an intermolecular 
competition experiment between electronically distinct substrates 41e’a and 41xa was performed 
(Scheme 3.6.3). The result showed that the electron-rich substrate 41e’a reacted preferentially 
under the reaction conditions (Scheme 3.6.3). 
 
Scheme 3.6.3 Intermolecular competition experiment. 
3.6.3.2 H/D Exchange Experiments 
Furthermore, H/D exchange studies were conducted in the presence of isotopically labeled acetic 
acid as the additive. A notable H/D scrambling in C-2 position of the re-isolated starting material 
41b was observed, indicating a reversible C─H metalation to be operative. Importantly, a deuterium 
incorporation of 65% in the β-position of the product [D]n-167ba was also observed. In contrast, no 
H/D exchange in the C-3 position of the product 167ba as well as the re-isolated starting material 
was detected (Scheme 3.6.4a). The catalytic reaction of deuterated substrate [D]1-41b further 
supported that the β-proton source of the product 167ba is from the C-2 position of indole 
substrate 41b, when catalytic amount of acetic acid was used (Scheme 3.6.4b). 




Scheme 3.6.4 H/D exchange experiments.  
 
3.6.3.3 C–H Activation/Hydroarylation with Complex 195 
 
Scheme 3.6.5 C─H activation/hydroarylation with complex 195. n.d. = no reaction. 
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At last, in order to elucidate the nature of the active manganese catalyst, the performance of 
cyclometalated complex 195 was investigated in stoichiometric and catalytic reactions (Scheme 
3.6.5). Interestingly, the stoichiometric reaction was conducted in absence of acetic acid, delivering 
only allene 194 in 46% yield by β-O elimination without any hydroarylation product being observed 
(Scheme 3.6.5a). In contrast, under acidic conditions, the cyclometalated complex 195 only afforded 
the hydroarylation product 167ba in 48% yield (Scheme 3.6.5b). Moreover, complex 195 showed a 
very high activity in the catalytic reaction in the presence of a catalytic amount of acetic acid and 
the desired product in almost quantitative yield (Scheme 3.6.5c). These results showed that this 
complex 195 could play a very important role in the manganese catalytic cycle. 
3.6.4 Continuous Flow Manganese-Catalyzed C–H Activation on Scale and Catalyst Separation 
 
Scheme 3.6.6 Continuous flow manganese-catalyzed C─H activation on scale and catalyst 
separation. 
 
In addition, the continuous flow C─H activation was conducted on a gram scale, and the desired 
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product 167ba could be obtained in excellent yield with high chemo-selectivity, reflecting the robust 
and efficient manganese catalysis (Scheme 3.6.6a). Furthermore, we developed a convenient 
separation strategy for removing the manganese catalyst by using different types of resins (Scheme 
3.6.6b). Further applications of this new technology in organic synthesis are still under investigation. 
3.6.5 Late-Stage Modifications of Product 167 
Finally, in order to demonstrate the unique synthetic utility of the obtained allylic carbonates 167, a 
large number of diversification reactions were carried out (Scheme 3.6.7). Notably, the 
hydroarylation product could be easily transformed into other useful compounds. Firsty, compound 
167ba was hydrolyzed by treatment with sodium hydroxide in 1,4-dioxane to afford the 1,2-diol 
product 196 in near to quantitative yield (a). Additionally, decarboxylation of 167ba provided the 
product 197 in 88% yield with palladium as catalyst (b).[174] Interestingly, when 167ba was reacted 
with Grignard reagent under copper catalysis, 1,3-diene product 198 was obtained (c).[175] Finally, 
nucleophilic substitution of compound 167ba by aniline catalyzed by palladium with DPEphos as the 
ligand smoothly provided product 199 in good yield (d),[176] which was performed by Dr. Pesciaioli.  
 
Scheme 3.6.7 Late-stage modifications of product 167ba. 
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3.7 Versatile and Robust C–C Activation by Chelation-Assisted Manganese-Catalysis 
Transition metal catalysis has emerged as an important and straightforward method for the 
syntheses of complex molecules, which are very useful in pharmaceutical and fine chemical 
industries.[119d, 177] Direct C─C bond cleavage by transition metal complexes has recently attracted 
considerable attention, in consequence of the potential applications to organic synthesis.[119b-d] An 
ideal reaction should be performed with high atom economy at low reaction temperature and 
pressure, minimizing the waste, and using Earth-abundant elements, such as water as the solvent 
and 3d metal as the catalyst. Although great breakthroughs in direct C─C functionalization have 
been achieved, there are still many challanges in this field, including 1) requirement of harsh 
conditions; 2) relying on the strained or polarized C─C bonds;[178] 3) using noble metals as the 
catalysts, especially rhodium,[179] ruthenium,[153] and palladium;[180] 4) often the mechanism is not 
fully understood; and 5) limited substrate scopes. In this context, here we will focus on a distinct 
approach, which would carry out the C─C functionalization in water with Earth-abundant 
manganese as the catalyst relying on a β-carbon elimination step.[135-136]  
3.7.1 Optimization of Manganese-Catalyzed C–C Cleavage 
Initially, we examined the reaction of 2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) with 
4-vinyl-1,3-dioxolan-2-one (110a) at 120 °C in the presence of MnBr(CO)5 as the catalyst by 
screening various solvents (Table 3.7.1, entries 1-6). Remarkably, nontoxic and nonflammable water 
turned out to be the optimal solvent for this manganese(I)-catalyzed C–C activation (entry 6). In 
contrast, other polar solvents, such as nBuOH and GVL, shut down the reaction completely (entries 
4 and 5). It was further shown that the addition of acid or base was not required for the reaction 
(entries 7 and 8). A decreased yield of the desired product was observed when lower or higher 
reaction temperature was employed (entries 9-11). It was found that attempts to lower the catalyst 
loading, led to a significant decrease in reactivity (entry 12). No reaction was observed without 
MnBr(CO)5 catalyst or with other manganese sources (entries 13-16). Furthermore, control 
experiments clearly showed that the manganese catalyst is unique and robust for this C–C 
functionalization, while other metals, such as palladium, rhodium, ruthenium, copper, and iron 
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complexes, failed to deliver the desired product 111aa (entries 17-23).  
 
Table 3.7.1 Optimization of manganese-catalyzed C–C cleavage 
 
Entry TM T / °C Solvent Yield[a] E/Z 
1 MnBr(CO)5 120 1,4-dioxane 65% 2.6 
2 MnBr(CO)5 120 toluene 63% 2.1 
3 MnBr(CO)5 120 DCE 71% 3.5 
4 MnBr(CO)5 120 nBuOH --- --- 
5 MnBr(CO)5 120 GVL --- --- 
6 MnBr(CO)5 120 H2O 75% 4.9 
7 MnBr(CO)5 120 H2O 17%
[b] 4.3 
8 MnBr(CO)5 120 H2O ---
[c] --- 
9 MnBr(CO)5 100 H2O 62% 4.5 
10 MnBr(CO)5 140 H2O 65% 5.1 
11 MnBr(CO)5 80 H2O 45% 4.6 
12 MnBr(CO)5 120 H2O 59%
[d] 4.1 
13 --- 120 H2O --- --- 
14 MnCl2 120 H2O --- --- 
15 Mn(OTf)2 120 H2O --- --- 
16 Mn2(CO)10 120 H2O --- --- 
17 Pd(OAc)2 120 H2O --- --- 
18 [Rh(COD)Cl]2 120 H2O --- --- 
19 [RuCl2(p-cymene)]2 120 H2O trace --- 
20 Cu(IPr)Cl 120 H2O -- -- 
21 CpFe(CO)2I 120 H2O -- -- 
22 [Cp*RhCl2]2 120 H2O --
[e] -- 
23 [Cp*RhCl2]2 120 1,4-dioxane --
[e] -- 
[a] Reaction conditions: 168a (0.25 mmol), 110a (0.50 mmol), [TM] (10 mol %), additive (20 mol %), 
solvent (1.0 mL), under N2, 16 h, isolated yield. 
[b] NaOAc (20 mol %). [c] HOPiv (20 mol %). [d] 
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MnBr(CO)5 (5.0 mol %). 
[e] [Cp*RhCl2]2 (5.0 mol %). TM = transition metal. 
3.7.2 Effect of Different Leaving Groups 
Subsequently, the effect of the leaving group at the substrate moiety under the optimized 
conditions was investigated (Scheme 3.7.1). As a result, the substrates 200 with arene groups 
reacted smoothly, delivering the desired products 111aa in moderate yields, while other secondary 
alcohols 200e-200g failed to achieve the C─C functionalization. It proves that the arene group of the 
secondary alcohol substrates is essential for the manganese-catalyzed C─C activation. It is 
noteworthy that ether 200h, ketone 200i, and acid 200j were not suitable leaving groups for the 
C─C activation reaction. 
 
Scheme 3.7.1 Effect of leaving groups. E/Z ratio in parentheses. 
3.7.3 Substrate Scope of C–C Functionalization in Water 
3.7.3.1 Scope of Manganese(I)-Catalyzed C–C Allylation in Water 
With the optimized catalytic system in hand, we evaluated the scope of the manganese(I)-catalyzed 
C–C functionalization with diversely decorated arenes 168 (Scheme 3.7.2). Notably, different 
directing groups, such as pyrazoles, pyridines and indazoles, could be smoothly converted in water. 
In addition, various valuable functional groups, such as bromo, amido and hydroxo, were well 
tolerated in this manganese catalytic system. Moreover, the manganese-catalyzed C–C activation 
protocol was not limited to the allylic alcoholic products 111ca. Indeed, allylic amides could be also 
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obtained in good yields (111cg, 111dg, 111gg and 111hg). The substituted propargylic alkene 110b 




Scheme 3.7.2 Manganese(I)-catalyzed C─C allylation by chelation assistance. E/Z ratio in parenthesis. 
[a] PhCHO as leaving group. 
3.7.3.2 Manganese(I)-Catalyzed C–C Activation for Additions of Alkynes in Water 
Likewise, the versatile C–C activation was accomplished with various alkynes 8 under otherwise 
identical reaction conditions (Scheme 3.7.3). At first, ortho- and para-substituted phenylacetylenes 
(8), including electron-donating and electron-withdrawing groups, were efficiently converted into 
the alkenylation products 74 with excellent diastereoselectivity. Importantly, the 
3-ethynylthiophene (8t) and dec-1-yne (8u) underwent this catalytic process with good catalytic 
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efficacy as well. It should be noted that the C–C activation was not limited to the internal alkynes, 
but terminal alkynes were also shown to be viable substrates and furnished the thermodynamically 
more stable isomer in good yields (74ca-74cj). The reaction of 2-[2-(pyridin-2-yl)phenyl]propan-2-ol 
(168j) also gave the corresponding products 74jo and 74jv in good yields with high 
diastereoselectivities. Finally, the manganese(I)-catalyzed C–C activation was also applied to amino 
acid (8w) and steroid (8x), affording the desired products in good yields without any racemization 
(74jw and 74jx).   
 
 
Scheme 3.7.3 Manganese(I)-catalyzed C–C activation for additions of alkynes 8 in water. 
3.7.3.3 Manganese(I)-Catalyzed C–C Activation with Alkenes in Water 
To our delight, the C–C hydroarylation manifold was not restricted to the alkynes 8, but the alkenes 
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11 were also identified as competent substrates, again featuring water as the ideal solvent. The 
manganese catalyst turned out to be efficient and widely applicable for this C─C hydroarylation 
reaction, furnishing the corresponding products in good to excellent yields (Scheme 3.7.4). The 
reaction of substrates 168k and 168l could be performed on 5.0 mmol scale as well and provided 
the alkylated products in comparable yields (102kf and 102lf). Moreover, the reaction with 
α,β-unsaturated ketone 11h also proceeded to give the desired product 102ch in 76% yield.   
 
 
Scheme 3.7.4 Manganese(I)-catalyzed C─C activation with alkenes 11 in water. 
3.7.3.4 Scope of Manganese(I)-Catalyzed C–C Allylation to Synthesize α,-Unsaturated Esters 
Furthmore, we also developed a new allylation reaction using various allylic reagents that provided 
expedient access to useful α,-unsaturated esters 201 (Scheme 3.7.5). Notably, this transformation 
showed a good functional group tolerance and high regio-selectivity. It was demonstrated that the 
electron-withdrawing substrates 168m and 168n could react smoothly to provide the allylation 
products in good yields (202ma and 202na). The challenging substrate 201b was also found to be 
reactive under the newly developed conditions (202ab). This remarkable C–C functionalization 
could be achieved by reacting with various alkenes 11, 201 and alkynes 8 in moderate to good yields 
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with good diastereoselectivies.  
 
 
Scheme 3.7.5 Manganese(I)-catalyzed C–C allylation. 
3.7.4 Position-Selective Manganese(I)-Catalyzed C–C Activation Highlighting Unique Benefits over 
C–H Activation 
3.7.4.1 Position-Selective Manganese(I)-Catalyzed C–C Activation 
In order to overcome the limitations in the synthetic utility of the reaction, we here highlighted the 
unique C–C activation strategy by achieving the position-selectivity for the synthesis of 
1,2,3-tri-substituted arenes 204, 205 and 206 (Scheme 3.7.6). As we expected, these products could 
not be obtained by a C–H activation process, instead the 1,2,5-tri-substituted isomers were formed 
by steric control in very low yields (Scheme 3.7.7). Both terminal and internal alkynes 8 afforded the 
1,2,3-tri-substituted products in moderate to good yields (a). High yields of the position-selective 
allylic products 205aa and 205ab were obtained from the reaction with substrates 201a and 201b 
(b). The desired allylic alcohol product 206 also could be obtained in 46% yield with good 
diastereoselectivity (c). 





Scheme3.7.6 Position-selective manganese(I)-catalyzed C–C activation. 
3.7.4.2 Manganese(I)-Catalyzed C–H Activation 
In contrast, the C–H bond activation, which was performed in the presence of acetic acid, with 
phenylacetylene (8o) and 4-vinyl-1,3-dioxolan-2-one (110a) furnished 1,2,5-tri-substituted products 
74co, 74do, and 111ca in low yields without any observation of 1,2,3-tri-substituted products 
(Scheme 3.7.7). These results reflected the unique benefits of the C–C activation strategy over the 
C–H process.  




Scheme 3.7.7 Manganese(I)-catalyzed C–H activation. [a] 20 mol % [MnBr(CO)5] was used. 
3.7.5 Key Mechanistic Findings 
3.7.5.1 C–C versus C–H Activation Experiments 
In order to showcase the benefits of the position-selective manganese(I)-catalyzed C–C activation, a 
set of mechanistic study experiments was conducted (Scheme 3.7.8). Firstly, C─C hydroarylation 
with the labelled substrate [D]1-168j did not lead to D/H scrambling, making a C─H activation 
unlikely (a). When the labelled compound [D]5-20b was tested in the absence of substrate 11f under 
the optimized conditions, we could still get 92% D incorporation at ortho-C─H position (b). When 
substrate 20a was reacted under the C─C activation conditions, it failed to furnish the C─H 
activation product 102jf (c). Lastly, an intermolecular competition experiment between substrate 
168c and arene 20e was investigated. The desired product 102cf was obtained as the sole product 
without any C─H product formation (d), further demonstrating the unique manganese(I)-catalyzed 
C─C activation process. 




Scheme 3.7.8 C–C versus C–H activation experiments. 
3.7.5.2 H/D Exchange Experiments 
H/D exchange experiments were also carried out to elucidate the mechanism of this C─C activation 
(Scheme 3.7.9). Firstly, the reactions were conducted with substrate 168a and phenylacetylene 80 in 
the presence of isotopically labelled D2O. A large amount of deuterium incorporation at both 
β-positions of the products [D]n-102af and [D]n-74co was observed (a and b). Moreover, the 
reactions of substrate [D]1-8o were conducted in different solvents and no H/D scrambling at 
β-position was observed in water, but a deuterium incorporation of 37% in 1,4-dioxane was 
determined (c and d). Importantly, when substrate [D]1-168c reacted with phenylacetylene (8o) 
under the optimized conditions, no deuterium was detected in product 74co (e). These findings 
clearly showed that the proto-demetalated step is caused by the vast excess of water. 




Scheme 3.7.9 H/D exchange experiments. 
3.7.5.3 Stoichiometric C–C Cleavage by X-ray and NMR Spectroscopy 
Thus, the stoichiometric C─C activation of compound 168a by BnMn(CO)5 provided the intermediate 
208, which was characterized by X-ray diffraction analysis. Further 1H NMR experiments of the 
stoichiometric reaction provided strong evidence for the generation of complex 208 by the 
formation of equimolar amounts of toluene and acetone (Scheme 3.7.10).  
 





Scheme 3.7.10 Stoichiometric C─C cleavage detected by X-ray and 1H NMR spectroscopy. 
3.7.5.4 Detection and Quantification of CO2 
Furthermore, in order to detect and quantify the generation of CO2. A volumetric analysis was 
perfomed (Scheme 3.7.11). The observed formation of CO2 is in good agreement with the results 
obtained from the C─C allylation reaction.  
 
 




Scheme 3.7.11 Detection and quantification of CO2. 
3.7.5.5 Kinetic Reaction Orders  
The kinetic order of the reaction with respect to the concentration of 
2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) as well as the manganese catalyst showed a first 
order dependence, indicating that the substrate 168a and the catalyst MnBr(CO)5 both are part of 
the turnover-limiting step of the catalytic cycle (Scheme 3.7.12a and b). In sharp contrast, a zero 
order dependence on the concentration of the substrate 11f was observed, providing strong 
support for a rate-determining C─C metalation (c). These results are also in good agreement with 














Scheme 3.7.12 Kinetic order of coumpounds 168a, 11f and manganese catalyst. 
3.7.6 Traceless Removal of the Pyrazole Group  
Finally, the synthetic utility of this C─C activation strategy was investigated by the traceless removal 
of the pyrazole group, delivering the corresponding anilines 209 in moderate to good yields, which 
could be easily transformed into other useful compounds (Scheme 3.7.13).  
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4 Summary and Outlook 
Metal-catalyzed C─H and C─C functionalizations have become an increasingly viable approach, 
which allows the direct formation of C─C and C─heteroatom bonds in an atom- and step-economical 
manner. However, the significant accomplishments in this field have heavily relied on the use of 
precious transition metals, such as rhodium, palladium, ruthenium, and iridium, over the last few 
decades. The high cost and potential toxicity of these metals limit the applications in 
pharmaceutical and fine chemical industries. Therefore, developing efficient and economic C─H and 
C─C functionalization by inexpensive and Earth-abundant metals is highly desirable. In this thesis, 
we summarize our recent achievements in direct C─H and C─C bond transformations by cobalt(III)- 
and manganese(I)-catalysis. 
In the first project, a cobalt(III)-catalyzed C─H/N─O functionalization was achieved for the synthesis 
of substituted isoquinolines derivatives (Scheme 3.8.1). Notable features of this developed 
annulation reaction were a wide substrate scope applicable and tolerance of various functional 
groups. The N─O bond of the oxime was successfully utilized as the internal oxidant in this process. 
Importantly, the reaction was not limited to the symmetrical alkynes, but also unsymmetrical and 
terminal alkynes could be employed in the reaction to afford the isoquinolines in good yields with 
high regio-selectivities. In many cases, the annulation products were obtained high yields within 
only 15 min. The mechanistic findings, including H/D exchange, competition experiments and KIE 
studies, revealed a reversible and facile BIES-type C─H metalation pathway was involved.  
 
Scheme 3.8.1 Cobalt(III)-catalyzed C─H/N─O functionalization for the synthesis of isoquinolines. 
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In the second project, a good site- and regio-selective cobalt(III)-catalyzed C─H annulation of various 
nitrones approached the novel and useful indole synthesis (Scheme 3.8.2). The versatile cobalt(III) 
catalyst proved to be particularly effective for challenging unsymmetrically substituted alkynes, 
when employing a catalytic amounts of Piv-Leu-OH as ligand, delivering unprotected indoles in good 
yields with excellent levels of regioselectivity. Detailed mechanistic studies, such as H/D exchange 
and KIE experiments, provided strong support for a rate-determining C─H metalation step.  
 
 
Scheme 3.8.2 Cobalt(III)-catalyzed C─H/N─O functionalization for the synthesis of indoles. 
 
In the third project, we developed the first cobalt(III)-catalyzed position-selective C─H 
functionalization, which fully tolerated strongly coordinating heterocycles, such as pyridines, 
pyrimidines, and pyrazoles (Scheme 3.8.3). This reaction was showed a wide substrate scope with 
various functional groups tolerance, such as chloro, fluoro, ester, ketone, nitro, and thiophene. The 
preliminary mechanistic studies, especially the H/D exchange experiments, indicated that the 
positional selectivity of this C─H amination is determined in the C─N bond forming step. 
 




Scheme 3.8.3 Cobalt(III)-catalyzed position-selective C─H functionalization. 
 
In the fourth project, a cobalt(III)-catalyzed domino C─H/N─H allylation reaction of aryl imidates 
with dioxolanones was accomplished (Scheme 3.8.4). The reaction was performed under mild 
reaction conditions with water and generated CO2 as the only byproducts. This step-economic 
method using an earth-abundant cobalt catalyst provided expedient access to decorated vinyl 
3,4-dihydroisoquinolines, which could not be obtained using a rhodium catalysis.[181] 
Aryl-substituted imidates bearing various electron-donating and electron-withdrawing groups are 
compatible with the reaction conditions, delivering the cyclization products 164 in good yields with 
high levels of regio-selectivity. Furthermore, the obtained product 164 could be easily transformed 
to dihydroisoquinolone 191 and acetylated isoquinoline 192.   
 
Scheme 3.8.4 Cobalt(III)-catalyzed domino C─H/N─H allylation. 
 
In the fifth project, a manganese(I)-catalyzed decarboxylative C─H/N─O allylation in water was 
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developed (Scheme 3.8.5). When indole substrates were employed, the reaction features a broad 
substrate scope and good functional group tolerance. This organometallic C─H activation was also 
tolerant to air and water. The organomanganese intermediate 193 could be isolated and showed 
high catalytic efficiency in both catalytic and stoichiometric experiments. The detailed mechanistic 
findings including competition experiments, H/D exchange and KIE studies strongly support a facile 
and reversible C─H metalation step. At last, this versatile C─H allylation was also successfully applied 
to the amino acids and aryl ketimines, delivering the allylation products in good yields with high 
levels of chemo- and regio-selectivities. 
 
 
Scheme 3.8.5 Manganese(I)-catalyzed decarboxylative C─H/N─O functionalization. 
 
In the sixth project, a synergistic Brønsted acid/manganese(I)-catalyzed C─H hydroarylation with 
high chemo- and regio-selectivities in continuous flow was accomplished (Scheme 3.8.6). With the 
assistance of carboxylic acid, the undesired β-O elimination could be avoided and provided a robust 
access to allylic carbonates in high yields with excellent chemo- and regio-selectivities. Moreover, 
this catalytic system tolerated a variety of valuable functional groups, including chloro, bromo, iodo, 
ether, carboxylic acid, and ester. The first manganese(I)-catalyzed C─H activation in continuous flow 
could be conducted within only 20 minutes under an atmosphere of air. Mechanistic findings 
indicated that a fast organometallic C─H metalation step, as well as an intramolecular proton 
transfer were involved.[152] Furthermore, late-stage diversification of the allylic carbonates 167ba 
could be achieved, giving rise to a plethora of valuable building blocks. 





Scheme 3.8.6 Synergistic manganese(I)-catalyzed C─H hydroarylation in continuous flow. 
 
In the last project, we have developed versatile C─C activations in water by inexpensive and 
Earth-abundant manganese catalysis (Scheme 3.8.7). The organometallic C─C functionalizations, 
including C─C allylations, C─C alkenylations, and C─C alkylations, occurred efficiently in 
environmentally-benign solvent with excellent levels of chemo-, regio-, and position-selectivities. 
The unique manganese(I)-catalyzed C─C activation was characterized by a broad substrate scopes, 
functional group tolerance and position-selective synthesis. Competition and H/D exchange 
experiments clearly showed that the C─C cleavage is much faster than the C─H activation under the 
optimal condition. This result was showcased by the synthesis of 1,2,3-tri-substituted arenes, which 
could not be achieved by C─H activation. Importantly, the pyrazole group could be easily removed, 
furnishing the synthetically useful anilines 209. 











5 Experimental Section 
5.1 General Remarks 
The catalysis in water or under an atmosphere of air use the sealed tubes or Schlenk tubes. Unless 
otherwise noted, other reactions were performed under N2 atmosphere using pre-dried glassware 
and standard Schlenk techniques. 
If not otherwise noted, yields refer to isolated compounds, estimated to be >95% pure as 
determined by 1H-NMR.  
 
Vacuum 
The following pressures were measured on the used vacuum pump and were not corrected: 
membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
 
Melting Points (M.p.) 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from BARLOWORLD 
SCIENTIFIC. The reported values are uncorrected. 
 
CO2  
The CO2 was detected and quantified by a GM5-KONT instrument from MesSen Nord. 
 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates were visualized under 
UV-light or developed by treatment with a KMnO4 solution followed by careful applying a heat gun. 
Chromatographic purification of products was accomplished by flash column chromatography on 






Gas Chromatograpgy (GC)  
The conversion of the reactions was monitored applying coupled gas chromatography/mass 
spectrometry using G1760C GCDplus with mass detector HP 5971, 5890 Series II with mass detector 
HP 5972 from HEWLETT-PACKARD and 7890A GC-System with mass detector 5975C 
(Triplex-Axis-Detector) from AGILENT TECHNOLOGIES equipped with HP-5MS columns (30 m × 0.25 
mm × 0.25 m) were used. 
 
Gel permeation chromatography (GPC)  
GPC purifications were performed on a JAI system (JAI-LC-9260 II NEXT) equipped with two 
sequential columns (JAIGEL-2HR, gradient rate: 5.000; JAIGEL-2.5HR, gradient rate: 20.000; internal 
diameter = 20 mm; length = 600 mm; Flush rate = 10.0 mL/min and chloroform (HPLC-quality with 
0.6% ethanol as stabilizer) was used as the eluent. 
 
Infrared Spectroscopy  
Infrared spectra were recorded at a BRUKER Alpha-P ATR FT-IR spectrometer. Liquid samples were 
measured as a film, solid samples neat. The analysis of the spectra was carried out using the 
software from BRUKER OPUS 6. The absorption is given in wave numbers (cm−1) and the spectra 
were recorded in the range of 4000–400 cm‒1. In situ-IR studies were performed on METTLER 
TOLEDO ReactIR™ 15 with an iC IR 4.3 software. 
 
Mass Spectrometry  
Electron ionization (EI) and EI high resolution mass spectra (HR-MS) were measured on a 
time-of-flight mass spectrometer AccuTOF from JOEL. Electrospray ionization (ESI) mass spectra 
were recorded on an Ion-Trap mass spectrometer LCQ from FINNIGAN, a quadrupole time-of-flight 
maXis from BRUKER DALTONIC or on a time-of-flight mass spectrometer microTOF from BRUKER 
DALTONIC. ESI-HRMS spectra were recorded on a BRUKER Apex IV or a BRUKER Daltonic 7T, fourier 
transform ion cyclotron resonance (FTICR) mass spectrometer. The ratios of mass to charge (m/z) 






Nuclear Magnetic Resonance Spectroscopy (NMR)  
Nuclear magnetic resonance (NMR) spectra were recorded on VARIAN Inova 500, 600, VARIAN 
Mercury 300, VX 300, VARIAN Avance 300, VARIAN VNMRS 300 and BRUKER Avance III 300, 400 and 
HD 500 spectrometers. All chemical shifts are given as δ-values in ppm relative to the residual 
proton peak of the deuterated solvent or its carbon atom, respectively. 1H and 13C NMR spectra 
were referenced using the residual proton or solvent carbon peak (see table), respectively. 13C and 
19F NMR were measured as proton-decoupled spectra. 
 1H-NMR 13C-NMR 
CDCl3 7.26 77.16 
[D]6-DMSO 2.50 39.52 
The observed resonance-multiplicities were described by the following abbreviations: s (singlet), d 
(doublet), t (triplet), q (quartet), hept (heptet), m (multiplet) or analogous representations. The 
coupling constants J are reported in Hertz (Hz). Analysis of the recorded spectra was carried out 
with MestReNova 10 software. 
 
Solvents 
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored 
under an inert atmosphere (Ar or N2) according to the following standard procedures.  
1,2-Dichloroethane (DCE), N,N-dimethylformamide (DMF) and γ-Valerolactone (GVL) were dried 
over CaH2 for 8 h, degassed and distilled under reduced pressure.  
1,1,1,3,3,3-Hexafluoropropan-2-ol (HFIP) and Chlorobenzene (PhCl) were distilled from 3 Å 
molecular sieves. 
Methanol (MeOH) was stirred over magnesium turnings at 65 °C for 3 h prior to distillation from 
Mg(OMe)2. 
Toluene (PhMe), Tetrahydrofuran (THF), Dichloromethane (DCM) and ethyl ether (Et2O) were 
purified using a solvent purification system (SPS-800) from M. BRAUN. 
Acetonitrile (MeCN) was dried over P2O5 for 24 h degassed and distilled under reduced pressure.  
2,2,2-Trifluoroethanol (TFE) was stirred over CaSO4 and distilled under reduced pressure. 




1,4-Dioxane and Di-(n-butyl)-ether (nBu2O) were distilled from sodium benzophenone ketyl. 
 
Reagents 
Chemicals obtained from commercial sources with purity above 95% were used without further 
purification. The following compounds are known and were synthesized according to previously 
described methods: 
Cp*CoI2(CO),
[56] O-acyloximes 158a-158n,[182] [D]1-158a,
[113] [D]5-158a, alkynes 8b-8j,
[183] 
(E)-1-{2-[(E)-1,2-diphenylvinyl]phenyl}ethanone O-acetyl oxime 158u.[184] , nitrones 159,[185] aryl 
alkyl alkynes 8p-8r.[186] [Cp*Co(CH3CN)3](PF6)2, [Cp*Co(CH3CN)3](BF4)2, and 
[Cp*Co(MeCN)3][SbF6]2,
[136a] Benzimidates 161a-161n,[187] dioxazolones 162a-162k,[188] substrates 
41a,[57, 189] 41b-41e,[190] 20a,[191] 110b-110f,[192] 168a-168g,[135] 110g,[137] and complex 193.[193]  
 
The following compounds were obtained by the generous courtesy of the following persons: 
M. Sc. Julian Koeller: (E)-1-(2-[(E)-1,2-diphenylvinyl)phenyl]ethanone O-acetyl oxime 158u. 
Dr. Mélanie M. Lorion: 3-tosyl-5-vinyloxazolidin-2-one 110g. 
Dr. Weiping Liu: (E)-N-[1-(4-fluorophenyl) ethylidene]-4-methoxyaniline 34d, 
(E)-N-{1-[(1,1'-biphenyl)-4-yl]ethylidene}-4- methoxyaniline 34b. 
M. Sc. Issac Choi: [2-(1H-pyrazol-1-yl)phenyl)(phenyl)methanol 200a. 





5.2 General Procedures 
General Procedure A: Cobalt(III)−Catalyzed C−H/N−O Functionalization for the Synthesis of 
Isoquinolines 119 
A suspension of O-acetyl oxime 158 (0.50 mmol, 1.0 equiv), alkynes 8 (0.75 mmol, 1.5 equiv), 
Cp*CoI2(CO) (24.0 mg, 10.0 mol %), AgSbF6 (34.4 mg, 20.0 mol %) and NaOAc (8.2 mg, 20.0 mol %) 
in DCE (2.0 mL) was stirred at 120 °C for 15 min or 16 h under air. After cooling to ambient 
temperature, the solvent was evaporated in vacuo and the remaining residue was purified by 
column chromatography on silica gel to afford the desired products 119. 
 
General Procedure B: Cobalt(III)–Catalyzed C–H/N–O Functionalization for the Synthesis of 
Indoles 160 
A suspension of nitrone 159 (0.50 mmol, 1.0 equiv), alkyne 8 (0.75 mmol, 1.5 equiv), Cp*CoI2(CO) 
(12.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20.0 mol %), NaOAc (8.2 mg, 20.0 mol %) or Piv-Leu-OH 
(22.1 mg, 20.0 mol %) was stirred at 100 °C for 16 h under air. After cooling to ambient temperature, 
the mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in 
vacuo. Purification by column chromatography on silica gel and optionally by GPC afforded the 
desired products 160. 
 
General Procedure C: Cobalt(III)–Catalyzed C–H Functionalization for the Synthesis of 
Quinazolines 163 
A suspension of benzimidates 161 (0.25 mmol, 1.0 equiv), dioxazolones 162 (0.30 mmol, 1.2 equiv), 
[Cp*Co(CH3CN)3](SbF6)2 (180) (6.9 mg, 5.0 mol %) in DCE (1.0 mL) was stirred at 100 ˚C for 13 h 
under air. After cooling to ambient temperature, the mixture was transferred into a round bottom 
flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column chromatography on 
silica gel afforded the desired products 163. 
 





A suspension of benzimidates 161 (0.25 mmol, 1.0 equiv), dioxolanone 110 (0.75 mmol, 3.0 equiv), 
NaOAc (8.2 mg, 40.0 mol %), BPh3 (24.2 mg, 40.0 mol %), [Cp*Co(CH3CN)3](PF6)2 (7.6 mg, 5.0 mol %) 
in HFIP (1.0 mL) was stirred at 55 °C for 16 h under N2. After cooling to ambient temperature, the 
mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. 
Purification by column chromatography on silica gel afforded the desired products 164. 
 
General Procedure E: Manganese(I)-Catalyzed C─H/C─O Activation with Heteroarenes  
A suspension of heteroarenes 41 (0.25 mmol, 1.0 equiv), dioxolanones 110 (0.75 mmol, 3.0 equiv), 
[MnBr(CO)5] (6.9 mg, 10.0 mol %) and NaOAc (4.1 mg, 20.0 mol %) in H2O or TFE (1.0 mL) was 
stirred at 100 °C for 16 h under air (or under N2 when specified). After cooling to ambient 
temperature, the mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and 
concentrated in vacuo. Purification by column chromatography on silica gel afforded the desired 
products 111. 
 
General Procedure F: Manganese(I)-Catalyzed C─H/C─O Activation with Ketimines 34 
A suspension of ketimines 34 (0.25 mmol, 1.0 equiv), dioxolanones 110 (0.75 mmol, 3.0 equiv), 
[MnBr(CO)5] (6.9 mg, 10.0 mol %) and NaOAc (4.1 mg, 20.0 mol %) in TFE (1.0 mL) was stirred at 
100 °C for 16 h under N2. After cooling to ambient temperature, HCl (2 N, 3.0 mL) was added. The 
resulting mixture was stirred for 30 min at 25 °C and extracted with Et2O (3 × 20 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography on silica gel afforded the desired products 165. 
 
General procedure G: Manganese(I)-Catalyzed C–H Hydroarylation in Flow 
A 10 mL oven-dried volumetric flask was charged with heteroarenes 41 (0.25 mmol, 1.0 equiv), 
propargylic alkynes 166 (0.50 mmol, 2.0 equiv), [MnBr(CO)5] (6.9 mg, 10.0 mol %), HOAc (2.8 μL, 
20.0 mol %) and 1,4-dioxane (1.0 mL) under air. Subsequently, the solution was connected to the 
inlet of the 10 mL standard heated reactor by a syringe pump (Vapourtec V-3). The syringe pump 
was operated at a flow rate of 500 μL / min (20 min residence time). The back pressure was set up 
around 8.0 bar and the temperature of the standard heated reactor was set at 100 °C. Using the 




in vacuo. Purification by column chromatography on silica gel afforded the desired products 167. 
 
General Procedure H: Manganese(I)-Catalyzed C–C Allylation with Dioxolanones 110 
A suspension of heteroarenes 168 (0.25 mmol, 1.0 equiv), dioxolanones 110 (0.50 mmol, 2.0 equiv), 
[MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O (1.0 mL) was stirred at 120 °C for 16 h under N2. After 
cooling to ambient temperature, EtOAc (10 mL) was added and the mixture was dried over Na2SO4, 
washed with EtOAc (30 mL) and concentrated in vacuo. Purification by column chromatography on 
silica gel afforded the desired products 111. 
 
General Procedure I: Manganese(I)-Catalyzed C–C Alkenylation with Alkynes 8 
A suspension of heteroarenes 168 (0.25 mmol, 1.0 equiv), alkynes 8 (0.50 mmol, 2.0 equiv), 
[MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O (1.0 mL) was stirred at 140 °C for 16 h under N2. After 
cooling to ambient temperature, EtOAc (10 mL) was added and the mixture was dried over Na2SO4, 
washed with EtOAc (30 mL) and concentrated in vacuo. Purification by column chromatography on 
silica gel afforded the desired products 74. 
 
General procedure J: Manganese(I)-Catalyzed C–C Alkylation with Alkenes 11 
A suspension of heteroarenes 168 (0.25 mmol, 1.0 equiv), alkenes 11 (0.50 mmol, 2.0 equiv), 
[MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O (1.0 mL) was stirred at 120 °C for 16 h under N2. After 
cooling to ambient temperature, EtOAc (10 mL) was added and the mixture was dried over Na2SO4, 
washed with EtOAc (30 mL) and concentrated in vacuo. Purification by column chromatography on 
silica gel afforded the desired products 102. 
 
General procedure K: Manganese(I)-Catalyzed C–C Allylation with Morita-Baylis-Hillman Adducts 
201 
A suspension of heteroarenes 168 (0.25 mmol, 1.0 equiv), Morita-Baylis-Hillman adducts 201 (0.50 
mmol, 2.0 equiv), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in 1,4-dioxane (1.0 mL) was stirred at 120 °C for 
16 h under N2. After cooling to ambient temperature, the mixture was transferred into a round 
bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 




5.3 Experimental and Analytical Data 
5.3.1 Data for Cobalt(III)-Catalyzed C─H/N─O Functionalizations: Isohypsic Access to Isoquinolines  
Characterization Data 
 
1-Methyl-3,4-diphenylisoquinoline (119aa): The general procedure A was followed using 
(E)-acetophenone O-acetyl oxime (158a) (89 mg, 0.50 mmol) and diphenylacetylene (8a) (134 mg, 
0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 25/1 → 20/1) 
yielded 119aa (129 mg, 87%) as a pale yellow solid.  
M.p. = 153−155 °C. 1H NMR (500 MHz, CDCl3): δ = 8.23–8.19 (m, 1H), 7.71–7.67 (m, 1H), 7.62–7.57 
(m, 2H), 7.42–7.31 (m, 5H), 7.27–7.16 (m, 5H), 3.10 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 157.7 
(Cq), 149.4 (Cq), 141.0 (Cq), 137.6 (Cq), 136.0 (Cq), 131.4 (CH), 130.2 (CH), 130.0 (CH), 129.1 (Cq), 
128.2 (CH), 127.6 (CH), 127.1 (CH), 126.9 (CH), 126.5 (CH), 126.2 (CH), 126.1 (Cq), 125.5 (CH), 22.7 
(CH3). IR (ATR) ν = 1567, 1389, 1334, 1072, 1026, 765, 695, 612, 563, 496 cm
-1. MS (ESI) m/z 
(relative intensity): 296 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H18N [M+H]
+: 296.1434, found: 
296.1434.  
The analytical data were in accordance with those reported in the literature.[109c] 
 
 
1,6-Dimethyl-3,4-diphenylisoquinoline (119ba): The general procedure A was followed using 
(E)-1-(p-tolyl)ethanone O-acetyl oxime (158b) (96 mg, 0.50 mmol) and diphenylacetylene (8a) (134 
mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 40/1 → 
20/1) yielded 119ba (94 mg, 61%) as a white solid.  
M.p. = 168−169 °C. 1H NMR (500 MHz, CDCl3): δ = 8.08 (d, J = 8.9 Hz, 1H), 7.43–7.39 (m, 2H), 7.37–
7.30 (m, 5H), 7.23–7.14 (m, 5H), 3.04 (s, 3H), 2.42 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 157.3 (Cq), 




128.1 (CH), 127.5 (CH), 127.0 (CH), 126.8 (CH), 125.4 (CH), 125.0 (CH), 124.5 (Cq), 22.6 (CH3), 22.1 
(CH3). IR (ATR) ν = 3061, 2917, 1621, 1566, 1493, 1384, 1335, 1070, 1028, 796, 696, 612 cm
-1. MS 
(ESI) m/z (relative intensity): 310 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H20N [M+H]
+: 310.1590, 
found: 310.1593.  
The analytical data were in accordance with those reported in the literature.[109c] 
 
 
6-Methoxy-1-methyl-3,4-diphenylisoquinoline (119ca): The general procedure A was followed 
using (E)-1-(4-methoxyphenyl)ethanone O-acetyl oxime (158c) (104 mg, 0.50 mmol) and 
diphenylacetylene (8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 15/1 → 10/1) yielded 119ca (141 mg, 87%) as a pale yellow solid.  
M.p. = 180−182 °C. 1H NMR (500 MHz, CDCl3): δ = 8.11 (dd, J = 9.2, 0.5 Hz, 1H), 7.37–7.27 (m, 5H), 
7.25–7.12 (m, 6H), 6.92 (d, J = 2.5 Hz, 1H), 3.73 (s, 3H), 3.02 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 
160.7 (Cq), 157.1 (Cq), 150.3 (Cq), 141.4 (Cq), 138.2 (Cq), 138.1 (Cq), 131.5 (CH), 130.4 (CH), 128.7 (Cq), 
128.4 (CH), 127.7 (CH), 127.6 (CH), 127.2 (CH), 127.0 (CH), 122.0 (Cq), 118.8 (CH), 104.7 (CH), 55.4 
(CH3), 22.8 (CH3). IR (ATR) ν = 3059, 1500, 1410, 1273, 1229, 1205, 1070, 1024, 853, 696 cm
-1. MS 
(ESI) m/z (relative intensity): 326 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H20NO [M+H]
+: 
326.1539, found: 326.1538.  
The analytical data were in accordance with those reported in the literature.[194] 
 
 
1-Methyl-3,4,6-triphenylisoquinoline (119da): The general procedure A was followed using 
(E)-1-[(1,1'-biphenyl)-4-yl]ethanone O-acetyl oxime (158d) (127 mg, 0.50 mmol) and 
diphenylacetylene (8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 40/1 → 20/1) yielded 119da (154 mg, 83%) as a pale yellow solid.  




Hz, 1H), 7.85 (dd, J = 8.7, 1.8 Hz, 1H), 7.59–7.55 (m, 2H), 7.46–7.39 (m, 4H), 7.39–7.32 (m, 4H), 
7.31–7.27 (m, 2H), 7.25–7.18 (m, 3H), 3.11 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 157.5 (Cq), 149.9 
(Cq), 142.4 (Cq), 141.0 (Cq), 140.4 (Cq), 137.5 (Cq), 136.3 (Cq), 131.4 (CH), 130.2 (CH), 129.3 (Cq), 128.8 
(CH), 128.2 (CH), 127.9 (CH), 127.6 (CH), 127.4 (CH), 127.1 (CH), 127.0 (CH), 126.9 (CH), 126.1 (CH), 
125.1 (Cq), 123.9 (CH), 22.7 (CH3). IR (ATR) ν = 3058, 3025, 1611, 1567, 1434, 1340, 1158, 1073, 
1029, 955, 894, 760, 751, 691, 611 cm-1. MS (ESI) m/z (relative intensity): 372 (100) [M+H]+. HR-MS 
(ESI) m/z calcd for C28H22N [M+H]
+: 372.1747, found: 372.1751. 
 
 
6-(Trifluoromethyl)-1-methyl-3,4-diphenylisoquinoline (119ea): The general procedure A was 
followed using (E)-1-(4-(trifluoromethyl)phenyl)ethanone O-acetyl oxime (158e) (123 mg, 0.50 
mmol) and diphenylacetylene (8a) (134 mg, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc 30:1 → 20:1 → 15:1) yielded 119ea (173 mg, 95%) as a pale yellow solid.  
M.p. = 112−113 °C. 1H-NMR (500 MHz, CDCl3): δ = 8.33 (dt, J = 8.7, 0.8 Hz, 1H), 7.98–7.97 (m, 1H), 
7.76 (dd, J = 8.7, 1.8 Hz, 1H), 7.41–7.34 (m, 5H), 7.25–7.18 (m, 5H), 3.12 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ = 158.0 (Cq), 151.1 (Cq), 140.6 (Cq), 136.6 (Cq), 135.6 (Cq), 131.5 (q, 
2JC–F = 32 Hz, Cq), 131.4 
(CH), 130.4 (CH), 129.9 (Cq), 128.7 (CH), 127.9 (CH), 127.8 (CH), 127.5 (CH), 127.1 (Cq), 127.0 (CH), 
124.0 (q, 3JC–F = 5 Hz, CH), 123.8 (q, 
1JC−F = 273 Hz, Cq), 122.2 (q, 
4JC−F = 3 Hz, CH), 23.0 (CH3). 
19F NMR 
(282 MHz, CDCl3): δ = −63.3 (s). IR (ATR) ν = 2958, 1555, 1336, 1305, 1177, 1156, 1135, 1082, 909, 
696 cm-1. MS (ESI) m/z (relative intensity): 364 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H16F3N 
[M+H]+: 364.1308, found: 364.1315.  
The analytical data were in accordance with those reported in the literature.[109c] 
 
  
6-Fluoro-1-methyl-3,4-diphenylisoquinoline (119fa): The general procedure A was followed using 




(134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 30:1 → 
20:1) yielded 119fa (147 mg, 94%) as a pale yellow solid.  
M.p. = 139−140 °C. 1H NMR (500 MHz, CDCl3): δ = 8.22 (ddd, J = 9.2, 5.7, 0.5 Hz, 1H), 7.39–7.31 (m, 
6H), 7.28–7.25 (m, 1H), 7.23–7.15 (m, 5H), 3.06 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 163.3 (d, 
1JC−F = 251 Hz, Cq), 157.7 (Cq), 150.6 (Cq), 140.8 (Cq), 138.2 (d, 
3JC−F = 10 Hz, Cq), 137.3 (Cq), 131.4 (CH), 
130.4 (CH), 129.1 (d, 4JC−F = 5.2 Hz, Cq), 128.8 (d, 
3JC−F = 10 Hz, CH), 128.6 (CH), 127.8 (CH), 127.5 
(CH), 127.3 (CH), 123.6 (Cq), 116.8 (d, 
2JC−F = 25.2 Hz, CH), 110.0 (d, 
2JC−F = 22.2 Hz, CH), 23.0 (CH3). 
19F NMR (282 MHz, CDCl3): δ = −108.0 (ddd, J = 10.9, 8.0, 5.6 Hz). IR (ATR) ν = 1623, 1571, 1504, 
1398, 1260, 1183, 874, 830, 704 cm-1. MS (ESI) m/z (relative intensity): 314 (100) [M+H]+. HR-MS 
(ESI) m/z calcd for C22H17N19F [M+H]
+: 314.1340, found: 314.1339.  
The analytical data were in accordance with those reported in the literature.[195] 
 
 
6-Chloro-1-methyl-3,4-diphenylisoquinoline (119ga): The general procedure A was followed using 
(E)-1-(4-chlorophenyl)ethanone O-acetyl oxime (158g) (106 mg, 0.50 mmol) and diphenylacetylene 
(8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
40/1 → 20/1) yielded 119ga (156 mg, 94%) as a pale yellow solid.  
M.p. = 177−178 °C. 1H-NMR (500 MHz, CDCl3): δ = 8.11 (dd, J = 8.9, 0.5 Hz, 1H), 7.64 (dd, J = 2.2, 0.5 
Hz, 1H), 7.51 (dd, J = 8.9, 2.2 Hz, 1H), 7.39–7.32 (m, 5H), 7.22–7.17 (m, 5H), 3.04 (s, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 157.6 (Cq), 150.5 (Cq), 140.6 (Cq), 137.0 (Cq), 136.8 (Cq), 136.3 (Cq), 131.2 (CH), 
130.1 (CH), 128.4 (CH), 127.6 (CH), 127.4 (CH), 127.3 (CH), 127.3 (CH), 127.1 (CH), 125.0 (CH), 124.3 
(Cq), 22.7 (CH3). IR (ATR) ν = 3064, 3026, 1602, 1548, 1493, 1446, 1386, 1329, 1098, 957, 752, 698, 
626 cm-1. MS (ESI) m/z (relative intensity): 330 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H17ClN 
[M+H]+: 330.1044, found: 330.1043.  






6-Bromo-1-methyl-3,4-diphenylisoquinoline (119ha): The general procedure A was followed using 
(E)-1-(4-bromophenyl)ethanone O-acetyl oxime (158h) (128 mg, 0.50 mmol) and diphenylacetylene 
(8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
30/1 → 20/1 → 10/1) yielded 119ha (154 mg, 82%) as a slightly yellow solid.  
M.p. = 193−195 °C. 1H NMR (500 MHz, CDCl3): δ = 8.06 (dd, J = 8.9, 0.5 Hz, 1H), 7.81 (d, J = 2.0 Hz, 
1H), 7.67 (dd, J = 8.9, 2.0 Hz, 1H), 7.39–7.32 (m, 5H), 7.22–7.15 (m, 5H), 3.05 (s, 3H). 13C NMR (125 
MHz, CDCl3): δ = 157.6 (Cq), 150.5 (Cq), 140.6 (Cq), 137.4 (Cq), 136.8 (Cq), 131.2 (CH), 130.3 (CH), 
130.1 (CH), 128.4 (CH), 128.4 (CH) 128.3 (Cq), 127.6 (CH), 127.4 (CH), 127.3 (CH), 127.1 (CH), 125.0 
(Cq), 124.3 (Cq), 22.7 (CH3). IR (ATR) ν = 3064, 1597, 1561, 1481, 1445, 1386, 1329, 1071, 1029, 697 
cm-1. MS (ESI) m/z (relative intensity): 374 (100) [M+H]+, 296 (55). HR-MS (ESI) m/z calcd for 
C22H17BrN [M+H]
+: 374.0539, found: 374.0539.  
The analytical data were in accordance with those reported in the literature.[109c] 
 
 
1-Methyl-6-nitro-3,4-diphenylisoquinoline (119ia): The general procedure A was followed using 
(E)-1-(4-nitrophenyl)ethanone O-acetyl oxime (158i) (111 mg, 0.50 mmol) and diphenylacetylene 
(8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 
10:1→ 8:1 → 5:1) yielded 119ia (80 mg, 47%) as a yellow solid.  
M.p. = 170−173 °C. 1H NMR (300 MHz, CDCl3): δ = 8.59 (dd, J = 2.1, 0.8 Hz, 1H), 8.35 (d, J = 0.8 Hz, 
1H), 8.33 (d, J = 2.1 Hz, 1H), 7.50–7.29 (m, 5H), 7.26–7.18 (m, 5H), 3.14 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ = 158.2 (Cq), 151.8 (Cq), 148.4 (Cq), 140.1 (Cq), 136.1 (Cq), 136.0 (Cq), 131.3 (CH), 130.6 (Cq), 
130.3 (CH), 128.9 (CH), 128.2 (CH), 127.9 (Cq), 127.9 (CH), 127.8 (CH), 127.7 (CH), 122.9 (CH), 120.0 
(CH), 23.1 (CH3). IR (ATR) ν = 1531, 1343, 1326, 1312, 902, 832, 767, 738, 698, 623 cm
-1. MS (ESI) 
m/z (relative intensity): 341 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H17N2O2 [M+H]
+: 341.1285, 




The analytical data were in accordance with those reported in the literature.[194] 
 
 
1-Methyl-3,4-diphenylisoquinoline-6-carbonitrile (119ja): The general procedure A was followed 
using (E)-4-(1-(acetoxyimino)ethyl)benzonitrile (158j) (101 mg, 0.50 mmol) and diphenylacetylene 
(8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
30/1 → 10/1) yielded 119ja (144 mg, 90%) as a pale yellow solid.  
M.p. = 171–172 °C. 1H NMR (500 MHz, CDCl3): δ = 8.27 (dd, J = 8.6, 0.7 Hz, 1H), 8.03 (dd, J = 1.6, 0.7 
Hz, 1H), 7.71 (dd, J = 8.6, 1.6 Hz, 1H), 7.41–7.32 (m, 5H), 7.22–7.15 (m, 5H), 3.08 (s, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 158.0 (Cq), 151.3 (Cq), 140.1 (Cq), 136.1 (Cq), 135.5 (Cq), 132.5 (CH), 131.2 (CH), 
130.2 (CH), 129.0 (Cq), 128.6 (CH), 127.9 (CH), 127.8 (CH), 127.5 (CH), 127.1 (CH), 126.9 (CH), 126.7 
(Cq), 118.5 (Cq), 113.5 (Cq), 22.7 (CH3). IR (ATR) ν = 3067, 2229, 1612, 1564, 1493, 1441, 1385, 1330, 
900, 823, 799, 696, 608 cm-1. MS (ESI) m/z (relative intensity): 321 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C23H17N2 [M+H]
+: 321.1392, found: 321.1386. 
 
 
8-Chloro-1-methyl-3,4-diphenylisoquinoline (119ka): The general procedure A was followed using 
(E)-1-(2-chlorophenyl)ethanone O-acetyl oxime (158k) (106 mg, 0.50 mmol) and diphenylacetylene 
(8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
60/1 → 30/1) yielded 119ka (106 mg, 64%) as a pale green solid.  
M.p. = 139–141 °C. 1H NMR (400 MHz, CDCl3): δ = 7.62 (dd, J = 7.4, 1.2 Hz, 1H), 7.56 (dd, J = 8.5, 1.2 
Hz, 1H), 7.39–7.31 (m, 6H), 7.22–7.15 (m, 5H), 3.39 (s, 3H). 13C NMR (100 MHz, CDCl3): δ = 157.1 
(Cq), 149.3 (Cq), 140.2 (Cq), 139.2 (Cq), 137.5 (Cq), 132.2 (Cq), 131.3 (CH), 130.1 (CH), 129.5 (CH), 
129.2 (CH), 129.0 (Cq), 128.3 (CH), 127.6 (CH), 127.3 (CH), 127.2 (CH), 125.8 (CH), 124.5 (Cq), 29.9 
(CH3). IR (ATR) ν = 3022, 1601, 1432, 1382, 1260, 1087, 1027, 819, 787, 762, 695, 572 cm
-1. MS (EI) 
m/z (relative intensity): 330 [M+H]+. HR-MS (ESI) m/z calcd for C22H17ClN [M+H]







1,7-Dimethyl-3,4-diphenylisoquinoline (119la): The general procedure A was followed using 
(E)-1-(m-tolyl)ethanone O-acetyl oxime (158l) (96 mg, 0.50 mmol) and diphenylacetylene (8a) (134 
mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 40/1→ 20:1) 
yielded 119la (82 mg, 53%) as a pale yellow solid.  
M.p. = 132−134 °C. 1H NMR (400 MHz, CDCl3): δ = 7.95 (t, J = 2.0 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 
7.41 (dd, J = 8.8, 2.0 Hz, 1H), 7.38–7.26 (m, 5H), 7.24–7.10 (m, 5H), 3.05 (s, 3H), 2.57 (s, 3H). 13C 
NMR (100 MHz, CDCl3): δ = 157.0 (Cq), 148.6 (Cq), 141.1 (Cq), 137.7 (Cq), 136.3 (Cq), 134.1 (Cq), 132.0 
(CH), 131.4 (CH), 130.2 (CH), 129.0 (Cq), 128.1 (CH), 127.5 (CH), 127.0 (CH), 126.7 (CH), 126.3 (Cq), 
126.1 (CH), 124.5 (CH), 22.7 (CH3), 21.8 (CH3). IR (ATR) ν = 3055, 3023, 2916, 1553, 1505, 1443, 1387, 
1322, 1073, 1028, 905, 831, 767, 699 cm-1. MS (ESI) m/z (relative intensity): 310 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C23H20N [M+H]
+: 310.1590, found: 310.1588.  
The analytical data were in accordance with those reported in the literature.[109c] 
 
 
7-Chloro-1-methyl-3,4-diphenylisoquinoline (119ma): The general procedure A was followed using 
(E)-1-(3-chlorophenyl)ethanone O-acetyl oxime (158m) (106 mg, 0.50 mmol) and diphenylacetylene 
(8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
20/1 → 15/1) yielded 119ma (115 mg, 70%) as an off-white solid.  
M.p. = 145−147 °C. 1H NMR (500 MHz, CDCl3): δ = 8.17 (dd, J = 2.2, 0.6 Hz, 1H), 7.61 (dd, J = 9.0, 0.6 
Hz, 1H), 7.51 (dd, J = 9.0, 2.2 Hz, 1H), 7.38–7.31 (m, 5H), 7.23–7.15 (m, 5H), 3.04 (s, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 157.0 (Cq), 150.0 (Cq), 140.8 (Cq), 137.2 (Cq), 134.6 (Cq), 132.4 (Cq), 131.4 (CH), 
130.8 (CH), 130.4 (CH), 129.2 (Cq), 128.5 (CH), 128.3 (CH), 127.8 (CH), 127.5 (CH), 127.3 (CH), 127.0 





MS (ESI) m/z (relative intensity): 330 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H17ClN [M+H]
+: 
330.1044, found: 330.1048. 
 
 
7-Bromo-1-methyl-3,4-diphenylisoquinoline (119na): The general procedure A was followed using 
(E)-1-(3-bromophenyl)ethanone O-acetyl oxime (158n) (128 mg, 0.50 mmol) and diphenylacetylene 
(8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
20/1) yielded 119na (142 mg, 76%) as a yellow solid.  
M.p. = 133−135 °C. 1H NMR (300 MHz, CDCl3): δ = 8.34 (d, J = 2.0 Hz, 1H), 7.64 (dd, J = 9.0, 2.0 Hz, 
1H), 7.54 (d, J = 9.0 Hz, 1H), 7.39–7.31 (m, 5H), 7.24–7.16 (m, 5H), 3.04 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ = 156.9 (Cq), 150.0 (Cq), 140.7 (Cq), 137.1 (Cq), 134.8 (Cq), 133.4 (CH), 131.4 (CH), 130.3 
(CH), 129.2 (Cq), 128.5 (CH), 128.4 (CH), 128.0 (CH), 127.8 (CH), 127.5 (CH), 127.4 (Cq), 127.3 (CH), 
120.7 (Cq), 22.8 (CH3). IR (ATR) ν = 3052, 3023, 1544, 1496, 1434, 1407, 1380, 868, 766, 700 cm
-1. 
MS (ESI) m/z (relative intensity): 374 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H17BrN [M+H]
+: 
374.0539, found: 374.0541.  
The analytical data were in accordance with those reported in the literature.[182] 
 
 
5,6-(Methylenedioxy)-1-methyl-3,4-diphenylisoquinoline (119oa): The general procedure A was 
followed using (E)-1-(benzo[d][1,3]dioxol-5-yl)ethanone O-acetyl oxime (158o) (111 mg, 0.50 mmol) 
and diphenylacetylene (8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica 
gel (n-hexane/EtOAc: 10/1 → 8/1 → 5/1) yielded 119oa (76 mg, 45%) as a white solid.  
M.p. = 250−253 °C. 1H NMR (500 MHz, CDCl3): δ = 7.82 (d, J = 8.8 Hz, 1H), 7.29–7.26 (m, 2H), 7.25–
7.10 (m, 9H), 5.83 (s, 2H), 2.99 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 157.9 (Cq), 150.3 (Cq), 147.8 
(Cq) 141.8 (Cq), 141.0 (Cq), 138.6 (Cq), 131.3 (CH), 130.3 (CH), 127.6 (CH), 127.2 (CH), 127.0 (CH), 




ν = 1431, 1384, 1353, 1279, 1049, 1031, 794, 767, 698, 644 cm-1. MS (ESI) m/z (relative intensity): 
340 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H18NO2 [M+H]
+: 340.1332, found: 340.1335.  
The analytical data were in accordance with those reported in the literature.[109c] 
 
 
5-Fluoro-1-methyl-3,4-diphenylisoquinoline (119pa): The general procedure A was followed using 
(E)-1-(3-fluorophenyl)ethanone O-acetyl oxime (158p) (98 mg, 0.50 mmol) and diphenylacetylene 
(8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
30/1→ 15:1) yielded 119pa (130 mg, 83%) as a pale yellow solid.  
M.p. = 123−125 °C. 1H NMR (400 MHz, CDCl3): δ = 8.01 (ddd, J = 8.4, 1.2, 0.5 Hz, 1H), 7.53 (ddd, J = 
8.4, 7.7, 4.6 Hz, 1H), 7.32–7.12 (m, 11H), 3.08 (s, 3H). 13C NMR (100 MHz, CDCl3): δ = 159.0 (d, 
1JC−F = 
258 Hz, Cq), 157.4 (d, 
4JC−F = 2 Hz, Cq), 151.4 (Cq), 140.71 (Cq), 139.3 (d, 
3JC−F = 4 Hz, Cq), 130.4 (d, 
4JC−F = 3 Hz, CH), 130.1 (CH), 128.0 (d, 
4JC−F = 3 Hz, Cq), 127.3 (d, 
2JC−F = 22 Hz, CH), 126.83 (CH), 
126.76 (CH), 126.66 (CH), 125.9 (d, 3JC−F = 9 Hz, Cq), 125.6 (d, 
4JC−F = 3 Hz, Cq), 121.8 (d, 
3JC−F = 5 Hz, 
CH), 115.5 (d, 2JC−F = 22.1 Hz, CH), 23.21 (CH3). 
19F NMR (376 MHz, CDCl3): δ = -105.64 (dd, J = 12.7, 
4.5 Hz). IR (ATR) ν = 3087, 3056, 1552, 1502, 1430, 1391, 1326, 1245, 1028, 904, 769 cm-1. MS (ESI) 





2,3-Diphenyl-8,9-dihydro-7H-benzo[de]quinolone (119qa): The general procedure A was followed 
using (E)-3,4-dihydronaphthalen-1(2H)-one O-acetyl oxime (158q) (102 mg, 0.50 mmol) and 
diphenylacetylene (8a) (134 mg, 0.75 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 30/1 → 20/1 → 15/1) yielded 119qa (144 mg, 85%) as a light brown solid.  
M.p. = 148−150 °C. 1H NMR (500 MHz, CDCl3): δ = 7.52–7.45 (m, 2H), 7.38–7.28 (m, 6H), 7.24─7.14 




δ = 159.4 (Cq), 149.6 (Cq), 141.3 (Cq), 138.6 (Cq), 138.0 (Cq), 136.4 (Cq), 131.5 (CH), 130.4 (CH), 130.1 
(CH), 129.2 (Cq), 128.3 (CH), 127.7 (CH), 127.2 (CH), 127.0 (CH) 124.9 (CH), 124.0 (Cq), 123.7 (CH), 
35.0 (CH2), 31.0 (CH2), 23.6 (CH2). IR (ATR) ν = 2934, 1577, 1551, 1496, 1444, 1387, 1372, 765, 695, 
625 cm-1. MS (ESI) m/z (relative intensity): 322 (100) [M+H]+. HR-MS (ESI) m/z calcd for C24H20N 
[M+H]+: 322.1590, found: 322.1588.  
The analytical data were in accordance with those reported in the literature.[182] 
 
 
1-Ethyl-3,4-diphenylisoquinoline (119ra): The general procedure A was followed using 
(E)-propiophenone O-acetyl oxime (158r) (96 mg, 0.50 mmol) and diphenylacetylene (8a) (134 mg, 
0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 30/1 → 20/1) 
yielded 119ra (136 mg, 88%) as a colorless solid.  
M.p. = 114−116 °C. 1H NMR (500 MHz, CDCl3): δ = 8.28–8.24 (m, 1H), 7.70–7.65 (m, 1H), 7.61–7.55 
(m, 2H), 7.42–7.31 (m, 5H), 7.26–7.15 (m, 5H), 3.46 (q, J = 7.6 Hz, 2H), 1.55 (t, J = 7.6 Hz, 3H). 13C 
NMR (125 MHz, CDCl3): δ = 162.4 (Cq), 149.4 (Cq), 141.3 (Cq), 137.9 (Cq), 136.5 (Cq), 131.5 (CH), 
130.5 (CH), 129.8 (CH), 129.1 (Cq), 128.4 (CH), 127.7 (CH), 127.3 (CH), 127.0 (CH), 126.6 (CH), 125.4 
(Cq), 125.3 (CH), 29.0 (CH2), 14.1 (CH3). IR (ATR) ν = 3025, 2981, 2937, 1553, 1504, 1422, 1316, 762, 
704, 597 cm-1. MS (ESI) m/z (relative intensity): 310 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H20N 
[M+H]+: 310.1590, found: 310.1597.  
The analytical data were in accordance with those reported in the literature.[109c] 
 
 
1-Isopropyl-3,4-diphenylisoquinoline (119sa): The general procedure A was followed using 
acetophenone O-acetyl oxime (158s) (103 mg, 0.50 mmol) and diphenylacetylene (8a) (134 mg, 
0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 30/1 → 20/1) 




M.p. = 142−144 °C. 1H NMR (400 MHz, CDCl3): δ = 8.33–8.29 (m, 1H), 7.70–7.65 (m, 1H), 7.61–7.53 
(m, 2H), 7.49–7.44 (m, 2H), 7.42–7.33 (m, 3H), 7.29–7.24 (m, 2H), 7.24–7.16 (m, 3H), 4.05 (sept, J = 
6.8 Hz, 1H), 1.55 (d, J = 6.8 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ = 165.1 (Cq), 148.7 (Cq), 141.4 (Cq), 
138.3 (Cq), 136.7 (Cq), 131.6 (CH), 130.7 (CH), 129.5 (CH), 128.5 (Cq), 128.4 (CH), 127.5 (CH), 127.2 
(CH), 127.0 (CH), 126.6 (CH), 126.4 (CH), 124.9 (Cq), 124.7 (CH), 31.5 (CH), 22.4 (CH3). IR (ATR) ν = 
2969, 1551, 1381, 1032, 761, 703, 678, 633, 596, 569 cm-1. MS (ESI) m/z (re:lative intensity): 324 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C23H20N [M+H]
+: 324.1747, found: 324.1748.  
The analytical data were in accordance with those reported in the literature.[194]  
 
 
4-Methyl-6,7-diphenylthieno[3,2-c]pyridine (119ta): The general procedure A was followed using 
(E)-1-(thiophen-3-yl)ethanone O-acetyl oxime (158t) (92 mg, 0.50 mmol) and diphenylacetylene (8a) 
(134 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 30/1 → 
20/1) yielded 119ta (127 mg, 72%) as a pale solid.  
M.p. = 147–149 °C. 1H NMR (400 MHz, CDCl3): δ = 7.51 (d, J = 5.5 Hz, 1H), 7.45 (d, J = 5.5 Hz, 1H), 
7.41–7.36 (m, 2H), 7.34–7.29 (m, 5H), 7.23–7.17 (m, 3H), 2.93 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 
= 152.5 (Cq), 149.9 (Cq), 149.6 (Cq), 140.2 (Cq), 138.5 (Cq), 133.8 (Cq), 130.3 (CH), 129.7 (CH), 128.6 
(CH), 127.71 (CH), 127.68 (CH), 127.64 (Cq), 127.60 (CH), 127.2 (CH), 122.5 (CH), 22.8 (CH3). IR (ATR) 
ν = 3060, 1544, 1414, 1387, 1073, 1028, 898, 754, 728, 696, 619 cm-1. MS (EI) m/z (relative 
intensity): 302 [M+H]+. HR-MS (ESI) m/z calcd for C20H16NS [M+H]
+: 302.1003, found: 302.0998. 
 
 
Methyl-3,4-di-p-tolylisoquinoline (119ab): The general procedure A was followed using 




0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 40/1 → 20/1) 
yielded 119ab (145 mg, 89%) as a pale yellow solid.  
M.p. = 151−153 °C. 1H NMR (500 MHz, CDCl3): δ = 8.20–8.14 (m, 1H), 7.70–7.64 (m, 1H), 7.59–7.53 
(m, 2H), 7.31 (d, J = 8.2 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 7.03 (d, J = 7.6 Hz, 
1H), 3.07 (s, 3H), 2.40 (s, 3H), 2.29 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 157.3 (Cq), 149.3 (Cq), 
138.2 (Cq), 136.5 (Cq), 136.4 (Cq), 136.2 (Cq), 134.6 (Cq), 131.1 (CH), 130.1 (CH), 129.6 (CH), 128.9 
(CH), 128.8 (Cq), 128.3 (CH), 126.2 (CH), 126.0 (Cq), 125.4 (CH), 22.7 (CH3), 21.2 (CH3), 21.1 (CH3). IR 
(ATR) ν = 3024, 3000, 2918, 1607, 1569, 1546, 1510, 1430, 1389, 1370, 1329, 1261, 1182, 1106, 
1022, 817, 756, 728, 595, 564 cm-1. MS (ESI) m/z (relative intensity): 324 (100) [M+H]+. HR-MS (ESI) 
m/z calcd for C24H22N [M+H]
+: 324.1747, found: 324.1751.  
The analytical data were in accordance with those reported in the literature.[195] 
 
 
1-Methyl-3,4-bis(4-(trifluoromethyl)phenyl)isoquinoline (119ae): The general procedure A was 
followed using (E)-acetophenone O-acetyl oxime (158a) (89 mg, 0.50 mmol) and 
1,2-bis(4-(trifluoromethyl)phenyl)ethyne (8e) (236 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 40/1 → 20/1) yielded 119ae (140 mg, 65%) as a pale 
yellow solid.  
M.p. = 151–152 °C. 1H NMR (300 MHz, CDCl3): δ = 8.26–8.21 (m, 1H), 7.68–7.61 (m, 4H), 7.58–7.54 
(m, 1H), 7.46 (m, 4H), 7.36 (d, J = 7.8 Hz, 2H), 3.08 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 158.9 (Cq), 
148.0 (Cq), 144.1 (Cq), 141.1 (Cq), 135.4 (Cq), 131.7 (CH), 130.6 (CH), 130.5 (CH), 129.8 (q, 
2JC-F = 32 
Hz, Cq), 129.3 (q, 
2JC-F = 32 Hz, Cq), 128.3 (Cq), 127.3 (CH), 126.4 (Cq), 125.8 (Cq), 125.4 (q, 
3JC-F = 4 Hz, 
CH), 124.8 (q, 3JC-F = 4 Hz, CH), 124.0 (d, 
1JC-F = 272 Hz, Cq), 124.0 (d, 
1JC-F = 272 Hz, Cq), 22.74 (CH3). 
19F NMR (376 MHz, CDCl3): δ = 62.5, 62.6. IR (ATR) ν = 3063, 2985, 1618, 1556, 1411, 1394, 1320, 
1160, 1104, 1064, 1017, 951, 848, 834, cm-1. MS (ESI) m/z (relative intensity): 432 [M+H]+. HR-MS 
(ESI) m/z calcd for C24H16F6N [M+H]





3,4-Bis(4-fluorophenyl)-1-methylisoquinoline (119af): The general procedure A was followed using 
(E)-acetophenone O-acetyl oxime (158a) (89 mg, 0.50 mmol) and 1,2-bis(4-fluorophenyl)ethyne (8f) 
(161 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 40/1 → 
20/1) yielded 119af (111 mg, 67%) as a pale yellow solid.  
M.p. = 138−140 °C. 1H NMR (400 MHz, CDCl3): δ = 8.23–8.14 (m, 1H), 7.65–7.55 (m, 3H), 7.37–7.28 
(m, 2H), 7.21–7.13 (m, 2H), 7.11–7.01 (m, 2H), 6.95–6.86 (m, 2H), 3.05 (s, 3H). 13C NMR (100 MHz, 
CDCl3): δ = 162.0 (d, 
1JC−F = 248 Hz, Cq), 162.0 (d, 
1JC−F = 247 Hz, Cq), 158.0 (Cq), 148.6 (Cq), 136.9 (d, 
4JC−F = 4 Hz, Cq), 135.9 (Cq), 133.3 (d, 
4JC−F = 4 Hz, Cq), 132.9 (d, 
3JC−F = 8 Hz, CH), 131.9 (d, 
3JC−F = 8 Hz, 
CH), 130.1 (CH), 128.0 (Cq), 126.7 (CH), 126.2 (Cq), 125.9 (CH), 125.6 (CH), 115.4 (d, 
2JC−F = 21 Hz, CH), 
114.6 (d, 2JC−F = 21 Hz, CH), 22.7 (CH3). 
19F NMR (376 MHz, CDCl3): δ = 114.6 (tt, J = 8.8, 5.6 Hz), 
−115.2 (tt, J = 8.7, 5.5 Hz). IR (ATR) ν = 3071, 3035, 1603, 1572, 1507, 1437, 1391, 1222, 1093, 837, 
759, 728 cm-1. MS (ESI) m/z (relative intensity): 332 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C22H16F2N [M+H]
+: 332.1245, found: 332.1246.  
The analytical data were in accordance with those reported in the literature.[109c]  
 
 
3,4-Bis(4-chlorophenyl)-1-methylisoquinoline (119ag): The general procedure A was followed using 
(E)-acetophenone O-acetyl oxime (158a) (89 mg, 0.50 mmol) and 1,2-bis(4-chlorophenyl)ethyne (8g) 
(185 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 40/1 → 
20/1) yielded 119ag (120 mg, 66%) as a pale yellow solid.  




(m, 2H), 7.31–7.27 (m, 2H), 7.21–7.17 (m, 2H), 7.16–7.12 (m, 2H), 3.06 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ = 158.3 (Cq), 148.1 (Cq), 139.2 (Cq), 135.8 (Cq), 135.7 (Cq), 133.4 (Cq), 133.2 (Cq), 132.6 (CH), 
131.5 (CH), 130.2 (CH), 128.7 (CH), 128.0 (Cq), 127.9 (CH), 126.9 (CH), 126.2 (Cq), 125.8 (CH), 125.6 
(CH), 22.6 (CH3). IR (ATR) ν = 3070, 1568, 1552, 1488, 1431, 1333, 1084, 1013, 796, 460 cm
-1. MS 
(ESI) m/z (relative intensity): 364 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H16Cl2N [M+H]
+: 
364.0654, found: 364.0652.  
The analytical data were in accordance with those reported in the literature.[195] 
 
 
3,4-Bis(4-bromophenyl)-1-methylisoquinoline (119ah): The general procedure A was followed 
using (E)-acetophenone O-acetyl oxime (158a) (89 mg, 0.50 mmol) and 
1,2-bis(4-bromophenyl)ethyne (8h) (252 mg, 0.75 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 40/1 → 20/1) yielded 119ah (161 mg, 71%) as a pale yellow solid.  
M.p. = 176–178 °C. 1H NMR (500 MHz, CDCl3): δ = 8.22–8.13 (m, 1H), 7.65–7.55 (m, 3H), 7.54–7.46 
(m, 2H), 7.36–7.32 (m, 2H), 7.24–7.20 (m, 2H), 7.10–7.06 (m, 2H), 3.04 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ = 158.4 (Cq), 148.1 (Cq), 139.6 (Cq), 136.2 (Cq), 135.6 (Cq), 132.9 (CH), 131.9 (CH), 131.7 
(CH), 130.9 (CH), 130.3 (CH), 127.9 (Cq), 126.9 (CH), 126.2 (Cq), 125.8 (CH), 125.7 (CH), 121.6 (Cq), 
121.5 (Cq), 22.7 (CH3). IR (ATR) ν = 3060, 1544, 1414, 1387, 1073, 1028, 898, 754, 728, 696 cm
-1. MS 
(ESI) m/z (relative intensity): 454 [M+H]+. HR-MS (ESI) m/z calcd for C22H16Br2N [M+H]
+: 451.9649, 
found: 451.9643.  







3,4-Bis(3-chlorophenyl)-1-methylisoquinoline (119ai): The general procedure A was followed using 
(E)-acetophenone O-acetyl oxime (158a) (89 mg, 0.50 mmol) and 1,2-bis(3-chlorophenyl)ethyne (8i) 
(185 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 40/1 → 
20/1) yielded 119ai (95 mg, 52%) as a pale yellow solid.  
M.p. = 107–109 °C. 1H NMR (500 MHz, CDCl3): δ = 8.23–8.17 (m, 1H), 7.66–7.57 (m, 3H), 7.47–7.46 
(m, 1H), 7.36–7.23 (m, 3H), 7.19–7.14 (m, 1H), 7.14–7.06 (m, 3H), 3.06 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ = 158.5 (Cq), 147.9 (Cq), 142.4 (Cq), 139.1 (Cq), 135.6 (Cq), 134.3 (Cq), 133.8 (Cq), 131.2 (CH), 
130.4 (CH), 130.3 (CH), 129.7 (CH), 129.6 (CH), 128.8 (CH), 128.3 (CH), 128.1 (Cq), 127.7 (CH), 127.4 
(CH), 127.0 (CH), 126.3 (Cq), 125.9 (CH), 125.7 (CH), 22.7 (CH3). IR (ATR) ν = 3065, 1593, 1565, 1434, 
1390, 1330, 1078, 783, 760, 703, 631 cm-1. MS (ESI) m/z (relative intensity): 364 [M+H]+. HR-MS (ESI) 
m/z calcd for C22H16Cl2N [M+H]
+: 364.0654, found: 364.0656. 
 
 
1-Methyl-3,4-di(thiophen-3-yl)isoquinoline (119aj): The general procedure A was followed using 
(E)-acetophenone O-acetyl oxime (158a) (89 mg, 0.50 mmol) and 
2-(thiophen-3-ylethynyl)thiophene (8j) (143 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 60/1 → 30/1) yielded 119aj (129 mg, 84%) as a pale 
yellow solid.  
M.p. = 120–122 °C. 1H NMR (500 MHz, CDCl3): δ = 8.09 (dd, J = 8.2, 1.1 Hz, 1H), 7.63–7.55 (m, 3H), 
7.52 (ddd, J = 8.1, 6.5, 1.5 Hz, 1H), 7.30 (dd, J = 5.0, 1.1 Hz, 1H), 7.26 (dd, J = 5.2, 3.4 Hz, 1H), 7.09 
(dd, J = 3.4, 1.1 Hz, 1H), 6.91 (dd, J = 5.0, 3.8 Hz, 1H), 6.75 (dd, J = 3.8, 1.1 Hz, 1H), 3.03 (s, 3H). 13C 
NMR (125 MHz, CDCl3): δ = 158.7 (Cq), 144.9 (Cq), 144.2 (Cq), 137.9 (Cq), 137.7 (Cq), 130.3 (CH), 




(CH), 118.7 (Cq), 22.6 (CH3). IR (ATR) ν = 3097, 3066, 1609, 1558, 1530, 1433, 1382, 1233, 1063, 904, 
843, 816, 756, 702, 611, 541 cm-1. MS (ESI) m/z (relative intensity): 308 [M+H]+. HR-MS (ESI) m/z 
calcd for C18H14NS2 [M+H]
+: 308.0562, found: 308.0565.  
The analytical data were in accordance with those reported in the literature.[140a] 
 
 
6-Chloro-3,4-diethyl-1-methylisoquinoline (119gk): The general procedure A was followed using 
(E)-1-(4-chlorophenyl)ethanone O-acetyl oxime (158g) (106 mg, 0.50 mmol) and hex-3-yne (8k) (66 
mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 30/1 → 15/1) 
yielded 119gk (88 mg, 75%) as a pale yellow solid.  
M.p. = 34–36 °C. 1H NMR (400 MHz, CDCl3): δ = 7.97 (dd, J = 8.9, 0.5 Hz, 1H), 7.90 (dd, J = 2.1, 0.5 Hz, 
1H), 7.39 (dd, J = 8.9, 2.1 Hz, 1H), 2.94 (q, J = 7.6 Hz, 4H), 2.86 (s, 3H), 1.31 (t, J = 7.6 Hz, 3H), 1.25 (t, 
J = 7.6 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 155.7 (Cq), 153.9 (Cq), 136.2 (Cq), 135.8 (Cq), 127.9 
(CH), 126.5 (Cq), 126.1 (CH), 124.3 (Cq), 122.5 (CH), 28.5 (CH2), 22.3 (CH3), 20.6 (CH2), 15.1 (CH3), 
14.7 (CH3). IR (ATR) ν = 2963, 2931, 2870, 1606, 1565, 1448, 1387, 1308, 1164, 1097, 1001, 875, 817, 
805 cm-1. MS (ESI) m/z (relative intensity): 234 [M+H]+. HR-MS (ESI) m/z calcd for C14H17ClN [M+H]
+: 
234.1044, found: 234.1049. 
 
 
6-Chloro-1-methyl-3,4-dipropylisoquinoline (119gl): The general procedure A was followed using 
(E)-1-(4-chlorophenyl)ethanone O-acetyl oxime (158g) (106 mg, 0.50 mmol) and oct-4-yne (8l) (83 
mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 30/1 → 15/1) 
yielded 119gl (80 mg, 61%) as a pale yellow oil.  
1H NMR (400 MHz, CDCl3): δ = 7.97 (dd, J = 8.9, 0.5 Hz, 1H), 7.87 (dd, J = 2.1, 0.5 Hz, 1H), 7.39 (dd, J 
= 8.9, 2.0 Hz, 1H), 2.93–2.83 (m, 7H), 1.82–1.69 (m, 2H), 1.68–1.56 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H), 




127.8 (CH), 126.1 (CH), 125.5 (Cq), 124.2 (Cq), 122.7 (CH), 37.4 (CH2), 29.7 (CH2), 24.1 (CH2), 23.6 
(CH2), 22.3 (CH3), 14.5 (CH3), 14.3 (CH3). IR (ATR) ν = 2958, 2870, 1606, 1567, 1455, 1393, 1329, 
1102, 991, 870, 812, 625 cm-1. MS (ESI) m/z (relative intensity): 262 [M+H]+. HR-MS (ESI) m/z calcd 
for C16H21ClN [M+H]
+: 262.1357, found: 262.1358. 
 
 
3,4-Dibutyl-6-chloro-1-methylisoquinoline (119gm): The general procedure A was followed using 
(E)-1-(4-chlorophenyl)ethanone O-acetyl oxime (158g) (106 mg, 0.50 mmol) and dec-5-yne (8m) 
(104 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 40/1 → 
20/1) yielded 119gm (123 mg, 85%) as a pale yellow solid.  
M.p. = 41–42 °C. 1H NMR (400 MHz, CDCl3): δ = 7.97 (dd, J = 8.9, 0.5 Hz, 1H), 7.88 (dd, J = 2.1, 0.5 Hz, 
1H), 7.39 (dd, J = 8.9, 2.0 Hz, 1H), 2.93–2.86 (m, 4H), 2.85 (s, 3H), 1.76–1.66 (m, 2H), 1.62–1.38 (m, 
6H), 0.99 (t, J = 7.6 Hz, 3H), 0.95 (t, J = 7.6 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 155.5 (Cq), 153.2 
(Cq), 136.4 (Cq), 135.7 (Cq), 127.8 (CH), 126.0 (CH), 125.5 (Cq), 124.2 (Cq), 122.6 (CH), 35.3 (CH2), 33.0 
(CH2), 32.7 (CH2), 27.4 (CH2), 23.1 (CH2), 23.0 (CH2), 22.3 (CH3), 14.1 (CH3), 13.9 (CH3). IR (ATR) ν = 
2951, 2926, 2870, 1605, 1565, 1490, 1392, 1332, 1101, 991, 896, 877, 810, 773, 616 cm -1. MS (ESI) 
m/z (relative intensity): 290 [M+H]+. HR-MS (ESI) m/z calcd for C18H25ClN [M+H]




1,4-Dimethyl-3-phenylisoquinoline (119an): The general procedure A was followed using 
(E)-acetophenone O-acetyl oxime (158a) (89 mg, 0.50 mmol) and prop-1-yn-1-ylbenzene (8n) (88 
mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 40/1 → 20/1) 
yielded 119an (79 mg, 68%) as a pale yellow solid.  
M.p. = 95–97 °C. 1H NMR (500 MHz, CDCl3): δ = 8.17–8.13 (m, 1H), 8.04 (ddd, J = 7.5, 4.2, 3.4 Hz, 




2.98 (d, J = 0.4 Hz, 3H), 2.59 (d, J = 0.4 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ = 155.8 (Cq), 150.6 (Cq), 
141.6 (Cq), 136.2 (Cq), 129.8 (CH), 129.8 (CH), 128.1 (CH), 127.4 (CH), 126.2 (CH), 126.1 (Cq), 126.0 
(CH), 124.1 (CH), 122.1 (Cq), 22.5 (CH3), 15.4 (CH3). IR (ATR) ν = 2948, 1568, 1501, 1431, 1333, 1084, 
1013, 837, 757, 561 cm-1. MS (ESI) m/z (relative intensity): 234 [M+H]+. HR-MS (ESI) m/z calcd for 
C17H16N [M+H]
+: 234.1277, found: 234.1281.  
The analytical data were in accordance with those reported in the literature.[194] 
 
 
6-Chloro-1-methyl-3-phenylisoquinoline (119go): The general procedure A was followed using 
(E)-1-(4-chlorophenyl)ethanone O-acetyl oxime (158g) (106 mg, 0.50 mmol) and ethynylbenzene 
(8o) (77 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
60/1 → 30/1) yielded 119go (82 mg, 65%) as a pale yellow solid.  
M.p. = 90–92 °C. 1H NMR (500 MHz, CDCl3): δ = 8.12–8.07 (m, 2H), 8.01 (d, J = 10 Hz, 1H), 7.78 (t, J = 
5 Hz, 2H), 7.51–7.44 (m, 3H), 7.40 (t, J = 10 Hz, 1H), 2.98 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 
158.5 (Cq), 151.1 (Cq), 139.3 (Cq), 137.6 (Cq), 136.1 (Cq), 128.7 (CH), 128.6 (CH), 127.6 (CH), 127.3 
(CH), 127.0 (CH), 126.2 (CH), 124.7 (Cq), 114.2 (CH), 22.6 (CH3). IR (ATR) ν = 3068, 3032, 2922, 1615, 
1566, 1489, 1385, 1361, 1086, 912, 886, 814, 772, 688 cm-1. MS (ESI) m/z (relative intensity): 254 
[M+H]+. HR-MS (ESI) m/z calcd for C16H13ClN [M+H]
+: 254.0731, found: 254.0736. 
 
 
6-Chloro-1-methyl-3-(p-tolyl)isoquinoline (119gp): The general procedure A was followed using 
(E)-1-(4-chlorophenyl)ethanone O-acetyl oxime (158g) (106 mg, 0.50 mmol) and 
1-ethynyl-4-methylbenzene (8p) (87 mg, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 60/1 → 30/1) yielded 119gp (68 mg, 51%) as a pale yellow solid.  
M.p. = 92–93 °C. 1H NMR (500 MHz, CDCl3): δ = 8.04–7.97 (m, 3H), 7.78 (d, J = 2.1 Hz, 1H), 7.76 (s, 




(100 MHz, CDCl3): δ = 158.4 (Cq), 151.1 (Cq), 138.6 (Cq), 137.7 (Cq), 136.5 (Cq), 136.0 (Cq), 129.5 (CH), 
127.4 (CH), 126.8 (CH), 126.2 (CH), 124.6 (Cq), 113.6 (CH), 22.6 (CH3), 21.3 (CH3). IR (ATR) ν = 3063, 
2918, 1613, 1568, 1439, 1178, 1085, 914, 881, 818 cm-1. MS (ESI) m/z (relative intensity): 268 
[M+H]+. HR-MS (ESI) m/z calcd for C17H15ClN [M+H]
+: 268.0888, found: 268.0888. 
 
Intermolecular Competition Experiment 
 
A suspension of (E)-1-(4-methoxyphenyl)ethanone O-acetyl oxime (158c) (104 mg, 0.5 mmol), 
(E)-1-[4-(trifluoromethyl)phenyl]ethanone O-acetyl oxime (158e) (123 mg, 0.5 mmol), 
diphenylacetylene (8a) (89 mg, 0.5 mmol), Cp*Co(CO)I2 (24 mg, 10 mol %), AgSbF6 (34.4 mg, 20 
mol %) and NaOAc (8.2 mg, 20 mol %) in DCE (2.0 mL) was stirred at 120 °C for 15 min under air. 
After cooling to ambient temperature, the mixture was transferred into a round bottom flask with 
DCM (20 mL) and concentrated under reduced pressure, purified by flash column chromatography 
on silica gel (n-hexane/EtOAc: 30/1 → 20/1 → 10/1) yielded the products 119ca (45 mg, 28%) and 
119ea (31 mg, 17%). 
 
Intramolecular Competition Experiment 
 
A suspension of (4-methoxyphenyl)(phenyl)methanone O-acetyl oxime (158u) (135mg, 0.5 mmol), 
diphenylacetylene (8a) (89 mg, 0.5 mmol), Cp*Co(CO)I2 (24 mg, 10 mol %), AgSbF6 (34.4 mg, 20 
mol %) and NaOAc (8.2 mg, 20 mol %) in DCE (2.0 mL) was stirred at 120 °C for 15 min under air. 




DCM (20 mL) and concentrated under reduced pressure, purified by flash column chromatography 




6-Methoxy-1,3,4-triphenylisoquinoline (119ua): A white solid.  
M.p. = 183–185 °C. 1H NMR (300 MHz, CDCl3): δ = 8.09 (d, J = 9.2 Hz, 1H), 7.86–7.73 (m, 2H), 7.58–
7.47 (m, 3H), 7.45–7.28 (m, 7H), 7.22–7.10 (m, 4H), 6.98 (d, J = 2.6 Hz, 1H), 3.73 (s, 3H). 13C NMR 
(125 MHz, CDCl3): δ = 160.5 (Cq), 159.1 (Cq), 150.3 (Cq), 141.1 (Cq), 139.9 (Cq), 139.0 (Cq), 137.8 (Cq), 
131.2 (CH), 130.4 (CH), 130.1 (CH), 129.4 (CH), 129.0 (Cq), 128.4 (CH), 128.4 (CH), 128.2 (CH), 127.4 
(CH), 127.2 (CH), 126.9 (CH), 121.2 (Cq), 118.8 (CH), 104.2 (CH), 55.2 (CH3). IR (ATR) ν = 1407, 1374, 
1220, 1029, 833, 775, 752, 702, 694, 666 cm-1. MS (ESI) m/z (relative intensity): 388 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C28H22NO [M+H]
+: 388.1696, found: 388.1699. 
 
 
1-(4-Methoxyphenyl)-3,4-diphenylisoquinoline (119ua’): A white solid.  
M.p. = 155–157 °C. 1H NMR (400 MHz, CDCl3): δ = 8.22 (ddd, J = 8.3, 1.4, 0.7 Hz, 1 H), 7.84─7.75 (m, 
2 H), 7.70 (ddd, J = 8.5, 1.3, 0.7 Hz, 1 H), 7.57 (ddd, J = 8.4, 6.7, 1.4 Hz, 1 H), 7.51 (ddd, J = 8.1, 6.7, 
1.3 Hz, 1 H), 7.45─7.32 (m, 5 H), 7.31─7.27 (m, 2 H), 7.21─7.14 (m, 3 H), 7.08 (d, J = 8.7 Hz, 2 H), 3.90 
(s, 3 H). 13C NMR (100 MHz, CDCl3): δ = 160.0 (Cq), 159.4 (Cq), 149.6 (Cq), 141.0 (Cq), 137.6 (Cq), 
137.0 (Cq), 132.4 (Cq), 131.6 (CH), 131.4 (CH), 130.4 (CH), 129.8 (CH), 129.3 (Cq), 128.3 (CH), 127.5 
(CH), 127.5 (CH), 127.2 (CH), 126.9 (CH), 126.4 (CH), 126.0 (Cq), 125.4 (CH), 113.8 (CH), 55.4 (CH3). IR 
(ATR) ν = 3055, 2928, 1736, 1606, 1540, 1501, 1384, 1245, 1170, 1028, 980, 841, 768, 700 cm-1. MS 
(ESI) m/z (relative intensity): 388 (100) [M+H]+. HR-MS (ESI) m/z calcd for C28H22NO [M+H]
+: 




The analytical data were in accordance with those reported in the literature.[196] 
Intermolecular Competition Experiment between Alkynes 
 
 
To a solution of (E)-acetophenone O-acetyl oxime (158a) (89 mg, 0.5 mmol), diphenylacetylene (8a) 
(89 mg, 0.5 mmol), dec-5-yne (8m) (69 mg, 0.5 mmol), Cp*Co(CO)I2 (24 mg, 10 mol %), AgSbF6 (34.4 
mg, 20 mol %) and NaOAc (8.2 mg, 20 mol %) in DCE (2.0 mL) was stirred at 120 °C for 15 min under 
air. After cooling to ambient temperature, the mixture was transferred into a round bottom flask 
with DCM (20 mL) and concentrated under reduced pressure, purified by flash column 
chromatography on silica gel (n-hexane/EtOAc: 20/1) to afford the products (119aa + 119am: 73 mg) 
and the yields were determined by 1H NMR spectroscopy. 
 
H/D Exchange Experiment 
 
(E)-1-(4-Methoxyphenyl)ethanone O-acetyl oxime (158c) (104 mg, 0.5 mmol), diphenylacetylene (8a) 
(89 mg, 0.50 mmol), Cp*Co(CO)I2 (24 mg, 10 mol %), AgSbF6 (34.4 mg, 20 mol %), NaOAc (8.2 mg, 
20 mol %), DCE (1.8 mL) and D2O (0.2 ml) were placed in a 25 mL Schlenk tube under air and then 
were stirred at 120 °C for 15 min. At ambient temperature, the reaction mixture was diluted with 
H2O (10 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layers were dried over 
Na2SO4 and concentrated under reduced pressure. Purification by flash column chromatography on 
silica gel (n-hexane/EtOAc: 40/1→15/1) yielded [D]n-158c (53 mg, 51%) and [D]n-119ca (54 mg, 






6-Methoxy-1-methyl-3,4-diphenylisoquinoline (119ca) (163mg, 0.5 mmol), Cp*Co(CO)I2 (24 mg, 10 
mol %), AgSbF6 (34.4 mg, 20 mol %), NaOAc (8.2 mg, 20 mol %), DCE (1.8 mL) and D2O (0.2 ml) were 
placed in a 25 mL Schlenk tube under air and were then stirred at 120 °C for 15 min. At ambient 
temperature, the reaction mixture was filtered over a short plug of silica and the result of H/D 
exchange experiment was determined by crude 1H NMR. Then the reaction mixture was transferred 
into a round bottom flask with DCM (20 mL) and concentrated under reduced pressure, purified by 




Kinetic Isotope Effect Experiment 
 
 
Two parallel reactions of 8a with 158a and [D]5-158a respectively were performed to determine the 
corresponding KIE value: 158a (89 mg, 0.5 mmol) or [D]5-158a (93 mg, 0.5 mmol), 
diphenylacetylene (8a) (134 mg, 0.75 mmol), Cp*Co(CO)I2 (12 mg, 5 mol %), AgSbF6 (17.2 mg, 10 
mol %), NaOAc (4 mg, 20 mol %), 1,3,5-trimethoxybenzene (28 mg, 0.5/3 mmol) and DCE (2.0 mL) 
were placed in a 25 mL Schlenk tube. The mixture was stirred at 60 °C, a periodic aliquot (0.05 mL) 





        t / min 
yield / % 
5 10 15 20 30 
119aa 4 13 20 29 40 




Attempted Cyclization of ortho-Alkenylated Arene 119aa 
 
 
(E)-1-{2-[(E)-1,2-diphenylvinyl]phenyl}ethanone O-acetyl oxime (169) (25mg, 70 umol), Cp*Co(CO)I2 
(3.4 mg, 10 mol %), AgSbF6 (5 mg, 20 mol %), NaOAc (2 mg, 20 mol %), DCE (0.3 mL) were placed in 
a 25 mL Schlenk tube under air and were then stirred at 120 °C for 16 h. After cooling to ambient 
temperature, the reaction mixture was transferred into a round bottom flask with DCM (10 mL) and 
concentrated under reduced pressure, purified by flash column chromatography on silica gel 
(n-hexane/EtOAc: 25/1) yielded 119aa (15%). In the absence of the Co-catalyst no reaction was 
observed and only starting material was recovered. 
 
y = 0.9919x - 1.2703 
























(E)-1-{2-[(E)-1,2-Diphenylvinyl]phenyl}ethanone O-acetyl oxime (169): A white solid.  
M.p. = 110−114 °C. 1H NMR (500 MHz, CDCl3): δ = 7.46–7.38 (m, 3H), 7.35–7.23 (m, 5H), 7.19–7.09 
(m, 3H), 7.04–6.99 (m, 3H), 2.01 (s, 3H), 1.89 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 170.8 (Cq), 
163.5 (Cq), 142.7 (Cq), 141.2 (Cq), 139.4 (Cq), 137.1 (Cq), 136.4 (Cq), 132.0 (CH), 130.0 (CH), 129.5 (CH), 
129.4 (CH), 129.1 (CH), 128.4 (CH), 128.2 (CH), 128.1 (CH), 127.8 (CH), 127.5 (CH), 127.2 (CH), 20.1 
(CH3), 16.6 (CH3). IR (ATR) ν = 1772, 1317, 1210, 924, 762, 750, 697, 644 cm
-1. MS (ESI) m/z (relative 
intensity): 378 (100) [M+Na]+, 296 (70) [M−OAc]+. HR-MS (ESI) m/z calcd for C24H21N2NaO [M+Na]
+: 
378.1465, found: 378.1466.  
The analytical data were in accordance with those reported in the literature.[182] 
 





5-Methyl-2,3-diphenyl-1H-indole (160aa): The general procedure B was followed using 
N-(4-methoxybenzylidene)-4-methylaniline oxide (159a) (121 mg, 0.50 mmol) and 
1,2-diphenylethyne (8a) (134 mg, 0.75 mmol). Purification by coloumn chromatography on silica gel 
(n-hexane/CH2Cl2: 3/1) yielded 160aa (130 mg, 92%) as a white solid.  
M. p. = 143−145 °C. 1H NMR (300 MHz, CDCl3): δ = 8.11 (s, 1H), 7.58─7.37 (m, 7H), 7.36─7.19 (m, 
5H), 7.09 (dd, J = 8.3, 1.6 Hz, 1H), 2.46 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 135.2 (Cq), 134.2 (Cq), 
134.2 (Cq), 132.8 (Cq), 130.2 (CH), 129.7 (Cq), 129.0 (Cq), 128.6 (CH), 128.5 (CH), 128.1 (CH), 127.5 
(CH), 126.1 (CH), 124.3 (CH), 119.2 (CH), 114.6 (Cq), 110.5 (CH), 21.5 (CH3). IR (ATR) ν = 3368, 3056, 




HR-MS (ESI) m/z calcd for C21H17N [M-H]
-: 282.1288, found: 282.1292.  
The analytical data were in accordance with those reported in the literature.[161] 
 
 
2,3-Diphenyl-1H-indole (160ba): The general procedure B was followed using 
N-(4-methoxybenzylidene)aniline oxide (159b) (113.6 mg, 0.50 mmol) and 1,2-diphenylethyne (8a) 
(134 mg, 0.75 mmol). Purification by coloumn chromatography on silica gel (n-hexane/CH2Cl2: 3/1) 
yielded 160ba (102.3 mg, 76%) as a white solid.  
M. p. = 98−100 °C. 1H NMR (300 MHz, CDCl3): δ = 8.18 (s, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.55─7.38 (m, 
7H), 7.38─7.22 (m, 5H), 7.17 (t, J = 7.5 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ = 135.8 (Cq), 135.0 (Cq), 
134.0 (Cq), 132.6 (Cq), 130.1 (CH), 128.7 (Cq), 128.6 (CH), 128.5 (CH), 128.1 (CH), 127.7 (CH), 126.2 
(CH), 122.7 (CH), 120.4 (CH), 119.7 (CH), 115.0 (Cq), 110.7 (CH). IR (ATR) ν = 3389, 3039, 1601, 1455, 
1151, 1008, 748, 694, 606, 515 cm-1. MS (ESI) m/z (relative intensity): 269 (100), 296 (85), 381 (20) 
[M]+. HR-MS (ESI) m/z calcd for C20H15N [M]
+: 269.1199, found: 269.1197.  
The analytical data were in accordance with those reported in the literature.[161] 
 
 
5-Fluoro-2,3-diphenyl-1H-indole (160ca): The general procedure B was followed using 
4-fluoro-N-(4-methoxybenzylidene)aniline oxide (159c) (122.6 mg, 0.50 mmol) and 
1,2-diphenylethyne (8a) (134 mg, 0.75 mmol). Purification by coloumn chromatography on silica gel 
(n-hexane/CH2Cl2: 3/1) yielded 160ca (101 mg, 70%) as a white solid.  
M. p. = 124−126 °C. 1H NMR (300 MHz, CDCl3): δ = 8.13 (s, 1H), 7.50─7.37 (m, 7H), 7.36─7.26 (m, 
5H), 7.01 (td, J = 9.0, 2.5 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ = 158.4 (d, 
1JC-F = 235.3 Hz, Cq), 135.8 
(Cq), 134.6 (Cq), 132.3 (Cq), 132.3 (Cq), 129.9 (CH), 129.2 (d, 
3JC-F = 10.1 Hz, Cq), 128.7 (CH), 128.6 (CH), 
128.1 (CH), 127.9 (CH), 126.4 (CH), 115.2 (d, 4JC-F = 4.7 Hz, Cq), 111.6 (d, 
3JC-F = 9.8 Hz, CH), 111.0 (d, 
2JC-F = 26.5 Hz, CH), 104.6 (d, 
2JC-F = 24.1 Hz, CH). 




4.4 Hz). IR (ATR) ν = 3423, 1600, 1474, 1069, 951, 859, 754, 692 cm-1. MS (ESI) m/z (relative 
intensity): 286 (100) [M-H]-. HR-MS (ESI) m/z calcd for C20H14NF [M-H]
-: 286.1038, found: 286.1040.  
The analytical data were in accordance with those reported in the literature.[161] 
 
 
5-Chloro-2,3-diphenyl-1H-indole (160da): The general procedure B was followed using 
4-chloro-N-(4-methoxybenzylidene)aniline oxide (159d) (131 mg, 0.50 mmol) and 
1,2-diphenylethyne (8a) (134 mg, 0.75 mmol). Purification by coloumn chromatography on silica gel 
(n-hexane/CH2Cl2: 3/1) yielded 160da (115 mg, 76%) as a pale yellow solid.  
M. p. = 110−112 °C. 1H NMR (300 MHz, CDCl3): δ = 8. 20 (s, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.50─7.34 
(m, 6H), 7.34─7.25 (m, 5H), 7.18 (dd, J = 8.6, 2.0 Hz, 1H). 13C NMR (76 MHz, CDCl3): δ = 135.4 (Cq), 
134.3 (Cq), 134.2 (Cq), 132.1 (Cq), 130.0 (CH), 129.9 (Cq), 128.7 (CH), 128.6 (CH), 128.1 (CH), 128.0 
(CH), 126.5 (CH), 126.1 (Cq), 122.9 (CH), 119.1 (CH), 114.7 (Cq), 111.9 (CH). IR (ATR) ν = 3438, 3420, 
1506, 1458, 762, 694, 607 cm-1. MS (ESI) m/z (relative intensity): 302 (100), 304 (30) [M-H]-. HR-MS 
(ESI) m/z calcd for C20H14NCl [M-H]
-: 302.0742, found: 302.0743.  
The analytical data were in accordance with those reported in the literature.[161] 
 
 
5-Bromo-2,3-diphenyl-1H-indole (160ea): The general procedure B was followed using 
4-bromo-N-(4-methoxybenzylidene)aniline oxide (159e) (153 mg, 0.50 mmol) and 
1,2-diphenylethyne (8a) (134 mg, 0.75 mmol). Purification by coloumn chromatography on silica gel 
(n-hexane/CH2Cl2: 3/1) yielded 160ea (158 mg, 91%) as a pale yellow solid.  
M. p. = 133−135 °C. 1H NMR (300 MHz, CDCl3): δ = 8.19 (s, 1H), 7.78 (d, J = 1.8 Hz, 1H), 7.49─7.36 (m, 
6H), 7.35─7.21 (m, 6H). 13C NMR (75 MHz, CDCl3): δ = 135.2 (Cq), 134.4 (Cq), 134.3 (Cq), 132.0 (Cq), 
130.5 (Cq), 130.0 (CH), 128.7 (CH), 128.6 (CH), 128.1 (CH), 128.0 (CH), 126.5 (CH), 125.4 (CH), 122.1 




445 cm-1. MS (ESI) m/z (relative intensity): 346 (100) [M-H]-. HR-MS (ESI) m/z calcd for C20H14NBr 
[M-H]-: 346.0237, found: 346.0231.  
The analytical data were in accordance with those reported in the literature.[161] 
 
 
6-Methyl-2,3-diphenyl-1H-indole (160fa): The general procedure B was followed using 
N-(4-methoxybenzylidene)-3-methylaniline oxide (159f) (121 mg, 0.50 mmol) and 
1,2-diphenylethyne (8a) (134 mg, 0.75 mmol). Purification by coloumn chromatography on silica gel 
(n-hexane/CH2Cl2: 3/1) yielded 160fa (126 mg, 89%) as a white solid.  
M. p. = 95−97 °C. 1H NMR (300 MHz, CDCl3): δ = 8.07 (s, 1H), 7.56 (d, J = 8.2 Hz, 1H), 7.48─7.36 (m, 
5H), 7.35─7.24 (m, 5H), 7.22─7.19 (m, 1H), 6.99 (dd, J = 8.2, 0.9 Hz, 1H), 2.49 (s, 3H). 13C NMR (75 
MHz, CDCl3): δ = 136.3 (Cq), 135.2 (Cq), 133.3 (Cq), 132.8 (Cq), 132.6 (Cq), 130.1 (CH), 128.6 (CH), 
128.5 (CH), 128.0 (CH), 127.5 (CH), 126.6 (Cq), 126.1 (CH), 122.2 (CH), 119.3 (CH), 114.9 (Cq), 110.8 
(CH), 21.7 (CH3). IR (ATR) ν = 3406, 1601, 1502, 1449, 1439, 1250, 914, 804, 763, 697 cm
-1. MS (ESI) 
m/z (relative intensity): 282 (100) [M-H]-. HR-MS (ESI) m/z calcd for C21H17N [M-H]
-: 282.1288, found: 
282.1289.  
The analytical data were in accordance with those reported in the literature.[161] 
 
 
5-Methyl-2,3-di-p-tolyl-1H-indole (160ab): The general procedure B was followed using 
N-(4-methoxybenzylidene)-4-methylaniline oxide (159a) (121 mg, 0.50 mmol) and 
1,2-di-p-tolylethyne (8b) (155 mg, 0.75 mmol). Purification by coloumn chromatography on silica gel 
(n-pentane/EtOAc: 30/1) yielded 160ab (115.2 mg, 74%) as a white solid.  
M. p. = 157─160 °C. 1H NMR (300 MHz, CDCl3): δ = 8.05 (s, 1H), 7.44 (s, 1H), 7.35─7.28 (m, 5H), 




3H). 13C NMR (125 MHz, CDCl3): δ = 137.2 (Cq), 135.5 (Cq), 134.0 (Cq), 132.2 (Cq), 130.0 (Cq), 129.9 
(CH), 129.9 (Cq) 129.4 (Cq), 129.2 (CH), 129.1 (CH), 129.1 (Cq), 127.8 (CH), 123.9 (CH), 119.1 (CH), 
114.1 (Cq), 110.4 (CH), 21.6 (CH3), 21.3 (CH3), 21.3 (CH3). IR (ATR) ν = 3379, 2917, 1510, 1439, 821, 
798, 723, 517 cm-1. MS (EI) m/z (relative intensity): 327 (17), 311 (100) [M]+. HR-MS (ESI) m/z calcd 
for C23H21N [M]
+: 311.1674, found: 311.1665.  
The analytical data were in accordance with those reported in the literature.[197] 
 
 
2,3-Bis(4-methoxyphenyl)-5-methyl-1H-indole (160ac): The general procedure B was followed 
using N-(4-methoxybenzylidene)-4-methylaniline oxide (159a) (121 mg, 0.50 mmol) and 
1,2-bis(4-methoxyphenyl)ethyne (8c) (178 mg, 0.75 mmol). Purification by coloumn 
chromatography on silica gel (n-pentane/EtOAc: 10/1) yielded 160ac (122 mg, 71%) as a yellow 
solid.  
M. p. = 147−150 °C. 1H NMR (500 MHz, CDCl3): δ = 8.03 (s, 1H), 7.40 (s, 1H), 7.37─7.30 (m, 4H), 7.27 
(d, J = 8.2 Hz, 1H), 7.03 (s, 1H), 6.93 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.9 Hz, 2H), 3.85 (s, 3H), 3.80 (s, 
3H), 2.43 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 159.0 (Cq), 157.9 (Cq), 134.0 (Cq), 133.8 (Cq), 131.1 
(CH), 129.4 (Cq), 129.2 (CH), 127.7 (Cq), 125.4 (Cq), 123.8 (CH), 119.0 (CH), 114.3 (Cq), 114.1 (CH), 
114.0 (CH), 113.3 (Cq) 110.4 (CH), 55.2 (CH3), 55.2 (CH3), 21.5 (CH3). IR (ATR) ν = 3362, 2928, 2835, 
1510, 1455, 1231, 1172, 1023, 829, 791 cm-1. MS (EI) m/z (relative intensity): 343 (100) [M]+, 328 
(50). HR-MS (ESI) m/z calcd for C23H21NO2 [M]
+: 343.1572, found: 343.1572. 
 
 
2,3-Bis(3-chlorophenyl)-5-methyl-1H-indole (160ah): The general procedure B was followed using 




1,2-bis(3-chlorophenyl)ethyne (8h) (185 mg, 0.75 mmol). Purification by coloumn chromatography 
on silica gel (n-hexane/CH2Cl2: 3/1) yielded 160ah (146 mg, 83%) as a yellow oil.  
1H NMR (400 MHz, CDCl3): δ = 8.10 (s, 1H), 7.46─7.39 (m, 3H), 7.34─7.28 (m, 3H), 7.28─7.18 (m, 4H), 
7.10 (dd, J = 8.5, 1.4 Hz, 1H), 2.45 (s, 3H). 13C NMR (100 MHz, CDCl3): δ = 136.7 (Cq), 134.6 (Cq), 
134.3 (Cq), 134.2 (Cq), 134.1 (Cq) 132.9 (Cq), 130.3 (Cq), 129.9 (CH), 129.8 (CH), 129.8 (CH), 128.5 (Cq), 
128.3 (CH), 127.8 (CH), 127.7 (CH), 126.5 (CH), 126.4 (CH), 125.0 (CH), 119.0 (CH), 114.1 (Cq), 110.7 
(CH), 21.5 (CH3). IR (ATR) ν = 3399, 2917, 1594, 1562, 1485, 1458, 1077, 883, 784, 733 cm
-1. MS (EI) 
m/z (relative intensity): 351 (100), 315 (11), 381 (10), 178 (7). HR-MS (ESI) m/z calcd for C23H21NO2 
[M]+: 351.0582, found: 351.0588. 
 
 
2,3-Bis(4-chlorophenyl)-5-methyl-1H-indole (160ag): The general procedure B was followed using 
nitrone (159a) (121 mg, 0.50 mmol) and 1,2-bis(4-chlorophenyl)ethyne (8g) (185 mg, 0.75 mmol). 
Purification by coloumn chromatography on silica gel (n-hexane/CH2Cl2: 3/1) yielded 160ag (99 mg, 
56%) as a pale yellow solid.  
M. p. = 131─132 °C. 1H NMR (300 MHz, CDCl3): δ = 8.08 (s, 1H), 7.40 (s, 1H), 7.39–7.31 (m, 9H), 7.08 
(d, J = 9.4 Hz, 1H), 2.43 (s, 3H). 13C NMR (125 MHz, CDCl3): δ = 134.2 (Cq), 133.6 (Cq), 133.3 (Cq), 
133.1 (Cq), 132.1 (Cq), 131.2 (CH), 130.9 (Cq), 130.1 (Cq), 129.2 (CH), 128.9 (CH), 128.8 (CH), 128.6 
(Cq), 124.7 (CH), 118.9 (CH), 113.8 (Cq), 110.6 (CH), 21.6 (CH3). IR (ATR) ν = 3452, 3390, 1498, 1471, 
1086, 1013, 833, 784 cm-1. MS (ESI) m/z (relative intensity): 350 (100), 351 (20), 352 (60) [M-H]-. 
HR-MS (ESI) m/z calcd for C21H15NCl2 [M-H]
-: 350.0509, found: 350.0508. 
 
 




followed using N-(4-methoxybenzylidene)-4-methylaniline oxide (159a) (121 mg, 0.50 mmol) and 
1,2-bis[4-(trifluoromethyl)phenyl]ethyne (8e) (236 mg, 0.75 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/CH2Cl2: 3/1) yielded 160ae (153 mg, 73%) as a yellow solid.  
M. p. = 149−150 °C. 1H NMR (300 MHz, CDCl3): δ = 8.21 (s, 1H), 7.68─7.54 (m, 4H), 7.49 (t, J = 8.7 Hz, 
4H), 7.42 (s, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.13 (dd, J = 8.3, 1.6 Hz, 1H), 2.45 (s, 3H). 13C NMR (75 MHz, 
CDCl3): δ = 138.7 (Cq), 135.8 (Cq), 134.6 (Cq), 133.1 (Cq), 130.7 (Cq), 129.8 (q, 
2JC-F = 33.1 Hz, Cq), 130.3 
(CH), 128.5 (q, 2JC-F = 31.9 Hz, Cq), 128.5 (Cq), 128.3 (CH), 125.9 (q, 
3JC-F = 3.8 Hz, CH), 125.6 (q, 
3JC-F = 
3.8 Hz, CH), 125.4 (CH), 124.3 (q, 1JC-F = 272.0 Hz, Cq), 124.0 (q,
 1JC-F =273.0 Hz, Cq), 119.1 (CH), 114.7 
(Cq), 111.0 (CH), 21.5 (CH3). 
19F NMR (282 MHz, CDCl3): δ = -62.34, -62.67. IR (ATR) ν = 3474, 2922, 
1617, 1319, 1154, 1090, 1060, 840, 793 cm-1. MS (EI) m/z (relative intensity): 343 (100), 328 (50), 
268 (9) 171 (5). HR-MS (ESI) m/z calcd for C23H15F6N [M]
+: 419.1109, found: 419.1120. 
 
 
2-(4-Fluorophenyl)-5-methyl-3-pentyl-1H-indole (160as): The general procedure B was followed 
using nitrone (159a) (121 mg, 0.50 mmol, 1.0 equiv) and 1-fluoro-4-(hept-1-yn-1-yl)benzene (8s) 
(143 mg, 0.75 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 10/1) 
and GPC yielded 160as (114 mg, 77%) as a pale yellow solid.  
M. p. = 118−120 °C. 1H NMR (300 MHz, DMSO-d6): δ = 10.98 (s, 1H), 7.65-7.58 (m, 2H), 7.35 (d, J = 
8.9 Hz, 2H), 7.31 (d, J = 1.8 Hz, 1H), 7.24 (d, J = 8.1 Hz, 1H), 6.92 (dd, J = 8.2, 1.6 Hz, 1H), 2.78 (t, J = 
7.8 Hz, 2H), 2.39 (s, 3H), 1.62 (p, J = 7.2 Hz, 2H), 1,35-1.25 (m, 4H), 0.83 (t, J = 7.1 Hz, 3H). 13C NMR 
(75 MHz, DMSO-d6): δ = 161.3 (d, 
1JC-F = 245 Hz, Cq), 134.3 (Cq), 132.9 (Cq), 129.5 (d, 
3JC-F = 8.1 Hz, 
CH), 128.9 (Cq), 127.0 (Cq), 123.0 (CH), 119.9 (Cq), 118.1 (CH), 115.6 (d, 
2JC-F = 21.5 Hz, CH), 111.7 (Cq), 
110.8 (CH), 31.4 (CH3), 30.3 (CH2), 24.0 (CH2), 22.0 (CH3), 21.3 (CH2), 13.9 (CH2). 
19F NMR (282 MHz, 
DMSO-d6): δ = 115.01. IR (ATR) ν = 3381, 2923, 2857, 1506, 1441, 1225, 838, 797, 516, 477 cm
-1. MS 
(ESI) m/z (relative intensity): 295 (6) [M]+, 312 (100), 334 (34), 350 (24). HR-MS (ESI) m/z calcd for 
C20H22FN [M]






Ethyl 5-methyl-2-phenyl-1H-indole-3-carboxylate (160at): The general procedure B was followed 
using nitrone (159a) (121 mg, 0.50 mmol, 1.0 equiv) and ethyl 3-phenylpropiolate (8t) (131 mg, 0.75 
mmol, 1.5 equiv). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 10/1) and 
GPC yielded 160at (86.6 mg, 63%) as a colorless solid.  
M. p. = 145─147 °C. 1H NMR (300 MHz, DMSO-d6): δ = 11.97 (s, 1H), 7.86 (d, J = 1.0 Hz, 1H), 
7.68─7.65 (m, 2H), 7.52─7.45 (m, 3H), 7.33 (d, J = 8.2 Hz, 1H), 7.44 (dd, J = 8.2, 1.1 Hz, 1H), 4.19 (q, J 
= 7.1 Hz, 2H), 2.43 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 164.5 (Cq), 
144.3 (Cq), 133.9 (Cq), 132.0 (Cq), 129.9 (Cq), 129.8 (CH), 128.6 (CH), 127.7 (CH), 127.5 (Cq), 124.0 
(CH), 120.8 (CH), 111.4 (CH), 102.4 (Cq), 58.8 (CH2), 21.4 (CH3), 14.1 (CH3). IR (ATR) ν = 3232, 1652, 
1476, 1451, 1268, 1218, 1145, 1049, 777, 696 cm-1. MS (ESI) m/z (relative intensity): 280 (6) [M+H]+, 
302 (100) [M+Na]+. HR-MS (ESI) m/z calcd for C18H17NNaO2 [M+Na]
+: 302.1157, found: 302.1159.  
The analytical data were in accordance with those reported in the literature.[198] 
 
 
3-Butyl-5-methyl-2-(4-nitrophenyl)-1H-indole (160au): The general procedure B was followed 
using nitrone (159a) (121 mg, 0.50 mmol, 1.0 equiv) and 1-(hex-1-yn-1-yl)-4-nitrobenzene (8u) (152 
mg, 0.75 mmol, 1.5 equiv). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 
30/1) and GPC yielded 160au (84 mg, 54%) as a yellow solid.  
M. p. = 126─128 °C. 1H NMR (300 MHz, DMSO-d6): δ = 11.23 (s, 1H), 8.34 (d, J = 8.9 Hz, 2H), 7.87 (d, 
J = 8.9 Hz, 2H), 7.37 (d, J = 1.6 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.00 (dd, J = 8.4, 1.5 Hz, 1H), 2.89 (dd, 
J = 8.7, 6.8 Hz, 2H), 2.40 (s, 3H), 1.62 (tt, J = 8.0, 6.2 Hz, 2H), 1.39 (tt, J = 7.3, 7.3 Hz, 2H), 0.90 (t, J = 
7.3 Hz, 3H). 13C NMR (75 MHz, DSMO-d6): δ = 145.5 (Cq), 139.7 (Cq), 135.1 (Cq), 131.3 (Cq), 128.3 (Cq), 
127.7 (CH), 127.5 (Cq), 124.5 (CH), 123.9 (CH), 118.5 (CH), 115.2 (Cq), 111.1 (CH), 32.6 (CH2), 23.9 
(CH2), 22.0 (CH2), 21.2 (CH3), 13.7 (CH3). IR (ATR) ν = 3313, 1684, 1306, 1234, 1106, 755, 693, 654, 




calcd for C19H20N2O2Na [M+Na]
+: 331.1422, found: 331.1410. 
 
 
1-[3-Ethyl-2-(4-methoxyphenyl)-5-methyl-3H-indol-3-yl]propan-1-one (161): The general 
procedure B was followed using nitrone (159a) (121 mg, 0.50 mmol, 1.0 equiv) and 3-hexyne (8r) 
(61.6 mg, 0.75 mmol, 1.5 equiv). Purification by coloumn chromatography on silica gel 
(n-hexane/EtOAc: 10/1) and GPC yielded 161 (74 mg, 46%) as a colorless solid.  
M. p. = 96─98 °C. 1H NMR (300 MHz, CDCl3): δ = 7.87 (d, J = 8.9 Hz, 2H), 7.60 (d, J = 7.9 Hz, 1H), 7.24 
(ddd, J = 8.0, 1.7, 0.8 Hz, 1H), 6.99 (d, J = 0.8 Hz, 1H), 6.96 (d, J = 9.0 Hz, 2H), 3.86 (s, 3H), 2.53─2.27 
(m, 2H), 2.40 (s, 3H), 2.03-1.75 (m, 2H), 0.8 (t, J = 7.2 Hz, 3H), 0.24 (t, J = 7.4 Hz, 3H). 13C NMR (75 
MHz, CDCl3): δ = 207.3 (Cq), 175.8 (Cq), 162.2 (Cq), 155.0 (Cq), 139.1 (Cq), 136.3 (Cq), 129.9 (CH), 
129.7 (CH), 125.7 (Cq), 122.7 (CH), 120.4 (CH), 114.6 (CH), 75.4 (Cq), 55.6 (CH3), 31.3 (CH3), 26.6 
(CH2), 21.7 (CH2), 8.3 (CH3), 7.3 (CH3). IR (ATR) ν = 2967, 3935, 1706, 1603, 1505, 1459, 1254, 1174, 
1033, 836 cm-1. MS (ESI) m/z (relative intensity): 306.2 (70) [M-Me]+, 322.2 (41) [M+H]+, 344.2 (100) 
[M+Na]+. HR-MS (ESI) m/z calcd for C21H23NO2Na [M+Na]
+: 344.1626, found: 344.1624. 
 
Intermolecular Competition Experiment 
 
 
A suspension of N-(4-methoxybenzylidene)-4-methylaniline oxide (159a) (121 mg, 0.5 mmol), 
4-fluoro-N-(4-methoxybenzylidene)aniline oxide (159c) (123 mg, 0.5 mmol), diphenylacetylene (8a) 
(89 mg, 0.5 mmol), Cp*CoI2(CO) (12 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and NaOAc (8.2 mg, 
20 mol %) in HFIP (2.0 mL) was stirred under air at 100 °C for 16 h. After cooling to ambient 




concentrated in vacuo. Purification by flash column chromatography on silica gel (n-hexane/CH2Cl2: 




Competition Experiment between Alkynes 8 
 
 
A suspension of 1,2-bis(4-methoxyphenyl)ethyne (8a) (119 mg, 0.5 mmol), 
1,2-bis[4-(trifluoromethyl)phenyl]ethyne (8e) (157 mg, 0.5 mmol), 
N-(4-methoxybenzylidene)-4-methylaniline oxide (159a) (121 mg, 0.5 mmol), Cp*CoI2(CO) (12 mg, 
5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and NaOAc (8.2 mg, 20 mol %) in HFIP (2.0 mL) was stirred 
at 100 °C for 16 h under air. After cooling to ambient temperature, the mixture was filtered through 
a short pad of celite, rinsed with CH2Cl2 (20 mL) and concentrated in vacuo. The crude 




measured to determine the conversions to the products 160ac (62%) and 160ae (17%) using the 
1,3,5-trimethoxybenzene as the internal standard. 
 
 




N-(4-methoxybenzylidene)-4-methylaniline oxide (159a) (121 mg, 0.5 mmol), diphenylacetylene (8a) 
(89 mg, 0.5 mmol), Cp*CoI2(CO) (12 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and NaOAc (8.2 mg, 
20 mol %), HFIP (1.8 mL) and D3COD (0.2 ml) were placed in a 25 mL Schlenk tube under air and the 
mixture was stirred at 100 °C for 2 h. After cooling to ambient temperature, the mixture was 
transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by 




21%) and 159a (31 mg, 25%) (n-hexane/EtOAc: 3/1). 
 




Two parallel reactions of 8a with 159a or [D]5-159a were performed to determine the 
corresponding KIE value. 159a (113.6 mg, 0.5 mmol) or [D]5-159a (116.2 mg, 0.5 mmol), 
diphenylacetylene (8a) (134 mg, 0.75 mmol), Cp*CoI2(CO) (12 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 
mol %), NaOAc (8.2 mg, 20 mol %), 1,3,5-trimethoxybenzene (28 mg, 0.17 mmol) as internal 
standard and HFIP (2.0 mL) were placed in a 25 mL Schlenk tube. The mixture was stirred at 100 °C, 
a periodic aliquot (0.05 mL) was removed by syringe and analyzed by GC to determine the following 
conversions: 
         t / min    
 yield / %   
10 20 30 40 50 60 
160ba 3 14.5 24.8 37.3 44.6 50.2 
[D]5-160ba 0.4 3.4 7.5 13.8 44.6 50.2 
 
y = 0.8569x 





















5.3.3 Data for the Products of Quinazolines by Cobalt(III)-Catalyzed C─H/N─O Functionalizations 




4-Ethoxy-2-phenylquinazoline (163aa): The general procedure C was followed using ethyl 
benzimidate (161a) (37.3 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 
mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 30/1) yielded 163aa 
(60 mg, 96%) as a white solid.  
M. p. = 64─65 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.58 (dd, J = 7.3, 2.3 Hz, 2H), 8.15 (d, J = 8.8 Hz, 1H), 
7.97 (d, J = 8.4 Hz, 1H), 7.79 (t, J = 7.7 Hz, 1H), 7.58─7.40 (m, 4H), 4.76 (q, J = 7.1 Hz, 2H), 1.56 (t, J = 
7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.6 (Cq), 160.0 (Cq), 151.8 (Cq), 138.2 (Cq), 133.3 (CH), 
130.4 (CH), 128.4 (CH), 128.3 (CH), 127.9 (CH), 126.2 (CH), 123.5 (CH), 115.3 (Cq), 62.8 (CH2), 14.4 
(CH3).
 IR (ATR) ν = 3056, 2973, 1575, 1557, 1422, 1324, 1045, 1020, 763, 693 cm-1. MS (ESI) m/z 
(relative intensity): 224 (40), 251 (100) [M+H]+, 273 (10) [M+Na]+. HR-MS (ESI) m/z calcd for 
C16H15N2O [M+H]
+: 251.1179, found: 251.1183.  
The analytical data were in accordance with those reported in the literature.[199] 
 
 
4-Methoxy-2-phenylquinazoline (163ba): The general procedure C was followed using methyl 
benzimidate (161b) (33.8 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 
mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 163ba 
(43.0 mg, 73%) as a white solid.  
M. p. = 49─50 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.63─8.60 (m, 2H), 8.16 (ddd, J = 8.2, 1.5, 0.7 Hz, 
1H), 8.00 (ddd, J = 8.4, 1.2, 0.7 Hz, 1H), 7.81 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.55─7.48 (m, 4H), 4.29 (s, 




(CH), 128.6 (CH), 128.5 (CH), 128.1 (CH), 126.5 (CH), 123.6 (CH), 115.4 (Cq), 54.2 (CH3). IR (ATR) ν = 
3058, 1620, 1557, 1501, 1444, 1375, 1103, 911, 759, 672 cm-1. MS (ESI) m/z (relative intensity): 237 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C15H13N2O [M+H]
+: 237.1022, found: 237.1026.  
The analytical data were in accordance with those reported in the literature.[199] 
 
 
4-Ethoxy-7-methyl-2-phenylquinazoline (163ca): The general procedure C was followed using ethyl 
4-methylbenzimidate (161c) (40.8 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 
0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 
163ca (60.0 mg, 91%) as a white solid.  
M. p. = 92−93 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.56 (dd, J = 7.5, 2.3 Hz, 2H), 8.03 (d, J = 8.3 Hz, 1H), 
7.76 (s, 1H), 7.58–7.40 (m, 3H), 7.30 (dd, J = 8.3, 1.6 Hz, 1H), 4.74 (q, J = 7.1 Hz, 2H), 2.53 (s, 3H), 
1.55 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.5 (Cq), 160.1 (Cq), 152.1 (Cq), 144.1 (Cq), 
138.4 (Cq), 130.3 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 127.1 (CH), 123.2 (CH), 113.2 (Cq), 62.6 
(CH2), 22.1 (CH3), 14.4 (CH3). IR (ATR) ν = 2958, 1622, 1553, 148.95, 1414, 1326, 1018, 927, 799, 679 
cm-1. MS (ESI) m/z (relative intensity): 237 (25), 265 (100) [M+H]+, 287 (10) [M+Na]+. HR-MS (ESI) 
m/z calcd for C17H17N2O [M+H]
+: 265.1335, found: 265.1339.  
The analytical data were in accordance with those reported in the literature.[199] 
 
 
4-Ethoxy-7-methoxy-2-phenylquinazoline (163da): The general procedure C was followed using 
ethyl 4-methoxybenzimidate (161d) (44.8 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) 
(48.9 mg, 0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 
40/1) yielded 163da (62.2 mg, 89%) as a white solid.  
M. p. = 131─132 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.55 (dd, J = 7.8, 1.9 Hz, 2H), 8.02 (d, J = 9.3 Hz, 




3.94 (s, 3H), 1.53 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.3 (Cq), 163.7 (Cq), 160.7 (Cq), 
154.2 (Cq), 138.3 (Cq), 130.3 (CH), 128.4 (CH), 128.3 (CH), 124.8 (CH), 118.5 (CH), 109.7 (Cq), 106.5 
(CH), 62.5 (CH2), 55.6 (CH3), 14.4 (CH3). IR (ATR) ν = 2982, 1622, 1584, 1438, 1348, 1210, 1158, 
1019, 768, 703 cm-1. MS (ESI) m/z (relative intensity): 253 (25), 281 (100) [M+H]+, 203 (10) [M+Na]+. 
HR-MS (ESI) m/z calcd for C17H17N2O2 [M+H]
+: 281.1285, found: 282.1281.  
The analytical data were in accordance with those reported in the literature.[199] 
 
 
4-Ethoxy-2-phenyl-7-(trifluoromethyl)quinazoline (163ea): The general procedure C was followed 
using ethyl 4-(trifluoromethyl)benzimidate (161e) (54.3 mg, 0.25 mmol) and 
5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 mmol). Purification by coloumn chromatography on 
silica gel (n-hexane/EtOAc: 40/1) yielded 163ea (66.9 mg, 84%) as a white solid.  
M. p. = 101─103 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.56 (dd, J = 6.5, 3.3 Hz, 2H), 8.23 (d, J = 7.9 Hz, 
2H), 7.64 (dd, J = 8.6, 1.6 Hz, 1H), 7.57─7.44 (m, 3H), 4.76 (q, J = 7.1 Hz, 2H), 1.57 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ = 166.5 (Cq), 161.3 (Cq), 151.3 (Cq), 137.5 (Cq), 134.9 (q, 
2JC-F = 32.9 Hz, 
Cq), 130.9 (CH), 128.5 (CH), 128.4 (CH), 125.6 (q, 
3JC-F = 4.1 Hz, CH), 124.9 (CH), 121.9 (q, 
3JC-F = 3.2 
Hz, CH), 123.6 (q, 1JC-F = 273.3 Hz, Cq), 117.0 (Cq), 63.3 (CH2), 14.3 (CH3). 
19F NMR (283 MHz, CDCl3) δ 
= -63.20. IR (ATR) ν = 2995, 1581, 1557, 1450, 1327, 1176, 1119, 895, 715 cm-1. MS (ESI) m/z 





4-Ethoxy-7-fluoro-2-phenylquinazoline (163fa): The general procedure C was followed using ethyl 
4-fluorobenzimidate (161f) (41.8 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 
0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 




M. p. = 93─94 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.55 (dd, J = 6.6, 3.2 Hz, 2H), 8.13 (dd, J = 9.0, 6.2 Hz, 
1H), 7.57 (dd, J = 10.1, 2.5 Hz, 1H), 7.52─7.47 (m, 3H), 7.21 (td, J = 8.7, 2.5 Hz, 1H), 4.73 (q, J = 7.1 Hz, 
2H), 1.54 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.4 (Cq), 165.7 (d, 
1JC-F = 253.1 Hz, Cq), 
161.2 (Cq), 153.7 (d, 
3JC-F = 13.9 Hz, Cq), 137.8 (Cq), 130.7 (CH), 128.5 (CH), 128.4 (CH), 126.2 (d, 
3JC-F 
= 11.1 Hz, CH), 116.0 (d, 2JC-F = 24.9 Hz, CH), 112.2 (d, 
4JC-F = 3.7 Hz, Cq), 112.0 (d, 
2JC-F = 20.4 Hz, CH), 
62.9 (CH2), 14.3 (CH3). 
19F NMR (283 MHz, CDCl3) δ = -104.33 (ddd, J = 10.1, 8.4, 6.2 Hz). IR (ATR) ν = 
2975, 1626, 1562, 1416, 1340, 1156, 1018, 861, 770, 676 cm-1. MS (ESI) m/z (relative intensity): 241 





7-Chloro-4-ethoxy-2-phenylquinazoline (163ga): The general procedure C was followed using ethyl 
4-chlorobenzimidate (161g) (45.9 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 
0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 
163ga (68.0 mg, 96%) as a white solid.  
M. p. = 104─105 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.56─8.52 (m, 2H), 8.05 (dd, J = 8.7, 0.5 Hz, 1H), 
7.94 (dd, J = 2.0, 0.5 Hz, 1H), 7.63─7.44 (m, 3H), 7.41 (dd, J = 8.7, 2.0 Hz, 1H), 4.73 (q, J = 7.1 Hz, 2H), 
1.54 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.5 (Cq), 161.1 (Cq), 152.6 (Cq), 139.4 (Cq), 
137.8 (Cq), 130.7 (CH), 128.5 (CH), 128.4 (CH), 127.1 (CH), 127.1 (CH), 124.9 (CH), 113.7 (Cq), 63.0 
(CH2), 14.3 (CH3). IR (ATR) ν = 2975, 1615, 1556, 1431, 1340, 1317, 1018, 871, 772, 704 cm
-1. MS (ESI) 
m/z (relative intensity): 257 (30), 285 (100) [M+H]+, 307 (20) [M+Na]
+. HR-MS (ESI) m/z calcd for 
C16H14N2OCl [M+H]
+: 285.0789, found: 285.0792.  








1-(4-Ethoxy-2-phenylquinazolin-7-yl)ethanone (163ha): The general procedure C was followed 
using ethyl 4-acetylbenzimidate (161h) (47.8 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) 
(48.9 mg, 0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) 
yielded 163ha (53.4 mg, 73%) as a pale yellow solid.  
M. p. = 139─140 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.56 (dd, J = 6.7, 3.2 Hz, 2H), 8.49 (d, J = 1.6 Hz, 
1H), 8.20 (d, J = 8.5 Hz, 1H), 8.03 (dd, J = 8.5, 1.6 Hz, 1H), 7.59─7.42 (m, 3H), 4.77 (q, J = 7.1 Hz, 2H), 
2.74 (s, 3H), 1.57 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 197.8 (Cq), 166.6 (Cq), 161.0 (Cq), 
151.8 (Cq), 140.8 (Cq), 137.7 (Cq), 130.8 (CH), 129.3 (CH), 128.5 (CH), 128.5 (CH), 124.2 (CH), 124.1 
(CH), 117.8 (Cq), 63.3 (CH2), 26.9 (CH3), 14.3 (CH3). IR (ATR) ν = 2974, 1686, 1551, 1384, 1318, 1221, 
1019, 777, 714, 676 cm-1. MS (ESI) m/z (relative intensity): 293 (95) [M+H]+, 315 (100) [M+Na]+. 
HR-MS (ESI) m/z calcd for C18H17N2O2 [M+H]
+: 293.1285, found: 293.1280. 
 
 
Methyl 4-methoxy-2-phenylquinazoline-7-carboxylate (163ia): The general procedure C was 
followed using methyl 4-[imino(methoxy)methyl]benzoate (161i) (48.3 mg, 0.25 mmol) and 
5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 mmol). Purification by coloumn chromatography on 
silica gel (n-hexane/EtOAc: 20/1) yielded 163ia (48.0 mg, 72%) as a white solid.  
M. p. = 124─125 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.62 (d, J = 2.1 Hz, 1H), 8.60─8.54 (m, 2H), 8.14 
(dd, J =8.5, 0.7 Hz, 1H), 8.07─8.03 (m, 1H), 7.55─7.45 (m, 3H), 4.26 (s, 3H), 3.97 (s, 3H). 13C NMR 
(100 MHz, CDCl3) δ = 166.9 (Cq), 166.3 (Cq), 160.7 (Cq), 151.4 (Cq), 137.7 (Cq), 134.5 (Cq), 130.7 (CH), 
130.1 (CH), 128.5 (CH), 128.4 (CH), 125.9 (CH), 123.7 (CH), 117.6 (Cq), 54.3 (CH3), 52.5 (CH3). IR (ATR) 
ν = 2945, 1718, 1556, 148.99, 1373, 1267, 909, 753, 713 cm-1. MS (ESI) m/z (relative intensity): 295 
(100) [M+H]+, 317 (95) [M+Na]+. HR-MS (ESI) m/z calcd for C17H15N2O3 [M+H]







4-Ethoxy-7-nitro-2-phenylquinazoline (163ja): The general procedure C was followed using ethyl 
4-nitrobenzimidate (161j) (48.9 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 
0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 
163ja (42.0 mg, 57%) as a white solid. 
M. p. = 151─153 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.74 (dd, J = 2.2, 0.6 Hz, 1H), 8.62─8.48 (m, 2H), 
8.24 (dd, J = 8.9, 0.6 Hz, 1H), 8.17 (dd, J = 8.9, 2.2 Hz, 1H), 7.41─6.70 (m, 3H), 4.76 (q, J = 7.1 Hz, 2H), 
1.57 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.4 (Cq), 162.0 (Cq), 151.7 (Cq), 150. 9 (Cq), 
137.1 (Cq), 131.2 (CH), 128.6 (CH), 128.5 (CH), 125.5 (CH), 123.7 (CH), 119.5 (CH), 118.5 (Cq), 63.7 
(CH2), 14.2 (CH3). IR (ATR) ν = 2982, 1565, 1531, 1337, 1068, 1012, 892, 821, 739, 670 cm
-1. MS (ESI) 
m/z (relative intensity): 296 (95) [M+H]+, 318 (100) [M+Na]+. HR-MS (ESI) m/z calcd for C16H13N3O3 
[M+H]+: 296.1030, found: 296.1027. 
 
 
4-Ethoxy-6-methyl-2-phenylquinazoline (163ka): The general procedure C was followed using ethyl 
3-methylbenzimidate (161k) (41.0 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 
0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 
163ka (60.0 mg, 91%) as a white solid.  
M. p. = 89─91 ˚C. 1H NMR (500 MHz, CDCl3) δ = 8.56 (dd, J = 8.1, 1.6 Hz, 2H), 7.92 (s, 1H), 7.87 (d, J = 
8.5 Hz, 1H), 7.61 (dd, J = 8.5, 1.9 Hz, 1H), 7.54─7.40 (m, 3H), 4.75 (q, J = 7.1 Hz, 2H), 2.51 (s, 3H), 
1.56 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 166.2 (Cq), 159.2 (Cq), 150.2 (Cq), 138.3 (Cq), 
136.3 (Cq), 135.3 (CH), 130.2 (CH), 128.3 (CH), 128.3 (CH), 127.6 (CH), 122.4 (CH), 115.1 (Cq), 62.6 
(CH2), 21.6 (CH3), 14.4 (CH3). IR (ATR) ν = 2976, 1562, 1383, 1312, 1108, 1023, 780, 707 cm
-1. MS 
(ESI) m/z (relative intensity): 265 (100) [M+H]+. HR-MS (ESI) m/z calcd for C17H17N2O [M+H]
+: 
265.1335, found: 265.1338.  





4-Ethoxy-2-phenyl-6-(trifluoromethyl)quinazoline (163la): The general procedure C was followed 
using ethyl 3-(trifluoromethyl)benzimidate (161l) (54.3 mg, 0.25 mmol) and 
5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 mmol). Purification by coloumn chromatography on 
silica gel (n-hexane/EtOAc: 40/1) yielded 163la (46.0 mg, 58%) as a white solid.  
M. p. = 129─130 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.62─8.52 (m, 2H), 8.45 (t, J = 0.9 Hz, 1H), 8.05 (d, 
J = 8.8 Hz, 1H), 7.95 (dd, J = 8.8, 2.1 Hz, 1H), 7.57─7.46 (m, 3H), 4.80 (q, J = 7.1 Hz, 2H), 1.58 (t, J = 
7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 167.0 (Cq), 162.0 (Cq), 153.3 (Cq), 137. 6 (Cq), 131.1 (CH), 
129.2 (q, 3JC-F = 3.6 Hz, CH), 128.9 (CH), 128.7 (CH), 128.5 (CH), 127.9 (q, 
2JC-F = 33.0 Hz, Cq) 123.8 (q, 
1JC-F = 271.9 Hz, Cq), 121.8 (q, 
3JC-F = 4.5 Hz, CH), 114.7 (Cq), 63.4 (CH2), 14.3 (CH3). 
19F NMR (283 MHz, 
CDCl3) δ = -62.27. IR (ATR) ν = 2992, 1634, 1575, 1443, 1320, 1107, 873, 686 cm
-1. MS (ESI) m/z 
(relative intensity): 295 (90), 319 (100) [M+H]+. HR-MS (ESI) m/z calcd for C17H14N2OF3 [M+H]
+: 
319.1053, found: 319.1049. 
 
 
6-Chloro-4-ethoxy-2-phenylquinazoline (163ma): The general procedure C was followed using ethyl 
3-chlorobenzimidate (161m) (46 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 
0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 
163ma (62.3 mg, 88%) as a white solid.  
M. p. = 132─133 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.53 (dd, J = 6.7, 3.2 Hz, 2H), 8.09 (d, J = 2.4 Hz, 
1H), 7.87 (d, J = 8.9 Hz, 1H), 7.69 (dd, J = 8.9, 2.4 Hz, 1H), 7.53─7.43 (m, 3H), 4.73 (q, J = 7.1 Hz, 2H), 
1.55 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 165.8 (Cq), 160.2 (Cq), 150.3 (Cq), 137.8 (Cq), 
134.1 (CH), 131.7 (Cq), 130.6 (CH), 129.5 (CH), 128.4 (CH), 128.4 (CH), 122.7 (CH), 115.9 (Cq), 63.1 
(CH2), 14.3 (CH3). IR (ATR) ν = 2975, 1555, 1488, 1412, 1306, 1022, 834, 670, 547 cm
-1. MS (ESI) m/z 
(relative intensity): 285 (100) [M+H]+, 287 (30). HR-MS (ESI) m/z calcd for C16H14N2OCl [M+H]
+: 





4-Ethoxy-2-phenylthieno[2,3-d]pyrimidine (163na): The general procedure C was followed using 
ethyl thiophene-3-carbimidate (161n) (39 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) 
(48.9 mg, 0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 15/1) 
yielded 163na (38.0 mg, 60%) as a white solid.  
M. p. = 51─53 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.54─8.51 (m, 2H), 7.53─7.46 (m, 3H), 7.38 (d, J = 
5.9 Hz, 1H), 7.33 (d, J = 5.9 Hz, 1H), 4.75 (q, J = 7.1 Hz, 2H), 1.54 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ = 169.7 (Cq), 163.8 (Cq), 159.9 (Cq), 137.8 (Cq), 130.5 (CH), 128.6 (CH), 128.5 (CH), 124.1 
(CH), 118.8 (CH), 117.5 (Cq), 62.7 (CH2), 14.7 (CH3). IR (ATR) ν = 2982, 1618, 1567, 1535, 1468, 1381, 
1319, 1038, 889, 686, 664 cm-1. MS (ESI) m/z (relative intensity): 257 (100) [M+H]+, 279 (23) 
[M+Na]+. HR-MS (ESI) m/z calcd for C14H13N2OS [M+H]
+: 257.0749, found: 257.0745. 
 
 
2-Benzyl-4-ethoxyquinazoline (163ab): The general procedure C was followed using ethyl 
benzimidate (161a) (37.3 mg, 0.25 mmol) and 5-benzyloxazol-2(5H)-one (162b) (52.6 mg, 0.30 
mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 15/1) yielded 163ab 
(56.9 mg, 88%) as a yellow oil.  
1H NMR (300 MHz, CDCl3) δ = 8.11 (ddd, J = 8.2, 1.5, 0.7 Hz, 1H), 7.88 (ddd, J = 8.4, 1.2, 0.6 Hz, 1H), 
7.77 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.50─7.44 (m, 3H), 7.32─7.27 (m, 2H), 7.23─7.17 (m, 1H), 4.59 (q, 
J = 7.1 Hz, 2H), 4.26 (s, 2H), 1.45 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.8 (Cq), 165.3 
(Cq), 151.1 (Cq), 138.9 (Cq), 133.3 (CH), 129.5 (CH), 128.3 (CH), 127.4 (CH), 126.4 (CH), 126.2 (CH), 
123.5 (CH), 115.1 (Cq), 63.0 (CH2), 46.5 (CH2), 14.4 (CH3). IR (ATR) ν = 2926, 1619, 1573, 148.97, 1457, 
1420, 1325, 1105, 770, 696 cm-1. MS (EI) m/z (relative intensity): 265 (100) [M+H]+, 237 (29), 287 
(15) [M+Na]+. HRMS (ESI) calcd for C17H17N2O ([M+H]
+): 265.1335; found 265.1337.  





4-Ethoxy-2-phenethylquinazoline (163ac): The general procedure C was followed using ethyl 
benzimidate (161c) (37.3 mg, 0.25 mmol) and 5-phenethyloxazol-2(5H)-one (162a) (56.8 mg, 0.30 
mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 163ac 
(56.9 mg, 82%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.12 (ddd, J = 8.2, 1.6, 0.7 Hz, 1H), 7.86 (ddd, J = 8.4, 1.3, 0.7 Hz, 1H), 
7.76 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.47 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.32─7.24 (m, 4H), 7.20─7.14 
(m, 1H), 4.63 (q, J = 7.1 Hz, 2H), 3.31─3.29 (m, 4H), 1.50 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) 
δ = 166.6 (Cq), 166.1 (Cq), 151.4 (Cq), 141.9 (Cq), 133.3 (CH), 128.5 (CH), 128.4 (CH), 127.2 (CH), 
126.0 (CH), 125.9 (CH), 123.5 (CH), 115.0 (Cq), 62.9 (CH2), 41.5 (CH2), 35.0 (CH2), 14.6 (CH3). MS (ESI) 
m/z (relative intensity): 279 (100) [M+H]+. IR (ATR) ν = 2979, 1620, 1572, 1496, 1419, 1322, 1103, 
769, 683 cm-1. HR-MS (ESI) m/z calcd for C18H18N2O [M+H]
+: 279.1492, found: 279.1497. 
 
 
4-Ethoxy-2-tridecylquinazoline (163ad): The general procedure C was followed using ethyl 
benzimidate (161a) (37.3 mg, 0.25 mmol) and 5-tridecyloxazol-2(5H)-one (162d) (80.8 mg, 0.30 
mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 30/1) yielded 163ad 
(54.0 mg, 61%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.12 (dd, J = 8.2, 1.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.75 (ddd, J = 8.4, 
6.9, 1.5 Hz, 1H), 7.46 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 4.63 (q, J = 7.1 Hz, 2H), 2.94─2.89 (m, 2H), 
1.91─1.81 (m, 2H), 1.50 (t, J = 7.1 Hz, 3H), 1.42─1.14 (m, 20H), 0.89─0.85 (m, 3H). 13C NMR (75 MHz, 
CDCl3) δ = 167.5 (Cq), 166.6 (Cq), 151.5 (Cq), 133.3 (CH), 127.2 (CH), 125.9 (CH), 125.5 (CH), 115.0 
(Cq), 62.8 (CH2), 40.1 (CH2), 32.1 (CH2), 29.8 (CH2), 29.8 (CH2), 29.8 (CH2), 29.8 (CH2), 29.7 (CH2), 29.7 
(CH2), 29.6 (CH2), 29.5 (CH2), 28.8 (CH2), 22.8 (CH2), 14.5 (CH3), 14.3 (CH3). IR (ATR) ν = 2922, 2852, 
1621, 1571, 1496, 1419, 1325, 1102, 768 cm-1. MS (ESI) m/z (relative intensity): 357 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C23H36N2O [M+H]





4-Ethoxy-2-(thiophen-3-yl)quinazoline (163ae): The general procedure C was followed using ethyl 
benzimidate (161a) (37.3 mg, 0.25 mmol) and 5-(thiophen-3-yl)oxazol-2(5H)-one (162e) (50.7 mg, 
0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 
163ae (58.1 mg, 91%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.12 (dd, J = 8.2, 1.4 Hz, 1H), 8.08 (dd, J = 3.7, 1.3 Hz, 1H), 7.91 (d, J = 
8.4 Hz, 1H), 7.77 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H), 7.48─7.43 (m, 2H), 7.16 (dd, J = 5.0, 3.7 Hz, 1H), 4.73 
(q, J = 7.1 Hz, 2H), 1.56 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.6 (Cq), 157.0 (Cq), 151.2 
(Cq), 144.4 (Cq), 133.6 (CH), 129.6 (CH), 128.9 (CH), 128.2 (CH), 127.6 (CH), 126.1 (CH), 123.7 (CH), 
115.4 (Cq), 63.1 (CH2), 14.5 (CH3). IR (ATR) ν = 2980, 1618, 1560, 1494, 1417, 1339, 1104, 845, 767 
cm-1. MS (ESI) m/z (relative intensity): 229 (40), 257 (100) [M+H]+, 279 (20) [M+Na]+. HR-MS (ESI) 
m/z calcd for C14H12N2OS [M+H]
+: 257.0743, found: 257.0744. 
 
 
4-Ethoxy-2-(4-methoxyphenyl)quinazoline (163af): The general procedure C was followed using 
ethyl benzimidate (161a) (37.3 mg, 0.25 mmol) and 5-(4-methoxyphenyl)oxazol-2(5H)-one (162f) 
(57.9 mg, 0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 20/1) 
yielded 163af (46.9 mg, 68%) as a white solid.  
M. p. = 70─71 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.54 (d, J = 9.0 Hz, 2H), 8.14 (ddd, J = 8.2, 1.5, 0.7 Hz, 
1H), 7.94 (ddd, J = 8.5, 1.2, 0.7 Hz, 1H), 7.78 (ddd, J = 8.5, 1.2, 1.6 Hz, 1H), 7.46 (ddd, J = 8.2, 7.0, 1.2 
Hz, 1H), 7.02 (d, J = 9.0 Hz, 2H), 4.76 (q, J = 7.1 Hz, 2H), 3.89 (s, 3H), 1.57 (t, J = 7.1 Hz, 3H). 13C NMR 
(125 MHz, CDCl3) δ = 165.5 (Cq), 161.7 (Cq), 159.9 (Cq), 152.0 (Cq), 133.3 (CH), 131.1 (Cq), 130.1 (CH), 
127.7 (CH), 125.8 (CH), 123.5 (CH), 115.2 (Cq), 113.8 (CH), 62.8 (CH2), 55.5 (CH3), 14.7 (CH3). IR (ATR) 
ν = 3047, 1603, 1574, 1497, 1328, 1249, 1151, 765, 680, 542 cm-1. MS (ESI) m/z (relative intensity): 
281 (100) [M+H]+. HRMS (ESI) m/z calcd for C17H17N2O2 [M+H]




The analytical data were in accordance with those reported in the literature.[200] 
 
 
4-Ethoxy-2-(m-tolyl)quinazoline (163ag): The general procedure C was followed using ethyl 
benzimidate (161a) (37.3 mg, 0.25 mmol) and 5-(m-tolyl)oxazol-2(5H)-one (162g) (53.2 mg, 0.30 
mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 163ag 
(56.9 mg, 86%) as a white solid.  
M. p. = 72─74 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.42─8.34 (m, 2H), 8.15 (ddd, J = 8.2, 1.5, 0.6 Hz, 
1H), 7.97 (ddd, J = 8.4, 0.7 Hz, 1H), 7.78 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.48 (ddd, J = 8.1, 7.0, 1.1 Hz, 
1H), 7.39 (t, J = 7.6 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 4.77 (q, J = 7.1 Hz, 2H), 2.48 (s, 3H), 1.56 (t, J = 
7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.6 (Cq), 160.2 (Cq), 151.8 (Cq), 138.2 (Cq), 137.9 (Cq), 
133.3 (CH), 131.2 (CH), 128.9 (CH), 128.3 (CH), 127.8 (CH), 126.1 (CH), 125.7 (CH), 123.5 (CH), 115.3 
(Cq), 62.8 (CH2), 21.5 (CH3), 14.4 (CH3). IR (ATR) ν = 2982, 1620, 1561, 1498, 1418, 1323, 1161, 1104, 
1018, 765 cm-1. MS (ESI) m/z (relative intensity): 265 (100) [M+H]+, 287 [M+Na]+. HR-MS (ESI) m/z 
calcd for C17H17N2O [M+H]
+: 265.1335, found: 265.1332. 
 
 
2-(3-Chlorophenyl)-4-ethoxyquinazoline (163ah): The general procedure C was followed using ethyl 
benzimidate (161a) (37.3 mg, 0.25 mmol) and 5-(3-chlorophenyl)oxazol-2(5H)-one (162h) (59.3 mg, 
0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) yielded 
163ah (43.4 mg, 61%) as a white solid.  
M. p. = 85─87 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.54 (td, J = 1.7, 0.7 Hz, 1H), 8.48.9─8.38 (m, 1H), 
8.15 (ddd, J = 8.2, 1.5, 0.7 Hz, 1H), 7.95 (ddd, J = 8.4, 1.1, 0.7 Hz, 1H), 7.79 (ddd, J = 8.5, 7.0, 1.5 Hz, 
1H), 7.50 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.45─7.36 (m, 2H), 4.74 (q, J = 7.1 Hz, 2H), 1.56 (t, J = 7.1 Hz, 




(CH), 130.3 (CH), 129.6 (CH), 128.5 (CH), 127.9 (CH), 126.6 (CH), 126.5 (CH), 123.5 (CH), 115.5 (Cq), 
63.0 (CH2), 14.4 (CH3). IR (ATR) ν = 2975, 1620, 1575, 1499, 1418, 1325, 1171, 1015, 764, 672 cm
-1. 
MS (ESI) m/z (relative intensity): 285 (100) [M+H]+, 307 (30) [M+Na]+. HR-MS (ESI) m/z calcd for 
C16H14N2OCl [M+H]
+: 285.0789, found: 285.0788.  
The analytical data were in accordance with those reported in the literature.[199] 
 
 
4-Ethoxy-2-(3-fluorophenyl)quinazoline (163ai): The general procedure C was followed using ethyl 
benzimidate (161a) (37.3 mg, 0.25 mmol) and 3-(3-fluorophenyl)-1,4,2-dioxazol-5H-one (162i) (54.3 
mg, 0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 40/1) 
yielded 163ai (51.3 mg, 76%) as a white solid.  
M. p. = 84─86 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.36 (ddd, J = 7.8, 1.5, 1.0 Hz, 1H), 8.26 (ddd, J = 
10.5, 2.5, 1.4 Hz, 1H), 8.14 (ddd, J = 8.2, 1.5, 0.7 Hz, 1H), 7.95 (ddd, J = 8.4, 1.1, 0.7 Hz, 1H), 7.79 
(ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.58─7.37 (m, 2H), 7.16 (ddd, J = 8.3, 2.7, 1.0 Hz, 1H), 4.74 (q, J = 7.1 
Hz, 2H), 1.55 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.7 (Cq), 163.1 (d, 
1J = 246.3 Hz, Cq), 
168.8 (d, 4J = 3.8 Hz, Cq), 151.7 (Cq), 140.7 (d, 
3J = 7.8 Hz, Cq), 133.5 (CH), 130.0 (d, 
3J = 7.8 Hz, CH), 
127.9 (CH), 126.5 (CH), 124.0 (d, 4J = 2.9 Hz, CH), 123.5 (CH), 117.2 (d, 2J = 21.4 Hz, CH), 115.5 (Cq), 
115.3 (d, 2J = 22.2 Hz, CH), 62.9 (CH2), 14.4 (CH3). 
19F NMR (376 MHz, CDCl3) δ = -113.58 (ddd, J = 
10.3, 8.4, 5.9 Hz). IR (ATR) ν = 2984, 1622, 1575, 1499, 1424, 1325, 1167, 1018, 902, 770 cm-1. MS 
(ESI) m/z (relative intensity): 265 (100) [M+H]+, 287 [M+Na]+. HR-MS (ESI) m/z calcd for C16H14FN2O 
[M+H]+: 269.1085, found: 269.1086. 
 
 
2-(4-Chlorophenyl)-4-ethoxyquinazoline (163aj): The general procedure C was followed using ethyl 




0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 30/1) yielded 
163aj (66.0 mg, 93%) as a white solid.  
M. p. = 119─120 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.57 (d, J = 8.6 Hz, 2H), 8.15 (d, J = 7.1 Hz, 1H), 
7.95 (d, J = 8.3 Hz, 1H), 7.79 (ddd, J = 8.5, 6.9, 1.6 Hz, 1H), 7.53─7.49 (m, 1H), 7.46 (d, J = 8.6 Hz, 2H), 
4.73 (q, J = 7.1 Hz, 2H), 1.56 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.8 (Cq), 159.1 (Cq), 
151.8 (Cq), 138.8 (Cq), 136.6 (Cq), 133.6 (CH), 129.9 (CH), 128.7 (CH), 128.0 (CH), 126.6 (CH), 123.6 
(CH), 115.5 (Cq), 63.0 (CH2), 14.5 (CH3). IR (ATR) ν = 2979, 1620, 1575, 1501, 1325, 1088, 937, 837, 
763, 539 cm-1. MS (ESI) m/z (relative intensity): 285 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C16H14N2OCl [M+H]
+: 285.0789, found: 285.0789.  
The analytical data were in accordance with those reported in the literature.[199] 
 
 
4-Ethoxy-2-(4-nitrophenyl)quinazoline (163ak): The general procedure C was followed using ethyl 
benzimidate (161a) (37.3 mg, 0.25 mmol) and 5-(4-nitrophenyl)oxazol-2(5H)-one (162k) (62.4 mg, 
0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 
163ak (44.8 mg, 60%) as a pale yellow solid.  
M. p. = 154─155 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.74 (d, J = 9.0 Hz, 2H), 8.33 (d, J = 9.0 Hz, 2H), 
8.21 (d, J = 8.3 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.86 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.58 (ddd, J = 8.2, 
7.0, 1.2 Hz, 1H), 4.79 (q, J = 7.1 Hz, 2H), 1.60 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 167.1 
(Cq), 157.9 (Cq), 151.7 (Cq), 148.9 (Cq), 144.3 (Cq), 134.0 (CH), 129.3 (CH), 128.3 (CH), 127.5 (CH), 
123.8 (CH), 123.7 (CH), 115.7 (Cq), 63.3 (CH2), 14.5 (CH3). IR (ATR) ν = 2987, 1622, 1576, 1501, 1343, 
1331, 1081, 765, 715, 670 cm-1. MS (EI) m/z (relative intensity): 268 (15), 296 (100) [M+H]+, 318 (60) 
[M+Na]+. HRMS (ESI) m/z calcd for C16H14N3O3 [M+H]







4-Ethoxy-2-phenyl-7-(1H-pyrazol-1-yl)quinazoline (163ka): The general procedure C was followed 
using ethyl 4-(1H-pyrazol-1-yl)benzimidate (161k) (53.8 mg, 0.25 mmol) and 
5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 mmol). Purification by coloumn chromatography on 
silica gel (n-hexane/EtOAc: 25/1) yielded 163ka (55.4 mg, 70%) as a white solid.  
M. p. = 129─130 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.62─8.50 (m, 2H), 8.21 (dd, J = 8.9, 0.5 Hz, 1H), 
8.12 (dd, J = 2.6, 0.6 Hz, 1H), 8.10 (dd, J = 2.2, 0.4 Hz, 1H), 8.04 (dd, J = 8.9, 2.2 Hz, 1H), 7.79 (dd, J = 
1.7, 0.6 Hz, 1H), 7.55─7.45 (m, 3H), 6.53 (dd, J = 2.6, 1.7 Hz, 1H), 4.75 (q, J = 7.1 Hz, 2H), 1.56 (t, J = 
7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.5 (Cq), 161.2 (Cq), 152.8 (Cq), 143.7 (Cq), 142.0 (CH), 
138.0 (Cq), 130.6 (CH), 128.5 (CH), 128.4 (CH), 127.1 (CH), 125.3 (CH), 118.4 (CH), 115.1 (CH), 113.3 
(Cq), 108.6 (CH), 63.0 (CH2), 14.4 (CH3). IR (ATR) ν = 2974, 1713, 1626, 1565, 1472, 1394, 1333, 1025, 
740, 698 cm-1. MS (ESI) m/z (relative intensity): 317 (100) [M+H]+, 339 (75) [M+Na]+. HR-MS (ESI) 
m/z calcd for C19H17N4O [M+H]
+: 317.1397, found: 317.1400. 
 
 
4-Ethoxy-2-(4-methoxyphenyl)-7-(1H-pyrazol-1-yl)quinazoline (163kf): The general procedure C 
was followed using ethyl 4-(1H-pyrazol-1-yl)benzimidate (161k) (53.8 mg, 0.25 mmol) and 
3-(4-methoxyphenyl)-1,4,2-dioxazol-5-one (162f) (58.0 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 163kf (51.0 mg, 59%) as a white solid.  
M. p. = 138─140 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.51 (d, J = 9.0 Hz, 2H), 8.19 (dd, J = 8.9, 0.6 Hz, 
1H), 8.11 (d, J = 3.0 Hz, 1H), 8.06 (d, J = 1.8 Hz, 1H), 8.00 (dd, J = 8.8, 2.2 Hz, 1H), 7.78 (d, J = 1.4 Hz, 
1H), 7.00 (d, J = 9.0 Hz, 2H), 6.52 (dd, J = 2.5, 1.7 Hz, 1H), 4.73 (q, J = 7.1 Hz, 2H), 3.87 (s, 3H), 1.55 (t, 
J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.3 (Cq), 161.8 (Cq), 161.0 (Cq), 152.9 (Cq), 143.7 
(Cq), 141.9 (CH), 130.7 (Cq), 130.1 (CH), 127.1 (CH), 125.3 (CH), 117.9 (CH), 114.8 (CH), 113.7 (CH), 




1422, 1331, 1159, 1018, 749 cm-1. MS (ESI) m/z (relative intensity): 236 (20), 347 (100) [M+H]+, 369 
(20) [M+Na]+, 715 (10) [2M+Na]+. HR-MS (ESI) m/z calcd for C20H19N4O2 [M+H]




4-Ethoxy-7-(1H-pyrazol-1-yl)-2-(m-tolyl)quinazoline (163kg): The general procedure C was followed 
using ethyl 4-(1H-pyrazol-1-yl)benzimidate (161k) (53.8 mg, 0.25 mmol) and 
3-(m-tolyl)-1,4,2-dioxazol-5-one (162g) (53.2 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 163kg (51.8 mg, 63%) as a white solid.  
M. p. = 149─151 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.38─8.33 (m, 2H), 8.23 (dd, J = 8.9, 0.6 Hz, 1H), 
8.13 (dd, J = 2.6, 0.6 Hz, 1H), 8.11 (dd, J = 2.2, 0.6 Hz, 1H), 8.05 (dd, J = 8.9, 2.2 Hz, 1H), 7.79 (dd, J = 
1.7, 0.6 Hz, 1H), 7.39 (td, J = 7.5, 0.8 Hz, 1H), 7.32─7.28 (m, 1H), 6.53 (dd, J = 2.6, 1.7 Hz, 1H), 4.76 (q, 
J = 7.1 Hz, 2H), 2.47 (s, 3H), 1.57 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.5 (Cq), 161.4 
(Cq), 152.8 (Cq), 143.7 (Cq), 142.0 (CH), 138.0 (Cq), 137.9 (Cq), 131.5 (CH), 129.0 (CH), 128.3 (CH), 
127.1 (CH), 125.7 (CH), 125.4 (CH), 118.4 (CH), 115.0 (CH), 113.3 (Cq), 108.6 (CH), 63.0 (CH2), 21.6 
(CH3), 14.4 (CH3). IR (ATR) ν = 3127, 2977, 1625, 1579, 1435, 1333, 1017, 870, 767, 600 cm
-1. MS (ESI) 
m/z (relative intensity): 331 (100) [M+H]+, 353 (20) [M+Na]+, 683 (20) [2M+Na]+. HR-MS (ESI) m/z 
calcd for C20H19N4O [M+H]
+: 331.1553, found: 331.1557. 
 
 
4-Ethoxy-2-(3-fluorophenyl)-7-(1H-pyrazol-1-yl)quinazoline (163ki): The general procedure C was 
followed using ethyl 4-(1H-pyrazol-1-yl)benzimidate (161k) (53.8 mg, 0.25 mmol) and 
3-(3-fluorophenyl)-1,4,2-dioxazol-5-one (162i) (54.4 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 15/1) yielded 163ki (49.1 mg, 59%) as a white solid.  




8.16 (dd, J = 2.6, 0.4 Hz, 1H), 8.15─8.07 (m, 2H), 7.83 (d, J = 1.6 Hz, 1H), 7.49 (td, J = 8.0, 5.8 Hz, 1H), 
7.21 (tdd, J = 8.3, 2.7, 1.0 Hz, 1H), 6.58 (dd, J = 2.6, 1.6 Hz, 1H), 4.79 (q, J = 7.1 Hz, 2H), 1.60 (t, J = 
7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.5 (Cq), 163.1 (d, 
1J = 244.4 Hz, Cq), 160.0 (d, 
4J = 3.4 
Hz, Cq), 152.6 (Cq), 143.8 (Cq), 142.1 (CH), 140.4 (d, 
3J = 7.8 Hz, Cq), 129.8 (d, 
3J = 7.8 Hz, CH), 127.1 
(CH), 125.4 (CH), 124.1 (d, 4J = 2.8 Hz, CH), 118.7 (CH), 117.4 (d, 2J = 21.5 Hz, CH), 115.3 (d, 2J = 23.2 
Hz, CH), 115.0 (CH), 113.4 (Cq), 108.7 (CH), 63.1 (CH2), 14.4 (CH3). 
19F NMR (376 MHz, CDCl3) δ = 
-113.44 (ddd, J = 10.5, 8.5, 5.9 Hz). IR (ATR) ν = 3129, 2979, 1624, 1578, 1564, 1333, 956, 875, 778, 
676 cm-1. MS (ESI) m/z (relative intensity): 335 (100) [M+H]+, 357 (80), 691 [2M+Na]+. HR-MS (ESI) 
m/z calcd for C19H16FN4O [M+H]
+: 335.1303, found: 335.1305. 
 
 
2-(3-Chlorophenyl)-4-ethoxy-7-(1H-pyrazol-1-yl)quinazoline (163kh): The general procedure C was 
followed using ethyl 4-(1H-pyrazol-1-yl)benzimidate (161k) (53.8 mg, 0.25 mmol) and 
3-(3-chlorophenyl)-1,4,2-dioxazol-5-one (162h) (59.3 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 163kh (56.3 mg, 64%) as a white solid.  
M. p. = 168─170 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.56 (d, J = 1.8 Hz, 1H), 8.46 (dt, J = 6.8, 1.8 Hz, 
1H), 8.24 (dd, J = 8.7, 0.6 Hz, 1H), 8.15 (d, J = 2.6 Hz, 1H), 8.12─8.00 (m, 2H), 7.82 (d, J = 1.5 Hz, 1H), 
7.56─7.37 (m, 2H), 6.57 (dd, J = 2.5, 1.8 Hz, 1H), 4.77 (q, J = 7.1 Hz, 2H), 1.59 (t, J = 7.1 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ = 166.6 (Cq), 159.8 (Cq), 152.6 (Cq), 143.8 (Cq), 142.1 (CH), 139.9 (Cq), 134.5 
(Cq), 130.5 (CH), 129.6 (CH), 128.5 (CH), 127.1 (CH), 126.6 (CH), 125.4 (CH), 118.7 (CH), 115.0 (CH), 
113.4 (Cq), 108.7 (CH), 63.2 (CH2), 14.4 (CH3). IR (ATR) ν = 2979, 1626, 1578, 1381, 1333, 875, 745, 
676, 603 cm-1. MS (ESI) m/z (relative intensity): 351 (100) [M+H]+, 732 (60) [2M+Na]+. HR-MS (ESI) 
m/z calcd for C19H16ClN4O [M+H]







4-Ethoxy-2-phenethyl-7-(1H-pyrazol-1-yl)quinazoline (163kc): The general procedure C was 
followed using ethyl 4-(1H-pyrazol-1-yl)benzimidate (161k) (53.8 mg, 0.25 mmol) and 
3-phenethyl-1,4,2-dioxazol-5-one (162c) (57.4 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 163kc (47.2 mg, 55%) as a white solid.  
M. p. = 92─93 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.20 (dd, J = 8.9, 0.6 Hz, 1H), 8.09 (dd, J = 2.6, 0.6 
Hz, 1H), 8.05 (dd, J = 8.9, 2.2 Hz, 1H), 7.99 (dd, J = 2.2, 0.5 Hz, 1H), 7.78 (dd, J = 1.8, 0.6 Hz, 1H), 
7.31─7.24 (m, 4H), 7.20─7.13 (m, 1H), 6.52 (dd, J = 2.6, 1.7 Hz, 1H), 4.62 (q, J = 7.1 Hz, 2H), 
3.31─3.17 (m, 4H), 1.50 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 167.4 (Cq), 166.4 (Cq), 
152.3 (Cq), 143.6 (Cq), 142.0 (CH), 141.7 (Cq), 128.5 (CH), 128.3 (CH), 127.0 (CH), 125.9 (CH), 125.3 
(CH), 118.2 (CH), 114.3 (CH), 112.9 (Cq), 108.7 (CH), 62.9 (CH2), 41.3 (CH2), 34.3 (CH2), 14.4 (CH3). IR 
(ATR) ν = 3118, 3027, 2932, 1622, 1573, 1474, 1338, 1107, 863, 695 cm-1. MS (ESI) m/z (relative 





4-Ethoxy-7-(1H-pyrazol-1-yl)-2-(thiophen-3-yl)quinazoline (163ke): The general procedure C was 
followed using ethyl 4-(1H-pyrazol-1-yl)benzimidate (161k) (53.8 mg, 0.25 mmol) and 
3-(thiophen-3-yl)-1,4,2-dioxazol-5-one (162e) (51.8 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 163ke (65.0 mg, 81%) as a white solid.  
M. p. = 167─169 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.20─8.11 (m, 1H), 8.09 (d, J = 2.6 Hz, 1H), 8.04 
(dd, J = 3.7, 1.2 Hz, 1H), 8.02─7.96 (m, 2H), 7.77 (d, J = 1.4 Hz, 1H), 7.46 (dd, J = 5.0, 1.2 Hz, 1H), 7.13 
(dd, J = 5.0, 3.7 Hz, 1H), 6.50 (dd, J = 2.6, 1.8 Hz, 1H), 4.68 (q, J = 7.1 Hz, 2H), 1.53 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ = 166.2 (Cq), 157.8 (Cq), 152.6 (Cq), 144.0 (Cq), 143.7 (Cq), 141.9 (CH), 




(CH), 63.1 (CH2), 14.3 (CH3). IR (ATR) ν = 3115, 2979, 1624, 1565, 1414, 1330, 1167, 875, 779, 704 
cm-1. MS (ESI) m/z (relative intensity): 323 (100) [M+H]+, 345 (55) [M+Na]+, 667 (45) [2M+Na]+. 
HR-MS (ESI) m/z calcd for C17H15N4OS [M+H]
+: 323.0961, found: 323.0960. 
 
 
4-Ethoxy-2-phenyl-6-(1H-pyrazol-1-yl)quinazoline (163la): The general procedure C was followed 
using ethyl 3-(1H-pyrazol-1-yl)benzimidate (161l) (53.8 mg, 0.25 mmol) and 
5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 mmol). Purification by coloumn chromatography 
on silica gel (n-hexane/EtOAc: 10/1 to 6/1) yielded 163la (48.9 mg, 62%) as a white solid.  
M. p. = 130─131 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.61─8.50 (m, 2H), 8.35 (d, J = 2.5 Hz, 1H), 8.19 
(dd, J = 9.1, 2.6 Hz, 1H), 8.07─7.95 (m, 2H), 7.77 (d, J = 1.7 Hz, 1H), 7.53─7.44 (m, 3H), 6.51 (dd, J = 
2.5, 1.8 Hz, 1H), 4.76 (d, J = 7.1 Hz, 2H), 1.56 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.5 
(Cq), 159.9 (Cq), 150.2 (Cq), 141.6 (CH), 137.9 (Cq), 137.7 (Cq), 130.5 (CH), 129.5 (CH), 128.7 (CH), 
128.3 (CH), 126.9 (CH), 125.4 (CH), 115.6 (Cq), 112.0 (CH), 108.1 (CH), 63.1 (CH2), 14.4 (CH3). IR 
(ATR) ν = 2983, 1579, 1507, 1391, 1312, 1019, 774, 701, 560 cm-1. MS (ESI) m/z (relative intensity): 





2-(4-Bromophenyl)-4-ethoxy-7-(5-methyl-1H-pyrazol-1-yl)quinazoline (163ml): The general 
procedure C was followed using ethyl 4-(5-methyl-1H-pyrazol-1-yl)benzimidate (161m) (57.3 mg, 
0.25 mmol) and 3-(4-bromophenyl)-1,4,2-dioxazol-5-one (162l) (72.6 mg, 0.30 mmol). Purification 
by coloumn chromatography on silica gel (n-hexane/EtOAc: 15/1) yielded 163ml (63.1 mg, 64%) as a 
white solid.  
M. p. = 184─186 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.39 (d, J = 8.6 Hz, 2H), 8.15 (d, J = 9.7 Hz, 1H), 




3H), 1.54 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.5 (Cq), 160.0 (Cq), 152.7 (Cq), 151.6 
(Cq), 143.8 (Cq), 137.0 (Cq), 131.5 (CH), 130.0 (CH), 127.6 (CH), 125.3 (Cq), 125.2 (CH), 118.2 (CH), 
114.1 (CH), 112.9 (Cq), 108.8 (CH), 63.0 (CH2), 14.4 (CH3), 13.8 (CH3). IR (ATR) ν = 2974, 1628, 1579, 
1536, 1426, 1337, 1010, 935, 754 cm-1. MS (ESI) m/z (relative intensity): 372 (15), 409 (100) [M+H]+, 
411 (100), 431 (15) [M+Na]+. HR-MS (ESI) m/z calcd for C20H18N4OBr [M+H]




4-Ethoxy-7-(5-methyl-1H-pyrazol-1-yl)-2-(4-nitrophenyl)quinazoline (163mk): The general 
procedure C was followed using ethyl 4-(5-methyl-1H-pyrazol-1-yl)benzimidate (161m) (57.3 mg, 
0.25 mmol) and 5-(4-nitrophenyl)oxazol-2(5H)-one (162k) (62.4 mg, 0.30 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 10/1 to 4/1) yielded 163mk (54.4 mg, 58%) 
as a yellow solid.  
M. p. = 182─184 °C. 1H NMR (300 MHz, CDCl3) δ = 8.70 (d, J = 8.9 Hz, 2H), 8.31 (d, J =8.9 Hz, 2H), 
8.21 (dd, J = 8.3, 1.2 Hz, 1H), 8.06-8.03 (m, 2H), 8.01 (d, J = 2.5 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 4.75 
(q, J = 7.1 Hz, 2H), 2.42 (s, 3H), 1.59 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.8 (Cq), 
158.9 (Cq), 152.7 (Cq), 152.0 (Cq), 149.3 (Cq), 144.1 (Cq), 144.0 (Cq), 129.4 (CH), 127.8 (CH), 125.5 (CH), 
123.7 (CH), 119.7 (CH), 114.5 (CH), 113.2 (Cq), 109.2 (CH), 63.4 (CH2), 14.5 (CH3), 14.0 (CH3). IR (ATR) 
ν = 2985, 1622, 1577, 1539, 1512, 1427, 1340, 1319, 1038, 867 cm-1. MS (ESI) m/z (relative 
intensity): 376 (100) [M+H]+, 398 (58) [M+Na]+. HR-MS (ESI) m/z calcd for C20H18N5O3 [M+H]
+: 
376,1410, found: 376.1404. 
 
 
4-Ethoxy-2-phenyl-7-(pyrimidin-2-yl)quinazoline (163na): The general procedure C was followed 




5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 mmol). Purification by coloumn chromatography on 
silica gel (n-hexane/EtOAc: 5/1) yielded 163na (60 mg, 73%) as a white solid. 
M. p. = 145─146 ˚C. 1H NMR (300 MHz, CDCl3) δ = 9.08 (d, J = 1.1 Hz, 1H), 8.86 (d, J = 4.8 Hz, 2H), 
8.67─8.57 (m, 2H), 8.54 (dd, J = 8.6, 1.6 Hz, 1H), 8.23 (dd, J = 8.6, 0.6 Hz, 1H), 7.70─7.41 (m, 3H), 
7.24 (t, J = 4.8 Hz, 1H), 4.77 (q, J = 7.1 Hz, 2H), 1.57 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 
166.5 (Cq), 163.8 (Cq), 160.2 (Cq), 157.2 (CH), 152.1 (Cq), 142.1 (Cq), 138.1 (Cq), 130.3 (CH), 128.4 (CH), 
128.3 (CH), 128.0 (CH), 125.4 (CH), 123.7 (CH), 119.7 (CH), 116.5 (Cq), 62.9 (CH2), 14.5 (CH3). IR (ATR) 
ν = 2974, 1623, 1562, 1431, 1324, 1163, 1025, 756, 708 cm-1. MS (ESI) m/z (relative intensity): 329 
(100) [M+H]+, 351 (40) [M+Na]+. HR-MS (ESI) m/z calcd for C20H17N4O [M+H]




2-(4-Chlorophenyl)-4-ethoxy-7-(pyrimidin-2-yl)quinazoline (163nj): The general procedure C was 
followed using ethyl 4-(pyrimidin-2-yl)benzimidate (161n) (56.8 mg, 0.25 mmol) and 
3-(4-chlorophenyl)-1,4,2-dioxazol-5-one (162j) (59.3 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 163nj (64.4 mg, 71%) as a yellow solid.  
M. p. = 198─190 ˚C. 1H NMR (300 MHz, CDCl3) δ = 9.02 (d, J = 1.2 Hz, 1H), 8.85 (d, J = 4.8 Hz, 2H), 
8.56─8.46 (m, 3H), 8.18 (d, J = 8.6 Hz, 1H), 7.49─7.39 (m, 2H), 7.27─7.18 (m, 1H), 4.71 (q, J = 7.1 Hz, 
2H), 1.55 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.6 (Cq), 163.7 (Cq), 159.2 (Cq), 157.3 
(CH), 152.0 (Cq), 142.2 (Cq), 136.6 (Cq), 136.5 (Cq), 129.7 (CH), 128.5 (CH), 128.0 (CH), 125.6 (CH), 
123.7 (CH), 119.8 (CH), 116.5 (Cq), 63.0 (CH2), 14.4 (CH3). IR (ATR) ν = 2982, 1623, 1560, 1494, 1415, 
1325, 1012, 840, 787 cm-1. MS (ESI) m/z (relative intensity): 363 (100) [M+H]+, 364 (20), 365 (30), 








2-(4-Bromophenyl)-4-ethoxy-7-(pyrimidin-2-yl)quinazoline (163nl): The general procedure C was 
followed using ethyl 4-(pyrimidin-2-yl)benzimidate (161n) (56.8 mg, 0.25 mmol) and 
3-(4-bromophenyl)-1,4,2-dioxazol-5-one (162l) (72.6 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 163nl (87.0 mg, 85%) as a white solid.  
M. p. = 191─193 ˚C. 1H NMR (300 MHz, CDCl3) δ = 9.03 (d, J = 1.3 Hz, 1H), 8.85 (d, J = 4.8 Hz, 2H), 
8.53 (dd, J = 8.6, 1.7 Hz, 1H), 8.43 (d, J = 8.6 Hz, 2H), 8.20 (d, J = 8.6 Hz, 1H), 7.59 (d, J = 8.6 Hz, 2H), 
7.24 (t, J = 4.8 Hz, 1H), 4.72 (q, J = 7.1 Hz, 2H), 1.55 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 
166.7 (Cq), 163.7 (Cq), 159.3 (Cq), 157.4 (CH), 152.0 (Cq), 142.3 (Cq), 137.1 (Cq), 131.5 (CH), 130.0 (CH), 
128.0 (CH), 125.7 (CH), 125.1 (Cq), 123.7 (CH), 119.8 (CH), 116.5 (Cq), 63.0 (CH2), 14.4 (CH3). IR (ATR) 
ν = 2976, 1625, 1560, 1414, 1325, 1160, 1011, 837, 785, 738 cm-1. MS (ESI) m/z (relative intensity): 
301 (10), 360 (10), 407 (100) [M+H]+, 409 (100). HR-MS (ESI) m/z calcd for C20H16N4OBr [M+H]
+: 
407.0502, found: 407.0499. 
 
 
4-Ethoxy-2-phenyl-7-(pyrazin-2-yloxy)quinazoline (163oa): The general procedure C was followed 
using ethyl 4-(pyrazin-2-yloxy)benzimidate (161o) (60.8 mg, 0.25 mmol) and 
5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 mmol). Purification by coloumn chromatography on 
silica gel (n-hexane/EtOAc: 10/1) yielded 163oa (76.9 mg, 89%) as a white solid.  
M. p. = 129─130 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.60─8.45 (m, 3H), 8.33 (d, J = 2.7 Hz, 1H), 8.20 
(dd, J = 8.9, 0.4 Hz, 1H), 8.13 (dd, J = 2.7, 1.4 Hz, 1H), 7.70 (dd, J = 2.3, 0.4 Hz, 1H), 7.53─7.42 (m, 3H), 
7.29 (dd, J = 8.9, 2.3 Hz, 1H), 4.76 (q, J = 7.1 Hz, 2H), 1.55 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, 
CDCl3) δ = 166.3 (Cq), 160.8 (Cq), 159.3 (Cq), 157.2 (Cq), 153.3 (Cq), 141.1 (CH), 139.3 (CH), 137.9 (Cq), 




(CH2), 14.5 (CH3). IR (ATR) ν = 2975, 1623, 1579, 1405, 1343, 1285, 1150, 1107, 848, 706 cm
-1. MS 
(ESI) m/z (relative intensity): 317 (100) [M+H]+, 339 (40) [M+Na]+. HR-MS (ESI) m/z calcd for 
C19H17N4O [M+H]
+: 317.1397, found: 317.1397. 
 
 
4-Ethoxy-7-(pyrazin-2-yloxy)-2-(p-tolyl)quinazoline (163om): The general procedure C was followed 
using ethyl 4-(pyridin-2-yloxy)benzimidate (161o) (60.8 mg, 0.25 mmol) and 
3-(p-tolyl)-1,4,2-dioxazol-5-one (162m) (53.1 mg, 0.30 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 163om (67.2 mg, 75%) as a white 
solid.  
M. p. = 151─153 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.54 (d, J = 1.4 Hz, 1H), 8.45 (d, J = 8.2 Hz, 2H), 
8.35 (d, J = 2.7 Hz, 1H), 8.22 (d, J = 8.9 Hz, 1H), 8.16 (dd, J = 2.7, 1.4 Hz, 1H), 7.70 (d, J = 2.3 Hz, 1H), 
7.35─7.24 (m, 3H), (dd, J = 8.8, 2.3 Hz, 1H), 4.78 (q, J = 7.1 Hz, 2H), 2.43 (s, 3H), 1.57 (t, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ = 166.6 (Cq), 161.3 (Cq), 159.7 (Cq), 157.5 (Cq), 153.7 (Cq), 141.4 (CH), 
141.0 (Cq), 139.6 (CH), 136.5 (CH), 135.5 (Cq), 129.3 (CH), 128.7 (CH), 125.7 (CH), 120.6 (CH), 117.8 
(CH), 112.9 (Cq), 63.0 (CH2), 21.7 (CH3), 14.6 (CH3). IR (ATR) ν = 2981, 1623, 1575, 1558, 1419, 1399, 
1381, 1275, 1177, 1160 cm-1. MS (ESI) m/z (relative intensity): 359 (100) [M+H]+, 376 (4) [M+Na]+. 
HR-MS (ESI) m/z calcd for C21H19N4O2 [M+H]
+: 359.1508, found: 359.1503. 
 
 
4-Ethoxy-7-(pyrazin-2-yloxy)-2-(thiophen-3-yl)quinazoline (163og): The general procedure C was 
followed using ethyl 4-(pyrazin-2-yloxy)benzimidate (161o) (60.8 mg, 0.25 mmol) and 
5-(m-tolyl)oxazol-2(5H)-one (162g) (53.1 mg, 0.30 mmol). Purification by column chromatography 




M. p. = 114─116 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.55 (s, 1H), 8.37-8.34 (m, 3H), 8.23 (dd, J = 8.8, 
0.5 Hz, 1H), 8.16 (dd, J = 2.7, 1.4 Hz, 1H), 7.72 (d, J = 2.3 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.34─7.29 
(m, 2H), 4.79 (q, J = 7.1 Hz, 2H), 2.47 (s, 3H), 1.57 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 
166.7 (Cq), 166.6 (Cq), 161.4 (Cq), 159.7 (Cq), 157.5 (Cq), 153.6 (Cq), 141.4 (CH), 139.6 (CH), 138.2 (Cq), 
136.6 (CH), 131.5 (CH), 129.2 (CH), 128.4 (CH), 125.9 (CH), 125.7 (CH), 120.8 (CH), 117.8 (CH), 112.9 
(Cq), 63.1 (CH2), 21.7 (CH3), 14.6 (CH3). IR (ATR) ν = 2923, 1623, 1576, 1497, 1419, 1325, 1106 cm
-1. 
MS (ESI) m/z (relative intensity): 359 (100) [M+H]+, 739 (11) [2M+Na]+. HR-MS (ESI) m/z calcd for 
C21H19N4O2 [M+H]
+: 359.1508, found: 359.1505. 
 
 
2-(4-Chlorophenyl)-4-ethoxy-7-(pyrazin-2-yloxy)quinazoline (163oj): The general procedure C was 
followed using ethyl 4-(pyrazin-2-yloxy)benzimidate (161o) (60.8 mg, 0.25 mmol) and 
5-(4-chlorophenyl)oxazol-2(5H)-one (162j) (59.3 mg, 0.30 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 163oj (82.3 mg, 87%) as a white solid.  
M. p. = 167─169 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.54 (dd, J = 1.4, 0.5 Hz, 1H), 8.53─8.47 (m, 2H), 
8.36 (dd, J = 2.7, 0.5 Hz, 1H), 8.23 (dd, J = 8.9, 0.5 Hz, 1H), 8.16 (dd, J = 2.7, 1.4 Hz, 1H), 7.70 (dd, J = 
2.3, 0.5 Hz, 1H), 7.56─7.40 (m, 2H), 7.33 (dd, J = 8.9, 2.4 Hz, 1H), 4.77 (q, J = 7.1 Hz, 2H), 1.57 (t, J = 
7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.7 (Cq), 160.1 (Cq), 159.5 (Cq), 157.6 (Cq), 153.5 (Cq), 
141.3 (CH), 139.6 (CH), 136.9 (Cq), 136.6 (Cq), 136.5 (CH), 130.0 (CH), 128.7 (CH), 125.7 (CH), 121.0 
(CH), 117.8 (CH), 112.9 (Cq), 63.1 (CH2), 14.5 (CH3). IR (ATR) ν = 2984, 1623, 1576, 1499, 1444, 1403, 
1285, 1108, 937 cm-1. MS (ESI) m/z (relative intensity): 379 (100) [M+H]+, 779 (19) [2M+Na]+. HR-MS 
(ESI) m/z calcd for C20H16ClN4O2 [M+H]







4-Ethoxy-2-(4-nitrophenyl)-7-(pyrazin-2-yloxy)quinazoline (163ok): The general procedure C was 
followed using ethyl 4-(pyridin-2-yloxy)benzimidate (161o) (60.8 mg, 0.25 mmol) and 
5-(4-nitrophenyl)oxazol-2(5H)-one (162k) (62.4 mg, 0.30 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1 to 4/1) yielded 163ok (69.1 mg, 71%) as a 
yellow solid.  
M. p. = 188─190 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.73 (d, J = 9.1 Hz, 2H), 8.57 (dd, J = 1.4, 0.5 Hz, 
1H), 8.38 (dd, J = 2.7, 0.5 Hz, 1H), 8.33 (d, J = 9.1 Hz, 2H), 8.27 (dd, J = 8.9, 0.5 Hz, 1H), 8.17 (dd, J = 
2.7, 1.4 Hz, 1H), 7.76 (dd, J = 2.3, 0.5 Hz, 1H), 7.40 (dd, J = 8.9, 2.3 Hz, 1H), 4.80 (q, J = 7.1 Hz, 2H), 
1.59 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.9 (Cq), 159.5 (Cq), 158.9 (Cq), 157.8 (Cq), 
153.3 (Cq), 149.3 (Cq), 144.0 (Cq), 141.3 (CH), 139.8 (CH), 136.6 (CH), 129.5 (CH), 125.8 (CH), 123.7 
(CH), 121.9 (CH), 118.0 (CH), 113.1 (Cq), 63.5 (CH2), 14.5 (CH3). IR (ATR) ν = 2987, 1621, 1576, 1520, 
1401, 1345, 1280, 1167, 1082 cm-1. MS (ESI) m/z (relative intensity): 412 (100) [M+Na]+. HR-MS (ESI) 
m/z calcd for C20H15N5O4Na [M+Na]
+: 412.1022, found: 412.1016. 
 
 
2-Benzyl-4-ethoxy-7-(pyrazin-2-yloxy)quinazoline (163ob): The general procedure C was followed 
using ethyl 4-(pyrazin-2-yloxy)benzimidate (161o) (60.8 mg, 0.25 mmol) and 
5-benzyloxazol-2(5H)-one (162b) (53.1 mg, 0.30 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 3/2) yielded 163ob (69.9 mg, 78%) as a white solid.  
M. p. = 122─124 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.54 (d, J = 1.4 Hz, 1H), 8.36 (d, J = 2.7 Hz, 1H), 
8.18 (d, J = 8.9 Hz, 1H), 8.16 (dd, J = 2.8, 1.4 Hz, 1H), 7.64 (dd, J = 2.4, 0.5 Hz, 1H), 7.48─7.45 (m, 2H), 
7.33─7.28 (m, 3H), 7.25─7.19 (m, 1H), 4.62 (q, J = 7.1 Hz, 2H), 4.25 (s, 2H), 1.46 (t, J = 7.1 Hz, 3H). 13C 




(CH), 138.7 (Cq), 136.6 (CH), 129.4 (CH), 128.4 (CH), 126.5 (CH), 125.5 (CH), 120.7 (CH), 117.2 (CH), 
112.4 (Cq), 63.1 (CH2), 46.5 (CH2), 14.4 (CH3). IR (ATR) ν = 2981, 1623, 1575, 1421, 1344, 1278, 1136 
cm-1. MS (ESI) m/z (relative intensity): 359 (100) [M+H]+, 381 (5) [M+Na]+. HR-MS (ESI) m/z calcd for 
C21H19N4O2 [M+H]
+: 359.1508, found: 359.1503.  
 
 
4-Ethoxy-2-phenethyl-7-(pyrazin-2-yloxy)quinazoline (163oc): The general procedure C was 
followed using ethyl 4-(pyrazin-2-yloxy)benzimidate (161o) (60.6 mg, 0.25 mmol) and 
5-phenethyloxazol-2(5H)-one (162c) (57.3 mg, 0.30 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 4/1) yielded 163oc (81.0 mg, 87%) as a white solid.  
M. p. = 94─96 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.52 (d, J = 1.4 Hz, 1H), 8.35 (d, J = 2.6 Hz, 1H), 8.20 
(d, J = 8.9 Hz, 1H), 8.14 (dd, J = 2.6, 1.4 Hz, 1H), 7.60 (d, J = 2.3 Hz, 1H), 7.32─7.24 (m, 5H), 7.22─7.15 
(m, 1H), 4.64 (q, J = 7.1 Hz, 2H), 3.28─3.19 (m, 4H), 1.50 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ = 167.4 (Cq), 166.5 (Cq), 159.5 (Cq), 157.4 (Cq), 153.1 (Cq), 141.9 (Cq), 141.4 (CH), 139.6 (CH), 136.6 
(CH), 128.6 (CH), 128.5 (CH), 126.0 (CH), 125.6 (CH), 120.5 (CH), 117.0 (CH), 112.5 (Cq), 63.6 (CH2), 
41.4 (CH2), 34.5 (CH2), 14.5 (CH3). IR (ATR) ν = 2980, 1623, 1574, 1495, 1420, 1278, 1136 cm
-1. MS 
(ESI) m/z (relative intensity): 373 (100) [M+H]+, 395 (10) [M+Na]+. HR-MS (ESI) m/z calcd for 
C22H21N4O2 [M+H]
+: 373.1665, found: 373.1659. 
 
 
4-Ethoxy-7-(pyrazin-2-yloxy)-2-(thiophen-3-yl)quinazoline (163oe): The general procedure C was 
followed using ethyl 4-(pyrazin-2-yloxy)benzimidate (161o) (60.8 mg, 0.25 mmol) and 
5-(thiophen-3-yl)oxazol-2(5H)-one (162e) (50.7 mg, 0.30 mmol). Purification by column 




M. p. = 145─147 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.53 (dd, J = 1.4, 0.4 Hz, 1H), 8.36 (dd, J = 2.7, 0.4 
Hz, 1H), 8.19 (dd, J = 8.9, 0.5 Hz, 1H), 8.16 (dd, J = 2.7, 1.4 Hz, 1H), 8.07 (dd, J = 3.7, 1.3 Hz, 1H), 7.64 
(dd, J = 2.3, 0.5 Hz, 1H), 7.48 (dd, J = 5.0, 1.3 Hz, 1H), 7.28 (dd, J = 8.9, 2.3 Hz, 1H), 7.15 (d, J = 5.0, 
3.7 Hz, 1H), 4.74 (q, J = 7.1 Hz, 2H), 1.55 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.5 (Cq), 
159.6 (Cq), 157.9 (Cq), 157.7 (Cq), 153.5 (Cq), 144.2 (Cq), 141.4 (CH), 139.6 (CH), 136.6 (CH), 129.9 
(CH), 129.3 (CH), 128.2 (CH), 125.7 (CH), 120.5 (CH), 117.4 (CH), 112.8 (Cq), 63.3 (CH2), 14.5 (CH3). IR 
(ATR) ν = 2981, 1621, 1575, 1496, 1452, 1400, 1343, 1318, 1150 cm-1. MS (ESI) m/z (relative 
intensity): 351 (100) [M+H]+, 723 (11) [2M+Na]+. HR-MS (ESI) m/z calcd for C18H15N4O2S [M+H]
+: 
351.0916, found: 351.0914.  
 
 
N-[4-Ethoxy-2-(m-tolyl)quinazolin-7-yl]pivalamide (163pg): The general procedure C was followed 
using ethyl 4-pivalamidobenzimidate (161p) (62.1 mg, 0.25 mmol) and 
3-(m-tolyl)-1,4,2-dioxazol-5-one (162g) (53.2 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 163pg (77.0 mg, 85%) as a white solid.  
M. p. = 199─201 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.39 (s, 1H), 8.36 (s, 1H), 8.08 (d, J = 8.9 Hz, 1H), 
8.02 (d, J = 2.1 Hz, 1H), 7.83 (dd, J = 8.9, 2.1 Hz, 1H), 7.65 (s, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 
7.4 Hz, 1H), 4.75 (q, J = 7.1 Hz, 2H), 2.49 (s, 3H), 1.57 (t, J = 7.1 Hz, 3H), 1.38 (s, 9H). 13C NMR (75 
MHz, CDCl3) δ = 176.8 (Cq), 166.2 (Cq), 160.7 (Cq), 152.8 (Cq), 142.6 (Cq), 138.2 (Cq), 137.9 (Cq), 131.2 
(CH), 129.0 (CH), 128.2 (CH), 125.7 (CH), 124.5 (CH), 119.5 (CH), 116.0 (CH), 111.8 (Cq), 62.7 (CH2), 
39.9 (Cq), 27.6 (CH3), 21.6 (CH3), 14.4 (CH3). IR (ATR) ν = 3333, 2958, 1665, 1572, 1436, 1326, 1028, 
1169, 1110, 788 cm-1. MS (ESI) m/z (relative intensity): 364 (100) [M+H]+, 386 (10) [M+Na]+, 727 
(10) [2M+Na]+. HR-MS (ESI) m/z calcd for C22H26N3O2 [M+H]







N-[4-Ethoxy-2-(4-methoxyphenyl)quinazolin-7-yl]pivalamide (163pf): The general procedure C was 
followed using ethyl 4-pivalamidobenzimidate (161p) (62.1 mg, 0.25 mmol) and 
3-(4-methoxyphenyl)-1,4,2-dioxazol-5-one (162f) (57.9 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 163pf (81.0 mg, 85%) as a white solid.  
M. p. = 211─213 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.48 (d, J = 9.0 Hz, 2H), 8.01 (d, J = 8.8 Hz, 1H), 
7.95 (d, J = 2.1 Hz, 1H), 7.73 (dd, J = 8.9, 2.1 Hz, 1H), 7.61 (s, 1H), 6.97 (d, J = 9.0 Hz, 2H), 4.68 (q, J = 
7.1 Hz, 2H), 3.85 (s, 3H), 1.51 (t, J = 7.1 Hz, 3H), 1.33 (s, 9H). 13C NMR (100 MHz, CDCl3) δ = 176.8 
(Cq), 166.0 (Cq), 161.6 (Cq), 160.3 (Cq), 152.9 (Cq), 142.4 (Cq), 130.9 (Cq), 130.0 (CH), 124.4 (CH), 119.1 
(CH), 115.8 (Cq), 113.6 (CH), 111.5 (CH), 62.5 (CH2), 55.3 (CH3), 39.8 (Cq), 27.5 (CH3), 14.4 (CH3). IR 
(ATR) ν = 3351, 2969, 1662, 1579, 1442, 1326, 1251, 1164, 1027, 845, 791 cm-1. MS (ESI) m/z 





N-[2-(4-Chlorophenyl)-4-ethoxyquinazolin-7-yl]pivalamide (163pj): The general procedure C was 
followed using ethyl 4-pivalamidobenzimidate (161p) (62.1 mg, 0.25 mmol) and 
3-(4-chlorophenyl)-1,4,2-dioxazol-5-one (162j) (59.3 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 163pj (86.0 mg, 90%) as a white solid.  
M. p. = 228─230 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.48 (d, J = 8.6 Hz, 2H), 8.06 (d, J = 8.9 Hz, 1H), 
8.02 (d, J = 2.1 Hz, 1H), 7.79 (dd, J = 8.9, 2.1 Hz, 1H), 7.66 (s, 1H), 7.45 (d, J = 8.6 Hz, 2H), 4.70 (q, J = 
7.1 Hz, 2H), 1.55 (t, J = 7.1 Hz, 3H), 1.39 (s, 9H). 13C NMR (75 MHz, CDCl3) δ = 176.8 (Cq), 166.3 (Cq), 
159.5 (Cq), 152.8 (Cq), 142.7 (Cq), 136.8 (Cq), 136.5 (Cq), 129.8 (CH), 128.5 (CH), 124.5 (Cq), 119.7 (CH), 




1579, 1437, 1324, 1205, 1089, 1014, 789 cm-1. MS (ESI) m/z (relative intensity): 384 (100) [M+H]+, 
406 (10) [M+Na]+. HR-MS (ESI) m/z calcd for C21H23N3O2 [M+H]
+: 384.1473, found: 384.1476. 
 
 
4-Ethoxy-2-phenethyl-7-(pyridin-2-yloxy)quinazoline (163qc): The general procedure C was 
followed using ethyl 4-(pyridin-2-yloxy)benzimidate (161q) (60.8 mg, 0.25 mmol) and 
5-phenethyloxazol-2(5H)-one (162c) (57.3 mg, 0.30 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 10/1) yielded 163qc (75.2 mg, 81%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.25 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 8.15 (dd, J = 8.9, 0.4 Hz, 1H), 
7.78─7.72 (m, 1H), 7.51 (dd, J = 2.4, 0.6 Hz, 1H), 7.34─7.24 (m, 5H), 7.22─7.15 (m, 1H), 7.08 (dd, J = 
7.3, 5.0 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 4.63 (q, J = 7.1 Hz, 2H), 3.28─3.18 (m, 4H), 1.49 (t, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ = 167.0 (Cq), 166.5 (Cq), 162.8 (Cq), 158.9 (Cq), 153.2 (Cq), 148.1 (CH), 
141.9 (Cq), 139.9 (CH), 128.6 (CH), 128.4 (CH), 125.9 (CH), 125.3 (CH), 120.6 (CH), 119.7 (CH), 115.9 
(CH), 112.9 (CH), 111.8 (Cq), 62.8 (CH2), 41.4 (CH2), 34.5 (CH2), 14.5 (CH3). IR (ATR) ν = 2979, 1622, 
1569, 1416, 1340, 1238, 1135, 1104 cm-1. MS (ESI) m/z (relative intensity): 372 (100) [M+H]+, 394 
(10) [M+Na]+. HR-MS (ESI) m/z calcd for C23H22N3O2 [M+H]
+: 372.1712, found: 372.1707. 
 
 
4-Ethoxy-7-(pyridin-2-yloxy)-2-n-tridecylquinazoline (163qd): The general procedure C was 
followed using ethyl 4-(pyridin-2-yloxy)benzimidate (161q) (60.6 mg, 0.25 mmol), 
5-tridecyloxazol-2(5H)-one (162d) (80.8 mg, 0.30 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 4/1) yielded 163qd (96.7 mg, 86%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.23 (ddd, J = 4.9, 2.0, 0.6 Hz, 1H), 8.14 (d, J = 8.9 Hz, 1H), 7.77─7.71 




Hz, 1H), 4.63 (q, J = 7.1 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 1.84 (q, J = 7.6 Hz, 2H), 1.48 (t, J = 7.1 Hz, 3H), 
1.41─1.24 (m, 20H), 0.89─0.84 (m, 3H). 13C NMR (75 MHz, CDCl3) δ = 168.3 (Cq), 166.6 (Cq), 162.7 
(Cq), 159.1 (Cq), 148.1 (CH), 139.9 (CH), 125.3 (CH), 120.6 (CH), 119.7 (CH), 115.7 (Cq), 115.6 (CH), 
112.9 (CH), 111.6 (Cq), 62.9 (CH2), 39.8 (CH2), 32.0 (CH2), 29.8 (CH2), 29.8 (CH2), 29.7 (CH2), 29.7 
(CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 28.7 (CH2), 22.8 (CH2), 14.5 (CH3), 14.2 (CH3). IR 
(ATR) ν = 2922, 2852, 1623, 1571, 1464, 1341, 1241, 1137, 779 cm-1. MS (ESI) m/z (relative intensity): 
450 (100) [M+H]+. HR-MS (ESI) m/z calcd for C28H39N3O2Na [M+Na]
+: 472.2940, found: 472.2934. 
 
 
4-Ethoxy-2-phenyl-7-(pyridin-2-yloxy)quinazoline (163qa): The general procedure C was followed 
using ethyl 4-(pyridin-2-yloxy)benzimidate (161q) (60.6 mg, 0.25 mmol) and 
5-phenyloxazol-2(5H)-one (162a) (48.9 mg, 0.30 mmol). Purification by coloumn chromatography on 
silica gel (n-hexane/EtOAc: 15/1) yielded 163qa (69.1 mg, 80%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 8.63─8.46 (m, 2H), 8.24 (dd, J = 4.9, 1.9 Hz, 1H), 8.18 (d, J = 8.9 Hz, 
1H), 7.73 (ddd, J = 8.3, 7.4, 1.9 Hz, 1H), 7.63 (d, J = 2.3 Hz, 1H), 7.54─7.43 (m, 3H), 7.30 (dd, J = 8.9, 
2.3 Hz, 1H), 7.11─6.97 (m, 2H), 4.76 (q, J = 7.1 Hz, 2H), 1.54 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ = 166.4 (Cq), 162.7 (Cq), 160.7 (Cq), 158.8 (Cq), 153.5 (Cq), 147.9 (CH), 139.7 (CH), 138.1 (Cq), 
130.4 (CH), 128.4 (CH), 128.3 (CH), 125.2 (CH), 120.8 (CH), 119.5 (CH), 116.7 (CH), 112.6 (CH), 112.1 
(Cq), 62.7 (CH2), 14.4 (CH3). IR (ATR) ν = 2980, 1620, 1573, 148.95, 1417, 1343, 1242, 969, 774, 710 
cm-1. MS (ESI) m/z (relative intensity): 344 (100) [M+H]+, 366 (45) [M+Na]+. HR-MS (ESI) m/z calcd 
for C21H18N3O2 [M+H]
+: 344.1394, found: 344.1396. 
 
 




was followed using ethyl 4-(pyridin-2-yloxy)benzimidate (161q) (60.6 mg, 0.25 mmol) and 
5-(4-methoxyphenyl)oxazol-2(5H)-one (162f) (57.9 mg, 0.30 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/2) yielded 163qf (68.1 mg, 73%) as a white solid.  
M. p. = 118─119 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.51 (d, J = 9.0 Hz, 2H), 8.26 (ddd, J = 5.0, 2.0, 0.8 
Hz, 1H), 8.17 (dd, J = 8.9, 0.5 Hz, 1H), 7.76 (ddd, J = 8.2, 7.3, 2.0 Hz, 1H), 7.59 (d, J = 2.3 Hz, 1H), 7.28 
(dd, J = 9.2, 2.3 Hz, 1H), 7.08 (ddd, J = 7.3, 5.0, 0.9 Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), 6.99 (d, J = 9.0 Hz, 
2H), 4.76 (q, J = 7.1 Hz, 2H), 3.88 (s, 3H), 1.56 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.5 
(Cq), 162.9 (Cq), 161.8 (Cq), 160.7 (Cq), 158.9 (Cq), 153.8 (Cq), 148.2 (CH), 139.7 (CH), 131.0 (Cq), 130.3 
(CH), 125.4 (CH), 120.5 (CH), 119.7 (CH), 116.7 (CH), 113.8 (CH), 112.8 (CH), 112.1 (Cq), 62.8 (CH2), 
55.5 (CH3), 14.6 (CH3). IR (ATR) ν = 2977, 1624, 1577, 1497, 1445, 1344, 1250, 1106 cm
-1. MS (ESI) 
m/z (relative intensity): 374 (100) [M+H]+, 396 (7) [M+Na]+. HR-MS (ESI) m/z calcd for C22H19N3NaO3 
[M+Na]+: 396.1324, found: 396.1321. 
 
 
4-Ethoxy-2-(3-fluorophenyl)-7-(pyridin-2-yloxy)quinazoline (163qi): The general procedure C was 
followed using ethyl 4-(pyridin-2-yloxy)benzimidate (161q) (60.6 mg, 0.25 mmol) and 
3-(3-fluorophenyl)-1,4,2-dioxazol-5H-one (162i) (54.3 mg, 0.30 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 163qi (79.5 mg, 88%) as a white solid.  
M. p. = 101─104 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.34 (dt, J = 7.9, 1.2 Hz, 1H), 8.27─8.26 (m, 2H), 
8.20 (dd, J = 8.9, 0.5 Hz, 1H), 7.78 (ddd, J = 8.2, 7.3, 2.0 Hz, 1H), 7.63 (d, J = 2.3 Hz, 1H), 7.44 (td, J = 
8.0, 5.8 Hz, 1H), 7.34 (dd, J = 8.9, 2.4 Hz, 1H), 7.16 (tdd, J = 8.3, 2.7, 1.0 Hz, 1H), 7.10 (ddd, J = 7.4, 
5.0, 1.0 Hz, 1H), 7.06 (dt, J = 8.3, 0.9 Hz, 1H) 4.77 (q, J = 7.1 Hz, 2H), 1.57 (t, J = 7.1 Hz, 3H). 13C NMR 
(125 MHz, CDCl3) δ = 166.6 (Cq), 163.1 (d, 
1J = 243.9 Hz, Cq), 162.7 (Cq), 160.0 (d, 
4J = 3.3 Hz, Cq) 
159.0 (Cq), 153.5 (Cq), 148.0 (CH), 140.7 (d, 
3J = 7.8 Hz, Cq), 139.9 (CH), 129.8 (d, 
3J = 7.8 Hz, CH), 
125.3 (CH), 124.1 (d, 4J = 2.8 Hz, CH), 121.3 (CH), 119.7 (CH), 117.3 (d, 2J = 21.4 Hz, CH), 116.9 (CH), 
115.4 (d, 2J = 23.0 Hz, CH), 112.8 (CH), 112.4 (Cq), 63.1 (CH2), 14.7 (CH3). 
19F NMR (282 MHz, CDCl3) δ 




cm-1. MS (ESI) m/z (relative intensity): 362 (100) [M+H]+, 745 (10) [2M+Na]+. HR-MS (ESI) m/z calcd 
for C21H17FN3O2 [M+H]
+: 362.1305, found: 362.1299. 
 
 
4-Ethoxy-7-[(4-methylpyridin-2-yl)oxy]-2-(p-tolyl)quinazoline (163rm): The general procedure C 
was followed using ethyl 4-[(4-methylpyridin-2-yl)oxy]benzimidate (161r) (64.1 mg, 0.25 mmol) and 
3-(p-tolyl)-1,4,2-dioxazol-5-one (162m) (53.2 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 163rm (77.2 mg, 83%) as a white solid.  
M. p. = 102─104 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.42 (d, J = 8.2 Hz, 2H), 8.14 (d, J = 8.9 Hz, 1H), 
8.07 (d, J = 2.4 Hz, 1H), 7.59─7.50 (m, 2H), 7.30─7.20 (m, 3H), 6.93 (d, J = 8.3 Hz, 1H), 4.74 (q, J = 7.1 
Hz, 2H), 2.41 (s, 3H), 2.31 (s, 3H), 1.54 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 166.3 (Cq), 
160.8 (Cq), 160.7 (Cq), 159.5 (Cq), 153.5 (Cq), 147.8 (CH), 140.6 (Cq), 140.5 (CH), 135.4 (Cq), 129.1 (Cq), 
129.1 (CH), 128.4 (CH), 125.2 (CH), 120.2 (CH), 115.7 (CH), 112.4 (CH), 111.8 (Cq), 62.7 (CH2), 21.5 
(CH3), 17.6 (CH3), 14.4 (CH3). IR (ATR) ν = 2976, 2921, 1603, 1568, 1470, 1341, 1279, 1156, 890, 788 
cm-1. MS (ESI) m/z (relative intensity): 372 (100) [M+H]+, 394 (5) [M+Na]+. HR-MS (ESI) m/z calcd for 
C23H22N3O2 [M+H]
+: 372.1707, found: 372.1706. 
 
 
4-Ethoxy-2-phenyl-7-(pyridin-2-yl)quinazoline (163sa): The general procedure C was followed using 
ethyl 4-(pyridin-2-yl)benzimidate (161s) (56.9 mg, 0.25 mmol) and 5-phenyloxazol-2(5H)-one (162a) 
(48.9 mg, 0.30 mmol). Purification by coloumn chromatography on silica gel (n-hexane/EtOAc: 15/1) 
yielded 163sa (44.2 mg, 54%) as a white solid.  
M. p. = 130─131 ˚C. 1H NMR (400 MHz, CDCl3) δ = 8.76 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.64─8.55 (m, 
2H), 8.50 (dd, J = 1.5, 0.7 Hz, 1H), 8.30─8.20 (m, 2H), 7.93 (dt, J = 8.0, 1.0 Hz, 1H), 7.85─7.73 (m, 1H), 




13C NMR (100 MHz, CDCl3) δ = 166.7 (Cq), 160.5 (Cq), 156.3 (Cq), 152.3 (Cq), 148.9 (CH), 144.1 (Cq), 
138.3 (Cq), 136.9 (CH), 130.4 (CH), 128.5 (CH), 128.4 (CH), 125.8 (CH), 125.2 (CH), 124.0 (CH), 122.9 
(CH), 121.3 (CH), 115.4 (Cq), 62.9 (CH2), 14.4 (CH3). IR (ATR) ν = 2968, 1703, 1621, 1553, 1431, 1321, 
1261, 1106, 1016, 769 cm-1. MS (ESI) m/z (relative intensity): 328 (100) [M+H]+, 350 (30) [M+Na]+. 
HR-MS (ESI) m/z calcd for C21H17N3O [M+H]
+: 328.1444, found: 328.1446. 
 
 
2-(4-Chlorophenyl)-4-ethoxy-7-(pyridin-2-yl)quinazoline (163sj): The general procedure C was 
followed using ethyl 4-(pyridin-2-yl)benzimidate (161s) (56.6 mg, 0.25 mmol) and 
3-(4-chlorophenyl)-1,4,2-dioxazol-5-one (162j) (59.3 mg, 0.30 mmol). Purification by coloumn 
chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 163sj (56.0 mg, 62%) as a white solid.  
M. p. = 192─194 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.78 (d, J = 4.8 Hz, 1H), 8.53 (d, J = 8.7 Hz, 2H), 
8.48 (s, 1H), 8.32─8.19 (m, 2H), 7.93 (d, J = 8.0 Hz, 1H), 7.82 (dd, J = 7.7, 1.8 Hz, 1H), 7.47 (d, J = 8.6 
Hz, 2H), 7.38─7.25 (m, 1H), 4.76 (q, J = 7.1 Hz, 2H), 1.59 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ = 166.7 (Cq), 159.4 (Cq), 156.1 (Cq), 152.1 (Cq), 149.9 (CH), 144.2 (Cq), 136.9 (CH), 136.7 (Cq), 136.6 
(Cq), 129.8 (CH), 128.6 (CH), 125.7 (CH), 125.4 (CH), 124.0 (CH), 123.0 (CH), 121.2 (CH), 115.4 (Cq), 
63.0 (CH2), 14.4 (CH3). IR (ATR) ν = 2978, 1624, 1566, 1379, 1327, 1089, 1013, 990, 770, 738 cm
-1. 
MS (ESI) m/z (relative intensity): 362 (100) [M+H]+, 384 (10) [M+Na]+, 745 (10) [2M+Na]+. HR-MS 
(ESI) m/z calcd for C21H17ClN3O [M+H]
+: 362.1055, found: 362.1056. 
 
 
4-Ethoxy-7-(pyridin-2-yl)-2-(thiophen-3-yl)quinazoline (163te): The general procedure C was 
followed using ethyl 4-(pyridin-2-yl)benzimidate (161t) (56.6 mg, 0.25 mmol) and 
3-(thiophen-3-yl)-1,4,2-dioxazol-5-one (162e) (50.7 mg, 0.30 mmol). Purification by coloumn 




M. p. = 109─111 ˚C. 1H NMR (300 MHz, CDCl3) δ = 8.75 (ddd, J = 4.8, 1.9, 1.0 Hz, 1H), 8.41 (dd, J = 
1.6, 0.7 Hz, 1H), 8.30─8.15 (m, 2H), 8.07 (dd, J = 3.7, 1.3 Hz, 1H), 7.92 (dd, J = 8.0, 1.1 Hz, 1H), 7.80 
(ddd, J = 8.0, 7.5, 1.8 Hz, 1H), 7.46 (dd, J = 5.0, 1.3 Hz, 1H), 7.29 (ddd, J = 7.4, 4.8, 1.2 Hz, 1H), 7.15 
(dd, J = 5.0, 3.7 Hz, 1H), 4.73 (q, J = 7.1 Hz, 2H), 1.56 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 
= 166.4 (Cq), 157.1 (Cq), 156.1 (Cq), 152.0 (Cq), 149.7 (CH), 144.2 (Cq), 144.1 (Cq), 136.8 (CH), 129.5 
(CH), 128.8 (CH), 128.0 (CH), 125.3 (CH), 124.9 (CH), 124.0 (CH), 122.9 (CH), 121.2 (CH), 115.2 (Cq), 
63.1 (CH2), 14.5 (CH3). IR (ATR) ν = 3069, 2977, 1623, 1555, 1416, 1319, 1110, 846, 774, 703 cm
-1. 
MS (ESI) m/z (relative intensity): 306 (10), 334 (100) [M+H]+, 356 (10) [M+Na]+, 689 (10) [2M+Na]+. 
HR-MS (ESI) m/z calcd for C19H16N3OS [M+H]
+: 334.1009, found: 334.1013. 
 
Intermolecular competition experiments between different benzimidates 161 
 
A suspension of ethyl 4-methoxybenzimidate (161d) (53.8 mg, 0.3 mmol), ethyl 
4-(trifluoromethyl)benzimidate (161e) (65.2 mg, 0.3 mmol), 5-phenyloxazol-2(5H)-one (162a) (40.8 
mg, 0.25 mmol) and [Cp*Co(CH3CN)3](SbF6)2 (180) (6.9 mg, 5.0 mol %) in DCE (1.0 mL) was stirred 
under air at 100 °C for 13 h. After cooling to ambient temperature, the mixture was filtered through 
a short pad of celite, rinsed with CH2Cl2 (20 mL) and concentrated in vacuo. The crude 
1H NMR was 
measured to determine the conversions to the products 163da (42%) and 163ea (24%) using 










A suspension of ethyl benzimidate (161a) (37.3 mg, 0.25 mmol), 3-(m-tolyl)-1,4,2-dioxazol-5H-one 
(162g) (53.2 mg, 0.3 mmol), 3-(3-fluorophenyl)-1,4,2-dioxazol-5H-one (162i) (54.4 mg, 0.3 mmol) 
and [Cp*Co(CH3CN)3](SbF6)2 (180) (6.9 mg, 5.0 mol %) in DCE (1.0 mL) was stirred under air at 
100 °C for 13 h. After cooling to ambient temperature, the mixture was filtered through a short pad 
of celite, rinsed with CH2Cl2 (20 mL) and concentrated in vacuo. The crude 
1H NMR was measured to 
determine the conversions to the products 163ag (72%) and 163ai (27%) using 






Kinetic Isotope Effect Experiment 
 
 
Two parallel reactions of 162a with 161a or [D]5-161a were performed to determine the 
corresponding KIE value. 161a (37.3 mg, 0.25 mmol) or [D]5-161a (38.6 mg, 0.25 mmol), 
3-phenyl-1,4,2-dioxazol-5H-one (162a) (48.9 mg, 0.30 mmol), [Cp*Co(CH3CN)3](SbF6)2 (180) (6.9 mg, 
5.0 mol %) and 1,3,5-trimethoxybenzene (42.0 mg, 0.25 mmol) as internal standard and DCE (1.0 mL) 
were placed in a 25 mL Schlenk tube. The mixture was stirred at 100 °C, a periodic aliquot (0.05 mL) 






yield / % 
5 10 15 20 25 
163aa 10 38 56 75 81 








1-Ethoxy-6-methoxy-3-vinyl-3,4-dihydroisoquinoline (164da): The general procedure D was 
followed using ethyl 4-methoxybenzimidate (161d) (44.8 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-pentane/Et2O: 20/1) yielded 164da (41 mg, 71%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.61 (d, J = 8.5 Hz, 1H), 6.75 (dd, J = 8.5, 2.5 Hz, 1H), 6.68 (d, J = 2.5 Hz, 
1H), 5.95 (ddd, J = 17.1, 10.3, 5.9 Hz, 1H), 5.26 (dt, J = 17.1, 1.7 Hz, 1H), 5.07 (dt, J = 10.3, 1.6 Hz, 1H), 
4.35─4.14 (m, 3H), 3.80 (s, 3H), 2.87 (dd, J = 15.6, 5.5 Hz, 1H), 2.62 (dd, J = 15.6, 9.5 Hz, 1H), 1.36 (t, 
J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 161.5 (Cq), 159.6 (Cq), 140.3 (CH), 140.2 (Cq), 126.4 (CH), 
118.8 (Cq), 114.4 (CH2), 112.6 (CH), 111.9 (CH), 60.8 (CH2), 57.0 (CH), 55.3 (CH3), 33.1 (CH2), 14.4 
(CH3). IR (ATR) ν = 2977, 2936, 1636, 1606, 1298, 1254, 1150, 1034, 918, 675 cm
-1. MS (ESI) m/z 
y = 3.4873x 
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(relative intensity): 232 (100) [M+H]+, 204 (40). HR-MS (ESI) m/z calcd for C14H18NO2 [M+H]
+: 
232.1332, found: 232.1339. 
 
 
1-Ethoxy-6-methyl-3-vinyl-3,4-dihydroisoquinoline (164ca): The general procedure D was followed 
using ethyl 4-methylbenzimidate (164c) (40.8 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) 
(72.0 µL, 0.75 mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 20/1) 
yielded 164ca (34 mg, 63%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.56 (d, J = 7.8 Hz, 1H), 7.05 (d, J = 7.8 Hz, 1H), 6.97 (s, 1H), 5.95 (ddd, 
J = 17.0, 10.3, 5.8 Hz, 1H), 5.26 (dt, J = 17.1, 1.7 Hz, 1H), 5.07 (dt, J = 10.3, 1.6 Hz, 1H), 4.42─4.10 (m, 
3H), 2.86 (dd, J = 15.6, 5.5 Hz, 1H), 2.61 (dd, J = 15.6, 9.6 Hz, 1H), 2.34 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ = 159.8 (Cq), 141.1 (Cq), 140.3 (CH), 138.1 (Cq), 128.0 (CH), 127.4 (CH), 
124.6 (CH), 123.1 (Cq), 114.4 (CH2), 60.8 (CH2), 57.1 (CH), 32.7 (CH2), 21.5 (CH3), 14.4 (CH3). IR (ATR) 
ν = 2977, 1648, 1637, 1575, 1298, 1168, 1099, 918, 827, 674 cm-1. MS (ESI) m/z (relative intensity): 
216 (100) [M+H]+, 188 (40). HR-MS (ESI) m/z calcd for C14H18NO [M+H]
+: 216.1383, found: 216.1387. 
 
 
1-Ethoxy-6-(trifluoromethyl)-3-vinyl-3,4-dihydroisoquinoline (164ea): The general procedure D 
was followed using ethyl 4-(trifluoromethyl)benzimidate (161e) (54.3 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-pentane/Et2O: 20/1) yielded 164ea (38 mg, 57%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.77 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.42 (s, 1H), 5.93 (ddd, 
J = 17.1, 10.3, 5.8 Hz, 1H), 5.27 (dt, J = 17.1, 1.6 Hz, 1H), 5.10 (dt, J = 10.3, 1.5 Hz, 1H), 4.48─4.10 (m, 
3H), 2.96 (dd, J = 15.8, 5.6 Hz, 1H), 2.70 (dd, J = 15.8, 9.6 Hz, 1H), 1.38 (t, J = 7.1 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ = 158.4 (Cq), 139.5 (CH), 138.8 (Cq), 132.5 (q, 
2J = 32.1 Hz, Cq), 128.5 (Cq), 125.1 
(CH), 124.2 (q, 3J = 3.7 Hz, CH), 123.8 (q, 1J = 273.3 Hz, Cq), 123.7 (q, 




61.3 (CH2), 56.7 (CH), 32.5 (CH2), 14.3 (CH3). 
19F NMR (376 MHz, CDCl3) δ = -62.90. IR (ATR) ν = 2981, 
1651, 1297, 1167, 1125, 1101, 1070, 920, 844, 679 cm-1. MS (ESI) m/z (relative intensity): 270 (100) 
[M+H]+, 242 (40). HR-MS (ESI) m/z calcd for C14H15F3NO [M+H]
+: 270.1100, found: 270.1110. 
 
 
1-Ethoxy-6-(p-tolyl)-3-vinyl-3,4-dihydroisoquinoline (164ua): The general procedure D was 
followed using ethyl 4'-methyl-(1,1'-biphenyl)-4-carbimidate (161u) (59.8 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-pentane/Et2O: 20/1) yielded 164ua (37.9 mg, 52%) as a white solid.  
M.p. = 64─66 °C. 1H NMR (300 MHz, CDCl3) δ = 7.73 (d, J = 8.0 Hz, 1H), 7.55─7.44 (m, 3H), 7.38 (s, 
1H), 7.24 (d, J = 7.9 Hz, 2H), 5.99 (ddd, J = 17.0, 10.3, 5.9 Hz, 1H), 5.30 (dt, J = 17.0, 1.6 Hz, 1H), 5.10 
(dt, J = 10.3, 1.6 Hz, 1H), 4.65─4.12 (m, 3H), 2.97 (dd, J = 15.7, 5.6 Hz, 1H), 2.72 (dd, J = 15.7, 9.6 Hz, 
1H), 2.39 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 159.7 (Cq), 143.7 (Cq), 140.1 
(CH), 138.6 (Cq), 137.7 (Cq), 137.4 (Cq), 129.5 (CH), 127.0 (CH), 125.8 (CH), 125.3 (CH), 125.2 (CH), 
124.2 (Cq), 114.7 (CH2), 61.2 (CH2), 57.0 (CH), 32.9 (CH2), 21.1 (CH3), 14.4 (CH3). IR (ATR) ν = 2977, 
1634, 1314, 1291, 1100, 919, 814, 674 cm-1. MS (ESI) m/z (relative intensity): 292 (100) [M+H]+, 264 
(20). HR-MS (ESI) m/z calcd for C20H22NO [M+H]
+: 292.1696, found: 292.1697.  
 
 
6-Chloro-1-ethoxy-3-vinyl-3,4-dihydroisoquinoline (164ga): The general procedure D was followed 
using ethyl 4-chlorobenzimidate (161g) (45.9 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) 
(72.0 µL, 0.75 mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 30/1) 
yielded 164ga (38 mg, 64%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.60 (d, J = 8.2 Hz, 1H), 7.22 (dt, J = 8.2, 2.1 Hz, 1H), 7.15 (d, J = 2.1 Hz, 
1H), 5.92 (ddd, J = 17.1, 10.3, 5.8 Hz, 1H), 5.25 (dt, J = 17.1, 1.6 Hz, 1H), 5.08 (dt, J = 10.3, 1.6 Hz, 1H), 




3H). 13C NMR (100 MHz, CDCl3) δ = 158.8 (Cq), 140.0 (Cq), 139.7 (CH), 136.6 (Cq), 127.4 (CH), 126.9 
(CH), 126.1 (CH), 124.1 (Cq), 114.8 (CH2), 61.1 (CH2), 56.8 (CH), 32.5 (CH2), 14.3 (CH3). IR (ATR) ν = 
2978, 1638, 1595, 1294, 1103, 920, 830, 665 cm-1. MS (ESI) m/z (relative intensity): 236 (100) 
[M+H]+, 208 (60). HR-MS (ESI) m/z calcd for C13H15NOCl [M+H]
+: 236.0837, found: 236.0840. 
 
 
6-Bromo-1-ethoxy-3-vinyl-3,4-dihydroisoquinoline (164va): The general procedure D was followed 
using ethyl 4-bromobenzimidate (161v) (57.1 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) 
(72.0 µL, 0.75 mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 20/1) 
yielded 164va (50 mg, 71%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.52 (d, J = 8.2 Hz, 1H), 7.38 (dd, J = 8.2, 2.0 Hz, 1H), 7.31 (d, J = 2.0 Hz, 
1H), 5.92 (ddd, J = 17.1, 10.3, 5.8 Hz, 1H), 5.25 (dt, J = 17.1, 1.6 Hz, 1H), 5.08 (dt, J = 10.3, 1.6 Hz, 1H), 
4.46─4.12 (m, 3H), 2.87 (dd, J = 15.8, 5.6 Hz, 1H), 2.62 (dd, J = 15.8, 9.5 Hz, 1H), 1.36 (t, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ = 158.9 (Cq), 140.1 (Cq), 139.7 (CH), 130.3 (CH), 129.9 (CH), 126.3 
(CH), 125.0 (Cq), 124.5 (Cq), 114.8 (CH2), 61.1 (CH2), 56.8 (CH), 32.3 (CH2), 14.3 (CH3). IR (ATR) ν = 
2938, 2898, 1638, 1588, 1366, 1273, 1101, 918, 828, 665 cm-1. MS (ESI) m/z (relative intensity): 282 
(98) [M+H]+ (81Br), 280 (100) [M+H]+ (79Br), 254 (48) (81Br), 252 (50) (79Br). HR-MS (ESI) m/z calcd for 
C13H15NO
79Br [M+H]+: 280.0332, found: 280.0333, C13H15NO




Methyl 1-methoxy-3-vinyl-3,4-dihydroisoquinoline-6-carboxylate (164ia): The general procedure D 
was followed using methyl 4-[imino(methoxy)methyl]benzoate (161i) (48.3 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-pentane/Et2O: 20/1) yielded 164ia (38 mg, 71%) as a white solid.  




8.0 Hz, 1H), 5.94 (ddd, J = 17.1, 10.3, 5.7 Hz, 1H), 5.27 (dt, J = 17.1, 1.6 Hz, 1H), 5.09 (dt, J = 10.3, 1.6 
Hz, 1H), 4.25 (ddd, J = 9.5, 5.7, 1.5 Hz, 1H), 3.90 (s, 3H), 3.88 (s, 3H), 2.96 (dd, J = 15.8, 5.7 Hz, 1H), 
2.69 (dd, J = 15.7, 9.7 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ = 166.5 (Cq), 159.3 (Cq), 139.6 (CH), 138.2 
(Cq), 132.0 (Cq), 129.0 (Cq), 128.4 (CH), 128.1 (CH), 124.6 (CH), 114.9 (CH2), 56.8 (CH), 52.9 (CH3), 
52.3 (CH3), 32.5 (CH2). IR (ATR) ν = 2947, 1724, 1651, 1433, 1289, 1266, 1197, 1114, 906, 736 cm
-1. 
MS (ESI) m/z (relative intensity): 246 (100) [M+H]+. HR-MS (ESI) m/z calcd for C14H16NO3 [M+H]
+: 
246.1125, found: 246.1125. 
 
 
1-(1-Ethoxy-3-vinyl-3,4-dihydroisoquinolin-6-yl)ethanone (164ha): The general procedure D was 
followed using ethyl 4-acetylbenzimidate (161h) (47.8 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-pentane/Et2O: 20/1→10/1) yielded 164ha (37 mg, 61%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.82 (dd, J = 8.1, 1.7 Hz, 1H), 7.77─7.68 (m, 2H), 5.92 (ddd, J = 17.1, 
10.3, 5.7 Hz, 1H), 5.25 (dt, J = 17.1, 1.6 Hz, 1H), 5.08 (dt, J = 10.3, 1.5 Hz, 1H), 4.50─4.10 (m, 3H), 
2.96 (dd, J = 15.7, 5.6 Hz, 1H), 2.69 (dd, J = 15.7, 9.5 Hz, 1H), 2.58 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ = 197.6 (Cq), 158.7 (Cq), 139.6 (CH), 138.6 (Cq), 138.4 (Cq), 129.2 (Cq), 127.0 
(CH), 126.9 (CH), 124.8 (CH), 114.8 (CH2), 61.2 (CH2), 56.8 (CH), 32.5 (CH2), 26.7 (CH3), 14.3 (CH3). IR 
(ATR) ν = 2978, 1685, 1637, 1421, 1359, 1300, 1280, 1105, 918, 671 cm-1. MS (ESI) m/z (relative 
intensity): 266 (60) [M+Na]+, 244 (100) [M+H]+, 216 (50). HR-MS (ESI) m/z calcd for C15H18NO2 
[M+H]+: 244.1332, found: 244.1334. 
 
 
N-(1-Ethoxy-3-vinyl-3,4-dihydroisoquinolin-6-yl)pivalamide (164pa): The general procedure D was 




4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-pentane/Et2O: 4/1) yielded 164pa (61 mg, 81%) as a white solid.  
M.p. = 54─56 °C. 1H NMR (400 MHz, CDCl3) δ = 7.61 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 2.3 Hz, 1H), 7.37 
(brs, 1H), 7.25 (dd, J = 8.4, 2.3 Hz, 1H), 5.91 (ddd, J = 17.1, 10.3, 5.8 Hz, 1H), 5.23 (dt, J = 17.1, 1.7 Hz, 
1H), 5.05 (dt, J = 10.3, 1.7 Hz, 1H), 4.43─4.08 (m, 3H), 2.88 (dd, J = 15.7, 5.6 Hz, 1H), 2.62 (dd, J = 
15.7, 9.2 Hz, 1H), 1.36 (t, J = 7.1 Hz, 3H), 1.29 (s, 9H). 13C NMR (100 MHz, CDCl3) δ = 176.7 (Cq), 159.3 
(Cq), 140.2 (Cq), 140.0 (CH), 139.5 (Cq), 125.6 (CH), 121.6 (Cq), 118.2 (CH), 117.4 (CH), 114.6 (CH2), 
60.9 (CH2), 56.9 (CH), 39.7 (Cq), 32.9 (CH2), 27.6 (CH3), 14.4 (CH3). IR (ATR) ν = 3331, 2973, 1650, 
1636, 1585, 1520, 1302, 1166, 917, 732 cm-1. MS (ESI) m/z (relative intensity): 323 (25) [M+Na]+, 
301 (100) [M+H]+, 273 (10). HR-MS (ESI) m/z calcd for C18H25N2O2 [M+H]




1-Methoxy-3-vinyl-3,4-dihydroisoquinoline (164ba): The general procedure D was followed using 
methyl benzimidate (161b) (33.8 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 
0.75 mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 20/1) yielded 
164ba (27 mg, 58%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.65 (dd, J = 7.5, 1.5 Hz, 1H), 7.35 (td, J = 7.4, 1.5 Hz, 1H), 7.29─7.21 
(m, 1H), 7.17 (d, J = 8.0 Hz, 1H), 5.97 (ddd, J = 17.1, 10.3, 5.8 Hz, 1H), 5.29 (dt, J = 17.1, 1.7 Hz, 1H), 
5.09 (dt, J = 10.3, 1.7 Hz, 1H), 4.22 (ddd, J = 9.9, 5.7, 1.5 Hz, 1H), 3.88 (s, 3H), 2.91 (dd, J = 15.7, 5.7 
Hz, 1H), 2.66 (dd, J = 15.7, 9.9 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ = 160.0 (Cq), 140.1 (CH), 138.1 
(Cq), 130.9 (CH), 127.3 (CH), 126.7 (CH), 125.5 (Cq), 124.6 (CH), 114.6 (CH2), 57.0 (CH), 52.7 (CH3), 
32.7 (CH2). IR (ATR) ν = 2942, 1650, 1638, 1436, 1310, 1901, 919, 738, 671 cm
-1. MS (ESI) m/z 
(relative intensity): 188 (100) [M+H]+. HR-MS (ESI) m/z calcd for C12H14NO [M+H]







1-Ethoxy-3-vinyl-3,4-dihydroisoquinoline (164aa): The general procedure D was followed using 
ethyl benzimidate (161a) (37.3 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 
mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 20/1) yielded 164aa 
(36 mg, 72%) as a colorless oil.  
1H NMR (500 MHz, CDCl3) δ = 7.68 (dd, J = 7.7, 1.4 Hz, 1H), 7.34 (td, J = 7.5, 1.4 Hz, 1H), 7.25 (d, J = 
7.2 Hz, 1H), 7.16 (d, J = 7.4 Hz, 1H), 5.96 (ddd, J = 17.1, 10.3, 5.8 Hz, 1H), 5.28 (dt, J = 17.1, 1.6 Hz, 
1H), 5.08 (dt, J = 10.3, 1.6 Hz, 1H), 4.45─4.07 (m, 3H), 2.90 (dd, J = 15.6, 5.5 Hz, 1H), 2.65 (dd, J = 
15.6, 9.8 Hz, 1H), 1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 159.5 (Cq), 140.2 (CH), 138.1 
(Cq), 130.8 (CH), 127.2 (CH), 126.7 (CH), 125.7 (Cq), 124.6 (CH), 114.5 (CH2), 60.9 (CH2), 57.0 (CH), 
32.7 (CH2), 14.4 (CH3). IR (ATR) ν = 2978, 1649, 1638, 1366, 1300, 1093, 917, 738, 680 cm
-1. MS (ESI) 
m/z (relative intensity): 202 (100) [M+H]+, 174 (75). HR-MS (ESI) m/z calcd for C13H16NO [M+H]
+: 
202.1226, found: 202.1230. 
 
 
1-Isopropoxy-3-vinyl-3,4-dihydroisoquinoline (164wa): The general procedure D was followed 
using isopropyl benzimidate (161w) (40.8 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) 
(72.0 µL, 0.75 mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 20/1) 
yielded 164wa (36 mg, 67%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.67 (dd, J = 7.5, 1.5 Hz, 1H), 7.33 (ddd, J = 7.7, 7.5, 1.5 Hz, 1H), 7.25 
(ddd, J = 7.7, 7.5, 1.5 Hz, 1H), 7.15 (d, J = 7.3 Hz, 1H), 5.96 (ddd, J = 17.2, 10.3, 5.7 Hz, 1H), 5.42─5.20 
(m, 2H), 5.07 (dt, J = 10.3, 1.7 Hz, 1H), 4.27─4.16 (m, 1H), 2.90 (dd, J = 15.6, 5.5 Hz, 1H), 2.64 (dd, J = 
15.6, 9.7 Hz, 1H), 1.34 (d, J = 6.2 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ = 158.7 (Cq), 140.4 (CH), 138.2 
(Cq), 130.7 (CH), 127.2 (CH), 126.6 (CH), 126.1 (Cq), 124.7 (CH), 114.4 (CH2), 67.0 (CH), 56.9 (CH), 
32.7 (CH2), 22.0 (CH3), 21.8 (CH3). IR (ATR) ν = 2975, 1637, 1359, 1298, 1114, 1089, 918, 778, 739, 
682 cm-1. MS (ESI) m/z (relative intensity): 238 (10) [M+Na]+, 216 (10) [M+H]+, 196 (20), 174 (100). 
HR-MS (ESI) m/z calcd for C14H18NO [M+H]





(E)-1-Ethoxy-3-styryl-3,4-dihydroisoquinoline (164ab): The general procedure D was followed using 
ethyl benzimidate (161a) (37.3 mg, 0.25 mmol) and (trans)-4-phenyl-5-vinyl-1,3-dioxolan-2-one 
(110b) (142.7 mg, 0.75 mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 
20/1) yielded 164ab (34.7 mg, 50%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.71 (dd, J = 7.4, 1.3 Hz, 1H), 7.43─7.32 (m, 3H), 7.31─7.23 (m, 3H), 
7.22─7.12 (m, 2H), 6.66 (dd, J = 15.8, 1.4 Hz, 1H), 6.31 (dd, J = 15.8, 6.3 Hz, 1H), 4.50─4.25 (m, 3H), 
2.98 (dd, J = 15.7, 5.4 Hz, 1H), 2.74 (dd, J = 15.7, 9.8 Hz, 1H), 1.41 (t, J = 7.1 Hz, 3H). 13C NMR (125 
MHz, CDCl3) δ = 159.6 (Cq), 138.1 (Cq), 137.3 (Cq), 131.9 (CH), 130.8 (CH), 129.8 (CH), 128.3 (CH), 
127.2 (CH), 127.1 (CH), 126.7 (CH), 126.3 (CH), 125.7 (Cq), 124.7 (CH), 61.1 (CH2), 56.9 (CH), 33.3 
(CH2), 14.5 (CH3). IR (ATR) ν = 2977, 1639, 1493, 1367, 1298, 1095, 964, 731, 691 cm
-1. MS (ESI) m/z 
(relative intensity): 278 (100) [M+H]+. HR-MS (ESI) m/z calcd for C19H20NO [M+H]




(E)-3-(4-Chlorostyryl)-1-ethoxy-3,4-dihydroisoquinoline (164ac): The general procedure D was 
followed using ethyl benzimidate (161a) (37.3 mg, 0.25 mmol) and 
(trans)-4-(4-chlorophenyl)-5-vinyl-1,3-dioxolan-2-one (110c) (168.5 mg, 0.75 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 164ac (41.2 mg, 53%) as a 
white solid.  
M.p. = 120─123 °C. 1H NMR (500 MHz, CDCl3) δ = 7.70 (d, J = 7.7 Hz, 1H), 7.36 (dd, J = 7.5, 1.4 Hz, 
1H), 7.29─7.17 (m, 6H), 6.62 (dd, J = 15.8, 1.4 Hz, 1H), 6.29 (dd, J = 15.8, 10.3 Hz, 1H), 4.38─4.28 (m, 
3H), 2.96 (dd, J = 15.6, 5.4 Hz, 1H), 2.72 (dd, J = 15.6, 10.3 Hz, 1H), 1.39 (t, J = 7.1 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ = 160.0 (Cq), 138.2 (Cq), 136.0 (Cq), 132.9 (Cq), 132.8 (CH), 131.2 (CH), 128.9 (CH), 
128.7 (CH), 127.8 (CH), 127.5 (CH), 127.0 (CH), 125.8 (Cq), 125.0 (CH), 61.4 (CH2), 56.9 (CH), 33.2 
(CH2), 14.5 (CH3). IR (ATR) ν = 2972, 1640, 1488, 1366, 1217, 1160, 1011, 779, 504 cm




m/z (relative intensity): 312 (100) [M+H]+, 240 (20). HR-MS (ESI) m/z calcd for C19H19ClNO [M+H]
+: 
312.1150, found: 312.1153. 
 
 
(E)-1-Ethoxy-3-(4-fluorostyryl)-3,4-dihydroisoquinoline (164ad): The general procedure D was 
followed using ethyl benzimidate (161a) (37.3 mg, 0.25 mmol) and 
(trans)-4-(4-fluorophenyl)-5-vinyl-1,3-dioxolan-2-one (110d) (156.2 mg, 0.75 mmol). Purification by 
column chromatography on silica gel (n-pentane/Et2O: 20/1) yielded 164ad (45.0 mg, 61%) as a 
white solid.  
M.p. = 89─90 °C. 1H NMR (300 MHz, CDCl3) δ = 7.71 (dd, J = 7.6, 1.2 Hz, 1H), 7.42─7.25 (m, 4H), 7.19 
(dd, J = 7.4, 1.5 Hz, 1H), 7.05─6.88 (m, 2H), 6.63 (dd, J = 15.8, 1.4 Hz, 1H), 6.23 (dd, J = 15.8, 6.4 Hz, 
1H), 4.50─4.22 (m, 3H), 2.97 (dd, J = 15.7, 5.4 Hz, 1H), 2.73 (dd, J = 15.7, 10.0 Hz, 1H), 1.40 (t, J = 7.1 
Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 162.0 (d, 
1JC-F = 247.0 Hz, Cq), 159.6 (Cq), 138.0 (Cq), 133.4 (d, 
4JC-F = 3.2 Hz, Cq), 131.7 (CH), 130.9 (CH), 128.6 (CH), 127.8 (d, 
3JC-F = 8.0 Hz, CH), 127.2 (CH), 126.7 
(CH), 125.6 (Cq), 124.7 (CH), 115.3 (d, 
2JC-F = 21.6 Hz, CH), 61.1 (CH2), 56.9 (CH), 33.3 (CH2), 14.5 
(CH3). 
19F NMR (282 MHz, CDCl3) δ = -115.23 (ddd, J = 14.0, 8.7, 5.4 Hz). IR (ATR) ν = 1638, 1508, 
1365, 1296, 1224, 1160, 1097, 730, 677 cm-1. MS (ESI) m/z (relative intensity): 296 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C19H19FNO [M+H]
+: 296.1445, found: 296.1450. 
 
 
7-Chloro-1-ethoxy-3-vinyl-3,4-dihydroisoquinoline (164ma): The general procedure D was followed 
using ethyl 3-chlorobenzimidate (161m) (45.9 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) 
(72.0 µL, 0.75 mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 20/1) 
yielded 164mq (36 mg, 61%) as a colorless oil.  
1H NMR (500 MHz, CDCl3) δ = 7.65 (d, J = 2.2 Hz, 1H), 7.31 (dd, J = 8.0, 2.2 Hz, 1H), 7.10 (d, J = 8.0 Hz, 




4.53─3.99 (m, 3H), 2.87 (dd, J = 15.7, 5.6 Hz, 1H), 2.61 (dd, J = 15.7, 9.6 Hz, 1H), 1.38 (t, J = 7.1 Hz, 
3H). 13C NMR (100 MHz, CDCl3) δ = 158.5 (Cq), 139.8 (CH), 136.4 (Cq), 132.4 (Cq), 130.7 (CH), 128.6 
(CH), 127.0 (Cq) 124.9 (CH), 114.8 (CH2), 61.2 (CH2), 56.9 (CH), 32.0 (CH2), 14.3 (CH3). IR (ATR) ν = 
2977, 1650, 1482, 1302, 1258, 1106, 1019, 792, 512 cm-1. MS (ESI) m/z (relative intensity): 236 (100) 
[M+H]+, 208 (60). HR-MS (ESI) m/z calcd for C13H15ClNO [M+H]
+: 236.0837, found: 236.0838. 
 
 
7-Bromo-1-ethoxy-3-vinyl-3,4-dihydroisoquinoline (164xa): The general procedure D was followed 
using ethyl 3-bromobenzimidate (161x) (57.0 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) 
(72.0 µL, 0.75 mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 20/1) 
yielded 164xa (49 mg, 70%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.81 (d, J = 2.0 Hz, 1H), 7.46 (dd, J = 8.0, 2.0 Hz, 1H), 7.04 (d, J = 8.0 Hz, 
1H), 5.91 (ddd, J = 17.1, 10.3, 5.8 Hz, 1H), 5.25 (dt, J = 17.1, 1.6 Hz, 1H), 5.08 (dt, J = 10.3, 1.5 Hz, 1H), 
4.61─4.06 (m, 3H), 2.86 (dd, J = 15.8, 5.6 Hz, 1H), 2.59 (dd, J = 15.8, 9.5 Hz, 1H), 1.38 (t, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ = 158.4 (Cq), 139.5 (CH), 136.9 (Cq), 133.8 (CH), 128.9 (CH), 127.8 
(CH), 127.1 (Cq), 120.3 (Cq), 114.9 (CH2), 61.5 (CH2), 56.7 (CH), 32.0 (CH2), 14.3 (CH3). IR (ATR) ν = 
2977, 1650, 1567, 1479, 1303, 1258, 1101, 919, 815 cm-1. MS (ESI) m/z (relative intensity): 282 (98) 
(81Br), 280 (100) [M+H]+ (79Br), 254 (50) (81Br), 252 (48) (79Br). HR-MS (ESI) m/z calcd for 
C13H15NO
79Br [M+H]+: 280.0332, found: 280.0334, C13H15NO




1-Ethoxy-7-(trifluoromethyl)-3-vinyl-3,4-dihydroisoquinoline (164la): The general procedure D was 
followed using ethyl 3-(trifluoromethyl)benzimidate (161l) (54.3 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 mmol). Purification by column chromatography on 




1H NMR (400 MHz, CDCl3) δ = 7.92 (s, 1H), 7.59 (dd, J = 7.9, 1.3 Hz, 1H), 7.28 (d, J = 7.9 Hz, 1H), 5.93 
(ddd, J = 17.1, 10.3, 5.7 Hz, 1H), 5.27 (dt, J = 17.1, 1.6 Hz, 1H), 5.10 (dt, J = 10.3, 1.6 Hz, 1H), 
4.46─4.16 (m, 3H), 2.96 (dd, J = 15.9, 5.6 Hz, 1H), 2.70 (dd, J = 15.9, 9.6 Hz, 1H), 1.40 (t, J = 7.1 Hz, 
3H). 13C NMR (100 MHz, CDCl3) δ = 158.3 (Cq), 142.0 (Cq), 139.6 (CH), 129.3 (q, 
2JC-F = 32.4 Hz, Cq), 
127.8 (CH), 127.3 (q, 3JC-F = 3.7 Hz, CH), 126.2 (Cq), 123.9 (q, 
1JC-F = 272.8 Hz, Cq), 121.7 (q, 
3JC-F = 3.9 
Hz, CH), 114.9 (CH2), 61.3 (CH2), 56.6 (CH), 32.5 (CH2), 14.3 (CH3). 
19F NMR (376 MHz, CDCl3) δ = 
-62.50. IR (ATR) ν = 2981, 1653, 1336, 1301, 1259, 1167, 1124, 1101, 917 cm-1. MS (ESI) m/z 
(relative intensity): 270 (100) [M+H]+, 242 (50). HR-MS (ESI) m/z calcd for C14H15NOF3 [M+H]
+: 
270.1100, found: 2270.1101. 
 
 
1-Ethoxy-5-fluoro-3-vinyl-3,4-dihydroisoquinoline (164ya): The general procedure D was followed 
using ethyl 3-fluorobenzimidate (161y) (41.8 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) 
(72.0 µL, 0.75 mmol). Purification by column chromatography on silica gel (n-pentane/Et2O: 20/1) 
yielded 164ya (37 mg, 67%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.48 (dd, J = 7.6, 0.8 Hz, 1H), 7.31─7.16 (m, 1H), 7.09 (dd, J = 8.6, 1.2 
Hz, 1H), 5.96 (ddd, J = 17.1, 10.3, 5.7 Hz, 1H), 5.28 (dt, J = 17.1, 1.6 Hz, 1H), 5.10 (dt, J = 10.3, 1.6 Hz, 
1H), 4.50─4.10 (m, 3H), 2.98 (dd, J = 16.1, 5.7 Hz, 1H), 2.60 (dd, J = 16.2, 9.7 Hz, 1H), 1.37 (t, J = 7.1 
Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 159.1 (d, 
1JC-F = 243.9 Hz, Cq), 158.5 (d, 
4JC-F = 4.3 Hz, Cq), 
139.8 (CH), 127.3 (d, 3JC-F = 6.1 Hz, Cq), 127.2 (d, 
3JC-F = 8.0 Hz, CH), 124.8 (d, 
2JC-F = 19.4 Hz, Cq), 120.4 
(d, 4JC-F = 3.3 Hz, CH), 117.5 (d, 
2JC-F = 21.7 Hz, CH), 114.6 (CH2), 61.1 (CH2), 56.3 (CH), 24.9 (d, 
3JC-F = 
1.4 Hz, CH2), 14.4 (CH3). 
19F NMR (282 MHz, CDCl3) δ = -120.72 (dd, J = 8.9, 5.5 Hz). IR (ATR) ν = 2979, 
1651, 1583, 1467, 1293, 1040, 920, 798, 732 cm-1. MS (ESI) m/z (relative intensity): 220 (100) 
[M+H]+, 192 (80). HR-MS (ESI) m/z calcd for C13H15NOF [M+H]







Intermolecular Competition Experiments 
 
A suspension of ethyl 4-methoxybenzimidate (161d) (44.8 mg, 0.25 mmol), ethyl 
4-(trifluoromethyl)benzimidate (161e) (54.3 mg, 0.25 mmol), 4-vinyl-1,3-dioxolan-2-one  (110a) 
(28.6 mg, 0.25 mmol), NaOAc (8.2 mg, 40 mol %), Ph3B (24.2 mg, 40 mol %) and 
[Cp*Co(CH3CN)3](PF6)2 (180) (7.6 mg, 5.0 mol %) in HFIP (1.0 mL) was stirred under N2 at 55 °C for 5 
h. After cooling to ambient temperature, the mixture was transferred into a round bottom flask with 
CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column chromatography on silica gel 
(n-pentane/Et2O: 20/1→10/1) afforded product 164da (10 mg, 18%) and 164ea (11 mg, 16%). 
 
 
A suspension of ethyl 4-methylbenzimidate (161c) (40.8 mg, 0.25 mmol), ethyl 4-fluorobenzimidate 
(161f) (41.8 mg, 0.25 mmol), 4-vinyl-1,3-dioxolan-2-one (110a) (28.6 mg, 0.25 mmol), NaOAc (8.2 
mg, 40 mol %), Ph3B (24.2 mg, 40 mol %) and [Cp*Co(CH3CN)3](PF6)2 (180) (7.6 mg, 5.0 mol %) in 
HFIP (1.0 mL) was stirred under N2 at 55 °C for 5 h. After cooling to ambient temperature, the 
mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. 
Purification by column chromatography on silica gel (n-pentane/Et2O: 20/1→10/1) afforded product 





H/D Exchange Experiment 
 
 
A suspension of benzimidate (161a) (37.3 mg, 0.25 mmol), 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 
µL, 0.75 mmol), NaOAc (8.2 mg, 40 mol %), Ph3B (24.2 mg, 40 mol %) and [Cp*Co(CH3CN)3](PF6)2 
(180) (7.6 mg, 5.0 mol %) in (CF3)2CHOD (1.0 mL) was stirred under N2 at 55 °C for 5 h. After cooling 
to ambient temperature, the mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) 
and concentrated in vacuo. Purification by column chromatography on silica gel (n-pentane/Et2O: 










Intermolecular KIE Experiment 
 
Two parallel reactions of 110a with 161a or [D]5-161a were performed to determine the 
corresponding KIE value. 164aa (37.3 mg, 0.25 mmol) or [D]5-164aa (38.6 mg, 0.25 mmol), 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 mmol), NaOAc (8.2 mg, 40 mol %), Ph3B (24.2 mg, 
40 mol %), and [Cp*Co(CH3CN)3](PF6)2 (7.6 mg, 5.0 mol %), 1,3,5-trimethoxybenzene (42.0 mg, 0.25 
mmol) as internal standard and HFIP (1.0 mL) were placed in a 25 mL Schlenk tube. The mixture was 
stirred at 55 °C, and a periodic aliquot (0.05 mL) was removed by syringe and analyzed by GC to 
determine the following conversions: 
 
t / min 
yield / % 
30 60 90 120 150 180 
164aa 3.1 9.2 13.5 17.5 21.6 24.0 





y = 0.1388x + 0.2467 
























A suspension of [D]1-161a (37.6 mg 0.25 mmol), 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 µL, 0.75 
mmol), NaOAc (8.2 mg, 40 mol %), Ph3B (24.2 mg, 40 mol %), and [Cp*Co(CH3CN)3](PF6)2 (180) (7.6 
mg, 5.0 mol %) in HFIP (1.0 mL) was stirred for 16 h at 55 °C. After cooling to ambient temperature, 
the reaction mixture was transferred into a round flask with CH2Cl2 (20 mL) and concentrated under 
reduced pressure, purified by column chromatography on silica gel (n-hexane/EtOAc: 20/1) to afford 
[D]n-164aa (25.3 mg, 50%). The kinetic isotope effect of this reaction was determined to be kH/kD = 







Diversification of Vinylated Heteroarenes 164 
a) Synthesis of Dihydroisoquinolone 191 
 
 
To a solution of 164aa (50.4 mg 0.25 mmol) in THF (2.0 mL) was added aqueous HCl (3 M, 2.0 mL), 
and the mixture was stirred at 80 °C for 12 h. After cooling to ambient temperature, the solution 
was neutralized with a saturated NaHCO3 solution and extracted with EtOAc (3 × 20 mL). The 
combined organic layers were washed with brine (40 mL), dried over Na2SO4, and evaporated in 
vacuo. Purification by column chromatography (EtOAc/n-hexane: 4/1) afforded product 191 (39.4 




M.p.: 90─92 °C. 1H NMR (300 MHz, CDCl3) δ = 8.04 (dd, J = 7.6, 1.5 Hz, 1H), 7.42 (td, J = 7.5, 1.5 Hz, 
1H), 7.32 (t, J = 7.3 Hz, 1H), 7.16 (d, J = 7.4 Hz, 1H), 6.34 (brs, 1H), 5.88 (ddd, J = 17.0, 10.2, 6.6 Hz, 
1H), 5.29 (dd, J = 17.0, 1.5 Hz, 1H), 5.18 (dd, J = 10.3, 1.5 Hz, 1H), 4.31─4.17 (m, 1H), 3.05 (dd, J = 
15.6, 5.0 Hz, 1H), 2.91 (dd, J = 15.6, 9.3 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ = 166.0 (Cq), 137.3 (CH), 
132.3 (CH), 128.4 (Cq), 127.9 (CH), 127.4 (CH), 127.1 (CH), 117.2 (Cq), 117.1 (CH2), 53.9 (CH), 34.4 
(CH2). IR (ATR) ν = 3188, 3039, 2925, 1659, 1470, 1406, 1346, 915, 740, 535 cm
-1. MS (ESI) m/z 
(relative intensity) 296 (60) [M+Na]+, 174 (100) [M+H]+. HR-MS (ESI) m/z calcd for C11H12NO [M+H]
+: 









b) Synthesis of Acetylated Isoquinoline 192 by Wacker-Type Oxidation 
 
To a stirred solution of PdCl2 (4.4 mg, 0.025 mmol) and CuCl (24.8 mg, 0.25 mmol) in DMF and H2O 
(7:1, 2 mL) was added 164da (57.8 mg, 0.25 mmol) under ambient O2 atmosphere. The reaction 
mixture was stirred at ambient temperature for 12 h and extracted with Et2O. The organic layer was 
dried over Na2SO4 and evaporated in vacuo. The crude product was separated by column 




M.p. = 127─129 °C. 1H NMR (300 MHz, CDCl3) δ = 8.16 (d, J = 9.1 Hz, 1H), 7.91 (s, 1H), 7.21 (dd, J = 
9.1, 2.5 Hz, 1H), 7.12 (d, J = 2.5 Hz, 1H), 4.60 (q, J = 7.1 Hz, 2H), 3.91 (s, 3H), 2.71 (s, 3H), 1.50 (t, J = 
7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 200.5 (Cq), 161.2 (Cq), 159.7 (Cq), 145.4 (Cq), 139.4 (Cq), 
125.9 (CH), 120.5 (CH), 116.4 (Cq), 113.8 (CH), 106.7 (CH), 62.1 (CH2), 55.5 (CH3), 26.5 (CH3), 14.6 
(CH3). IR (ATR) ν = 3076, 2937, 1685, 1574, 1412, 1327, 1236, 1160, 910, 630 cm
-1. MS (ESI) m/z 
(relative intensity) 268 (100) [M+Na]+, 246 (95) [M+H]+, 218 (60). HR-MS (ESI) m/z calcd for 
C14H16NO3 [M+H]










5.3.5 Data for Maganese(I)-Catalyzed C─H Activation for Decarboxylative C─H/C─O 




(E/Z)-4-[1-(Pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111aa): The general procedure E was 
followed using 1-(pyrimidin-2-yl)-1H-indole (41a) (48.8 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 111aa (61.7 mg, 93%, E/Z = 5.9/1.0 by 1H NMR) as a 
colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 8.75 (d, J = 4.8 Hz, 2H), 8.22 (d, J = 7.7 Hz, 1H), 7.52 (dd, J = 6.5, 1.5 Hz, 
1H), 7.31─7.07 (m, 2H), 7.10 (t, J = 4.8 Hz, 1H), 6.46 (s, 1H), 6.00─5.52 (m, 2H), 4.22 (d, J = 5.3 Hz, 
0.35H), 4.00 (dd, J = 5.8, 1.2 Hz, 1.65H), 3.98─3.85 (m, 2H), 1.54 (brs, 1H). 13C NMR (75 MHz, CDCl3) 
Major isomer: δ = 158.1 (CH), 158.1 (Cq), 139.6 (Cq), 137.0 (Cq), 131.0 (CH), 129.4 (CH), 129.1 (Cq), 
122.7 (CH), 121.8 (CH), 119.8 (CH), 117.1 (CH), 113.7 (CH), 106.4 (CH), 63.3 (CH2), 32.4 (CH2). Minor 
isomer: δ = 139.6 (Cq), 130.1 (CH), 129.0 (CH), 122.7 (CH), 121.9 (CH), 113.8 (CH), 106.2 (CH), 58.5 
(CH2), 28.1 (CH2). (Due to overlap, five peaks are missing). IR (ATR) ν = 3376, 2862, 1562, 1454, 1425, 
1348, 1207, 973, 802, 746 cm-1. MS (ESI) m/z (relative intensity): 288 (100) [M+Na]+, 266 (20) 
[M+H]+, 248 (40). HR-MS (ESI) m/z calcd for C16H16N3O [M+H]
+: 266.1288, found: 266.1288.  
The analytical data were in accordance with those reported in the literature.[69] 
 
 
(E/Z)-4-[1-(Pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ba): The general procedure E was followed 




(110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
1/1) yielded 111ba (64.8 mg, 98%, E/Z = 5.2/1.0 by 1H NMR) as a colorless oil. 
1H NMR (600 MHz, CDCl3) δ = 8.62 (dd, J = 4.9, 2.0 Hz, 1H), 7.89─7.81 (m, 1H), 7.58─7.50 (m, 1H), 
7.43 (d, J = 8.0 Hz, 0.17H), 7.40 (d, J = 8.0 Hz, 0.83H), 7.34─7.27 (m, 2H), 7.17─7.08 (m, 2H), 6.43 (s, 
1H), 5.73─5.38 (m, 2H), 4.06 (d, J = 4.7 Hz, 0.32H), 3.93 (d, J = 6.5 Hz, 1.68H), 3.63 (d, J = 5.3 Hz, 
0.32H), 3.60 (d, J = 6.6 Hz, 1.68H), 1.77 (brs, 1H). 13C NMR (75 MHz, CDCl3) Major isomer: δ = 151.2 
(Cq), 149.5 (CH), 138.9 (Cq), 138.3 (CH), 137.3 (Cq), 131.1 (CH), 128.5 (CH), 128.4 (Cq), 122.1 (CH), 
121.8 (CH), 121.1 (CH), 120.7 (CH), 120.0 (CH), 110.0 (CH), 103.1 (CH), 63.1 (CH2), 30.6 (CH2). Minor 
isomer: δ = 151.2 (Cq), 149.5 (CH), 139.2 (Cq), 138.4 (CH), 130.3 (CH), 128.2 (CH), 120.7 (CH), 110.0 
(CH), 102.9 (CH), 58.2 (CH2), 26.1 (CH2). (Due to overlap, six peaks are missing). IR (ATR) ν = 3355, 
2862, 1587, 1469, 1456, 1437, 1348, 1212, 972, 782, 754 cm-1. MS (ESI) m/z (relative intensity): 287 
(60) [M+Na]+, 265 (80) [M+H]+, 247 (100). HR-MS (ESI) m/z calcd for C17H17N2O [M+H]
+: 265.1335, 
found: 265.1337.  
The analytical data were in accordance with those reported in the literature.[66c] 
 
 
(E/Z)-1-[2-(4-Hydroxybut-2-en-1-yl)-1-(pyridin-2-yl)-1H-indol-3-yl]ethanone (111ea): The general 
procedure E was followed using 6-bromo-1-(pyrimidin-2-yl)-1H-indole (41e) (68.5 mg, 0.25 mmol) 
and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 1/1) yielded 111ea (79.2 mg, 92%, E/Z = 5.3/1.0 by 1H NMR) as a 
yellow oil.  
1H NMR (300 MHz, CDCl3) δ = 8.76 (d, J = 4.8 Hz, 2H), 8.48─8.44 (m, 1H), 7.37 (d, J = 8.3 Hz, 1H), 
7.28 (dd, J = 8.3, 1.7 Hz, 1H), 7.14 (t, J = 4.8 Hz, 1H), 6.43 (s, 1H), 5.87─5.59 (m, 2H), 4.23 (d, J = 4.9 
Hz, 0.26H), 4.02 (dd, J = 5.7, 1.2 Hz, 1.74H), 3.95─3.89 (m, 2H), 1.67 (brs, 1H). 13C NMR (75 MHz, 
CDCl3) Major Isomer: δ = 158.1 (CH), 157.7 (Cq), 140.4 (Cq), 137.6 (Cq), 131.2 (CH), 128.9 (CH), 127.9 
(Cq), 124.9 (CH), 120.8 (CH), 117.4 (CH), 116.9 (CH), 116.2 (Cq), 106.2 (CH), 63.2 (CH2), 32.5 (CH2). 




106.0 (CH), 58.5 (CH2), 28.1 (CH2). (Due to overlap, five peaks are missing). IR (ATR) ν = 3347, 2917, 
1575, 1422, 1343, 973, 815, 736 cm-1. MS (ESI) m/z (relative intensity): 368 (100) [M+Na]+ (81Br), 
366 (98) [M+Na]+ (79Br), 346 (50) [M+H]+ (81Br), 344 (50) [M+H]+ (79Br), 328 (45) (81Br), 326 (45) 
(79Br). HR-MS (ESI) m/z calcd for C16H14BrN3ONa [M+Na]
+: 366.0212, found: 366.0223. 
 
 
(E/Z)-Methyl 2-(4-hydroxybut-2-en-1-yl)-1-(pyrimidin-2-yl)-1H-indole-4-carboxylate (111fa): The 
general procedure E was followed using methyl 1-(pyrimidin-2-yl)-1H-indole-4-carboxylate (41f) 
(63.3 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 111fa (77.6 mg, 96%, E/Z = 
4.7/1.0 by 1H NMR) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.77 (d, J = 4.8 Hz, 2H), 8.38 (d, J = 8.3 Hz, 1H), 7.91 (dd, J = 7.6, 1.0 Hz, 
1H), 7.37─7.00 (m, 3H), 5.96─5.50 (m, 2H), 4.24 (d, J = 5.2 Hz, 0.34H), 4.06─3.85 (m, 6.66H), 1.63 (s, 
1H). 13C NMR (75 MHz, CDCl3) Major isomer: δ = 167.8 (Cq), 158.2 (CH), 157.7 (Cq), 142.0 (Cq), 137.7 
(Cq), 131.4 (CH), 129.1 (Cq), 128.9 (CH), 124.8 (CH), 121.9 (CH), 120.5 (Cq), 118.2 (CH), 117.6 (CH), 
106.9 (CH), 63.3 (CH2), 51.7 (CH3), 32.4 (CH2). Minor isomer: δ = 142.0 (Cq), 130.4 (CH), 128.5 (CH), 
124.8 (CH), 118.3 (CH), 106.8 (CH), 58.5 (CH2), 28.1 (CH2). (Due to overlap, nine peaks are missing). 
IR (ATR) ν = 3439, 2950, 1708, 1566, 1420, 1258, 1137, 973, 804, 753 cm-1. MS (ESI) m/z (relative 
intensity): 346 (100) [M+Na]+, 324 (40) [M+H]+, 306 (60). HR-MS (ESI) m/z calcd for C18H18N3O3 
[M+H]+: 324.1343, found: 324.1353.  
The analytical data were in accordance with those reported in the literature.[69] 
 
 




was followed using 5-methyl-1-(pyrimidin-2-yl)-1H-indole (41g) (52.3 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 111ga (65.4 mg, 94%, E/Z = 5.2/1.0 by 1H NMR) as a yellow 
oil.  
1H NMR (300 MHz, CDCl3) δ = 8.76 (d, J = 4.8 Hz, 2H), 8.16 (d, J = 8.5 Hz, 1H), 7.31 (s, 1H), 7.12 (t, J = 
4.8 Hz, 1H), 7.04 (dd, J = 8.5, 1.6 Hz, 1H), 6.40 (s, 1H), 5.92─5.62 (m, 2H), 4.27 (d, J = 5.5 Hz, 0.32 H), 
4.05 (d, J = 5.7 Hz, 1.68 H), 4.00─3.94 (m, 2H), 2.44 (s, 3H), 1.60 (brs, 1H). 13C NMR (75 MHz, CDCl3) 
Major Isomer: δ = 158.2 (Cq), 158.1 (CH), 139.7 (Cq), 135.3 (Cq), 131.2 (Cq), 130.9 (CH), 129.6 (CH), 
129.4 (Cq), 124.1 (CH), 119.8 (CH), 116.9 (CH), 113.6 (CH), 106.3 (CH), 66.4 (CH2), 32.7 (CH2), 21.4 
(CH3). Minor Isomer: δ = 158.2 (CH), 139.8 (Cq), 135.4 (Cq), 131.3 (Cq), 130.2 (CH), 129.6 (CH), 129.4 
(Cq), 129.1 (CH), 124.2 (CH), 116.9 (CH), 113.8 (CH), 106.2 (CH), 58.6 (CH2), 28.3 (CH2). (Due to 
overlap, two peaks are missing). IR (ATR) ν = 3315, 2924, 1646, 1429, 1137, 1027, 924, 661 cm-1. MS 
(ESI) m/z (relative intensity): 302 (100) [M+Na]+, 280 (43) [M+H]+. HR-MS (ESI) m/z calcd for 
C17H17N3ONa [M+Na]
+: 302.1264, found: 302.1265.  
The analytical data were in accordance with those reported in the literature.[69] 
 
 
(E/Z)-4-[5-Methoxy-1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ha): The general procedure 
E was followed using 5-methoxy-1-(pyrimidin-2-yl)-1H-indole (41h) (56.3 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 111ha (48.0 mg, 65%, E/Z = 6.7/1.0 by 1H NMR) as a 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.70 (d, J = 4.8 Hz, 2H), 8.18 (d, J = 9.1 Hz, 1H), 7.05 (t, J = 4.8 Hz, 1H), 
6.98 (d, J = 2.5 Hz, 1H), 6.84 (dd, J = 9.1, 2.5 Hz, 1H), 6.38 (d, J = 0.9 Hz, 1H), 5.93─5.57 (m, 2H), 4.22 
(d, J = 5.5 Hz, 0.31H), 4.00 (dd, J = 5.8, 1.1 Hz, 1.69H), 3.98–3.88 (m, 2H), 3.83 (s, 3H), 1.68 (brs, 1H). 
13C NMR (100 MHz, CDCl3) Major isomer: δ = 158.0 (Cq), 157.9 (CH), 155.3 (Cq), 140.3 (Cq), 131.9 (Cq), 




(CH2), 55.6 (CH3), 32.7 (CH2). Minor isomer: δ = 155.3 (Cq), 130.1 (CH), 129.0 (CH), 116.7 (CH), 115.1 
(CH), 111.6 (CH), 106.3 (CH), 58.5 (CH2), 28.4 (CH2). (Due to overlap, seven peaks are missing). IR 
(ATR) ν = 3389, 2995, 2832, 1613, 1561, 1422, 1204, 801 cm-1. MS (ESI) m/z (relative intensity): 318 
(100) [M+Na]+, 296 (56) [M+H]+. HR-MS (ESI) m/z calcd for C17H18N3O2 [M+H]
+: 296.1394, found: 
296.1405.  
The analytical data were in accordance with those reported in the literature.[69] 
 
 
(E/Z)-4-[5-Fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ia): The general procedure E 
was followed using 5-fluoro-1-(pyrimidin-2-yl)-1H-indole (41i) (53.3 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 111ia (58.7 mg, 82%, E/Z = 5.4/1 by 1H NMR) as a white 
solid. 
M.p. = 93─96 °C. 1H NMR (400 MHz, CDCl3) δ = 8.74 (d, J = 4.8 Hz, 2H), 8.25─8.16 (m, 1H), 7.18─7.05 
(m, 2H), 6.92 (td, J = 9.2, 2.6 Hz, 1H), 6.41 (d, J = 0.9 Hz, 1H), 5.97─5.53 (m, 2H), 4.23 (d, J = 5.4 Hz, 
0.29H), 4.02 (dd, J = 5.8, 1.2 Hz, 1.71H), 3.98─3.85 (m, 2H), 1.46 (brs, 1H). 13C NMR (100 MHz, CDCl3) 
Major isomer: δ = 158.9 (d, 1JC-F = 237.9 Hz, Cq), 158.1 (CH), 157.9 (Cq), 141.4 (Cq), 133.4 (Cq), 131.2 
(CH), 129.9 (d, 3JC-F = 9.6 Hz, Cq), 129.1 (CH), 117.2 (CH), 114.9 (d, 
3JC-F = 8.9 Hz, CH), 110.3 (d, 
2JC-F = 
25.3 Hz, CH), 106.3 (d, 4JC-F = 3.4 Hz, CH), 105.0 (d, 
2JC-F = 23.5 Hz, CH), 63.3 (CH2), 32.7 (CH2). Minor 
isomer: δ = 130.3 (CH), 128.8 (CH), 117.2 (CH), 115.0 (d, 3JC-F = 8.9 Hz, CH), 110.3 (d, 
2JC-F = 25.3 Hz, 
CH), 106.1 (d, 4JC-F = 3.4 Hz, CH), 58.5 (CH2), 28.3 (CH2). (Due to overlap, seven peaks are missing). 
19F NMR (376 MHz, CDCl3) Major isomer: δ = -122.33 (td, J = 9.2, 4.7 Hz). Minor isomer: -122.42 (td, 
J = 9.1, 4.7 Hz). IR (ATR) ν = 3272, 1562, 1431, 1174, 1109, 978, 782, 592 cm-1. MS (ESI) m/z (relative 
intensity): 306 (100) [M+Na]+, 284 (40) [M+H]+, 266 (90). HR-MS (ESI) m/z calcd for C16H15FN3O 
[M+H]+: 284.1194, found: 284.1195.  






(E/Z)-4-[5-Chloro-1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ja): The general procedure E 
was followed using 5-chloro-1-(pyrimidin-2-yl)-1H-indole (41j) (57.4 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 111ja (57.0 mg, 76%, E/Z = 5.5/1.0 by 1H NMR) as a 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.75 (d, J = 4.8 Hz, 2H), 8.16 (d, J = 8.9 Hz, 1H), 7.45 (d, J = 2.2 Hz, 1H), 
7.19─7.01 (m, 2H), 6.39 (s, 1H), 5.99─5.48 (m, 2H), 4.23 (dd, J = 4.6, 0.7 Hz, 0.23H), 4.02 (dd, J = 5.7, 
1.2 Hz, 1.77H), 3.97─3.88 (m, 2H), 1.50 (brs, 1H). 13C NMR (100 MHz, CDCl3) Major isomer: δ = 158.1 
(CH), 157.8 (Cq), 141.2 (Cq), 135.3 (Cq), 131.3 (CH), 130.3 (Cq), 129.0 (CH), 127.3 (Cq), 122.7 (CH), 
119.3 (CH), 117.3 (CH), 115.0 (CH), 105.8 (CH), 63.3 (CH2), 32.6 (CH2). Minor isomer: δ = 130.4 (CH), 
128.7 (CH), 127.3 (Cq), 122.8 (CH), 119.2 (CH), 117.3 (CH), 115.2 (CH), 105.6 (CH), 58.5 (CH2), 28.2 
(CH2). (Due to overlap, five peaks are missing). IR (ATR) ν = 3357, 2918, 1574, 1561, 1242, 1200, 
1069, 974, 802 cm-1. MS (ESI) m/z (relative intensity): 322 (100) [M+Na]+, 300 (40) [M+H]+, 282 (85). 
HR-MS (ESI) m/z calcd for C16H15ClN3O [M+H]
+: 300.0898, found: 300.0890.  
The analytical data were in accordance with those reported in the literature.[69] 
 
 
(E/Z)-4-[5-Bromo-1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ca): The general procedure E 
was followed using 5-bromo-1-(pyrimidin-2-yl)-1H-indole (41c) (68.5 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 111ca (80 mg, 93%, E/Z = 4.4/1.0 by 1H NMR) as a colorless 
oil.  




7.32─7.21 (m, 1H), 7.14 (t, J = 4.8 Hz, 1H), 6.38 (s, 1H), 5.89─5.75 (m, 1H), 5.74─5.52 (m, 1H), 4.23 (d, 
J = 4.8 Hz, 0.35H), 4.02 (d, J = 5.6 Hz, 1.65H), 3.98─5.85 (m, 2H), 1.41 (brs, 1H). 13C NMR (75 MHz, 
CDCl3) Major isomer: δ = 158.1 (CH), 157.8 (Cq), 141.0 (Cq), 135.7 (Cq), 131.3 (CH), 130.9 (Cq), 129.0 
(CH), 125.3 (CH), 122.3 (CH), 117.4 (CH), 115.4 (CH), 115.0 (Cq), 105.7 (CH), 63.3 (CH2), 32.5 (CH2). 
Minor isomer: δ = 130.4 (CH), 128.7 (CH), 125.4 (CH), 115.6 (CH), 115.0 (Cq), 58.5 (CH2), 28.2 (CH2). 
(Due to overlap, seven peaks are missing). IR (ATR) ν = 3357, 2863, 1560, 1420, 1198, 973, 799 cm-1. 
MS (ESI) m/z (relative intensity): 368 (98) [M+Na]+ (81Br), 366 (98) [M+Na]+ (79Br), 356 (95) [M+H]+ 
(81Br), 344 (95) [M+H]+ (79Br), 328 (100) (81Br), 326 (100) (79Br). HR-MS (ESI) m/z calcd for 
C16H15BrN3O [M+H]
+: 344.0393, found: 344.0394.  
The analytical data were in accordance with those reported in the literature.[201] 
 
 
(E/Z)-4-[5-Iodo-1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ka): The general procedure E 
was followed using 5-iodo-1-(pyridin-2-yl)-1H-indole (41k) (80.0 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 111ka (85.8 mg, 88%, E/Z = 5.5/1.0 by 1H NMR) as a yellow 
oil.  
1H NMR (300 MHz, CDCl3) δ = 8.62 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.89─7.84 (m, 2H), 7.39─7.30 (m, 
3H), 7.07 (dt, J = 8.6, 0.7 Hz, 1H), 6.34 (d, J = 0.9 Hz, 1H), 5.72─5.42 (m, 2H), 4.07 (d, J = 5.6 Hz, 0.31 
H), 3.95 (dd, J = 5.7, 1.2 Hz, 1.69H), 3.62─3.55 (m, 2H), 1.71 (brs, 1H). 13C NMR (125 MHz, CDCl3) 
Major Isomer: δ = 150.8 (Cq), 149.5 (CH), 139.8 (Cq), 138.3 (CH), 136.4 (Cq), 131.4 (CH), 130.8 (Cq), 
130.0 (CH), 128.7 (CH), 128.0 (CH), 122.3 (CH), 120.9 (CH), 112.0 (CH), 102.2 (CH), 84.1 (Cq), 63.1 
(CH2), 30.5 (CH2). Minor Isomer: δ = 150.7 (Cq), 149.6 (CH), 140.1 (Cq), 138.4 (CH), 130.4 (CH), 130.1 
(CH), 128.8 (CH), 127.8 (CH), 122.4 (CH), 120.9 (CH), 111.9 (CH), 102.0 (CH), 84.2 (Cq), 58.3 (CH2), 
26.1 (CH2). (Due to overlap, two peaks are missing). IR (ATR) ν = 3321, 2913, 2860, 1586, 1470, 1439, 
1274, 782, 580 cm-1. MS (ESI) m/z (relative intensity): 391 (100) [M+H]+, 413 (67) [M+H]+. HR-MS 
(ESI) m/z calcd for C17H16N2OI [M+H]





(E/Z)-4-[3-(3-Hydroxypropyl)-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111la): The general 
procedure E was followed using 3-[1-(pyridin-2-yl)-1H-indol-3-yl]propan-1-ol (41l) (63.1 mg, 0.25 
mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 111la (59.6 mg, 74%, E/Z = 5.3/1.0 by 
1H NMR) as a yellow oil.  
1H NMR (300 MHz, CDCl3) δ = 8.50 (d, J = 4.9 Hz, 1H), 7.74 (td, J = 7.7, 2.0 Hz, 1H), 7.48─7.44 (m, 1H), 
7.32─7.26 (m, 1H), 7.21─7.15 (m, 2H), 7.06─7.01 (m, 2H), 5.51─5.18 (m, 2H), 3.92 (d, J = 6.1 Hz, 0.32 
Hz), 3.72 (d, J = 5.9 Hz, 1.68H), 3.57─3.48 (m, 4H), 2.97 (brs, 2H), 2.74─2.69 (m, 2H), 1.86─1.68 (m, 
2H). 13C NMR (100 MHz, CDCl3) Major Isomer: δ = 151.4 (Cq), 149.5 (CH), 138.3 (CH), 136.7 (Cq), 
133.9 (Cq), 130.2 (CH), 128.9 (CH), 128.7 (CH), 128.5 (Cq), 121.9 (CH), 121.3 (CH), 120.2 (CH), 118.4 
(CH), 114.8 (Cq), 110.0 (CH), 62.8 (CH2), 61.9 (CH2), 33.0 (CH2), 27.8 (CH2), 20.4 (CH2). Minor Isomer: 
δ = 151.3 (Cq), 149.3 (CH), 138.3 (CH), 136.6 (Cq), 134.7 (Cq), 129.0 (CH), 128.7 (CH), 128.5 (Cq), 
121.9 (CH), 121.2 (CH), 120.3 (CH), 118.3 (CH), 114.6 (Cq), 109.9 (CH), 61.7 (CH2), 57.6 (CH2), 32.8 
(CH2), 23.5 (CH2), 20.3 (CH2). (Due to overlap, one peak is missing). IR (ATR) ν = 3315, 2928, 2857, 
1588, 1471, 1458, 1437, 1060, 742 cm-1. MS (ESI) m/z (relative intensity): 345 (87) [M+Na]+, 323 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C20H22N2O2Na [M+H]
+: 345.1573, found: 345.1586. 
 
 
(E/Z)-4-[3-Methyl-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ma): The general procedure E 
was followed using 3-methyl-1-(pyridin-2-yl)-1H-indole (41m) (52.1 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 





1H NMR (400 MHz, CDCl3) δ = 8.61 (d, J = 4.0 Hz, 1H), 7.87─7.81 (m, 1H), 7.55─7.53 (m, 1H), 
7.41─7.37 (m, 1H), 7.33─7.24 (m, 2H), 7.15─7.12 (m, 2H), 5.61─5.28 (m, 2H), 3.97 (d, J = 6.1 Hz, 
0.39H), 3.87 (d, J = 5.9 Hz, 1.61H), 3.68 (d, J = 6.1 Hz, 0.39H), 3.63 (d, J = 6.2 Hz, 1.61H), 2.32 (s, 
0.59H), 2.30 (s, 2.41H), 1.59 (brs, 1H). 13C NMR (100 MHz, CDCl3) Major Isomer: δ = 151.6 (Cq), 149.4 
(CH), 138.1 (CH), 136.5 (Cq), 133.7 (Cq), 130.1 (CH), 129.3 (Cq), 129.0 (CH), 122.0 (CH), 121.7 (CH), 
121.0 (CH), 120.2 (CH), 118.3 (CH), 110.7 (Cq), 109.9 (CH), 63.2 (CH2), 27.8 (CH2), 8.7 (CH3). Minor 
Isomer: δ = 151.6 (Cq), 149.9 (CH), 139.3 (CH), 134.4, 129.4 (Cq), 122.1 (CH), 121.7 (CH), 121.1 (CH), 
120.3 (CH), 118.3 (CH), 110.3 (Cq), 109.8 (CH), 58.1 (CH2), 23.8 (CH2), 8.8 (CH3). (Due to overlap, four 
peaks are missing). IR (ATR) ν = 3349, 3054, 2916, 1587, 1471, 1457, 1381, 1315, 1087, 740 cm-1. 
MS (ESI) m/z (relative intensity): 301 (85) [M+Na]+, 279 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C18H19N2O [M+H]
+: 279.1497, found: 279.1492. 
 
 
(E/Z)-4-[3-Bromo-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111na): The general procedure E 
was followed using 3-bromo-1-(pyridin-2-yl)-1H-indole (41n) (68.3 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 111na (64.4 mg, 75%, E/Z = 4.3/1 by 1H NMR) as a yellow 
oil. 
1H NMR (300 MHz, CDCl3) δ = 8.61 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.85 (ddd, J = 7.9, 7.4, 2.0 Hz, 1H), 
7.57─7.53 (m, 1H), 7.40─7.14 (m, 5H), 5.58─5.27 (m, 2H), 3.99 (d, J = 6.2 Hz, 0.36H), 3.83 (dd, J = 5.7, 
1.3 Hz, 1.64H), 3.72 (d, J = 6.2 Hz, 0.36H), 3.68 (dd, J = 6.2, 1.3 Hz, 1.64H), 2.03 (brs, 1H). 13C NMR 
(100 MHz, CDCl3) Major Isomer: δ = 150.6 (Cq), 149.5 (CH), 138.3 (CH), 136.1 (Cq), 135.7 (Cq), 131.0 
(CH), 127.3 (Cq), 127.0 (CH), 123.1 (CH), 122.5 (CH), 121.3 (CH), 121.1 (CH), 118.8 (CH), 110.3 (CH), 
94.2 (Cq), 62.9 (CH2), 28.6 (CH2). Minor Isomer: δ = 150.6 (Cq), 149.6 (CH), 138.5 (CH), 136.0 (Cq), 
135.7 (Cq), 135.2 (Cq), 129.8 (CH), 127.3 (Cq), 123.2 (CH), 122.5 (CH), 121.4 (CH), 110.2 (CH), 93.9 




1588, 1452, 1436, 1213, 994, 741 cm-1. MS (ESI) m/z (relative intensity): 367 (98) [M+Na]+ (81Br), 
365 (100) [M+Na]+ (79Br), 345 (88) [M+H]+ (81Br), 343 (90) [M+H]+ (79Br). HR-MS (ESI) m/z calcd for 
C17H16N2OBr [M+H]
+: 343.0446, found: 343.0441. 
 
 
(E/Z)-4-[7-Ethyl-1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111oa): The general procedure E 
was followed using 7-ethyl-1-(pyrimidin-2-yl)-1H-indole (41o) (55.8 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 111oa (46.2 mg, 63%, E/Z = 5.6/1.0 by 1H NMR) as a yellow 
oil. 
1H NMR (300 MHz, CDCl3) δ = 8.85 (d, J = 4.8, 2H), 7.43 (dd, J = 7.7, 1.3 Hz, 1H), 7.32 (t, J = 4.8 Hz, 
1H), 7.12 (t, J = 7.5 Hz, 1H), 7.02 (d, J = 7.3Hz, 1H), 6.44 (s, 1H), 5.72─5.38 (m, 2H), 4.11 (d, J = 5.4 Hz, 
0.30H), 3.94 (d, J = 5.6 Hz, 1.70H), 3.51 (d, J =6.4 Hz, 2H), 2.31 (q, J = 7.4 Hz, 2H), 1.60 (brs, 1H), 0.96 
(t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) Major Isomer: δ = 159.1 (Cq), 158.2 (CH), 139.5 (Cq), 
135.8 (Cq), 130.8 (CH), 129.6 (Cq), 128.6 (CH), 127.9 (Cq), 122.9 (CH), 121.4 (CH), 119.2 (CH), 118.0 
(CH), 104.2 (CH), 63.2 (CH2), 30.8 (CH2), 25.8 (CH2), 14.0 (CH3). Minor Isomer: δ = 159.1 (Cq), 158.3 
(CH), 139.8 (Cq), 136.0 (Cq), 130.2 (CH), 127.9 (Cq), 121.4 (CH), 119.2 (CH), 104.0 (CH), 58.3 (CH2), 
26.3 (CH2), 25.8 (CH2). (Due to overlap, four peaks are missing). IR (ATR) ν = 3312, 2966, 1561, 1416, 
1265, 1092, 743 cm-1. MS (ESI) m/z (relative intensity): 316 (100) [M+Na]+. HR-MS (ESI) m/z calcd 
for C18H19N3ONa [M+Na]
+: 316.1420, found: 316.1432.  
The analytical data were in accordance with those reported in the literature.[69] 
 
 




procedure E was followed using 1-[1-(pyridin-2-yl)-1H-indol-3-yl]ethanone (41p) (59.1 mg, 0.25 
mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 111pa (67.4 mg, 88%, E/Z = 5.7/1 by 1H 
NMR) as a yellow oil. 
1H NMR (300 MHz, CDCl3) δ = 8.65 (dd, J = 4.9, 2.0 Hz, 1H), 7.96 (dt, J = 8.1, 1.0 Hz, 1H), 7.88 (td, J = 
7.8, 1.9 Hz, 1H), 7.42─7.34 (m, 2H), 7.26─7.20 (m, 1H), 7.16─7.05 (m, 2H), 5.69─5.22 (m, 2H), 3.99 (d, 
J = 7.3 Hz, 0.3H), 3.89─3.85 (m, 3.7H), 2.69 (s, 0.45H), 2.67 (s, 2.55H), 1.60 (brs, 1H). 13C NMR (75 
MHz, CDCl3) Major Isomer: δ = 194.8 (Cq), 150.1 (CH), 149.8 (Cq), 145.4 (Cq), 138.7 (CH), 137.2 (Cq), 
131.0 (CH), 127.8 (CH), 126.2 (Cq), 123.8 (CH), 123.0 (CH), 122.7 (CH), 122.5 (CH), 120.9 (CH), 115.6 
(Cq), 110.9 (CH), 63.2 (CH2), 31.8 (CH3), 29.2 (CH2). Minor Isomer: δ = 195.3 (Cq), 150.3 (CH), 149.9 
(Cq), 146.5 (CH), 138.9 (CH), 137.1 (Cq), 129.9 (CH), 127.2 (CH), 126.1 (Cq), 124.0 (CH), 122.8 (CH), 
122.7 (CH), 120.7 (CH), 111.0 (CH), 57.8 (CH2), 31.9 (CH3), 25.3 (CH2). (Due to overlap, two peaks are 
missing). IR (ATR) ν = 3377, 3032, 2922, 1640, 1588, 1509, 1393, 1192, 743 cm-1. MS (ESI) m/z 
(relative intensity): 329 (100) [M+Na]+, 307 (26) [M+H]+. HR-MS (ESI) m/z calcd for C19H18N2O2Na 
[M+Na]+: 329.1260, found: 329.1262. 
 
 
(E/Z)-4-[2-(Pyridin-2-yl)phenyl]but-2-en-1-ol (111qa): The general procedure E was followed using 
2-phenylpyridine (20a) (38.8 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 4/1 to 1/1) yielded 
111qa (36.0 mg, 64%, E/Z = 7.3/1.0 by 1H NMR) as a yellow oil.  
1H NMR (300 MHz, CDCl3) δ = 8.69 (brs, 1H), 7.74 (t, J = 7.7 Hz, 1H), 7.41─7.24 (m, 6H), 5.74─5.42 (m, 
2H), 4.03 (d, J = 5.1 Hz, 0.25 Hz), 3.99 (d, J = 5.4 Hz, 1.75H), 3.54 (d, J = 5.4 Hz, 0.25 Hz), 3.49 (d, J = 
6.4 Hz, 1.75H), 1.67 (brs, 1H). 13C NMR (75 MHz, CDCl3) Major Isomer: δ = 159.9 (Cq), 149.1 (CH), 
140.3 (Cq), 137.8 (Cq), 136.3 (CH), 131.3 (CH), 130.2 (CH), 130.0 (CH), 129.9 (CH), 128.5 (CH), 126.4 
(CH), 124.2 (CH), 121.9 (CH), 63.4 (CH2), 36.0 (CH2). Minor Isomer: δ = 138.3 (Cq), 136.6 (CH), 131.2 




58.1 (CH2), 31.1 (CH2). (Due to overlap, two peaks are missing). IR (ATR) ν = 3308, 2853, 1586, 1468, 
1425, 1023, 995, 795, 751 cm-1. MS (ESI) m/z (relative intensity): 248 (13) [M+Na]+, 226 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C15H16NO [M+H]
+: 226.1226, found: 226.1226.  
The analytical data were in accordance with those reported in the literature.[69] 
 
 
(E/Z)-1-Phenyl-4-[1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ab): The general procedure E 
was followed using 1-(pyrimidin-2-yl)-1H-indole (41a) (48.8 mg, 0.25 mmol) and 
(trans)-4-phenyl-5-vinyl-1,3-dioxolan-2-one (110b) (142.6 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (CH2Cl2/Et2O: 20/1) yielded 111ab (68.3 mg, 80%, E/Z > 20/1 by 
1H 
NMR) as a colorless oil. 
1H NMR (500 MHz, CDCl3) δ = 8.68 (d, J = 4.8 Hz, 2H), 8.20 (dd, J = 8.4, 0.9 Hz, 1H), 7.52 (dd, J = 7.6, 
1.5 Hz, 1H), 7.39─7.09 (m, 7H), 7.01 (t, J = 4.8 Hz, 1H), 6.46 (s, 1H), 5.87 (ddt, J = 15.3, 6.5, 1.1 Hz, 
1H), 5.63 (ddt, J = 15.3, 6.9, 1.5 Hz, 1H), 5.08 (dd, J = 7.0, 3.0 Hz, 1H), 3.97 (d, J = 6.6 Hz, 2H), 1.81 (d, 
J = 3.5 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ = 158.0 (Cq), 157.9 (CH), 142.9 (Cq), 139.3 (Cq), 137.0 (Cq), 
134.2 (CH), 129.1 (Cq), 129.0 (CH), 128.4 (CH), 127.4 (CH), 126.0 (CH), 122.7 (CH), 121.8 (CH), 119.8 
(CH), 117.1 (CH), 113.6 (CH), 106.5 (CH), 74.8 (CH), 32.4 (CH2). IR (ATR) ν = 3385, 1561, 1453, 1424, 
1348, 1205, 971, 908, 802, 744, 699 cm-1. MS (ESI) m/z (relative intensity): 364 (40) [M+Na]+, 342 
(10) [M+H]+, 324 (100). HR-MS (ESI) m/z calcd for C22H20N3O [M+H]
+: 342.1601, found: 342.1598. 
 
 
(E/Z)-1-(4-Fluorophenyl)-4-[1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ad): The general 
procedure E was followed using 1-(pyrimidin-2-yl)-1H-indole (41a) (48.8 mg, 0.25 mmol) and 




column chromatography on silica gel (CH2Cl2/Et2O: 20/1) yielded 111ad (69.2 mg, 77%, E/Z = 2.8/1.0 
by 1H NMR) as a yellow oil.  
1H NMR (400 MHz, CDCl3) δ = 8.75 (d, J = 4.8 Hz, 0.44H), 8.68 (d, J = 4.8 Hz, 1.56H), 8.35─8.24 (m, 
0.28H), 8.20 (dd, J = 8.2, 1.4 Hz, 0.72H), 7.54─7.48 (m, 1H), 7.37─7.09 (m, 4H), 7.08─6.90 (m, 3H), 
6.45 (d, J = 0.9 Hz, 1H), 5.93─5.53 (m, 2H), 5.04 (d, J = 6.9 Hz, 1H), 4.24─3.90 (m, 2H), 2.05 (brs, 
0.22H), 1.90 (brs, 0.78H). 13C NMR (100 MHz, CDCl3) Major isomer: δ = 162.2 (d, 
1JC-F = 245.3 Hz, Cq), 
158.0 (Cq), 158.0 (CH), 139.2 (Cq), 138.8 (d, 
4JC-F = 3.2 Hz, Cq), 137.0 (Cq), 134.0 (CH), 129.1 (Cq), 129.2 
(CH), 127.7 (d, 3JC-F = 8.1 Hz, CH), 122.8 (CH), 121.9 (CH), 119.8 (CH), 117.0 (CH), 115.2 (d, 
2JC-F = 21.4 
Hz, CH), 113.7 (CH), 106.6 (CH), 74.1 (CH), 32.4 (CH2). Minor isomer: δ = 162.2 (d, 
1JC-F = 245.3 Hz, 
Cq), 158.1 (CH), 158.0 (Cq), 139.3 (Cq), 138.8 (d, 
4JC-F = 3.2 Hz, Cq), 137.0 (Cq), 133.4.0 (CH), 129.1 (Cq), 
128.6 (CH), 127.7 (d, 3JC-F = 8.1 Hz, CH), 122.9 (CH), 122.0 (CH), 119.9 (CH), 117.1 (CH), 115.3 (d, 
2JC-F 
= 21.4 Hz, CH), 114.0 (CH), 106.6 (CH), 69.0 (CH), 28.4 (CH2).
 19F NMR (376 MHz, CDCl3) Major 
isomer: δ = -115.2 (tt, J = 8.7, 5.4 Hz). Minor isomer: δ = -115.1 (tt, J = 8.8, 5.4 Hz). IR (ATR) ν = 3373, 
3047, 1562, 1507, 1454, 1425, 1349, 1218, 972, 803, 745 cm-1. MS (ESI) m/z (relative intensity): 382 





(E/Z)-1-(4-Chlorophenyl)-4-[1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ac): The general 
procedure E was followed using 1-(pyrimidin-2-yl)-1H-indole (41a) (48.8 mg, 0.25 mmol) and 
(trans)-4-(4-chlorophenyl)-5-vinyl-1,3-dioxolan-2-one (110c) (168.5 mg, 0.75 mmol). Purification by 
column chromatography on silica gel (CH2Cl2/Et2O: 20/1) yielded 111ac (78.1 mg, 83%, E/Z = 3.0/1.0 
by 1H NMR) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.71 (d, J = 4.8 Hz, 0.44H), 8.63 (d, J = 4.8 Hz, 1.56H), 8.30─8.23 (m, 
0.22H), 8.19─8.11 (m, 0.78H), 7.58─7.40 (m, 1H), 7.24─7.11 (m, 4H), 7.11─7.04 (m, 2H), 6.97 (t, J = 
4.8 Hz, 1H), 6.42 (s, 1H), 5.87─5.40 (m, 2H), 4.96 (d, J = 6.9 Hz, 1H), 4.16─3.81 (m, 2H), 2.23 (brs, 




(Cq), 139.0 (Cq), 137.0 (Cq), 133.7 (CH), 132.9 (Cq), 129.3 (CH), 128.9 (Cq), 128.4 (CH), 127.3 (CH), 
122.8 (CH), 121.8 (CH), 119.8 (CH), 117.0 (CH), 113.6 (CH), 106.6 (CH), 74.1 (CH), 32.4 (CH2). Minor 
isomer: δ = 158.0 (CH), 141.7 (Cq), 139.1 (Cq), 136.9 (Cq), 133.1 (CH), 133.0 (Cq), 129.0 (Cq), 128.7 
(CH), 128.4 (CH), 127.2 (CH), 122.7 (CH), 121.9 (CH), 119.8 (CH), 117.0 (CH), 113.9 (CH), 106.5 (CH), 
68.9 (CH), 28.4 (CH2). (Due to overlap, one peak is missing). IR (ATR) ν = 3375, 3046, 1562, 1454, 
1424, 1348, 1088, 1013, 907, 802, 730 cm-1. MS (ESI) m/z (relative intensity): 398 (30) [M+Na]+, 376 
(10) [M+H]+, 358 (100). HR-MS (ESI) m/z calcd for C22H19ClN3O [M+H]
+: 376.1211, found: 376.1211. 
 
 
(E/Z)-1-(4-Nitrophenyl)-4-[1-(pyrimidin-2-yl)-1H-indol-2-yl]but-2-en-1-ol (111ae): The general 
procedure E was followed using 1-(pyrimidin-2-yl)-1H-indole (41a) (48.8 mg, 0.25 mmol) and 
(trans)-4-(4-nitrophenyl)-5-vinyl-1,3-dioxolan-2-one (110e) (176.4 mg, 0.75 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 111ae (76.4 mg, 79%, E/Z = 
3.0/1 by 1H NMR) as a yellow solid.  
M.p. = 128─130 °C. 1H NMR (300 MHz, CDCl3) δ = 8.77 (d, J = 4.7 Hz, 0.66H), 8.67 (d, J = 4.8 Hz, 
1.34H), 8.27 (d, J = 8.0 Hz, 0.29H), 8.19 (d, J = 7.4 Hz, 0.71H), 8.16─8.03 (m, 2H), 7.58─7.42 (m, 2H), 
7.33 (d, J = 8.9 Hz, 1H), 7.29─7.09 (m, 2H), 7.03 (t, J = 4.8 Hz, 1H), 6.45 (d, J = 5.9 Hz, 1H), 6.02─5.79 
(m, 1H), 5.70─5.43 (m, 1H), 5.11 (d, J = 7.2 Hz, 1H), 4.27─3.84 (m, 2H), 2.26 (brs, 1H). 13C NMR (75 
MHz, CDCl3) Major isomer: δ = 158.0 (Cq), 158.0 (CH), 150.0 (Cq), 147.0 (Cq), 138.7 (Cq), 137.0 (Cq), 
132.9 (CH), 130.8 (CH), 129.0 (Cq), 126.6 (CH), 123.5 (CH), 122.9 (CH), 122.0 (CH), 119.9 (CH), 117.1 
(CH), 113.8 (CH), 106.8 (CH), 73.9 (CH), 32.3 (CH2). Minor isomer: δ = 158.2 (CH), 150.3 (Cq), 147.1 
(Cq), 138.8 (Cq), 137.0 (Cq), 132.4 (CH), 129.8 (CH), 129.0 (Cq), 126.6 (CH), 123.6 (CH), 123.0 (CH), 
122.1 (CH), 119.9 (CH), 117.2 (CH), 114.0 (CH), 106.6 (CH), 68.6 (CH), 28.4 (CH2). (Due to overlap, 
one peak is missing). IR (ATR) ν = 3377, 2917, 1562, 1515, 1474, 1422, 1342, 1208, 972, 804, 745 
cm-1. MS (ESI) m/z (relative intensity): 409 (40) [M+Na]+, 387 (35) [M+H]+, 369 (100). HR-MS (ESI) 
m/z calcd for C22H19N4O3 [M+H]






(E/Z)-2-Methyl-5-[1-(pyrimidin-2-yl)-1H-indol-2-yl]pent-3-en-2-ol (111af): The general procedure E 
was followed using 1-(pyrimidin-2-yl)-1H-indole (41a) (48.8 mg, 0.25 mmol) and 
4,4-dimethyl-5-vinyl-1,3-dioxolan-2-one (110f) (106.6. mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 111af (41.1 mg, 56%, E/Z > 20/1.0 by 1H 
NMR) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.76 (d, J = 4.8 Hz, 2H), 8.25─8.16 (m, 1H), 7.56─7.48 (m, 1H), 
7.23─7.07 (m, 3H), 6.45 (q, J = 0.9 Hz, 1H), 5.74 (dt, J = 15.6, 6.4 Hz, 1H), 5.56 (dt, J = 15.6, 1.3 Hz, 
1H), 3.92 (dt, J = 6.3, 1.2 Hz, 2H), 1.31 (bs, 1H), 1.18 (s, 6H). 13C NMR (125 MHz, CDCl3) δ = 158.1 (Cq), 
158.0 (CH), 139.8 (Cq), 139.8 (CH), 137.0 (Cq), 129.1 (Cq), 123.9 (CH), 122.6 (CH), 121.7 (CH), 119.7 
(CH), 117.0 (CH), 113.5 (CH), 106.4 (CH), 70.6 (Cq), 32.4 (CH2), 29.7 (CH3). IR (ATR) ν = 3426, 2971, 
1562, 1454, 1424, 1349, 1151, 974, 802, 745 cm-1. MS (ESI) m/z (relative intensity): 316 (40) 
[M+Na]+, 294 (15) [M+H]+, 276 (100). HR-MS (ESI) m/z calcd for C18H20N3O [M+H]





indol-3-yl]propanoate (111ra): The general procedure E was followed using (S)-methyl 
2-(1,3-dioxoisoindolin-2-yl)-3-[1-(pyrimidin-2-yl)-1H-indol-3-yl]propanoate (41r) (42.6 mg, 0.1 mmol) 
and 4-vinyl-1,3-dioxolan-2-one (110a) (34.2 mg, 0.3 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 1/2) yielded 111ra (34.8 mg, 70%, E/Z = 7.0/1.0 by 1H NMR) as a pale 




[α]D = + 38.8 °. M. p. = 71─73 °C.
 1H NMR (300 MHz, CDCl3) δ = 8.73 (d, J = 4.8 Hz, 2H), 8.06 (ddd, J = 
8.3, 1.3, 0.7 Hz, 1H), 7.77─7.71 (m, 2H), 7.67─7.63 (m, 2H), 7.53─7.49 (m, 1H), 7.16─7.03 (m, 3H), 
5.70─5.27 (m, 3H), 4.09─3.89 (m, 2H), 3.80 (s, 3H), 3.73 (dd, J = 5.9, 1.1 Hz, 2H), 3.76─3.71 (m, 2H), 
1.53 (brs, 1H). 13C NMR (75 MHz, CDCl3) δ = 169.6 (Cq), 167.8 (Cq), 158.3 (CH), 158.0 (Cq), 136.3 (Cq), 
136.1 (Cq), 134.2 (CH), 131.9 (Cq), 130.3 (CH), 130.2 (CH), 129.3 (Cq), 123.6 (CH), 123.2 (CH), 121.9 
(CH), 118.1 (CH), 117.4 (CH), 113.3 (CH), 113.1 (Cq), 63.4 (CH2), 53.1 (CH), 52.7 (CH3), 28.9 (CH2), 
24.2 (CH2). IR (ATR) ν = 3349, 2926, 2854, 1744, 1714, 1427, 1104, 721 cm
-1. MS (ESI) m/z (relative 
intensity): 519 (100) [M+Na]+, 497 (28) [M+H]+. HR-MS (ESI) m/z calcd for C28H24N4O5Na [M+Na]
+: 




3-yl]propanoate (111sa): The general procedure E was followed using (S)-benzyl 
2-(1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanoate (41s) (50.2 mg, 
0.1 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (34.2 mg, 0.3 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3/1) yielded 111sa (51.4 mg, 90%, E/Z = 6.4/1 by 1H 
NMR) as a yellow solid.  
M. p. = 59─61 °C. 1H NMR (300 MHz, CDCl3) δ = 8.58 (d, J = 4.8 Hz, 1H), 7.82 (td, J = 7.7, 1.9 Hz, 1H), 
7.77─7.72 (m, 2H), 7.67─7.64 (m, 2H), 7.59─7.63 (m, 1H), 7.34─7.25 (m, 7H), 7.23─7.20 (m, 1H), 
7.08─6.99 (m, 2H), 5.51─5.21 (m, 5H), 3.88─3.80 (m, 2H), 3.68 (dd, J = 14.0, 5.7 Hz, 4H), 1.55 (brs, 
1H). 13C NMR (125 MHz, CDCl3) Major Isomer: δ = 169.1 (Cq), 167.9 (Cq), 151.4 (Cq), 149.6 (CH), 
138.3 (CH), 136.7 (Cq), 135.8 (Cq), 135.4 (Cq), 134.2 (CH), 131.9 (Cq), 130.7 (CH), 129.1 (CH), 128.7 
(CH), 128.4 (Cq), 128.3 (CH), 128.2 (CH), 123.6 (CH), 122.2 (CH), 122.1 (CH), 121.4 (CH), 120.7 (CH), 
118.3 (CH), 110.2 (Cq), 110.1 (CH), 67.7 (CH2), 63.2 (CH2), 53.1 (CH), 27.9 (CH2), 24.4 (CH2). Minor 
Isomer: δ = 169.2 (Cq), 167.6 (Cq), 151.4 (Cq), 149.7 (CH), 138.5 (CH), 136.8 (Cq), 136.7 (Cq), 135.3 (Cq), 




(CH), 120.8 (CH), 118.1 (CH), 109.8 (Cq), 67.8 (CH2), 58.3 (CH2), 52.7 (CH), 29.8 (CH2), 24.6 (CH2). 
(Due to overlap, four peaks are missing). IR (ATR) ν = 3318, 2926, 1775, 1743, 1588, 1470, 1438, 
1388, 906, 722 cm-1. MS (ESI) m/z (relative intensity): 1143 (5) [2M+H]+, 572 (100) [M+H]+. HR-MS 
(ESI) m/z calcd for C35H30N3O5 [M+H]
+: 572.2180, found: 572. 2186. 
 
 
(E/Z)-1-[2-(4-hydroxybut-2-en-1-yl)-4-methylphenyl]ethanone (165aa): The general procedure F 
was followed using (E)-4-methoxy-N-[1-(p-tolyl)ethylidene]aniline (34a) (59.8 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 2/1) yielded 165aa (27.0 mg, 53%, E/Z > 20/1.0 by 1H NMR) as a 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.59 (d, J = 7.9 Hz, 1H), 7.15─6.99 (m, 2H), 5.85 (dtt, J = 15.7, 6.5, 1.4 
Hz, 1H), 5.62 (dtt, J = 15.3, 5.9, 1.5 Hz, 1H), 4.07 (dd, J = 5.9, 1.2 Hz, 2H), 3.62 (dd, J = 6.5, 1.4 Hz, 2H), 
2.53 (s, 3H), 2.34 (s, 3H), 1.53 (brs, 1H). 13C NMR (100 MHz, CDCl3) δ = 201.2 (Cq), 142.4 (Cq), 140.4 
(Cq), 134.6 (Cq), 132.1 (CH), 131.8 (CH), 129.9 (CH), 129.9 (CH), 126.8 (CH), 63.6 (CH2), 36.8 (CH2), 
29.5 (CH3), 21.4 (CH3). IR (ATR) ν = 3406, 2920, 1678, 1608, 1431, 1356, 1259, 971, 817 cm
-1. MS (ESI) 
m/z (relative intensity): 227 (100) [M+Na]+, 187 (80). HR-MS (ESI) m/z calcd for C13H16O2Na [M+Na]
+: 
227.1043, found: 227.1044. 
 
 
(E/Z)-1-{3-(4-Hydroxybut-2-en-1-yl)-[1,1'-biphenyl]-4-yl}ethanone (165ba): The general procedure 
F was followed using (E)-N-{1-[(1,1'-biphenyl)-4-yl]ethylidene}-4-methoxyaniline (34b) (75.4 mg, 
0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 165ba (44.0 mg, 66%, E/Z > 20/1.0 by 




1H NMR (300 MHz, CDCl3) δ = 7.76 (dd, J = 8.0, 0.5 Hz, 1H), 7.68─7.55 (m, 2H), 7.52─7.31 (m, 5H), 
5.90 (dtt, J = 15.5, 6.4, 1.3 Hz, 1H), 5.66 (dtt, J = 15.4, 5.8, 1.4 Hz, 1H), 4.08 (dd, J = 5.8, 1.2 Hz, 2H), 
3.72 (dd, J = 6.5, 1.4 Hz, 2H), 2.59 (s, 3H), 1.68 (bs, 1H). 13C NMR (125 MHz, CDCl3) δ = 201.1 (Cq), 
144.3 (Cq), 140.7 (Cq), 139.7 (Cq), 136.0 (Cq), 131.4 (CH), 130.2 (CH), 130.0 (CH), 30.0 (CH), 128.8 
(CH), 128.0 (CH), 127.1 (CH), 124.7 (CH), 63.5 (CH2), 36.9 (CH2), 29.7 (CH3). IR (ATR) ν = 3384, 2918, 
2860, 1677, 1605, 1430, 1250, 971, 764, 697 cm-1. MS (ESI) m/z (relative intensity): 289 (100) 
[M+Na]+, 249 (95). HR-MS (ESI) m/z calcd for C18H19O2 [M+H]
+: 267.1380, found: 267.1376. 
 
 
(E/Z)-1-[2-(4-Hydroxybut-2-en-1-yl)-4-(trifluoromethyl)phenyl]ethanone (165ca): The general 
procedure F was followed using (E)-4-methoxy-N-{1-[4-(trifluoromethyl)phenyl]ethylidene}aniline 
(34c) (73.3 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 165ca (44.5 mg, 69%, E/Z = 
10/1 by 1H NMR) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 7.68 (d, J = 8.0 Hz, 1H), 7.59─7.44 (m, 2H), 5.81 (dtt, J = 15.5, 6.4, 1.4 
Hz, 1H), 5.62 (dtt, J = 15.4, 5.7, 1.4 Hz, 1H), 4.25 (dd, J = 11.5, 3.2 Hz, 0.18H), 4.08 (d, J = 5.6 Hz, 
1.82H), 3.76 (d, J = 3.0 Hz, 0.19H), 3.62 (d, J = 7.0 Hz, 1.81), 2.56 (s, 3H), 1.53 (brs, 1H). 13C NMR (75 
MHz, CDCl3) δ = 201.5 (Cq), 141.2 (Cq), 140.3 (Cq), 133.0 (q, 
2J = 32.0 Hz, Cq), 132.2 (CH), 130.0 (CH), 
128.9 (CH), 127.9 (q, 3J = 3.6 Hz, CH), 123.5 (q, 1J = 273.6 Hz, Cq), 123.2 (d, 
3J = 4.0 Hz, CH), 63.3 (CH2), 
36.2 (CH2), 30.0 (CH3). 
19F NMR (283 MHz, CDCl3) δ = -63.07. IR (ATR) ν = 3373, 2918, 1691, 1359, 
1164, 1122, 1088, 970, 831 cm-1. MS (ESI) m/z (relative intensity): 281 (100) [M+Na]+, 241 (90). 
HR-MS (ESI) m/z calcd for C13H13F3O2Na [M+Na]
+: 281.0760, found: 281.0764. 
 
 
(E/Z)-1-[4-Fluoro-2-(4-hydroxybut-2-en-1-yl)phenyl]ethanone (165da): The general procedure F 




mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 165da (37.0 mg, 71%, E/Z > 20/1.0 by 
1H NMR) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.75─7.64 (m, 1H), 7.01─6.87 (m, 2H), 5.94─5.74 (m, 1H), 5.72─5.55 
(m, 1H), 4.08 (d, J = 5.6 Hz, 2H), 3.64 (d, J = 5.3 Hz, 2H), 2.54 (s, 3H), 1.58 (brs, 1H). 13C NMR (75 
MHz, CDCl3) δ = 200.1 (Cq), 164.2 (d, 
1J = 254.1 Hz, Cq) 144.1 (d, 
3J = 7.9 Hz, Cq), 133.6 (d, 
4J = 3.2 Hz, 
Cq), 132.0 (d, 
3J = 9.2 Hz, CH), 130.9 (CH), 130.4 (CH), 118.1 (d, 2J = 21.5 Hz, CH), 113.1 (d, 2J = 21.5 
Hz, CH), 63.4 (CH2), 36.6 (CH2), 29.6 (CH3). 
19F NMR (283 MHz, CDCl3) δ = -107.21 (ddd, J = 9.6, 7.9, 
5.7 Hz). IR (ATR) ν = 3393, 2861, 1680, 1581, 1356, 1233, 972, 817, 578 cm-1. MS (ESI) m/z (relative 





(E/Z)-1-[4-Chloro-2-(4-hydroxybut-2-en-1-yl)phenyl]ethanone (165ea): The general procedure F 
was followed using (E)-N-[1-(4-chlorophenyl)ethylidene]-4-methoxyaniline (34e) (64.9 mg, 0.25 
mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 165ea (41.0 mg, 73%, E/Z = 11.5/1.0 by 
1H NMR) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.59 (d, J = 9.0 Hz, 1H), 7.34─7.12 (m, 2H), 5.81 (dtt, J = 15.5, 6.3, 1.3 
Hz, 1H), 5.63 (dtt, J = 15.4, 5.7, 1.4 Hz, 1H), 4.08 (dd, J = 5.6, 1.2 Hz, 2H), 3.60 (dd, J = 6.4, 1.3 Hz, 2H), 
2.53 (s, 3H), 1.52 (brs, 1H). 13C NMR (125 MHz, CDCl3) δ = 200.4 (Cq), 142.2 (Cq), 137.6 (Cq), 135.8 
(Cq), 131.2 (CH), 130.9 (CH), 130.6 (CH), 130.3 (CH), 126.3 (CH), 63.4 (CH2), 36.4 (CH2), 29.7 (CH3). IR 
(ATR) ν = 3378, 2860, 1681, 1590, 1557, 1356, 1248, 1102, 970, 816 cm-1. MS (ESI) m/z (relative 








(E/Z)-1-[4-Bromo-2-(4-hydroxybut-2-en-1-yl)phenyl]ethanone (165fa): The general procedure F 
was followed using (E)-N-[1-(4-bromophenyl)ethylidene]-4-methoxyaniline (34f) (76.1 mg, 0.25 
mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 165fa (55.2 mg, 82%, E/Z = 9.0/1.0 by 
1H NMR) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 7.51 (d, J = 8.8 Hz, 1H), 7.46─7.33 (m, 2H), 5.81 (dtt, J = 15.5, 6.4, 1.3 
Hz, 1H), 5.62 (dtt, J = 15.4, 5.7, 1.3 Hz, 1H), 4.08 (dd, J = 5.7, 1.2 Hz, 2H), 3.59 (dd, J = 6.4, 1.3 Hz, 2H), 
2.53 (s, 3H), 1.51 (brs, 1H). 13C NMR (125 MHz, CDCl3) δ = 200.6 (Cq), 142.2 (Cq), 136.2 (Cq), 134.1 
(CH), 130.9 (CH), 130.6 (CH), 130.3 (CH), 129.3 (CH), 126.1 (Cq), 63.4 (CH2), 36.4 (CH2), 29.7 (CH3). IR 
(ATR) ν = 3379, 2861, 1681, 1584, 1554, 1355, 1250, 1092, 971, 814 cm-1. MS (ESI) m/z (relative 
intensity): 293 (100) [M+Na]+ (81Br), 291 (100) [M+Na]+ (79Br), 253 (90) (81Br), 251 (90) (79Br). HR-MS 
(ESI) m/z calcd for C12H13BrO2Na [M+Na]
+: 290.9991, found: 290.9999. 
 
 
(E/Z)-1-[2-(4-Hydroxybut-2-en-1-yl)phenyl]ethanone (165ga): The general procedure F was 
followed using (E)-4-methoxy-N-(1-phenylethylidene)aniline (34g) (63.8 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 2/1) yielded 165ga (33.3 mg, 70%, E/Z = 12/1.0 by 1H NMR) as a colorless 
oil.  
1H NMR (400 MHz, CDCl3) δ = 7.64 (dd, J = 7.6, 1.3 Hz, 1H), 7.39 (td, J = 7.5, 1.4 Hz, 1H), 7.34─7.19 
(m, 2H), 5.85 (dtt, J = 15.4, 6.5, 1.4 Hz, 1H), 5.61 (dtt, J = 15.3, 5.9, 1.5 Hz, 1H), 4.24 (dd, J = 7.1, 1.1 
Hz, 0.16H), 4.06 (dd, J = 5.8, 1.3 Hz, 0.84H), 3.62 (dd, J = 6.5, 1.3 Hz, 2H), 2.55 (s, 3H), 1.56 (brs, 1H). 
13C NMR (75 MHz, CDCl3) δ = 202.0 (Cq), 139.8 (Cq), 137.7 (Cq), 131.6 (CH), 131.5 (CH), 131.3 (CH), 




1429, 1356, 1252, 1089, 972, 759, 601 cm-1. MS (ESI) m/z (relative intensity): 213 (100) [M+Na]+, 
210 (40), 173 (80). HR-MS (ESI) m/z calcd for C12H14O2Na [M+Na]
+: 213.0886, found: 213.0891. 
 
 
(E/Z)-1-[2-(4-Hydroxybut-2-en-1-yl)phenyl]propan-1-one (165ga): The general procedure F was 
followed using (E)-4-methoxy-N-(1-phenylpropylidene)aniline (34h) (59.8 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 2/1) yielded 165ga (32.7 mg, 64%, E/Z > 20/1.0 by 1H NMR) as a colorless 
oil.  
1H NMR (400 MHz, CDCl3) δ = 7.56 (dd, J = 7.2, 1.7 Hz, 1H), 7.42─7.35 (m, 1H), 7.33─7.19 (m, 2H), 
5.84 (dtt, J = 15.7, 6.5, 1.4 Hz, 1H), 5.60 (dtt, J = 15.4, 5.9, 1.5 Hz, 1H), 4.06 (dd, J = 5.9, 1.2 Hz, 2H), 
3.56 (dd, J = 6.6, 1.4 Hz, 2H), 2.88 (q, J = 7.3 Hz, 2H), 1.49 (brs, 3H), 1.16 (t, J = 7.3 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ = 205.4 (Cq), 139.3 (Cq), 138.4 (Cq), 131.6 (CH), 131.1 (CH), 131.1 (CH), 130.2 
(CH), 128.1 (CH), 126.2 (CH), 63.5 (CH2), 36.4 (CH2), 35.0 (CH2), 8.3 (CH3). IR (ATR) ν = 3407, 2937, 
1685, 1445, 1220, 1089, 973, 755 cm-1. MS (ESI) m/z (relative intensity): 227 (100) [M+Na]+, 187 
(80). HR-MS (ESI) m/z calcd for C13H16O2Na [M+Na]
+: 227.1043, found: 227.1043. 
 
 
(E/Z)-1-{4-(4-Hydroxybut-2-en-1-yl)benzo[d][1,3]dioxol-5-yl}ethanone (165ia): The general 
procedure F was followed using (E)-N-{1-(benzo[d][1,3]dioxol-5-yl)ethylidene}-4-methoxyaniline (34i) 
(67.3 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 165ia (35.2 mg, 60%, E/Z > 
20/1.0 by 1H NMR) as a white solid.  
M.p. = 78─80 °C. 1H NMR (400 MHz, CDCl3) δ = 7.36 (d, J = 8.2 Hz, 1H), 6.69 (d, J = 8.2 Hz, 1H), 6.00 
(s, 2H), 5.85 (dtt, J = 15.4, 6.3, 1.3 Hz, 1H), 5.64 (dtt, J = 15.4, 5.9, 1.4 Hz, 1H), 4.03 (dq, J = 5.9, 1.2 




199.2 (Cq), 149.9 (Cq), 147.3 (Cq), 131.3 (Cq), 130.0 (CH), 129.9 (CH), 126.1 (CH), 122.4 (Cq), 105.6 
(CH), 101.5 (CH2), 63.6 (CH2), 29.4 (CH2), 29.2 (CH3). IR (ATR) ν = 3408, 2906, 1671, 1596, 1448, 1263, 
1050, 982, 807. MS (ESI) m/z (relative intensity): 257 (70) [M+Na]+, 217 (100). HR-MS (ESI) m/z calcd 
for C13H14O4Na [M+H]
+: 257.0784, found: 257.0784. 
 
 
(E/Z)-1-[3-(4-Hydroxybut-2-en-1-yl)naphthalen-2-yl]ethanone (165ja): The general procedure F 
was followed using (E)-4-methoxy-N-(1-(naphthalen-2-yl)ethylidene)aniline (34j) (68.8 mg, 0.25 
mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 165ja (41.0 mg, 68%, E/Z > 20/1.0 by 1H 
NMR) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.18 (s, 1H), 7.85 (d, J = 8.7 Hz, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.65 (s, 
1H), 7.59─7.40 (m, 2H), 5.92 (dtt, J = 15.6, 6.5, 1.4 Hz, 1H), 5.63 (dtt, J = 15.3, 5.9, 1.5 Hz, 1H), 4.08 
(dd, J = 5.9, 1.3 Hz, 2H), 3.79 (d, J = 6.5 Hz, 2H), 2.67 (s, 3H), 1.55 (brs, 1H). 13C NMR (100 MHz, 
CDCl3) δ = 201.7 (Cq), 136.3 (Cq), 136.2 (Cq), 134.7 (Cq), 131.8 (CH), 131.1 (Cq), 130.5 (CH), 130.3 (CH), 
129.6 (CH), 128.4 (CH), 128.2 (CH), 127.2 (CH), 126.3 (CH), 63.6 (CH2), 36.7 (CH2), 29.6 (CH3). IR (ATR) 
ν = 3401, 2862, 1678, 1460, 1356, 1271, 1200, 974, 750 cm-1. MS (ESI) m/z (relative intensity): 263 
(95) [M+Na]+, 223 (100). HR-MS (ESI) m/z calcd for C16H16O2Na [M+H]
+: 263.1043, found: 263.1046. 
 
 
(E/Z)-1-[3-Fluoro-2-(4-hydroxybut-2-en-1-yl)phenyl]ethanone (165ka): The general procedure F 
was followed using (E)-N-[1-(3-fluorophenyl)ethylidene]-4-methoxyaniline (34k) (60.8 mg, 0.25 
mmol) and 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 165ka (44.2 mg, 85%, E/Z = 7.3/1 by 1H 
NMR) as a brown oil.  




1.4 Hz, 1H), 5.87─5.57 (m, 2H), 4.27 (d, J = 7.1 Hz, 0.17H), 4.04 (dd, J = 5.8, 1.3 Hz, 1.83H), 3.62─3.58 
(m, 2H), 2.55 (s, 3H), 1.83 (brs, 1H). 13C NMR (125 MHz, CDCl3) Major isomer: δ = 201.4 (d, 
4JC-F= 2.6 
Hz, Cq), 161.7 (d, 
1J = 246.7 Hz, Cq), 140.1 (d, 
3JC-F = 4.1 Hz, Cq), 130.4 (CH), 129.9 (CH), 127.6 (d, 
3JC-F 
= 8.7 Hz, CH), 126.8 (d, 2JC-F = 16.8 Hz, Cq), 124.6 (d, 
4JC-F = 3.4 Hz, CH), 118.6 (d, 
2JC-F = 23.8 Hz, CH), 
63.5 (CH2), 30.1 (CH3), 28.1 (d, 
3JC-F = 3.9, CH2). Minor isomer: δ = 201.9 (d, 
4J = 2.4 Hz, Cq), 161.6 (d, 
1JC-F = 240.1 Hz, Cq), 139.9 (d, 
3JC-F = 4.0 Hz, Cq), 130.6 (CH), 130.2 (CH), 127.6 (d, 
3JC-F = 9.0 Hz, CH), 
127.4 (d, 2JC-F = 16.3 Hz, Cq), 125.0 (d, 
4JC-F = 3.3 Hz, CH), 118.8 (d, 
2JC-F = 23.9 Hz, CH), 58.2 (CH2), 
29.7 (CH3), 23.9 (d, 
3J = 4.0 Hz, CH2). 
19F NMR (376 MHz, CDCl3) Major isomer: δ = -115.82 (t, J = 6.8 
Hz). Minor isomer: δ = -115.95 (dd, J = 9.3, 6.0 Hz). IR (ATR) ν = 3419, 2925, 1687, 1576, 1452, 1259, 
792 cm-1. MS (ESI) m/z (relative intensity): 231 (100) [M+Na]+. HR-MS (ESI) m/z calcd for 
C12H13O2FNa [M+Na]
+: 231.0792, found: 231.0792. 
 
H/D Exchange Experiment 
 
Substrates 41a (48.8 mg, 0.25 mmol), 110a (85.5 mg, 0.75 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %), 
NaOAc (4.1 mg, 20.0 mol%) and D2O (1.0 mL) were placed in a 25 mL Schlenk tube under ambient 
air and stirred at 100 °C for 5 h. After cooling to ambient temperature, the mixture was transferred 
into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1 to 1/1) yielded [D]n-41a (9.8 mg, 20%) and 















Intermolecular Competition Experiment 
 
A suspension of (E)-4-methoxy-N-[1-(p-tolyl)ethylidene]aniline (34a) (59.8 mg, 0.25 mmol), 
(E)-N-[1-(4-fluorophenyl)ethylidene]-4-methoxyaniline (34d) (60.8 mg, 0.25 mmol), 
4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol), NaOAc (4.1 mg, 20.0 mol %) and 
[MnBr(CO)5] (6.9 mg, 10.0 mol %) in TFE (1.0 mL) was stirred at 100 °C for 16 h under N2. After 
cooling to ambient temperature, HCl (2 N, 3.0 mL) was added. The resulting mixture was stirred for 
30 min at 25 °C and extracted with Et2O (3 × 20 mL). The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The crude 
1H NMR was measured to determine the conversions 






Decarboxylative C–H/C–O Activation with Cyclometalated Complex 4 in catalytic reactions 
 
 
The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole (41a) (48.8 mg, 0.25 
mmol), 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol), NaOAc (4.1 mg, 20.0 mol %) and 
complex 193 (9.0 mg, 10.0 mol %). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 1/1) yielded 111aa (61.3 mg, 84% based on 0.275 mmol)  
 
The general procedure F was followed using 5-methyl-1-(pyrimidin-2-yl)-1H-indole (41g) (52.3 mg, 
0.25 mmol) 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol), NaOAc (4.1 mg, 20.0 mol %) 
and complex 193 (9.0 mg, 10.0 mol %). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 1/1) afforded 64.1 mg of a 9.4/1 mixture of 111ga (0.215 mmol, 86%) and 111ga’ 
(0.014 mmol, 56%)  
 
The general procedure F was followed using 5-fluoro-1-(pyrimidin-2-yl)-1H-indole (41i) (53.3 mg, 
0.25 mmol) 4-vinyl-1,3-dioxolan-2-one (110a) (72.0 μL, 0.75 mmol), NaOAc (4.1 mg, 20.0 mol %) 
and complex 193 (9.0 mg, 10.0 mol %). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 1/1) afforded 62.5 mg of a 9.2/1 mixture of 111ia (0.205 mmol, 82%) and 111ia’ 












Complex 193 (54.2 mg, 0.15 mmol), dioxolanone 110a (51.3 mg, 0.45 mmol) and TFE (1.0 mL) were 
placed in a 25 mL Schlenk tube under ambient air and stirred at 100 °C for 16 h. After cooling to 
ambient temperature, the mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) 
and concentrated in vacuo. Purification by column chromatography on silica gel (n-hexane/EtOAc: 
1/1) yielded 111aa (35.0 mg, 88%, E/Z = 5.5/1 by 1H NMR). 
 
 





(E)-4-Methyl-4-{2-[1-(pyridin-2-yl)-1H-indol-2-yl]vinyl}-1,3-dioxolan-2-one (167ba): The general 
procedure G was followed using 1-(pyridin-2-yl)-1H-indole (41b) (48.6 mg, 0.25 mmol) and 
4-ethynyl-4-methyl-1,3-dioxolan-2-one (166a) (58.0 μL, 0.5 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167ba (76.1 mg, 95%) as colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.66 (dd, J = 4.9, 1.9 Hz, 1H), 7.89 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.67–
7.57 (m, 1H), 7.49–7.41 (m, 1H), 7.37 (dt, J = 8.0, 1.0 Hz, 1H), 7.34 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 
7.22–7.12 (m, 2H), 6.87 (s, 1H), 6.77 (d, J = 16.0 Hz, 1H), 6.17 (d, J = 16.0 Hz, 1H), 4.29 (d, J = 8.4 Hz, 




(CH), 138.5 (CH), 137.7 (Cq), 135.5 (Cq), 128.7 (CH), 128.2 (Cq), 123.4 (CH), 122.3 (CH), 121.9 (CH), 
121.5 (CH), 121.1 (CH), 120.8 (CH), 110.8 (CH), 103.6 (CH), 82.6 (Cq), 74.6 (CH2), 24.4 (CH3). IR (ATR) 
ν = 2922, 1779, 1586, 1468, 1340, 1213, 1044, 969, 793, 754 cm-1. MS (ESI) m/z (relative intensity): 
369 (20), 337 (100) [M+Na]+, 321 (80) [M+H]+, 299 (20), 277 (20). HR-MS (ESI) m/z calcd for 
C19H17N2O3 [M+H]
+: 321.1234, found: 321.1233. 
 
 
(E)-4-Methyl-4-{2-[3-methyl-1-(pyridin-2-yl)-1H-indol-2-yl]vinyl}-1,3-dioxolan-2-one (167ma): The 
general procedure G was followed using 3-methyl-1-(pyridin-2-yl)-1H-indole (41m) (52.1 mg, 0.25 
mmol) and 4-ethynyl-4-methyl-1,3-dioxolan-2-one (166a). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 3/2) yielded 167ma (72.0 mg, 86%) as colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.63 (ddd, J = 4.8, 2.0, 1.0 Hz, 1H), 7.85 (ddd, J = 8.0, 7.4, 2.0 Hz, 1H), 
7.59 (dd, J = 6.5, 1.2 Hz, 1H), 7.45 (dd, J = 7.0, 1.2 Hz, 1H), 7.36–7.25 (m, 2H), 7.24–7.14 (m, 2H), 
6.79 (d, J = 16.3 Hz, 1H), 5.69 (d, J = 16.3 Hz, 1H), 4.22 (d, J = 8.4 Hz, 1H), 4.17 (d, J = 8.4 Hz, 1H), 
2.43 (s, 3H), 1.60 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 154.2 (Cq), 151.6 (Cq), 149.5 (CH), 138.3 (CH), 
137.4 (Cq), 130.9 (Cq), 130.0 (CH), 129.3 (Cq), 124.0 (CH), 122.0 (CH), 121.3 (CH), 121.2 (CH), 120.9 
(CH), 119.2 (CH), 115.0 (Cq), 110.7 (CH), 82.8 (Cq), 74.7 (CH2), 24.3 (CH3), 10.0 (CH3). IR (ATR) ν = 
2978, 1801, 1588, 1470, 1455, 1227, 1056, 743 cm-1. MS (ESI) m/z (relative intensity): 691 (70) 
[2M+Na]+, 357 (100) [M+Na]+, 335 (40) [M+H]+, 313 (35), 291 (30). HR-MS (ESI) m/z calcd for 
C20H19N2O3 [M+H]
+: 335.1390, found: 335.1387. 
 
 
(E)-4-{2-[3-Bromo-1-(pyridin-2-yl)-1H-indol-2-yl]vinyl}-4-methyl-1,3-dioxolan-2-one (167na): The 
general procedure G was followed using 3-bromo-1-(pyridin-2-yl)-1H-indole (41n) (68.3 mg, 0.25 




column chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 167na (62.9 mg, 63%) as 
colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.67 (dd, J = 4.9, 2.0 Hz, 1H), 7.91 (ddd, J = 7.9, 7.5, 2.0 Hz, 1H), 7.67–
7.56 (m, 1H), 7.48–7.31 (m, 3H), 7.31–7.21 (m, 2H), 6.71 (d, J = 16.4 Hz, 1H), 6.30 (d, J = 16.4 Hz, 1H), 
4.27 (d, J = 8.4 Hz, 1H), 4.20 (d, J = 8.4 Hz, 1H), 1.63 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 154.0 (Cq), 
150.5 (Cq), 149.7 (CH), 138.5 (CH), 136.8 (Cq), 132.3 (CH), 130.9 (Cq), 127.8 (Cq), 124.8 (CH), 122.8 
(CH), 122.0 (CH), 121.5 (CH), 119.7 (CH), 119.5 (CH), 110.9 (CH), 96.3 (Cq), 82.5 (Cq), 74.6 (CH2), 24.4 
(CH3). IR (ATR) ν = 2981, 1796, 1587, 1466, 1435, 1343, 1214, 1054, 739 cm
-1. MS (ESI) m/z (relative 
intensity): 423 (10) (81Br) [M+H]+, 421 (10) (79Br) [M+H]+, 401 (100) (81Br) [M+H]+, 399 (100) (79Br) 
[M+H]+, 342 (10). HR-MS (ESI) m/z calcd for C19H16N2O3
81Br [M+H]+: 401.0319, found: 401.0322, 
C19H16N2O3




The general procedure G was followed using 1-(pyridin-2-yl)-1H-indole-3-carbonitrile (41t) (54.8 mg, 
0.25 mmol) and 4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167ta (56.1 mg, 65%) as white 
solid.  
M.p. = 151–153 °C. 1H NMR (400 MHz, CDCl3) δ = 8.70 (dd, J = 4.9, 1.9 Hz, 1H), 7.97 (td, J = 7.7, 1.9 
Hz, 1H), 7.85–7.68 (m, 1H), 7.46 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.43–7.36 (m, 2H), 7.35–7.26 (m, 2H), 
6.84 (d, J = 16.2 Hz, 1H), 6.70 (d, J = 16.2 Hz, 1H), 4.37 (d, J = 8.5 Hz, 1H), 4.25 (d, J = 8.5 Hz, 1H), 
1.67 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 153.8 (Cq), 150.2 (CH), 148.9 (Cq), 141.2 (Cq), 139.1 (CH), 
136.2 (Cq), 135.4 (CH), 127.5 (Cq), 125.3 (CH), 124.0 (CH), 123.5 (CH), 121.5 (CH), 119.6 (CH), 118.0 
(CH), 116.3 (Cq), 111.6 (CH), 86.6 (Cq), 82.2 (Cq), 74.5 (CH2), 24.7 (CH3). IR (ATR) ν = 2923, 2215, 1788, 
1612, 1467, 1392, 1220, 1144, 1065, 760 cm-1. MS (ESI) m/z (relative intensity): 713 (30) [2M+Na]+, 
368 (60) [M+Na]+, 346 (100) [M+H]+. HR-MS (ESI) m/z calcd for C20H16N3O3 [M+H]






(E)-4-{2-[6-Bromo-1-(pyridin-2-yl)-1H-indol-2-yl]vinyl}-4-methyl-1,3-dioxolan-2-one (167ua): The 
general procedure G was followed using 6-bromo-1-(pyridin-2-yl)-1H-indole (41u) (68.3 mg, 0.25 
mmol) and 4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167ua (80.8 mg, 81%) as 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.66 (dd, J = 4.9, 2.0 Hz, 1H), 7.91 (td, J = 7.7, 2.0 Hz, 1H), 7.59 (d, J = 
1.9 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.36 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.32 (dt, J = 7.9, 1.0 Hz, 1H), 
7.28–7.22 (m, 1H), 6.81 (s, 1H), 6.70 (d, J = 16.0 Hz, 1H), 6.17 (d, J = 16.0 Hz, 1H), 4.27 (d, J = 8.4 Hz, 
1H), 4.18 (d, J = 8.4 Hz, 1H), 1.61 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 154.1 (Cq), 150.2 (Cq), 149.8 
(CH), 138.7 (CH), 138.4 (Cq), 136.1 (Cq), 129.5 (CH), 126.9 (Cq), 124.8 (CH), 122.7 (CH), 122.0 (CH), 
121.3 (CH), 121.1 (CH), 117.0 (Cq), 113.9 (CH), 103.4 (CH), 82.5 (Cq), 74.5 (CH2), 24.3 (CH3). IR (ATR) ν 
= 2981, 1798, 1587, 1470, 1441, 1340, 1229, 1057, 948 cm-1. MS (ESI) m/z (relative intensity): 423 
(95) (81Br) [M+H]+, 421 (100) (79Br) [M+H]+, 401 (30) (81Br) [M+H]+, 399 (30) (79Br) [M+H]+, 357 (30) 
(81Br), 355 (30) (79Br). HR-MS (ESI) m/z calcd for C19H16N2O3
81Br [M+H]+: 401.0321, found: 401.0314, 
C19H16N2O3
79Br [M+H]+: 399.0339, found: 399.0335. 
 
 
(E)-4-{2-[6-Chloro-1-(pyridin-2-yl)-1H-indol-2-yl]vinyl}-4-methyl-1,3-dioxolan-2-one (167va): The 
general procedure G was followed using 6-chloro-1-(pyridin-2-yl)-1H-indole (41v) (57.2 mg, 0.25 
mmol) and 4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167va (73.0 mg, 82%) as 
colorless oil.  




(d, J = 8.5 Hz, 1H), 7.44 (dt, J = 1.9, 0.7 Hz, 1H), 7.36 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.32 (dt, J = 7.9, 
0.9 Hz, 1H), 7.11 (dd, J = 8.4, 1.8 Hz, 1H), 6.81 (s, 1H), 6.70 (d, J = 16.0 Hz, 1H), 6.16 (d, J = 16.0 Hz, 
1H), 4.27 (d, J = 8.4 Hz, 1H), 4.18 (d, J = 8.4 Hz, 1H), 1.61 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 154.1 
(Cq), 150.2 (Cq), 149.8 (CH), 138.7 (CH), 138.0 (Cq), 136.2 (Cq), 129.3 (Cq), 129.3 (CH), 126.6 (Cq), 
122.7 (CH), 122.2 (CH), 121.6 (CH), 121.4 (CH), 121.0 (CH), 111.0 (CH), 103.4 (CH), 82.5 (Cq), 74.6 
(CH2), 24.3 (CH3). IR (ATR) ν = 2982, 1799, 1587, 1471, 1442, 1342, 1230, 1057, 956 cm
-1. MS (ESI) 
m/z (relative intensity): 377 (100) [M+Na]+, 355 (30) [M+H]+, 333 (25), 311 (30). HR-MS (ESI) m/z 
calcd for C19H16ClN2O3 [M+H]
+: 355.0844, found: 355.0845. 
 
 
(E)-4-{2-[5-Iodo-1-(pyridin-2-yl)-1H-indol-2-yl]vinyl}-4-methyl-1,3-dioxolan-2-one (167wa): The 
general procedure G was followed using 5-iodo-1-(pyridin-2-yl)-1H-indole (41w) (80.1 mg, 0.25 
mmol) and 4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167wa (104.9 mg, 94%) as 
white solid.  
M.p. = 49–51 °C. 1H NMR (400 MHz, CDCl3) δ = 8.66 (dd, J = 4.9, 2.0 Hz, 1H), 7.99–7.83 (m, 2H), 7.41 
(dd, J = 8.7, 1.6 Hz, 1H), 7.36 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.21 (d, J = 8.7 Hz, 
1H), 6.76 (s, 1H), 6.72 (d, J = 16.0 Hz, 1H), 6.19 (d, J = 16.0 Hz, 1H), 4.29 (d, J = 8.4 Hz, 1H), 4.19 (d, J 
= 8.4 Hz, 1H), 1.62 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 154.1 (Cq), 150.2 (Cq), 149.8 (CH), 138.6 
(CH), 136.8 (Cq), 136.2 (Cq), 131.7 (CH), 130.6 (Cq), 129.7 (CH), 129.5 (CH), 122.7 (CH), 121.3 (CH), 
121.1 (CH), 112.9 (CH), 102.3 (CH), 85.0 (Cq), 82.5 (Cq), 74.6 (CH2), 24.4 (CH3). IR (ATR) ν = 2978, 
1791, 1586, 1469, 1439, 1373, 1209, 1051, 956, 786 cm-1. MS (ESI) m/z (relative intensity): 915 (40) 
[2M+Na]+, 469 (35) [M+Na]+, 447 (100) [M+H]+, 425 (30), 314 (25). HR-MS (ESI) m/z calcd for 
C19H15IN2O3 [M+H]






(E)-4-{2-[5-Fluoro-1-(pyridin-2-yl)-1H-indol-2-yl]vinyl}-4-methyl-1,3-dioxolan-2-one (167xa): The 
general procedure G was followed using 5-fluoro-1-(pyridin-2-yl)-1H-indole (41x) (53.1 mg, 0.25 
mmol) and 4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167xa (76.0 mg, 90%) as 
colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.66 (dd, J = 4.9, 2.0 Hz, 1H), 7.90 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.46–
7.30 (m, 3H), 7.23 (dd, J = 9.1, 2.5 Hz, 1H), 6.92 (td, J = 9.1, 2.5 Hz, 1H), 6.81 (s, 1H), 6.73 (d, J = 16.0 
Hz, 1H), 6.19 (d, J = 16.0 Hz, 1H), 4.29 (d, J = 8.4 Hz, 1H), 4.20 (d, J = 8.4 Hz, 1H), 1.62 (s, 3H). 13C 
NMR (125 MHz, CDCl3) δ = 158.6 (d, 
1JC-F = 237.6 Hz, Cq), 154.0 (Cq), 150.4 (Cq), 149.6 (CH), 138.5 
(CH), 136.8 (Cq), 134.2 (Cq), 129.4 (CH), 128.6 (d, 
3JC-F = 9.9 Hz, Cq), 122.5 (CH), 121.5 (CH), 121.0 
(CH), 111.8 (d, 3JC-F = 9.2 Hz, CH), 111.7 (d, 
2JC-F = 26.3 Hz, CH), 105.5 (d, 
2JC-F = 24.0 Hz, CH), 103.3 (d, 
4JC-F = 4.5 Hz, CH), 82.5 (Cq), 74.6 (CH2), 24.5 (CH3). 
19F NMR (282 MHz, CDCl3) δ = -122.51 (td, J = 9.2, 
4.4 Hz). IR (ATR) ν = 2982, 1796, 1586, 1467, 1386, 1236, 1185, 1054, 958, 782 cm-1. MS (ESI) m/z 
(relative intensity): 699 (20) [2M+Na]+, 361 (20) [M+Na]+, 339 (100) [M+H]+, 317 (30). HR-MS (ESI) 
m/z calcd for C19H16N2O3F [M+H]
+: 339.1139, found: 339.1140. 
 
 
(E)-4-{2-[5-Bromo-1-(pyridin-2-yl)-1H-indol-2-yl]vinyl}-4-methyl-1,3-dioxolan-2-one (167ya): The 
general procedure G was followed using 5-bromo-1-(pyridin-2-yl)-1H-indole (41y) (68.3 mg, 0.25 
mmol) and 4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167ya (91.2 mg, 91%) as pale 
yellow solid.  




1.9 Hz, 1H), 7.71 (d, J = 1.9 Hz, 1H), 7.47–7.16 (m, 4H), 6.77 (s, 1H), 6.72 (d, J = 16.0 Hz, 1H), 6.19 (d, 
J = 16.0 Hz, 1H), 4.28 (d, J = 8.4 Hz, 1H), 4.19 (d, J = 8.4 Hz, 1H), 1.62 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ = 154.0 (Cq), 150.2 (Cq), 149.7 (CH), 138.5 (CH), 136.5 (Cq), 136.3 (Cq), 129.7 (Cq), 129.7 (CH), 
126.1 (CH), 123.1 (CH), 122.6 (CH), 121.3 (CH), 121.0 (CH), 114.5 (Cq), 112.4 (CH), 102.6 (CH), 82.4 
(Cq), 74.6 (CH2), 24.5 (CH3). IR (ATR) ν = 2981, 1791, 1586, 1440, 1382, 1228, 1209, 1050, 957, 786 
cm-1. MS (ESI) m/z (relative intensity): 401 (100) (81Br) [M+H]+, 399 (100) (79Br) [M+H]+, 357 (15) 
(81Br), 355 (15) (79Br). HR-MS (ESI) m/z calcd for C19H16N2O3
81Br [M+H]+: 401.0319, found: 401.0315, 
C19H16N2O3
79Br [M+H]+: 399.0339, found: 399.0334. 
 
 
(E)-4-Methyl-4-{2-[5-methyl-1-(pyridin-2-yl)-1H-indol-2-yl]vinyl}-1,3-dioxolan-2-one (167za): The 
general procedure G was followed using 5-methyl-1-(pyridin-2-yl)-1H-indole (41z) (52.1 mg, 0.25 
mmol) and 4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167za (65.2 mg, 78%) as 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.65 (dd, J = 5.1, 2.1 Hz, 1H), 7.88 (ddd, J = 8.0, 7.4, 2.0, Hz, 1H), 7.42–
7.28 (m, 4H), 7.01 (dd, J = 8.5, 1.7 Hz, 1H), 6.79 (s, 1H), 6.77 (d, J = 16.1 Hz, 1H), 6.15 (d, J = 16.1 Hz, 
1H), 4.29 (d, J = 8.4 Hz, 1H), 4.19 (dd, J = 8.4 Hz, 1H), 2.42 (s, 3H), 1.62 (s, 3H). 13C NMR (100 MHz, 
CDCl3) δ = 154.3 (Cq), 150.9 (Cq), 149.6 (CH), 138.5 (CH), 136.2 (Cq), 135.5 (Cq), 130.9 (Cq), 128.5 (Cq), 
128.4 (CH), 125.2 (CH), 122.2 (CH), 122.1 (CH), 121.0 (CH), 120.5 (CH), 110.6 (CH), 103.4 (CH), 82.7 
(Cq), 74.7 (CH2), 24.4 (CH3), 21.4 (CH3). IR (ATR) ν = 2924, 1800, 1588, 1470, 1437, 1384, 1301, 1187, 
1057 cm-1. MS (ESI) m/z (relative intensity): 335 (100) [M+H]+, 313 (40), 271 (40). HR-MS (EI) m/z 
calcd for C20H19N2O3 [M+H]







(167a’a): The general procedure G was followed using 1-(pyridin-2-yl)-1H-indole-5-carboxylic acid 
(41a’) (59.6 mg, 0.25 mmol) and 4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). 
Purification by column chromatography on silica gel (EtOAc/MeOH: 20/1) yielded 167a’a (61.1 mg, 
67%) as white solid.  
M.p. = 135–137 °C. 1H NMR (300 MHz, CDCl3) δ = 8.70 (dd, J = 4.9, 2.0 Hz, 1H), 8.45 (s, 1H), 8.11–
7.84 (m, 2H), 7.53–7.37 (m, 3H), 6.96 (s, 1H), 6.74 (dd, J = 16.0 Hz, 1H), 6.23 (d, J = 16.0 Hz, 1H), 4.31 
(d, J = 8.4 Hz, 1H), 4.21 (d, J = 8.4 Hz, 1H), 1.64 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 171.8 (Cq), 
154.0 (Cq), 150.9 (Cq), 149.8 (CH), 140.5 (Cq), 138.7 (CH), 137.1 (Cq), 130.0 (CH), 127.7 (Cq), 125.1 
(CH), 124.5 (CH), 123.0 (CH), 122.5 (Cq), 121.3 (CH), 121.1 (CH), 110.7 (CH), 104.3 (CH), 82.4 (Cq), 
74.6 (CH2), 24.6 (CH3). IR (ATR) ν = 2924, 1796, 1678, 1470, 1228, 1053, 905, 767, 726 cm
-1. MS (ESI) 
m/z (relative intensity): 751 (50) [2M+Na]+, 387 (70) [M+Na]+, 365 (100) [M+H]+, 343 (55). HR-MS 
(ESI) m/z calcd for C20H17N2O5 [M+H]




(167b’a): The general procedure G was followed using methyl 
1-(pyridin-2-yl)-1H-indole-5-carboxylate (41b’) (63.1 mg, 0.25 mmol) and 
4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167b’a (68.1 mg, 72%) as colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.67 (dd, J = 4.9, 1.9 Hz, 1H), 8.34 (d, J = 1.7 Hz, 1H), 7.92 (ddd, J = 8.0, 
7.5, 1.9 Hz, 1H), 7.86 (dd, J = 8.8, 1.7 Hz, 1H), 7.42 (dt, J = 8.7, 0.8 Hz, 1H), 7.40–7.31 (m, 2H), 6.92 (s, 
1H), 6.72 (d, J = 16.0 Hz, 1H), 6.21 (d, J = 16.0 Hz, 1H), 4.29 (d, J = 8.4 Hz, 1H), 4.19 (d, J = 8.4 Hz, 1H), 
3.91 (s, 3H), 1.61 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 167.6 (Cq), 154.1 (Cq), 150.2 (Cq), 149.8 (CH), 
140.0 (Cq), 138.7 (CH), 137.0 (Cq), 129.9 (CH), 127.7 (Cq), 124.6 (CH), 123.7 (CH), 123.5 (Cq), 122.9 
(CH), 121.2 (CH), 121.2 (CH), 110.6 (CH), 104.2 (CH), 82.4 (Cq), 74.6 (CH2), 51.9 (CH3), 24.4 (CH3). IR 




intensity): 779 (30) [2M+Na]+, 757 (30) [2M+H]+, 401 (10) [M+Na]+, 379 (100) [M+H]+, 357 (30), 335 
(35). HR-MS (ESI) m/z calcd for C21H19N2O3 [M+H]




(167c’a): The general procedure G was followed using 
1-(pyridin-2-yl)-6,7-dihydro-1H-indol-4(5H)-one (41c’) (53.1 mg, 0.25 mmol) and 
4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/3) yielded 167c’a (42.3 mg, 50%) as a white solid.  
M.p. = 149–151 °C. 1H NMR (300 MHz, CDCl3) δ = 8.59 (dd, J = 4.9, 1.9 Hz, 1H), 7.87 (td, J = 7.7, 1.9 
Hz, 1H), 7.38 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 6.79 (s, 1H), 6.31 (d, J = 16.0 Hz, 
1H), 5.89 (d, J = 16.0 Hz, 1H), 4.17 (d, J = 8.4 Hz, 1H), 4.11 (d, J = 8.4 Hz, 1H), 2.66 (td, J = 6.1, 2.7 Hz, 
2H), 2.49–2.37 (m, 2H), 2.14–1.97 (m, 2H), 1.51 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 194.1 (Cq), 
154.0 (Cq), 149.7 (CH), 149.4 (Cq), 145.5 (Cq), 138.6 (CH), 131.2 (Cq), 126.8 (CH), 123.7 (CH), 121.6 
(CH), 121.4 (Cq), 120.1 (CH), 105.0 (CH), 82.5 (Cq), 74.7 (CH2), 37.9 (CH2), 24.5 (CH3), 23.6 (CH2), 23.0 
(CH2). IR (ATR) ν = 2930, 1796, 1656, 1460, 1438, 1220, 1134, 1093, 1054, 733 cm
-1. MS (ESI) m/z 
(relative intensity): 699 (70) [2M+Na]+, 361 (40) [M+Na]+, 339 (100) [M+H]+, 317 (80). HR-MS (ESI) 
m/z calcd for C19H19N2O4 [M+H]
+: 339.1339, found: 339.1340. 
 
 
(E)-4-Methyl-4-{2-[3-(pyridin-2-yl)thiophen-2-yl]vinyl}-1,3-dioxolan-2-one (167d’a): The general 
procedure G was followed using 2-(thiophen-3-yl)pyridine (41d’) (40.3 mg, 0.25 mmol) and 
4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by column 




1H NMR (300 MHz, C6D6) δ = 8.62 (dt, J = 4.8, 1.5 Hz, 1H), 7.89 (d, J = 16.1 Hz, 1H), 7.32–7.08 (m, 3H), 
6.88 (d, J = 5.3 Hz, 1H), 6.72 (ddd, J = 5.7, 4.8, 2.9 Hz, 1H), 5.93 (d, J = 16.1 Hz, 1H), 3.54 (d, J = 8.4 Hz, 
1H), 3.34 (d, J = 8.4 Hz, 1H), 1.06 (s, 3H). 13C NMR (75 MHz, C6D6) δ = 154.5 (Cq), 154.0 (Cq), 149.7 
(CH), 139.9 (Cq), 138.1 (Cq), 136.2 (CH), 129.5 (CH), 128.5 (CH), 125.4 (CH), 124.1 (CH), 122.9 (CH), 
121.7 (CH), 81.8 (Cq), 73.8 (CH2), 23.4 (CH3). IR (ATR) ν = 1800, 1585, 1474, 1439, 1265, 1230, 1095, 
1057, 958, 772 cm-1. MS (ESI) m/z (relative intensity): 266 (70), 288 (100) [M+H]+, 310 (80) [M+Na]+, 
597 (40) [2M+Na]+. HR-MS (ESI) m/z calcd for C15H13NO3S [M+H]
+: 288.0689, found: 288.0691. 
 
 
(E)-4-Methyl-4-{2-[1-(pyrimidin-2-yl)-1H-indol-2-yl]vinyl}-1,3-dioxolan-2-one (167aa): The general 
procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole (41a) (48.8 mg, 0.25 mmol) and 
4-ethynyl-4-methyl-1,3-dioxolan-2-one (110a) (58.0 μL, 0.5 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167aa (57.8 mg, 72%) as colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.78 (d, J = 4.7 Hz, 2H), 8.35 (d, J = 8.3 Hz, 1H), 7.57 (d, J = 7.7 Hz, 1H), 
7.36 (d, J = 15.9 Hz, 1H), 7.32–7.04 (m, 3H), 6.85 (s, 1H), 6.19 (d, J = 15.9 Hz, 1H), 4.39 (d, J = 8.2 Hz, 
1H), 4.24 (d, J = 8.2 Hz, 1H), 1.70 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 158.2 (CH), 157.8 (Cq), 154.5 
(Cq), 137.2 (Cq), 136.4 (Cq), 128.9 (Cq), 127.6 (CH), 124.6 (CH), 124.1 (CH), 122.4 (CH), 120.6 (CH), 
117.3 (CH), 114.5 (CH), 106.5 (CH), 82.8 (Cq), 74.8 (CH2), 24.5 (CH3). IR (ATR) ν = 2981, 1791, 1562, 
1419, 1344, 1233, 1210, 1091, 947, 746 cm-1. MS (ESI) m/z (relative intensity): 665 (70) [2M+Na]+, 
344 (10) [M+Na]+, 322 (100) [M+H]+, 300 (20), 278 (60), 260 (20). HR-MS (ESI) m/z calcd for 
C18H16N3O3 [M+H]
+: 322.1186, found: 322.1195. 
 
 




was followed using 1-(pyridin-2-yl)-1H-indole (41b) (48.6 mg, 0.25 mmol) and 
4-ethynyl-1,3-dioxolan-2-one (110b) (56.1 mg, 0.5 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 3/2) yielded 167bb (63.6 mg, 83%) as colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.66 (dd, J = 4.9, 2.0 Hz, 1H), 7.91 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.70–
7.59 (m, 1H), 7.48–7.31 (m, 3H), 7.23–7.06 (m, 2H), 6.94 (s, 1H), 6.83 (d, J = 15.8 Hz, 1H), 6.10 (dd, J 
= 15.8, 7.9 Hz, 1H), 5.19 (qd, J = 7.9, 0.9 Hz, 1H), 4.57 (ddd, J = 8.7, 8.0, 0.9 Hz, 1H), 4.17 (ddd, J = 8.7, 
8.0, 0.9 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ = 154.5 (Cq), 150.6 (Cq), 149.6 (CH), 138.5 (CH), 137.8 
(Cq), 135.0 (Cq), 128.0 (Cq), 126.7 (CH), 123.7 (CH), 123.2 (CH), 122.4 (CH), 121.5 (CH), 121.2 (CH), 
121.0 (CH), 110.7 (CH), 104.4 (CH), 77.7 (CH), 69.2 (CH2). IR (ATR) ν = 3055, 1794, 1586, 1467, 1436, 
1160, 1149, 1047, 933, 743 cm-1. MS (ESI) m/z (relative intensity): 329 (10) [M+Na]+, 307 (100) 
[M+H]+, 285 (15), 245 (10). HR-MS (ESI) m/z calcd for C18H15N2O3 [M+H]




(E)-1-(Pyridin-2-yl)-2-[2-(2,2,4-trimethyl-1,3-dioxolan-4-yl)vinyl]-1H-indole (167bc): The general 
procedure G was followed using 1-(pyridin-2-yl)-1H-indole (41b) (48.6 mg, 0.25 mmol) and 
4-ethynyl-2,2,4-trimethyl-1,3-dioxolane (110c) (70.1 mg, 0.5 mmol) for 40 min. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 167bc (59.4 mg, 71%) as 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.66 (dd, J = 4.9, 2.0 Hz, 1H), 7.84 (ddd, J = 8.0, 7.4, 2.0 Hz, 1H), 7.62–
7.55 (m, 1H), 7.52–7.42 (m, 1H), 7.34 (dt, J = 8.0, 1.0 Hz, 1H), 7.30 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 
7.22–7.07 (m, 2H), 6.81 (s, 1H), 6.66 (d, J = 15.9 Hz, 1H), 6.25 (d, J = 15.9 Hz, 1H), 3.91 (d, J = 8.4 Hz, 
1H), 3.82 (d, J = 8.4 Hz, 1H), 1.42 (d, J = 0.7 Hz, 3H), 1.39 (s, 3H), 1.36 (d, J = 0.7 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ = 151.2 (Cq), 149.5 (CH), 138.1 (CH), 137.6 (Cq), 137.2 (Cq), 135.3 (CH), 128.5 (Cq), 
122.7 (CH), 121.9 (CH), 121.4 (CH), 121.2 (CH), 120.4 (CH), 118.8 (CH), 110.8 (CH), 109.9 (Cq), 102.3 
(CH), 80.7 (Cq), 74.6 (CH2), 27.1 (CH3), 26.5 (CH3), 25.4 (CH3). IR (ATR) ν = 2982, 1386, 1468, 1452, 




[M+H]+, 277 (20). HR-MS (ESI) m/z calcd for C21H23N2O2 [M+H]
+: 335.1754, found: 335.1749. 
 
Intermolecular Competition Experiment 
 
A suspension of 5-methoxy-1-(pyridin-2-yl)-1H-indole (41e‘a) (56.1 mg, 0.25 mmol), 
5-fluoro-1-(pyridin-2-yl)-1H-indole (41xa) (60.8 mg, 0.25 mmol), 
4-ethynyl-4-methyl-1,3-dioxolan-2-one (166a) (58.0 μL, 0.5 mmol), HOAc (2.8 µL, 20.0 mol %) and 
[MnBr(CO)5] (6.9 mg, 10.0 mol %) in 1,4-dioxane (1.0 mL) was stirred at 60 °C for 16 h under N2. 
After cooling to ambient temperature, the mixture was transferred into a round bottom flask with 
CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column chromatography on silica gel 







H/D Exchange Experiments 
 
Substrates 41b (48.6 mg, 0.25 mmol), 166a (58 µL, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %), 
1,4-dioxane (0.9 mL) and CD3CO2D (0.1 mL, 7.0 equiv) were placed in a 25 mL Schlenk tube under N2 
and stirred at 60 °C for 1 h. After cooling to ambient temperature, the mixture was transferred into 
a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1 to 3/2) yielded [D]n-167ba (46.5 mg, 58%), 


















Substrates [D]1-41b (48.8 mg, 0.25 mmol), 166a (58 µL, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 
mol %), HOAc (2.8 µL, 20.0 mol%) and 1,4-dioxane (1.0 mL) were placed in a 25 mL Schlenk tube 
under N2 and stirred at 60 °C for 16 h. After cooling to ambient temperature, the mixture was 
transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded [D]n-167ba (68.9 mg, 86%). The 










Synergistic hydroarylation with cyclometalated complex 195 
a) Stoichiometric reaction without HOAc 
 
 
Complex 195 (36.0 mg, 0.10 mmol), 4-ethynyl-4-methyl-1,3-dioxolan-2-one (166a) (25.3 mg, 0.2 
mmol) and 1,4-dioxane (0.5 mL) were placed in a 10 mL Schlenk tube under N2 and stirred at 60 °C 
for 16 h. After cooling to ambient temperature, the mixture was transferred into a round bottom 
flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 3/2) yielded 194 (32.0 mg, 46%) as colorless oil, the desired compound 




1H NMR (400 MHz, CDCl3) δ = 8.64 (d, J = 4.1 Hz, 1H), 7.86 (td, J = 7.7, 1.5 Hz, 1H), 7.59–7.50 (m, 1H), 
7.39 (dd, J = 8.0, 1.0 Hz, 1H), 7.31 (ddd, J = 7.6, 4.8, 1.0 Hz, 1H), 7.24–7.16 (m, 1H), 7.15–7.02 (m, 
2H), 6.63 (s, 1H), 6.42 (q, J = 3.1 Hz, 1H), 3.84 (s, 2H), 2.08 (brs, 1H), 1.51 (d, J = 3.0 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ = 201.4 (Cq), 151.5 (Cq), 149.6 (CH), 138.7 (Cq), 138.3 (CH), 133.2 (Cq), 128.4 (Cq), 
122.6 (CH), 122.5 (CH), 122.1 (CH), 121.0 (CH), 120.2 (CH), 110.2 (CH), 104.4 (CH), 104.3 (Cq), 88.2 
(CH), 63.6 (CH2), 15.2 (CH3). IR (ATR) ν = 3346, 2857, 1587, 1470, 1437, 1345, 1023, 780, 744 cm
-1. 
MS (ESI) m/z (relative intensity): 575 (100) [2M+Na]+, 431 (10), 299 (60) [M+Na]+, 276 (55) [M+H]+. 
HR-MS (ESI) m/z calcd for C18H17N2O [M+H]






b) Stoichiometric reaction with HOAc 
 
 
Complex 195 (36.0 mg, 0.10 mmol), 4-ethynyl-4-methyl-1,3-dioxolan-2-one (166a) (25.3 mg, 0.2 
mmol), HOAc (1.2 µL, 20.0 mol %) and 1,4-dioxane (0.5 mL) were placed in a 10 mL Schlenk tube 
under N2 and stirred at 60 °C for 16 h. After cooling to ambient temperature, the mixture was 
transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3/2) yielded 167ba (38.5 mg, 48%), the 
allene 194 was not detected coupled gas chromatography-mass spectrometry. 
 
c) Complex 195 as catalyst 
 
 
The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole (41b) (46.6 mg, 0.24 
mmol), 4-ethynyl-4-methyl-1,3-dioxolan-2-one (166a) (58.0 μL, 0.5 mmol), HOAc (2.8 µL, 20.0 mol %) 
and complex 195 (9.0 mg, 10.0 mol %). Purification by column chromatography on silica gel 







Evaluation of the Mxing Effect 
a) Continuous Flow C─H Activation: On Scale 
 
 
A solution of 41b (7.5 mmol, 1.0 equiv), [MnBr(CO)5] (206 mg, 10.0 mol %) and HOAc (85 µL, 20.0 
mol %) in 1,4-dioxane was prepared in vial 1 and brought to a volume of 15 mL. A solution of 166a 
(1.75 mL, 15 mmol) in dioxane was prepared in vial 2 and brought to a final volume of 15 mL. The 
solutions were taken into separate syringes and operated at a flow rate of 250 µL / min. The two 
solutions were mixed at a T-joint connection and subsequently reacted in a 10 mL reactor for 1 h 
residence time. Using the Flow Wizard system, the solution was collected automatically. Next, the 
mixture was concentrated in vacuo. Purification by column chromatography on silica gel yielded the 
desired product 167ba (2.24 g mg, 93%). 
 
b) Continuous Flow C─H Activation: Catalyst Separation 
 
 
A solution of 41b (0.50 mmol, 1.0 equiv), [MnBr(CO)5] (13.8 mg, 10.0 mol %) and HOAc (5.6 μL, 20.0 




(116.0 μL, 1.0 mmol) in dioxane was prepared in vial 2 and brought to a final volume of 1.0 mL. The 
solutions were taken into separate syringes and operated at a flow rate of 250 μL / min and the two 
solutions were mixed at a T-joint connection. Subsequently, the reaction media was connected to 
the inlet of 10 mL standard heated reactor coupled with a column reactor (Ø = 8 mm) packed with 
500 mg of QuadraPure® IDA (V = 2.5 mL). Using the Flow Wizard system, the solution was collected 
automatically. Next, the mixture was concentrated in vacuo. Purification by column 
chromatography on silica gel yielded the desired product 167ba (132.0 mg, 82%). 
 
Diversification of 167ba 
 
 
Reaction (a): The product 167ba (64.1 mg, 0.20 mmol) was dissolved in 1,4-dioxane (2.0 mL), 
followed by NaOH (1 N, 2.0 mL). The resulting solution was allowed to stir for 30 min at 25 °C. The 
mixture was transferred into a round bottom flask with CH2Cl2 (20.0 mL) and concentrated in vacuo. 
Purification by column chromatography on silica gel (EtOAc: 100%) afforded the desired products 







1H NMR (400 MHz, CDCl3) δ = 8.62 (dd, J = 4.9, 2.0 Hz, 1H), 7.86 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.66–
7.52 (m, 1H), 7.45–7.37 (m, 2H), 7.30 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.19─7.10 (m, 2H), 6.76 (s, 1H), 
6.62 (d, J = 16.0 Hz, 1H), 6.14 (d, J = 16.0 Hz, 1H), 3.50 (d, J = 11.1 Hz, 1H), 3.40 (d, J = 11.1 Hz, 1H), 
2.58 (brs, 2H), 1.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 151.0 (Cq), 149.5 (CH), 138.4 (CH), 137.5 
(Cq), 137.2 (Cq), 135.7 (CH), 128.5 (Cq), 122.8 (CH), 122.1 (CH), 121.4 (CH), 121.3 (CH), 120.5 (CH), 
119.9 (CH), 110.6 (CH), 102.3 (CH), 73.5 (Cq), 69.8 (CH2), 24.1 (CH3). IR (ATR) ν = 3352, 2929, 1587, 
1451, 1436, 1347, 1347, 1044, 907, 780, 730 cm-1. MS (ESI) m/z (relative intensity): 311 (100) 
[M+Na]+, 295 (80) [M+H]+, 277 (70). HR-MS (ESI) m/z calcd for C18H19N2O2 [M+H]
+: 295.1441, found: 
295.1440. 
 
Reaction (b): To 167ba (64.1 mg, 0.20 mmol) in THF (10 mL) was added Pd2(dba)3·CHCl3 (10.2 mg, 
5.0 mol %), PPh3 (2.6 mg, 5.0 mol %), Et3N (101.2 mg, 5.0 equiv) and HCO2H (38.0 µL, 5.0 equiv). The 
reaction was stirred at 70 °C for 30 min. The reaction was then allowed to cool to 25 °C, diluted 
with Et2O (10.0 mL) and filtered through a plug of silica gel. After concentration in vacuo the crude 
mixture was purified by silica gel column chromatography (n-hexane/EtOAc: 3/2) to yield 197 (49.0 




1H NMR (400 MHz, CDCl3) δ = 8.64 (dd, J = 4.9, 2.0 Hz, 1H), 7.86 (ddd, J = 8.1, 7.5, 2.0 Hz, 1H), 7.65–
7.53 (m, 1H), 7.48–7.37 (m, 2H), 7.30 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.17–7.10 (m, 2H), 6.76 (s, 1H), 
6.41 (dt, J = 15.9, 1.0 Hz, 1H), 6.03 (dd, J = 15.9, 8.0 Hz, 1H), 3.51 (dd, J = 10.7, 5.5 Hz, 1H), 3.42 (dd, 




NMR (100 MHz, CDCl3) δ = 151.1 (Cq), 149.4 (CH), 138.3 (CH), 137.8 (Cq), 137.3 (Cq), 135.3 (CH), 
128.6 (Cq), 122.5 (CH), 122.0 (CH), 121.3 (CH), 121.2 (CH), 121.2 (CH), 120.4 (CH), 110.5 (CH), 101.7 
(CH), 67.1 (CH2), 40.2 (CH), 16.1 (CH3). IR (ATR) ν = 3364, 2868, 1586, 1468, 1451, 1344, 1026, 783, 
744 cm-1. MS (ESI) m/z (relative intensity): 301 (20) [M+Na]+, 279 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C18H19N2O [M+H]
+: 279.1492, found: 279.1492. 
 
Reaction (c): To a stirred solution of CuI (57.1 mg, 3.0 equiv) in dry THF (1 mL) at -78 °C under N2 
was added vinylmagnesium bromide (1.0 M in THF, 1.2 mL, 6.0 equiv) and BF3·OEt2 (0.3 mL, 1.2 
equiv). Then, 167ba (64.1 mg, 0.20 mmol) in dry THF (0.5 mL) was added and the mixture was 
allowed to warm to 25 °C for 1 h. To the reaction mixture was added a saturated aqueous NH4Cl 
solution (2.0 mL) and extracted with Et2O (20.0 mL x 3). The organic layer was dried over Na2SO4 
and evaporated in vacuo. Purification by column chromatography (n-hexane/EtOAc: 10/1) yielded 




1H NMR (400 MHz, CDCl3) δ = 8.69 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.86 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 
7.63–7.57 (m, 1H), 7.52–7.44 (m, 1H), 7.37 (dt, J = 8.0, 0.9 Hz, 1H), 7.32 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 
7.19–7.10 (m, 2H), 6.88 (s, 1H), 6.87 (d, J = 16.1 Hz, 1H), 6.50 (d, J = 16.1 Hz, 1H), 5.08 (d, J = 2.1 Hz, 
1H), 5.04 (d, J = 2.1 Hz, 1H), 1.83 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 151.3 (Cq), 149.5 (CH), 141.9 
(Cq), 138.1 (CH), 138.0 (Cq), 137.8 (Cq), 133.6 (CH), 128.7 (Cq), 122.7 (CH), 122.0 (CH), 121.4 (CH), 
121.2 (CH), 120.4 (CH), 118.4 (CH), 117.7 (CH2), 110.8 (CH), 102.1 (CH), 18.3 (CH3). IR (ATR) ν = 3051, 
1585, 1467, 1450, 1435, 1335, 1213, 956, 784, 744 cm-1. MS (ESI) m/z (relative intensity): 261 (100) 
[M+H]+, 207 (30). HR-MS (ESI) m/z calcd for C18H17N2 [M+H]
+: 261.1386, found: 261.1387. 
 
Reaction (d): An oven-dired Schlenk tube, equipped with a stirring bar and a septum, was charged 




mol %). Then, DMF (0.4 mL) and aniline (27.5 mg, 0.3 mmol) were added. The reaction mixture was 
stirred at 25 °C for 16 h. Then the mixture was transferred into a round bottom flask with CH2Cl2 
(20.0 mL) and concentrated in vacuo. Purification by column chromatography on silica gel 




1H NMR (400 MHz, CDCl3) δ = 8.51 (dd, J = 4.8, 1.9 Hz, 1H), 7.68–7.55 (m, 2H), 7.50–7.42 (m, 1H), 
7.23–7.04 (m, 6H), 6.79 (s, 1H), 6.74–6.61 (m, 3H), 6.49 (d, J = 16.1 Hz, 1H), 6.19 (d, J = 16.1 Hz, 1H), 
3.60 (d, J = 11.0 Hz, 1H), 3.50 (d, J = 11.0 Hz, 1H), 2.79 (brs, 1H), 1.40 (s, 3H). 13C NMR (100 MHz, 
CDCl3) δ = 150.9 (Cq), 149.3 (CH), 145.6 (Cq), 138.8 (Cq), 138.3 (CH), 137.3 (Cq), 134.3 (CH), 128.8 
(CH), 128.6 (Cq), 122.8 (CH), 122.1 (CH), 121.8 (CH), 121.3 (CH), 121.1 (CH), 120.5 (CH), 117.7 (CH), 
116.1 (CH), 110.9 (CH), 102.3 (CH), 69.5 (CH2), 58.4 (Cq), 22.1 (CH3). IR (ATR) ν = 3500, 3052, 2928, 
1600, 1468, 1452, 1348, 1051, 783, 747 cm-1. MS (ESI) m/z (relative intensity): 383 (20) [M+Na]+, 
381 (100). HR-MS (ESI) m/z calcd for C24H23N3O [M]
+: 369.1836, found: 369.1828. 
 
 








2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (50.6 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 1/1) yielded 111aa (45.3 mg, 75%, E/Z = 4.9/1.0 by 1H NMR) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.68 (dd, J = 1.9, 0.7 Hz, 0.17H), 7.66 (dd, J = 1.9, 0.7 Hz, 0.83H), 7.57–
7.49 (m, 1H), 7.40–7.16 (m, 4H), 6.40 (dd, J = 2.4, 1.9 Hz, 0.17H), 6.38 (dd, J = 2.4, 1.9 Hz, 0.83H), 
5.58 (dtt, J = 15.4, 6.4, 1.4 Hz, 1H), 5.40 (dtt, J = 15.4, 5.6, 1.4 Hz, 1H), 3.97 (d, J = 5.8 Hz, 0.33H), 
3.91 (d, J = 5.8 Hz, 1.67H), 3.30 (d, J = 5.8 Hz, 0.33H), 3.25 (d, J = 5.8 Hz, 1.67H), 2.68 (s, 0.17H), 2.57 
(s, 0.83H). 13C NMR (125 MHz, CDCl3) Major isomer: δ = 140.2 (CH), 139.5 (Cq), 136.0 (Cq), 130.9 
(CH), 130.9 (CH), 130.6 (CH), 129.7 (CH), 128.7 (CH), 127.0 (CH), 126.6 (CH), 106.2 (CH), 63.0 (CH2), 
34.3 (CH2). Minor isomer: δ = 140.4 (CH), 139.3 (Cq), 136.5 (Cq), 130.9 (CH), 130.3 (CH), 130.0 (CH), 
129.5 (CH), 128.9 (CH), 126.9 (CH), 126.6 (CH), 106.4 (CH), 58.0 (CH2), 29.5 (CH2). IR (ATR) ν = 3347, 
2855, 1517, 1395, 1328, 1100, 972, 916, 755, 597 cm-1. MS (ESI) m/z (relative intensity): 237 (50) 
[M+Na]+, 215 (30) [M+H]+, 197 (100). HR-MS (ESI) m/z calcd for C13H15N2O [M+H]




4-[5-Methyl-2-(1H-pyrazol-1-yl)phenyl]but-2-en-1-ol (111ba): The general procedure H was 
followed using 2-[5-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168b) (54.1 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (48.0 μL, 0.50 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 2/1) yielded 111ba (35.0 mg, 61%, E/Z = 5.3/1.0 by 1H NMR) as a 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.69 (d, J = 1.9 Hz, 0.16H), 7.66 (d, J = 1.9 Hz, 0.84H), 7.55–7.50 (m, 
1H), 7.21–7.05 (m, 3H), 6.40 (t, J = 2.1 Hz, 0.16H), 6.38 (t, J = 2.1 Hz, 0.84H), 5.61 (dtt, J = 15.4, 6.5, 
1.2 Hz, 1H), 5.45 (dtt, J = 15.4, 5.8, 1.4 Hz, 1H), 4.01 (d, J = 6.0 Hz, 0.31H), 3.97 (d, J = 6.0 Hz, 1.69H), 
3.30 (dd, J = 6.8, 1.4 Hz, 0.31H), 3.25 (dd, J = 6.8, 1.4 Hz, 1.69H), 2.36 (s, 3H), 1.79 (brs, 0.16H), 1.71 
(brs, 0.84H). 13C NMR (100 MHz, CDCl3) Major isomer: δ = 140.1 (CH), 138.7 (Cq), 137.2 (Cq), 135.7 




34.3 (CH2), 21.1 (CH3). Minor isomer: δ = 140.3 (CH), 138.9 (Cq), 137.0 (Cq), 136.2 (Cq), 131.0 (CH), 
130.9 (CH), 130.1 (CH), 129.5 (CH), 127.6 (CH), 126.5 (CH), 106.2 (CH), 58.0 (CH2), 29.3 (CH2), 21.1 
(CH3). IR (ATR) ν = 3352, 2918, 1518, 1395, 1101, 972, 945, 820, 753, 626 cm
-1. MS (ESI) m/z 
(relative intensity): 479 (100) [2M+Na]+, 263 (40), 251 (100) [M+Na]+, 229 (30) [M+H]+. HR-MS (ESI) 
m/z calcd for C14H18N2O [M+H]
+: 229.1335, found: 229.1334. 
 
 
4-[4-Methyl-2-(1H-pyrazol-1-yl)phenyl]but-2-en-1-ol (111ca): The general procedure H was 
followed using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (48.0 μL, 0.50 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 3/2) yielded 111ca (45.1 mg, 79%, E/Z = 5.2/1.0 by 1H NMR) as a 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.69 (d, J = 1.9 Hz, 0.16H), 7.66 (d, J = 1.9 Hz, 0.84H), 7.55 (dd, J = 2.3, 
0.6 Hz, 0.16H), 7.54 (dd, J = 2.3, 0.6 Hz, 0.84H), 7.21–7.07 (m, 3H), 6.41 (t, J = 1.9 Hz, 0.16H), 6.38 (t, 
J = 1.9 Hz, 0.84H), 5.59 (dtt, J = 15.3, 6.4, 1.4 Hz, 1H), 5.58 (dtt, J = 15.3, 5.7, 1.6 Hz, 1H), 4.00 (d, J = 
6.8 Hz, 0.32H), 3.95 (dd, J = 6.8 Hz, 1.68H), 3.29 (d, J = 6.4 Hz, 0.32H), 3.25 (d, J = 6.4 Hz, 1.68H), 
2.33 (s, 3H), 2.11 (brs, 0.16H), 1.85 (brs, 0.84H). 13C NMR (100 MHz, CDCl3) Major isomer: δ = 140.2 
(CH), 139.4 (Cq), 137.0 (Cq), 132.6 (Cq), 130.7 (CH), 130.5 (CH), 130.4 (CH), 130.4 (CH), 129.4 (CH), 
127.1 (CH), 106.1 (CH), 63.2 (CH2), 33.9 (CH2), 20.7 (CH3). Minor isomer: δ = 140.3 (CH), 139.2 (Cq), 
136.9 (Cq), 133.2 (Cq), 130.9 (CH), 130.2 (CH), 130.1 (CH), 129.6 (CH), 129.5 (CH), 127.2 (CH), 106.2 
(CH), 57.9 (CH2), 29.0 (CH2), 20.7 (CH3). IR (ATR) ν = 3356, 1516, 1392, 1327, 1191, 1100, 1041, 970, 
752 cm-1. MS (ESI) m/z (relative intensity): 479 (100) [2M+Na]+, 251 (50) [M+Na]+, 229 (30) [M+H]+. 
HR-MS (ESI) m/z calcd for C14H17N2O [M+H]








The general procedure H was followed using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol 
(168c) (54.1 mg, 0.25 mmol) and 3-tosyl-5-vinyloxazolidin-2-one (110g) (133.7 mg, 0.50 mmol). 
Purification by column chromatography on silica gel (DCM: 100% → n-hexane/EtOAc: 2/1) yielded 
111cg (60.1 mg, 63%, E/Z = 4.6/1.0 by 1H NMR) as a colorless oil.  
1H NMR (600 MHz, CDCl3) δ = 7.74–7.58 (m, 3H), 7.49 (d, J = 2.4 Hz, 0.18H), 7.48 (d, J = 2.4 Hz, 
0.82H), 7.29–7.22 (m, 2H), 7.13–7.03 (m, 3H), 6.37 (t, J = 2.1 Hz, 1H), 5.47 (dtt, J = 15.6, 6.3, 1.3 Hz, 
0.82H), 5.40 (dtt, J = 10.7, 7.3, 1.2 Hz, 0.18H), 5.24 (dtt, J = 10.7, 6.9, 1.8 Hz, 0.18H), 5.13 (dtt, J = 
15.6, 6.3, 1.6 Hz, 0.82H), 4.76 (t, J = 6.3 Hz, 0.18H), 4.56 (t, J = 6.3 Hz, 0.82H), 3.44 (t, J = 6.9 Hz, 
0.34H), 3.39 (t, J = 6.6 Hz, 1.66H), 3.19 (d, J = 6.6 Hz, 0.34H), 3.16 (d, J = 6.6 Hz, 1.66H), 2.40 (s, 
0.51H), 2.38 (s, 2.49H), 2.32 (s, 2.49H), 2.31 (s, 0.51H). 13C NMR (125 MHz, CDCl3) Major isomer: δ = 
143.2 (Cq), 140.1 (CH), 139.3 (Cq), 137.1 (Cq), 136.9 (Cq), 132.3 (CH), 132.0 (Cq), 130.5 (CH), 130.3 
(CH), 129.5 (CH), 129.3 (CH), 127.0 (CH), 127.0 (CH), 125.7 (CH), 106.1 (CH), 45.0 (CH2), 34.0 (CH2), 
21.5 (CH3), 20.8 (CH3). Minor isomer: δ = 143.2 (Cq), 140.2 (CH), 139.1 (Cq), 137.0 (Cq), 137.0 (Cq), 
132.5 (Cq), 131.8 (CH), 130.6 (CH), 130.0 (CH), 129.5 (CH), 129.5 (CH), 127.1 (CH), 127.0 (CH), 124.9 
(CH), 106.2 (CH), 39.8 (CH2), 29.1 (CH2), 21.5 (CH3), 20.8 (CH3). IR (ATR) ν = 3278, 1516, 1405, 1326, 
1157, 1094, 1043, 911, 732, 663 cm-1. MS (ESI) m/z (relative intensity): 785 (40) [2M+Na]+, 404 (70) 
[M+Na]+, 382 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H24N3O2S [M+H]




4-[5-Methoxy-2-(1H-pyrazol-1-yl)phenyl)but-2-en-1-ol (111da): The general procedure H was 




and 4-vinyl-1,3-dioxolan-2-one (110a) (48.0 μL, 0.50 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 1/1) yielded 111da (40.0 mg, 65%, E/Z = 3.8/1.0 by 1H NMR) as a 
colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.67 (dd, J = 1.9, 0.7 Hz, 0.21H), 7.65 (dd, J = 1.9, 0.7 Hz, 0.79H), 7.53–
7.45 (m, 1H), 7.23–7.14 (m, 1H), 6.86–6.72 (m, 2H), 6.39 (dd, J = 2.3, 1.9 Hz, 0.21H), 6.37 (dd, J = 2.3, 
1.9 Hz, 0.79H), 5.60 (dtt, J = 15.3, 6.5, 1.1 Hz, 1H), 5.45 (dtt, J = 15.3, 5.7, 1.3 Hz, 1H), 4.08–3.93 (m, 
2H), 3.81 (s, 3H), 3.25 (dd, J = 6.8, 1.4 Hz, 0.42H), 3.20 (dd, J = 6.8, 1.4 Hz, 1.58H), 2.14 (s, 0.21H), 
1.90 (s, 0.79H). 13C NMR (100 MHz, CDCl3) Major isomer: δ = 159.6 (Cq), 140.0 (CH), 137.8 (Cq), 
132.9 (Cq), 131.1 (CH), 130.9 (CH), 129.7 (CH), 127.9 (CH), 115.7 (CH), 111.8 (CH), 105.9 (CH), 63.1 
(CH2), 55.5 (CH3), 34.3 (CH2). Minor isomer: δ = 159.7 (Cq), 140.2 (CH), 138.2 (Cq), 132.7 (Cq), 131.2 
(CH), 130.0 (CH), 129.5 (CH), 127.9 (CH), 115.4 (CH), 111.8 (CH), 106.1 (CH), 57.8 (CH2), 55.5 (CH3), 
29.4 (CH2). IR (ATR) ν = 3370, 2839, 1608, 1500, 1241, 1043, 756, 624 cm
-1. MS (ESI) m/z (relative 
intensity): 511 (100) [2M+Na]+, 267 (60) [M+Na]+, 245 (70) [M+H]+, 227 (20). HR-MS (ESI) m/z calcd 
for C14H17N2O2 [M+H]




The general procedure H was followed using 2-[5-methoxy-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol 
(168d) (58.1 mg, 0.25 mmol) and 3-tosyl-5-vinyloxazolidin-2-one (110g) (133.7 mg, 0.50 mmol). 
Purification by column chromatography on silica gel (Hexane/EtOAc/Et3N: 3/1/0.3 → 
n-hexane/EtOAc: 1/1) yielded 111dg (51.0 mg, 51%, E/Z = 5.3/1.0 by 1H NMR) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.75–7.65 (m, 2H), 7.63 (d, J = 1.9 Hz, 0.84H), 7.59 (d, J = 1.9 Hz, 
0.16H), 7.47–7.41 (m, 1H), 7.32–7.22 (m, 2H), 7.17 (d, J = 8.6 Hz, 0.84H), 7.13 (d, J = 8.6 Hz, 0.16H), 
6.84–6.73 (m, 1.16H), 6.71 (d, J = 2.9 Hz, 0.84H), 6.36 (dd, J = 2.3, 1.8 Hz, 1H), 5.47 (dtt, J = 15.3, 6.6, 
1.4 Hz, 1H), 5.27 (dtt, J = 10.5, 7.1, 1.7 Hz, 0.16H), 5.15 (dtt, J = 15.3, 6.3, 1.5 Hz, 0.84H), 4.72 (t, J = 
6.0 Hz, 0.16H), 4.51 (t, J = 6.0 Hz, 0.84H), 3.80 (s, 3H), 3.45–3.37 (m, 2H), 3.19–3.08 (m, 2H), 2.40 (s, 




(CH), 137.2 (Cq), 136.9 (Cq), 132.9 (Cq), 131.9 (CH), 131.0 (CH), 129.6 (CH), 127.9 (CH), 127.1 (CH), 
126.2 (CH), 115.7 (CH), 111.9 (CH), 106.0 (CH), 55.5 (CH3), 45.0 (CH2), 34.4 (CH2), 21.5 (CH3). Minor 
isomer: δ = 159.7 (Cq), 143.4 (Cq), 140.2 (CH), 137.6 (Cq), 137.1 (Cq), 132.7 (Cq), 131.3 (CH), 131.1 
(CH), 129.6 (CH), 127.9 (CH), 126.4 (CH), 125.4 (CH), 115.4 (CH), 111.9 (CH), 106.1 (CH), 65.8 (CH3), 
39.8 (CH2), 29.5 (CH2), 15.2 (CH3). IR (ATR) ν = 3274, 2918, 1599, 1518, 1324, 1156, 1093, 1041, 813, 
661 cm-1. MS (ESI) m/z (relative intensity): 817 (10) [2M+Na]+, 420 (20) [M+Na]+, 398 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C21H24N3O3S [M+H]
+: 398.1533, found: 398.1537. 
 
 
4-[2-(4-Bromo-1H-pyrazol-1-yl)phenyl]but-2-en-1-ol (111ea): The general procedure H was 
followed using 2-[2-(4-bromo-1H-pyrazol-1-yl)phenyl]propan-2-ol (168e) (70.3 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (48.0 μL, 0.50 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 2/1) yielded 111ea (39.0 mg, 53%, E/Z = 5.9/1.0 by 1H NMR) as a 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.67 (d, J = 0.7 Hz, 0.15H), 7.64 (d, J = 0.7 Hz, 0.85H), 7.60 (d, J = 0.7 
Hz, 0.15H), 7.59 (d, J = 0.7 Hz, 0.85H), 7.43–7.34 (m, 1H), 7.43–7.21 (m, 3H), 5.66 (dtt, J = 15.2, 6.5, 
1.2 Hz, 1H), 5.49 (dtt, J = 15.2, 5.8, 1.5 Hz, 1H), 4.09 (d, J = 6.5 Hz, 0.29H), 4.02 (d, J = 6.5 Hz, 1.71H), 
3.35 (dd, J = 6.5, 1.5 Hz, 0.29H), 3.31 (dd, J = 6.5, 1.5 Hz, 1.71H), 1.62 (brs, 0.15H), 1.41 (brs, 0.85H). 
13C NMR (100 MHz, CDCl3) Major isomer: δ = 140. 9 (CH), 139.1 (Cq), 135.8 (Cq), 130.9 (CH), 130.8 
(CH), 129.8 (CH), 129.8 (CH), 129.2 (CH), 127.3 (CH), 126.4 (CH), 94.5 (Cq), 63.3 (CH2), 34.2 (CH2). 
Minor isomer: δ = 141.0 (CH), 138.9 (Cq), 136.3 (Cq), 130.8 (CH), 130.5 (CH), 129.9 (CH), 129.8 (CH), 
129.4 (CH), 127.2 (CH), 126.5 (CH), 94.3 (Cq), 58.2 (CH2), 29.4 (CH2). IR (ATR) ν = 3357, 2916, 1494, 
1405, 1328, 954, 764, 614 cm-1. MS (ESI) m/z (relative intensity): 317 (100) [M+Na]+ (81Br), 315 (100) 
[M+Na]+ (79Br), 295 (20) [M+H]+ (81Br), 293 (20) [M+H]+ (79Br). HR-MS (ESI) m/z calcd for 
C13H14
81BrN2O [M+H]
+: 295.0265, found: 295.0260; C13H14
79BrN2O [M+H]







4-[2-(1H-Indazol-1-yl)phenyl]but-2-en-1-ol (111fa): The general procedure H was followed using 
2-[2-(1H-indazol-1-yl)phenyl]propan-2-ol (168f) (63.1 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (48.0 μL, 0.50 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 2/1) yielded 111fa (39.2 mg, 59%, E/Z = 4.6/1.0 by 1H NMR) as a 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.20 (d, J = 0.9 Hz, 0.18H), 8.18 (d, J = 0.9 Hz, 0.82H), 7.83–7.7 (m, 1H), 
7.52–7.30 (m, 5H), 7.23–7.11 (m, 2H), 5.46 (dtt, J = 15.3, 6.7, 1.2 Hz, 1H), 5.43–5.38 (m, 0.18H), 5.20 
(dtt, J = 15.3, 5.9, 1.4 Hz, 0.82H), 3.81 (d, J = 5.6 Hz, 0.36H), 3.75 (d, J = 5.6 Hz, 1.64H), 3.34–3.19 (m, 
2H), 1.73 (brs, 0.18H), 1.13 (brs, 0.82H). 13C NMR (100 MHz, CDCl3) Major isomer: δ = 140.6 (Cq), 
138.1 (Cq), 137.8 (Cq), 134.5 (CH), 130.9 (CH), 130.4 (CH), 129.8 (CH), 129.1 (CH), 127.8 (CH), 127.3 
(CH), 126.8 (CH), 123.9 (Cq), 121.1 (CH), 121.0 (CH), 110.0 (CH), 63.2 (CH2), 34.6 (CH2). Minor isomer: 
δ = 140.6 (Cq), 138.2 (Cq), 137.6 (Cq), 134.6 (CH), 130.5 (CH), 129.7 (CH), 129.5 (CH), 129.2 (CH), 
127.9 (CH), 127.2 (CH), 126.9 (CH), 123.9 (Cq), 121.2 (CH), 121.0 (CH), 110.0 (CH), 58.0 (CH2), 29.5 
(CH2). IR (ATR) ν = 3372, 2917, 1615, 1500, 1414, 1200, 984, 744 cm
-1. MS (ESI) m/z (relative 
intensity): 287 (100) [M+Na]+, 265 (30) [M+H]+, 247 (80). HR-MS (ESI) m/z calcd for C17H17N2O 
[M+H]+: 265.1335, found: 265.1336. 
 
 
4-[2-(Pyridin-2-yl)phenyl]but-2-en-1-ol (111ga): The general procedure H was followed using 
2-[2-(pyridin-2-yl)phenyl]propan-2-ol (168g) (53.4 mg, 0.25 mmol) and 4-vinyl-1,3-dioxolan-2-one 
(110a). Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 111ga 
(47.9 mg, 85%, E/Z = 7.2/1.0 by 1H NMR) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.71–8.61 (m, 1H), 7.84–7.65 (m, 1H), 7.43–7.15 (m, 6H), 5.67 (dtt, J = 




0.24H), 3.94 (dq, J = 5.9, 1.2 Hz, 1.76H), 3.53–3.48 (m, 0.24H), 3.45 (dt, J = 6.6, 1.2 Hz, 1.76H), 1.82 
(brs, 1H). 13C NMR (100 MHz, CDCl3) Major isomer: δ = 159.8 (Cq), 149.0 (CH), 140.3 (Cq), 137.7 (Cq), 
136.2 (CH), 131.4 (CH), 130.1 (CH), 130.0 (CH), 129.8 (CH), 128.5 (CH), 126.3 (CH), 124.1 (CH), 121.8 
(CH), 63.3 (CH2), 35.9 (CH2). Minor isomer: δ = 159.9 (Cq), 148.9 (CH), 140.0 (Cq), 138.2 (Cq), 136.5 
(CH), 131.3 (CH), 130.0 (CH), 129.7 (CH), 129.0 (CH), 128.6 (CH), 126.3 (CH), 124.3 (CH), 121.8 (CH), 
58.0 (CH2), 31.1 (CH2). IR (ATR) ν = 3321, 2851, 1586, 1468, 1426, 1092, 972, 753 cm
-1. MS (ESI) m/z 
(relative intensity): 248 (100) [M+Na]+, 226 (70) [M+H]+. HR-MS (ESI) m/z calcd for C15H16NO [M+H]
+: 
226.1226, found: 226.1226. 
 
 
4-Methyl-N-[4-(2-(pyridin-2-yl)phenyl)but-2-en-1-yl)benzenesulfonamide (111gg): The general 
procedure H was followed using 2-[2-(pyridin-2-yl)phenyl]propan-2-ol (168g) (53.4 mg, 0.25 mmol) 
and 3-tosyl-5-vinyloxazolidin-2-one (110g) (133.7 mg, 0.50 mmol). Purification by column 
chromatography on silica gel (Hexane/EtOAc/Et3N: 3/1/0.3) yielded 111gg (81.4 mg, 86%, E/Z = 
3.2/1.0 by 1H NMR) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.68–8.52 (m, 1H), 7.85–7.61 (m, 3H), 7.43–7.09 (m, 8H), 5.09 (dtt, J = 
15.2, 6.3, 1.5 Hz, 1H), 5.21 (dtt, J = 10.4, 7.0, 1.5 Hz, 0.24H), 5.53 (dtt, J = 15.2, 6.7, 1.3 Hz, 0.76H), 
4.99 (t, J = 6.0 Hz, 0.24H), 4.59 (t, J = 6.0 Hz, 0.76H), 3.65–3.26 (m, 4H), 2.39 (s, 0.71H), 2.38 (s, 
2.29H). 13C NMR (125 MHz, CDCl3) Major isomer: δ = 159.6 (Cq), 148.9 (CH), 143.1 (Cq), 140.2 (Cq), 
137.2 (Cq), 136.9 (Cq), 136.1 (CH), 133.3 (CH), 129.9 (CH), 129.7 (CH), 129.5 (CH), 128.3 (CH), 127.0 
(CH), 126.3 (CH), 125.5 (CH), 124.0 (CH), 121.7 (CH), 45.1 (CH2), 35.9 (CH2), 21.5 (CH3). Minor isomer: 
δ = 159.7 (Cq), 148.9 (CH), 143.1 (Cq), 140.0 (Cq), 137.6 (Cq), 137.1 (Cq), 136.4 (CH), 132.7 (CH), 129.9 
(CH), 129.6 (CH), 129.5 (CH), 128.5 (CH), 127.0 (CH), 126.3 (CH), 124.5 (CH), 124.1 (CH), 121.8 (CH), 
39.9 (CH2), 31.2 (CH2), 21.5 (CH3). IR (ATR) ν = 3274, 2922, 1587, 1426, 1325, 1156, 1093, 754, 661, 
550 cm-1. MS (ESI) m/z (relative intensity): 779 (10) [2M+Na]+, 401 (40) [M+Na]+, 379 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C22H22N2O2S [M+H]






4-Methyl-N-{4-[3-methyl-2-(pyridin-2-yl)phenyl]but-2-en-1-yl}benzenesulfon-amide (111hg): The 
general procedure H was followed using 2-[3-methyl-2-(pyridin-2-yl)phenyl]propan-2-ol (168h) (56.8 
mg, 0.25 mmol) and 3-tosyl-5-vinyloxazolidin-2-one (110g) (133.7 mg, 0.50 mmol). Purification by 
column chromatography on silica gel (Hexane/EtOAc/Et3N: 3/1/0.3) yielded 111hg (55.0 mg, 56%, 
E/Z = 2.8/1.0 by 1H NMR) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 9.06–8.55 (m, 1H), 7.72 (td, J = 7.7, 1.8 Hz, 1H), 7.68–7.60 (m, 2H), 
7.35–7.13 (m, 5H), 7.13–7.03 (m, 1H), 7.03–6.93 (m, 1H), 5.45 (dtt, J = 15.3, 6.9, 1.3 Hz, 1H), 5.16 
(dtt, J = 10.6, 7.1, 1.7 Hz, 0.26H), 4.98 (dtt, J = 15.3, 6.4, 1.5 Hz, 0.74H), 4.89 (t, J = 6.0 Hz, 0.26H), 
4.59 (t, J = 6.0 Hz, 0.74H), 3.35 (t, J = 6.0 Hz, 1.47H), 3.25 (t, J = 6.0 Hz, 0.53H), 3.06–2.95 (m, 2H), 
2.40 (s, 0.79H), 2.38 (s, 2.21H), 1.99 (s, 2.21H), 1.97 (s, 0.79H). 13C NMR (125 MHz, CDCl3) Major 
isomer: δ = 159.1 (Cq), 149.4 (CH), 143.1 (Cq), 140.1 (Cq), 137.1 (Cq), 136.9 (Cq), 136.1 (Cq), 136.1 (CH), 
133.1 (CH), 129.5 (CH), 128.1 (CH), 128.0 (CH), 127.0 (CH), 126.8 (CH), 125.3 (CH), 124.6 (CH), 121.8 
(CH), 45.1 (CH2), 36.5 (CH2), 21.5 (CH3), 20.3 (CH3). Minor isomer: δ = 159.1 (Cq), 149.5 (CH), 143.1 
(Cq), 139.9 (Cq), 137.4 (Cq), 137.1 (Cq), 136.2 (CH), 136.1 (Cq), 132.4 (CH), 129.5 (CH), 128.2 (CH), 
128.0 (CH), 126.9 (CH), 126.5 (CH), 124.7 (CH), 124.3 (CH), 121.8 (CH), 39.7 (CH2), 31.7 (CH2), 21.5 
(CH3), 20.3 (CH3). IR (ATR) ν = 3275, 3063, 1570, 1459, 1324, 1155, 1092, 970, 660 cm
-1. MS (ESI) 
m/z (relative intensity): 415 (20) [M+Na]+, 393 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H24N2O2S 
[M+H]+: 393.1631, found: 393.1634. 
 
 
4-[3-Methyl-2-(pyridin-2-yl)phenyl]but-2-en-1-ol (111ha): The general procedure H was followed 
using 2-[3-methyl-2-(pyridin-2-yl)phenyl]propan-2-ol (168h) (56.8 mg, 0.25 mmol) and 




silica gel (n-hexane/EtOAc: 1/3) yielded 111ha (44.9 mg, 75%, E/Z = 3.3/1.0 by 1H NMR) as a 
colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.72–8.64 (m, 1H), 8.79–8.69 (m, 1H), 7.34–7.18 (m, 3H), 7.15–7.04 
(m, 2H), 5.53 (dtt, J = 15.2, 6.6, 1.4 Hz, 0.77H), 5.52–5.43 (m, 0.46H), 5.09 (dtt, J = 15.2, 6.6, 1.4 Hz, 
0.77H), 3.91 (ddd, J = 5.8, 1.1, 1.1 Hz, 1.53H), 3.83 (d, J = 5.8 Hz, 0.47H), 3.15–3.00 (m, 2H), 2.06 (brs, 
1H), 2.01 (s, 3H). 13C NMR (125 MHz, CDCl3) Major isomer: δ = 159.2 (Cq), 149.3 (CH), 140.0 (Cq), 
137.7 (Cq), 136.1 (CH), 136.0 (Cq), 131.1 (CH), 129.9 (CH), 128.1 (CH), 128.0 (CH), 126.8 (CH), 124.7 
(CH), 121.8 (CH), 63.3 (CH2), 36.6 (CH2), 20.3 (CH3). Minor isomer: δ = 159.3 (Cq), 149.5 (CH), 139.9 
(Cq), 137.9 (Cq), 136.2 (CH), 136.1 (Cq), 130.8 (CH), 128.8 (CH), 128.2 (CH), 128.0 (CH), 126.5 (CH), 
124.8 (CH), 121.8 (CH), 58.0 (CH2), 31.7 (CH2), 20.3 (CH3). IR (ATR) ν = 3306, 2917, 1720, 1585, 1459, 
1424, 970, 751 cm-1. MS (ESI) m/z (relative intensity): 501 (50) [2M+Na]+, 262 (45) [M+Na]+, 240 
(100) [M+H]+, 222 (30). HR-MS (ESI) m/z calcd for C16H18NO [M+H]
+: 240.1383, found: 240.1383. 
 
 
4-[3-Methoxy-2-(pyridin-2-yl)phenyl]but-2-en-1-ol (111ia): The general procedure H was followed 
using 2-[3-methoxy-2-(pyridin-2-yl)phenyl]propan-2-ol (168i) (60.8 mg, 0.25 mmol) and 
4-vinyl-1,3-dioxolan-2-one (110a) (48.0 μL, 0.50 mmol). Purification by column chromatography on 
silica gel (Hexane/EtOAc/Et3N: 3/1/0.3) yielded 111ia (37.0 mg, 58%, E/Z = 4.1/1.0 by 
1H NMR) as a 
colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.72–8.58 (m, 1H), 7.76–7.62 (m, 1H), 7.44–7.12 (m, 3H), 6.97–6.74 
(m, 2H), 5.53 (dtt, J = 15.2, 6.8, 1.5 Hz, 0.82H), 5.50–5.45 (m, 0.36H), 5.29 (dtt, J = 15.2, 5.8, 1.3 Hz, 
0.82H), 3.88 (dq, J = 5.9, 1.1 Hz, 1.62H), 3.84 (dq, J = 5.9, 1.1 Hz, 0.38H), 3.67 (s, 3H), 3.16 (d, J = 6.2 
Hz, 0.38H), 3.12 (d, J = 6.2 Hz, 1.62H), 2.38 (brs, 1H). 13C NMR (125 MHz, CDCl3) Major isomer: δ = 
156.9 (Cq), 156.5 (Cq), 149.0 (CH), 139.7 (Cq), 135.6 (CH), 130.7 (CH), 130.0 (CH), 129.5 (Cq), 129.1 
(CH), 125.8 (CH), 121.8 (CH), 121.7 (CH), 108.9 (CH), 63.2 (CH2), 55.8 (CH3), 36.1 (CH2). Minor isomer: 
δ = 156.9 (Cq), 156.5 (Cq), 149.1 (CH), 140.0 (Cq), 135.8 (CH), 130.5 (CH), 129.5 (Cq), 129.2 (CH), 




ν = 3306, 2835, 1579, 1466, 1255, 1061, 971, 780, 745 cm-1. MS (ESI) m/z (relative intensity): 533 
(40) [2M+Na]+, 278 (30) [M+Na]+, 272 (40), 256 (100) [M+H]+. HR-MS (ESI) m/z calcd for C16H18NO2 
[M+H]+: 256.1332, found: 256.1334. 
 
 
1-Phenyl-4-[2-(pyridin-2-yl)phenyl]but-2-en-1-ol (111jb): The general procedure H was followed 
using phenyl [2-(pyridin-2-yl)phenyl]methanol (168j) (65.3 mg, 0.25 mmol) and 
(trans)-4-phenyl-5-vinyl-1,3-dioxolan-2-one (110b) (95.1 mg, 0.50 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3/1) yielded 111jb (56.7 mg, 75%, E/Z = 1.5/1.0 by 
1H NMR) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.67 (ddd, J = 4.9, 1.9, 1.0 Hz, 0.4H), 8.61 (ddd, J = 4.9, 1.9, 1.0 Hz, 
0.6H), 7.73 (td, J = 7.7, 1.8 Hz, 0.4H), 7.62 (td, J = 7.7, 1.8 Hz, 0.6H), 7.44–7.13 (m, 11H), 5.73 (dtd, J 
= 15.2, 6.6, 1.1 Hz, 0.6H), 5.67–5.56 (m, 0.8H), 5.40 (ddt, J = 15.2, 7.0, 1.5 Hz, 1H), 5.01 (d, J = 6.9 Hz, 
0.6H), 3.85–3.73 (m, 0.4H), 3.57–3.44 (m, 1.6H), 2.45 (brs, 1H). 13C NMR (100 MHz, CDCl3) Major 
isomer: δ = 159.6 (Cq), 148.9 (CH), 143.1 (Cq), 140.3 (Cq), 137.6 (Cq), 136.2 (CH), 133.5 (CH), 130.8 
(CH), 130.1 (CH), 129.8 (CH), 128.5 (CH), 128.3 (CH), 127.3 (CH), 126.4 (CH), 126.1 (CH), 124.1 (CH), 
121.7 (CH), 74.7 (CH), 36.0 (CH2). Minor isomer: δ = 159.9 (Cq), 148.9 (CH), 143.5 (Cq), 140.0 (Cq), 
138.1 (Cq), 136.6 (CH), 132.7 (CH), 130.4 (CH), 130.0 (CH), 129.8 (CH), 128.7 (CH), 128.4 (CH), 127.2 
(CH), 126.3 (CH), 125.9 (CH), 124.4 (CH), 121.9 (CH), 69.0 (CH), 31.4 (CH2). IR (ATR) ν = 3311, 3024, 
1586, 1468, 1443, 1023, 969, 750, 699 cm-1. MS (ESI) m/z (relative intensity): 625 (30) [2M+Na]+, 
324 (20) [M+Na]+, 318 (40), 302 (45) [M+H]+, 300 (70), 284 (100). HR-MS (ESI) m/z calcd for 
C21H20NO [M+H]








(E)-1-(5-Methyl-2-styrylphenyl)-1H-pyrazole (74co): The general procedure I was followed using 
phenyl 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol) and 
ethynylbenzene (8o) (51.1 mg, 0.50 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 20/1) yielded 74co (45.0 mg, 69%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.76 (d, J = 1.8 Hz, 1H), 7.67–7.58 (m, 2H), 7.47–7.34 (m, 2H), 7.34–
7.13 (m, 5H), 7.00 (d, J = 16.3 Hz, 1H), 6.90 (d, J = 16.3 Hz, 1H), 6.45 (d, J = 2.1 Hz, 1H), 2.39 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ = 140.5 (CH), 138.5 (Cq), 138.3 (Cq), 137.1 (Cq), 131.4 (CH), 130.3 (Cq), 
129.9 (CH), 129.1 (CH), 128.5 (CH), 127.6 (CH), 126.8 (CH), 126.5 (CH), 126.3 (CH), 123.8 (CH), 106.4 
(CH), 21.1 (CH3). IR (ATR) ν = 3024, 1515, 1449, 1391, 1097, 1042, 951, 813, 753, 691 cm
-1. MS (ESI) 
m/z (relative intensity): 283 (70) [M+Na]+, 261 (100) [M+H]+. HR-MS (ESI) m/z calcd for C18H17N2 
[M+H]+: 261.1386, found: 261.1385.  
The analytical data were in accordance with those reported in the literature.[202] 
 
 
(E)-1-[2-(4-Methoxystyryl)-5-methylphenyl]-1H-pyrazole (74cq): The general procedure I was 
followed using phenyl2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 
mmol) and 1-ethynyl-4-methoxybenzene (8q) (66.1 mg, 0.50 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 74cq (43.0 mg, 59%) as a white solid.  
M.p. = 70–72 °C. 1H NMR (300 MHz, CDCl3) δ = 7.75 (d, J = 1.8 Hz, 1H), 7.66–7.57 (m, 2H), 7.35–7.27 
(m, 2H), 7.26–7.14 (m, 2H), 6.94 (d, J = 16.3 Hz, 1H), 6.88–6.80 (m, 2H), 6.75 (d, J = 16.3 Hz, 1H), 
6.44 (dd, J = 2.4, 1.8 Hz, 1H), 3.79 (s, 3H), 2.38 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 159.3 (Cq), 
140.4 (CH), 138.3 (Cq), 137.9 (Cq), 131.4 (CH), 130.3 (Cq), 130.0 (Cq), 129.8 (CH), 129.1 (CH), 127.7 
(CH), 126.7 (CH), 126.1 (CH), 121.6 (CH), 114.0 (CH), 106.3 (CH), 55.3 (CH3), 21.0 (CH3). IR (ATR) ν = 




(100) [M+Na]+, 291 (50) [M+H]+. HR-MS (ESI) m/z calcd for C19H19N2O [M+H]




(E)-1-[2-(4-Bromostyryl)-5-methylphenyl]-1H-pyrazole (74cr): The general procedure I was 
followed using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol) and 
1-bromo-4-ethynylbenzene (8r) (90.5 mg, 0.50 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 20/1) yielded 74cr (61.1 mg, 72%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.76 (s, 1H), 7.67–7.54 (m, 2H), 7.45–7.37 (m, 2H), 7.27–7.18 (m, 4H), 
6.92 (d, J = 16.3 Hz, 1H), 6.86 (d, J = 16.3 Hz, 1H), 6.45 (d, J = 2.1 Hz, 1H), 2.39 (s, 3H). 13C NMR (125 
MHz, CDCl3) δ = 140.6 (Cq), 138.6 (Cq), 138.5 (Cq), 136.0 (CH), 131.6 (CH), 131.3 (CH), 129.6 (Cq), 
129.1 (CH), 128.8 (CH), 127.9 (CH), 126.8 (CH), 126.2 (CH), 124.5 (CH), 121.3 (Cq), 106.5 (CH), 21.0 
(CH3). IR (ATR) ν = 3026, 2918, 1613, 1515, 1485, 1390, 1191, 1071, 950, 750 cm
-1. MS (ESI) m/z 
(relative intensity): 363 (30) [M+Na]+ (81Br), 361 (30) [M+Na]+ (79Br), 341 (100) [M+H]+ (81Br), 339 
(100) [M+H]+ (79Br). HR-MS (ESI) m/z calcd for C18H16N2
81Br [M+H]+: 341.0472, found: 341.0474, 
C18H16N2
79Br [M+H]+: 339.0491, found: 339.0491. 
 
 
(E)-1-[2-(2-Fluorostyryl)-5-methylphenyl]-1H-pyrazole (74cs): The general procedure I was followed 
using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol) and 
1-ethynyl-2-fluorobenzene (8s) (60.1 mg, 0.50 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 20/1) yielded 74cs (60.5 mg, 87%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.68 (s, 1H), 7.63–7.53 (m, 2H), 7.33 (td, J = 7.7, 1.7 Hz, 1H), 7.22–7.07 
(m, 4H), 7.01–6.87 (m, 3H), 6.38 (s, 1H), 2.32 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 160.3 (d, 
1JC-F = 
251.3 Hz, Cq), 138.8 (Cq), 138.7 (Cq), 129.8 (Cq), 125.1 (d, 




128.9 (d, 3JC-F = 8.4 Hz, CH), 126.9 (d, 
4JC-F = 3.6 Hz, CH), 126.7 (CH), 126.4 (CH), 126.4 (CH), 125.9 (d, 
3JC-F = 4.8 Hz, CH), 124.1 (d, 
4JC-F = 3.7 Hz, CH), 122.2 (d, 
3JC-F = 3.8 Hz, CH), 115.6 (d, 
2JC-F = 22.2 Hz, 
CH), 106.5 (CH), 20.9 (CH3). 
19F NMR (282 MHz, CDCl3) δ = -118.13 (ddd, J = 10.8, 7.7, 5.3 Hz). IR 
(ATR) ν = 3065, 1615, 1516, 1455, 1230, 1095, 1038, 950, 751 cm-1. MS (ESI) m/z (relative intensity): 
301 (30) [M+Na]+, 279 (100) [M+H]+. HR-MS (ESI) m/z calcd for C18H16N2F [M+H]




(E)-1-{5-Methyl-2-[2-(thiophen-3-yl)vinyl]phenyl}-1H-pyrazole (74ct): The general procedure I was 
followed using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol) and 
3-ethynylthiophene (8t) (54.1 mg, 0.50 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 20/1) yielded 74ct (40.2 mg, 60%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.75 (s, 1H), 7.63 (d, J = 2.3 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.28–7.17 
(m, 4H), 7.14 (dd, J = 5.0, 1.3 Hz, 1H), 7.00 (d, J = 16.2 Hz, 1H), 6.73 (d, J = 16.2 Hz, 1H), 6.44 (d, J = 
2.3, 1.8 Hz, 1H), 2.38 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 140.6 (CH), 140.1 (Cq), 138.5 (Cq), 138.3 
(Cq), 131.5 (CH), 130.1 (Cq), 129.3 (CH), 126.9 (CH), 126.2 (CH), 126.1 (CH), 125.0 (CH), 124.5 (CH), 
123.9 (CH), 122.7 (CH), 106.5 (CH), 21.2 (CH3). IR (ATR) ν = 3104, 2918, 1677, 1517, 1401, 1044, 951, 
755, 623 cm-1. MS (ESI) m/z (relative intensity): 289 (20) [M+Na]+, 267 (100) [M+H]+. HR-MS (ESI) 
m/z calcd for C16H15N2S [M+H]
+: 267.0950, found: 267.0949. 
 
 
(E)-1-[2-(dec-1-En-1-yl)-5-methylphenyl]-1H-pyrazole (74cu): The general procedure I was followed 
using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol) and dec-1-yne 
(8u) (69.1 mg, 0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 




1H NMR (400 MHz, CDCl3) δ = 7.65 (d, J = 2.2 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 
7.14 (s, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.36 (t, J = 2.1 Hz, 1H), 6.09 (d, J = 15.7 Hz, 1H), 6.08–6.03 (m, 
1H), 2.29 (s, 3H), 2.05 (td, J = 7.3, 5.4 Hz, 2H), 1.51 (s, 1H), 1.33 (t, J = 7.3 Hz, 2H), 1.28–1.07 (m, 9H), 
0.80 (d, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 140.3 (CH), 137.8 (Cq), 137.4 (Cq), 133.2 (CH), 
131.3 (CH), 130.5 (Cq), 129.0 (CH), 126.7 (CH), 126.5 (CH), 124.8 (CH), 106.1 (CH), 33.1 (CH2), 31.8 
(CH2), 29.4 (CH2), 29.2 (CH2), 29.2 (CH2), 29.1 (CH2), 22.6 (CH2), 20.8 (CH3), 14.0 (CH3). IR (ATR) ν = 
2923, 2853, 1517, 1457, 1042, 950, 748, 624 cm-1. MS (ESI) m/z (relative intensity): 319 (20) 
[M+Na]+, 297 (100) [M+H]+. HR-MS (ESI) m/z calcd for C20H29N2 [M+H]
+: 297.2325, found: 297.2328. 
 
 
(E)-1-[2-(1,2-Diphenylvinyl)-5-methylphenyl]-1H-pyrazole (74ca): The general procedure I was 
followed using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol) and 
1,2-diphenylethyne (8a) (89.1 mg, 0.50 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 20/1) yielded 74ca (60.6 mg, 72%) as a colorless oil.  
1H NMR (600 MHz, CDCl3) δ = 7.40 (d, J = 2.4 Hz, 1H), 7.34 (d, J = 1.8 Hz, 1H), 7.25 (d, J = 7.8 Hz, 1H), 
7.19 (d, J = 1.3 Hz, 1H), 7.12 (dd, J = 7.7, 1.8, Hz, 1H), 7.04–6.91 (m, 8H), 6.89–6.84 (m, 2H), 6.54 (s, 
1H), 6.02 (dd, J = 2.4, 1.8 Hz, 1H), 2.32 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 140.0 (CH), 139.9 (Cq), 
139.2 (Cq), 139.0 (Cq), 138.6 (Cq), 137.2 (Cq), 137.0 (Cq), 131.5 (CH), 130.8 (CH), 130.6 (CH), 129.6 
(CH), 129.3 (CH), 128.8 (CH), 127.9 (CH), 127.8 (CH), 127.2 (CH), 127.1 (CH), 126.8 (CH), 106.2 (CH), 
21.1 (CH3). IR (ATR) ν = 3022, 1517, 1445, 1400, 1100, 952, 826, 747, 695 cm
-1. MS (ESI) m/z 
(relative intensity): 359 (10) [M+Na]+, 337 (100) [M+H]+. HR-MS (ESI) m/z calcd for C24H21N2 [M+H]
+: 
337.1699, found: 337.1700.  







(Z)-1-{2-[1,2-Di(thiophen-2-yl)vinyl]-5-methylphenyl}-1H-pyrazole (74cj): The general procedure I 
was followed using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol) 
and 1,2-di(thiophen-2-yl)ethyne (8j) (95.1 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 20/1) yielded 74cj (47.1 mg, 54%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.60 (d, J = 1.8 Hz, 1H), 7.56 (dd, J = 2.4 Hz, 1H), 7.33 (d, J = 7.9 Hz, 
1H), 7.31–7.27 (m, 2H), 7.20 (dd, J = 7.9, 1.8 Hz, 1H), 7.11 (dd, J = 5.0, 1.2 Hz, 1H), 6.92–6.86 (m, 3H), 
6.83 (dd, J = 3.5, 1.2 Hz, 1H), 6.68 (s, 1H), 6.26 (dd, J = 2.4, 1.8 Hz, 1H), 2.40 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ = 140.4 (Cq), 140.1 (Cq), 140.0 (CH), 139.0 (Cq), 138.7 (Cq), 135.9 (Cq), 131.0 (CH), 
130.7 (CH), 130.3 (Cq), 129.7 (CH), 129.0 (CH), 128.6 (CH), 127.5 (CH), 127.0 (CH), 126.6 (CH), 126.5 
(CH), 126.4 (CH), 121.5 (CH), 106.7 (CH), 21.1 (CH3). IR (ATR) ν = 3098, 1518, 1400, 1036, 950, 841, 
750, 699 cm-1. MS (ESI) m/z (relative intensity): 371 (30) [M+Na]+, 349 (100) [M+H]+, 252 (10). 
HR-MS (ESI) m/z calcd for C20H17N2S2 [M+H]
+: 349.0828, found: 349.0831. 
 
 
(E)-2-(2-Styrylphenyl)pyridine (74jo): The general procedure I was followed using phenyl 
2-[2-(pyridin-2-yl)phenyl]propan-2-ol (168j) (53.3 mg, 0.25 mmol) and ethynylbenzene (8o) (51.1 
mg, 0.50 mmol). Purification by column chromatography on silica gel (DCM: 100% → 
n-hexane/EtOAc: 8/1) yielded 74jo (46.3 mg, 72%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.75 (dt, J = 4.1, 1.2 Hz, 1H), 7.91–7.68 (m, 2H), 7.56 (dd, J = 7.6, 1.6 
Hz, 1H), 7.50–7.34 (m, 5H), 7.34–7.16 (m, 5H), 7.05 (d, J = 16.2 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 
= 158.9 (Cq), 149.5 (CH), 139.6 (Cq), 137.5 (Cq), 135.9 (CH), 135.7 (Cq), 130.2 (CH), 130.0 (CH), 128.6 
(CH), 128.6 (CH), 127.6 (CH), 127.5 (CH), 127.5 (CH), 126.5 (CH), 126.2 (CH), 125.0 (CH), 121.8 (CH). 




537 (20) [2M+Na]+, 515 (30) [2M+H]+, 280 (30) [M+Na]+, 258 (100) [M+H]+. HR-MS (ESI) m/z calcd 
for C19H16N [M+H]
+: 258.1277, found: 258.1277.  
The analytical data were in accordance with those reported in the literature.[77] 
 
 
(E)-2-{2-[4-(tert-Butyl)styryl]phenyl}pyridine (74jv): The general procedure I was followed using 
phenyl 2-(2-(pyridin-2-yl)phenyl)propan-2-ol (168j) (53.3 mg, 0.25 mmol) and 
1-(tert-butyl)-4-ethynylbenzene (8v) (79.2 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 10/1) yielded 74jv (62.7 mg, 80%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.75 (ddd, J = 4.8, 1.9, 1.0 Hz, 1H), 7.70 (dd, J = 7.7, 1.6 Hz, 1H), 7.75 
(dd, J = 7.7, 1.2 Hz, 1H), 7.55 (dd, J = 7.4, 1.6 Hz, 1H), 7.44 (ddd, J = 7.8, 1.2, 1.0 Hz, 1H), 7.41 (dd, J = 
7.6, 1.6 Hz, 1H), 7.37 (dd, J = 7.4, 1.6 Hz, 1H), 7.34–7.31 (m, 4H), 7.26 (ddd, J = 7.4, 4.8, 1.2 Hz, 1H), 
7.20 (d, J = 16.2 Hz, 1H), 7.04 (d, J = 16.2 Hz, 1H), 1.31 (s, 9H). 13C NMR (100 MHz, CDCl3) δ = 158.9 
(Cq), 150.7 (Cq), 149.5 (CH), 139.5 (Cq), 135.9 (CH), 135.9 (Cq), 135.0 (Cq), 130.2 (CH), 129.9 (CH), 
128.6 (CH), 127.5 (CH), 126.8 (CH), 126.3 (CH), 126.2 (CH), 125.5 (CH), 125.1 (CH), 121.8 (CH), 34.6 
(Cq), 31.2 (CH3). IR (ATR) ν = 2961, 1584, 1460, 1424, 1268, 965, 818, 750 cm
-1. MS (ESI) m/z (relative 





(S,E)-Methyl 2-{4-[2-(pyridin-2-yl)styryl]benzamido}propanoate (74jw): The general procedure I 
was followed at 120 °C using phenyl 2-(2-(pyridin-2-yl)phenyl)propan-2-ol (168j) (53.3 mg, 0.25 
mmol) and (S)-methyl 2-(4-ethynylbenzamido)propanoate (8w) (115.6 mg, 0.50 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 4/1) yielded 74jw (60.0 mg, 62%) as a 




1H NMR (300 MHz, CDCl3) δ = 8.73 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.90–7.67 (m, 4H), 7.64–7.50 (m, 
1H), 7.49─7.32 (m, 5H), 7.32–7.20 (m, 2H), 7.04 (d, J = 16.2 Hz, 1H), 6.76 (d, J = 7.2 Hz, 1H), 4.77 (dt, 
J = 14.4, 7.2 Hz, 1H), 3.76 (s, 3H), 1.49 (d, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 173.5 (Cq), 
166.2 (Cq), 158.6 (Cq), 149.4 (CH), 140.9 (Cq), 139.7 (Cq), 136.0 (CH), 135.1 (Cq), 132.4 (Cq), 130.2 (CH), 
129.6 (CH), 128.7 (CH), 128.6 (CH), 128.0 (CH), 127.3 (CH), 126.5 (CH), 126.2 (CH), 124.8 (CH), 121.9 
(CH), 52.5 (CH), 48.5 (CH3), 18.7 (CH3). IR (ATR) ν = 3323, 2951, 1742, 1641, 1536, 1501, 1458, 1213, 
1167, 752 cm-1. MS (ESI) m/z (relative intensity): 795 (10) [2M+Na]+, 773 (30) [M+H]+, 409 (10) 
[M+Na]+, 387 (100) [M+H]+. HR-MS (ESI) m/z calcd for C24H23N2O3 [M+H]





14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (74jx): The general procedure I 
was followed at 80 °C using phenyl 2-(2-(pyridin-2-yl)phenyl)propan-2-ol (168j) (53.3 mg, 0.25 
mmol) and 
(8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-6,7,8,9,10,11,12,13,14,15,16,17- 
dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (8x) (149.2 mg, 0.50 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 74jx (62.4 mg, 55%) as a 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.65 (dd, J = 4.9, 1.8 Hz, 1H), 7.68 (td, J = 7.9, 1.8 Hz, 1H), 7.54 (dd, J = 
7.5, 1.8 Hz, 1H), 7.46 (dd, J = 7.5, 1.8 Hz, 1H), 7.39 (dt, J = 7.9, 1.2 Hz, 1H), 7.37–7.27 (m, 2H), 7.22 
(ddd, J = 7.5, 4.9, 1.2 Hz, 1H), 6.57 (d, J = 16.0 Hz, 1H), 6.26 (d, J = 16.0 Hz, 1H), 5.80 (s, 1H), 2.50–
2.32 (m, 2H), 2.30–2.15 (m, 3H), 2.10–2.00 (m, 1H), 1.97–1.75 (m, 5H), 1.62–1.43 (m, 3H), 1.41–1.15 
(m, 5H), 1.07–0.97 (m, 1H), 0.94 (s, 3H), 0.84–0.70 (m, 1H). 13C NMR (100 MHz, CDCl3) δ = 199.8 (Cq), 
166.5 (Cq), 159.0 (Cq), 149.3 (CH), 139.2 (Cq), 136.4 (CH), 135.9 (CH), 135.6 (Cq), 130.0 (CH), 128.5 
(CH), 127.4 (CH), 127.1 (CH), 126.6 (CH), 124.7 (CH), 124.5 (CH), 121.8 (CH), 84.0 (Cq), 49.2 (CH), 




26.5 (CH2), 26.1 (CH2), 23.3 (CH2), 14.1 (CH3). IR (ATR) ν = 3436, 2927, 2867, 1660, 1461, 1425, 1260, 
1014, 910, 730 cm-1. MS (ESI) m/z (relative intensity): 907 (30) [2M+H]+, 476 (15) [M+Na]+, 454 (100) 
[M+H]+, 436 (30). HR-MS (ESI) m/z calcd for C31H36NO2 [M+H]
+: 454.2741, found: 454.2747. 
 
 
3-[2-(1H-Pyrazol-1-yl)phenyl]-1-methylpyrrolidine-2,5-dione (102af): The general procedure J was 
followed using 2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (50.6 mg, 0.25 mmol) and 
1-methyl-1H-pyrrole-2,5-dione (11f) (55.6 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 3/2) yielded 102af (43.4 mg, 68%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.70 (d, J = 2.4 Hz, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.43–7.36 (m, 2H), 
7.34–7.29 (m, 1H), 7.29–7.23 (m, 1H), 6.41 (dd, J = 2.4, 1.8 Hz, 1H), 4.12 (dd, J = 9.6, 5.6 Hz, 1H), 
3.07 (dd, J = 18.4, 9.6 Hz, 1H), 2.92 (s, 3H), 2.82 (dd, J = 18.4, 5.6 Hz, 1H). 13C NMR (100 MHz, CDCl3) 
δ = 177.5 (Cq), 176.2 (Cq), 140.8 (CH), 139.6 (Cq), 133.0 (Cq), 131.2 (CH), 129.9 (CH), 129.0 (CH), 
128.7 (CH), 126.6 (CH), 107.1 (CH), 43.3 (CH), 37.8 (CH2), 25.1 (CH3). IR (ATR) ν = 3136, 1694, 1518, 
1435, 1382, 1280, 1144, 1003, 760 cm-1. MS (ESI) m/z (relative intensity): 533 (100) [2M+Na]+, 278 
(70) [M+Na]+, 256 (40) [M+H]+. HR-MS (ESI) m/z calcd for C14H14N3O2 [M+H]




1-Methyl-3-[2-(pyridin-2-yl)phenyl]pyrrolidine-2,5-dione (102jf): The general procedure J was 
followed using phenyl 2-(2-(pyridin-2-yl)phenyl)propan-2-ol (168j) (53.3 mg, 0.25 mmol) and 
1-methyl-1H-pyrrole-2,5-dione (11f) (55.6 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 1/1) yielded 102jf (60.6 mg, 91%) as a colorless oil.  
1H NMR (600 MHz, CDCl3) δ = 8.52 (d, J = 4.8 Hz, 1H), 7.75 (t, J = 7.8 Hz, 1H), 7.54 (dd, J = 7.8, 1.0 Hz, 




J = 18.4, 9.6 Hz, 1H), 2.92 (s, 3H), 2.89 (dd, J = 18.4, 9.6 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ = 178.3 
(Cq), 176.5 (Cq), 158.9 (Cq), 148.4 (CH), 140.0 (Cq), 136.8 (CH), 135.4 (Cq), 130.5 (CH), 129.4 (CH), 
129.0 (CH), 127.9 (CH), 124.1 (CH), 122.0 (CH), 44.9 (CH), 38.6 (CH2), 25.0 (CH3). IR (ATR) ν = 3057, 
1696, 1436, 1382, 1282, 1120, 953, 757 cm-1. MS (ESI) m/z (relative intensity): 555 (100) [2M+Na]+, 
289 (70) [M+Na]+, 267 (90) [M+H]+. HR-MS (ESI) m/z calcd for C16H15N2O2 [M+H]
+: 267.1128, found: 
267.1126.  
The analytical data were in accordance with those reported in the literature.[204] 
 
 
1-Methyl-3-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]pyrrolidine-2,5-dione (102cf): The general 
procedure J was followed using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 
0.25 mmol) and 1-methyl-1H-pyrrole-2,5-dione (11f) (55.6 mg, 0.50 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 102cf (43.1 mg, 64%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.73 (d, J = 2.2 Hz, 1H), 7.64 (d, J = 1.8 Hz, 1H), 7.24 (dd, J = 7.8, 1.3 Hz, 
1H), 7.20–7.14 (m, 2H), 6.44 (dd, J = 2.2, 1.8 Hz, 1H), 4.10 (dd, J = 9.6, 5.6 Hz, 1H), 3.09 (dd, J = 18.4, 
9.6 Hz, 1H), 2.96 (s, 3H), 2.83 (dd, J = 18.4, 5.6 Hz, 1H), 2.40 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 
177.7 (Cq), 176.3 (Cq), 140.7 (CH), 139.4 (Cq), 139.0 (Cq), 131.1 (CH), 129.9 (Cq), 129.7 (CH), 129.6 
(CH), 127.2 (CH), 106.9 (CH), 42.9 (CH), 37.8 (CH2), 25.1 (CH3), 20.8 (CH3). IR (ATR) ν = 3118, 2924, 
1694, 1434, 1381, 1279, 1118, 950, 757 cm-1. MS (ESI) m/z (relative intensity): 561 (30) [2M+Na]+, 
292 (100) [M+Na]+, 270 (80) [M+H]+. HR-MS (ESI) m/z calcd for C15H16N3O2 [M+H]




1-Ethyl-3-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]pyrrolidine-2,5-dione (102cg): The general 




0.25 mmol) and 1-ethyl-1H-pyrrole-2,5-dione (11g) (62.6 mg, 0.50 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 102cg (44.0 mg, 62%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.76 (d, J = 2.4 Hz, 1H), 7.66 (d, J = 1.8 Hz, 1H), 7.24 (dd, J = 7.8, 1.8 Hz, 
1H), 7.19 (d, J = 1.3 Hz, 1H), 7.15 (d, J = 7.8 Hz, 1H), 6.45 (dd, J = 2.4, 1.8 Hz, 1H), 4.09 (dd, J = 9.6, 
5.6 Hz, 1H), 3.55 (qd, J = 7.2, 3.7 Hz, 2H), 3.07 (dd, J = 18.4, 9.6 Hz, 1H), 2.76 (dd, J = 18.4, 5.6 Hz, 
1H), 2.40 (s, 3H), 1.19 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 177.4 (Cq), 175.9 (Cq), 140.7 
(CH), 139.4 (Cq), 138.8 (Cq), 131.1 (CH), 129.9 (Cq), 129.7 (CH), 129.1 (CH), 127.1 (CH), 106.9 (CH), 
42.7 (CH), 37.8 (CH2), 34.0 (CH2), 20.9 (CH3), 13.0 (CH3). IR (ATR) ν = 3119, 2939, 1698, 1402, 1351, 
1222, 1126, 1044, 752 cm-1. MS (ESI) m/z (relative intensity): 589 (40) [2M+Na]+, 306 (98) [M+Na]+, 
284 (100) [M+H]+. HR-MS (ESI) m/z calcd for C16H18N3O2 [M+H]
+: 284.1394, found: 284.1395. 
 
 
3-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-methylphenyl]-1-methylpyrrolidine-2,5-dione (102kf): The 
general procedure J was followed using 
2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-methylphenyl]propan-2-ol (168k) (61.1 mg, 0.25 mmol) and 
1-methyl-1H-pyrrole-2,5-dione (11f) (55.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 1/1) yielded 102kf (60.0 mg, 85%) as a white solid.  
M.p. = 127–129 °C. 1H NMR (300 MHz, CDCl3) δ = 7.23–7.12 (m, 2H), 7.00 (dt, J = 1.5, 0.7 Hz, 1H), 
5.87 (s, 1H), 3.83 (dd, J = 8.6, 6.5 Hz, 1H), 3.00 (s, 1H), 2.98 (d, J = 3.3 Hz, 1H), 2.81 (s, 3H), 2.34 (s, 
3H), 2.16 (s, 3H), 2.09 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 177.3 (Cq), 176.1 (Cq), 148.8 (Cq), 141.3 
(Cq), 138.6 (Cq), 137.9 (Cq), 132.6 (Cq), 130.2 (CH), 130.0 (CH), 129.2 (CH), 105.6 (CH), 43.4 (CH), 37.9 
(CH2), 25.0 (CH3), 20.9 (CH3), 13.4 (CH3), 11.5 (CH3). IR (ATR) ν = 2925, 1693, 1433, 1283, 1119, 835, 
778, 689 cm-1. MS (ESI) m/z (relative intensity): 320 (40) [M+Na]+, 298 (100) [M+H]+. HR-MS (ESI) 
m/z calcd for C17H20N3O2 [M+H]






3-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]-1-methylpyrrolidine-2,5-dione (102lf): The general 
procedure J was followed using 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]propan-2-ol (168l) (57.6 
mg, 0.25 mmol) and 1-methyl-1H-pyrrole-2,5-dione (11f) (55.5 mg, 0.50 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 102lf (58.1 mg, 82%) as a white 
solid.  
M.p. = 100–102 °C. 1H NMR (400 MHz, CDCl3) δ = 7.43–7.33 (m, 2H), 7.32–7.13 (m, 2H), 5.88 (s, 1H), 
3.88 (dd, J = 9.0, 6.1 Hz, 1H), 3.15–2.89 (m, 2H), 2.80 (s, 3H), 2.15 (s, 3H), 2.08 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ = 177.2 (Cq), 176.1 (Cq), 148.9 (Cq), 141.4 (Cq), 138.1 (Cq), 135.8 (Cq), 130.6 (CH), 129.3 
(CH), 128.6 (CH), 128.5 (CH), 105.8 (CH), 43.8 (CH), 37.7 (CH2), 24.9 (CH3), 13.3 (CH3), 11.4 (CH3). IR 
(ATR) ν = 1691, 1508, 1436, 1380, 1279, 1121, 951, 766 cm-1. MS (ESI) m/z (relative intensity): 306 
(70) [M+Na]+, 284 (100) [M+H]+. HR-MS (ESI) m/z calcd for C16H18N3O2 [M+H]




4-[4-Methyl-2-(1H-pyrazol-1-yl)phenyl]butan-2-one (102ch): The general procedure J was followed 
using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol) and 
but-3-en-2-one (11h) (35.1 mg, 0.50 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 4/1) yielded 102ch (43.4 mg, 76%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.67 (d, J = 1.3 Hz, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.20–7.07 (m, 3H), 
6.40 (t, J = 2.1 Hz, 1H), 2.75 (t, J = 7.6 Hz, 2H), 2.53 (t, J = 7.6 Hz, 2H), 2.33 (s, 3H), 2.02 (s, 3H). 13C 
NMR (125 MHz, CDCl3) δ = 207.6 (Cq), 140.1 (CH), 139.3 (Cq), 136.8 (Cq), 133.7 (Cq), 130.4 (CH), 
130.2 (CH), 129.3 (CH), 127.0 (CH), 106.2 (CH), 44.4 (CH2), 29.8 (CH3), 25.5 (CH2), 20.7 (CH3). IR (ATR) 
ν = 2923, 1713, 1516, 1405, 1162, 1044, 951, 817, 754, 623 cm-1. MS (ESI) m/z (relative intensity): 





229.1335, found: 229.1344. 
 
 
Methyl 2-[2-(1H-pyrazol-1-yl)benzyl]acrylate (202aa): The general procedure K was followed using 
2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (50.6 mg, 0.25 mmol) and methyl 
2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate (201a) (108.1 mg, 0.50 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 4/1) yielded 202aa (48.3 mg, 80%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.68 (dd, J = 1.9, 0.7 Hz, 1H), 7.57 (dd, J = 2.4, 0.7 Hz, 1H), 7.38–7.28 
(m, 4H), 6.39 (dd, J = 2.4, 1.9 Hz, 1H), 6.13 (td, J = 1.2, 1.0 Hz, 1H), 5.20 (td, J = 1.5, 1.3 Hz, 1H), 3.67 
(s, 3H), 3.62 (dd, J = 1.5, 1.0 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ = 166.9 (Cq), 140.3 (CH), 139.8 (Cq), 
138.7 (Cq), 134.4 (Cq), 130.9 (CH), 130.6 (CH), 128.5 (CH), 127.3 (CH), 126.6 (CH), 126.5 (CH2), 106.2 
(CH), 51.9 (CH3), 33.5 (CH2). IR (ATR) ν = 2950, 1716, 1517, 1394, 1194, 1138, 1045, 939, 751 cm
-1. 
MS (ESI) m/z (relative intensity): 265 (75) [M+Na]+, 243 (100) [M+H]+, 211 (15). HR-MS (ESI) m/z 
calcd for C14H15N2O2 [M+H]
+: 243.1128, found: 243.1126. 
 
 
Methyl 2-[4-methyl-2-(1H-pyrazol-1-yl)benzyl]acrylate (202ca): The general procedure K was 
followed using 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (53.8 mg, 0.25 mmol) and 
methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate (201a) (108.1 mg, 0.50 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 202ca (46.1 mg, 72%) as a 
colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.67 (dd, J = 1.9, 0.7 Hz, 1H), 7.56 (dd, J = 2.3, 0.7 Hz, 1H), 7.20–7.11 
(m, 3H), 6.37 (dd, J = 2.3, 1.9 Hz, 1H), 6.11 (td, J = 1.9, 0.5 Hz, 1H), 5.20 (td, J = 1.5, 1.4 Hz, 1H), 3.66 
(s, 3H), 3.57 (dd, J = 1.5, 1.1 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ = 167.1 (Cq), 140.3 (CH), 139.7 (Cq), 
139.1 (Cq), 137.3 (Cq), 131.1 (Cq), 130.8 (CH), 130.6 (CH), 129.3 (CH), 127.2 (CH), 126.4 (CH2), 106.2 




753 cm-1. MS (ESI) m/z (relative intensity): 279 (100) [M+Na]+, 257 (50) [M+H]+, 225 (45), 197 (10). 
HR-MS (ESI) m/z calcd for C15H17N2O2 [M+H]
+: 257.1285, found: 257.1280. 
 
 
Methyl 2-[4-chloro-2-(1H-pyrazol-1-yl)benzyl]acrylate (202ma): The general procedure K was 
followed using 2-[4-chloro-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168m) (59.2 mg, 0.25 mmol) and 
methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate (201a) (108.1 mg, 0.50 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 202ma (57.3 mg, 83%) as a 
colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.68 (dd, J = 1.9, 0.7 Hz, 1H), 7.56 (dd, J = 2.4, 0.7 Hz, 1H), 7.30–7.28 
(m, 1H), 7.27–7.21 (m, 2H), 6.39 (dd, J = 2.4, 1.9 Hz, 1H), 6.16 (td, J = 1.9, 0.5 Hz, 1H), 5.27 (td, J = 
1.5, 1.2 Hz, 1H), 3.67 (s, 3H), 3.59 (s, 2H). 13C NMR (125 MHz, CDCl3) δ = 166.6 (Cq), 140.6 (CH), 
138.3 (Cq), 138.0 (Cq), 136.4 (Cq), 134.1 (Cq), 130.7 (CH), 130.6 (CH), 127.8 (CH), 127.4 (CH), 127.2 
(CH2), 106.6 (CH), 52.0 (CH3), 33.4 (CH2). IR (ATR) ν = 2932, 1717, 1517, 1490, 1394, 1195, 1142, 939, 
819, 753 cm-1. MS (ESI) m/z (relative intensity): 299 (70) [M+Na]+, 277 (100) [M+H]+, 245 (10). 
HR-MS (ESI) m/z calcd for C14H14ClN2O2 [M+H]
+: 277.0738, found: 277.0742. 
 
 
Methyl 2-[5-methyl-2-(1H-pyrazol-1-yl)benzyl]acrylate (202ba): The general procedure K was 
followed using 2-[5-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168b) (54.1 mg, 0.25 mmol) and 
methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate (201a) (108.1 mg, 0.50 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 6/1) yielded 202ba (54.4 mg, 85%) as a 
colorless oil.  




(m, 1H), 7.13–7.07 (m, 2H), 6.36 (dd, J = 2.3, 1.9 Hz, 1H), 6.13 (td, J = 2.0, 0.5 Hz, 1H), 5.21 (td, J = 
1.5, 1.3 Hz, 1H), 3.67 (s, 3H), 3.56 (m, 2H), 2.35 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 167.1 (Cq), 
140.2 (CH), 138.9 (Cq), 138.5 (Cq), 137.6 (Cq), 134.2 (Cq), 131.5 (CH), 130.7 (CH), 128.0 (CH), 126.6 
(CH2), 126.5 (CH), 106.1 (CH), 51.8 (CH3), 33.3 (CH2), 21.1 (CH3). IR (ATR) ν = 2949, 1717, 1519, 1436, 
1395, 1201, 1143, 819, 752 cm-1. MS (ESI) m/z (relative intensity): 279 (45) [M+Na]+, 257 (100) 
[M+H]+, 225 (10). HR-MS (ESI) m/z calcd for C15H17N2O2 [M+H]
+: 257.1285, found: 257.1294. 
 
 
Methyl 2-[2-(1H-pyrazol-1-yl)-5-(trifluoromethyl)benzyl]acrylate (202na): The general procedure K 
was followed using 2-[2-(1H-pyrazol-1-yl)-5-(trifluoromethyl)phenyl]propan-2-ol (168n) (53.8 mg, 
0.25 mmol) and methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate (201a) (108.1 mg, 0.50 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 202na (34.3 mg, 
57%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.72 (dd, J = 1.8, 0.6 Hz, 1H), 7.63 (dd, J = 2.4, 0.6 Hz, 1H), 7.60–7.55 
(m, 2H), 7.47–7.41 (m, 1H), 6.44 (dd, J = 2.4, 1.8 Hz, 1H), 6.17 (td, J = 1.9, 0.5 Hz, 1H), 5.25 (td, J = 
1.5, 1.1 Hz, 1H), 3.73 (dd, J = 1.5, 1.0 Hz, 2H), 3.68 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 166.5 (Cq), 
142.5 (Cq), 141.0 (CH), 137.9 (Cq), 135.2 (Cq), 130.6 (CH), 130.4 (q, 
2JC–F = 32.7 Hz, Cq), 128.1 (q, 
3JC–F 
= 3.6 Hz, CH), 127.2 (CH2), 126.8 (CH), 124.4 (q, 
3JC–F = 3.6 Hz, CH), 123.6 (q, 
1JC–F = 273.5 Hz, Cq), 
107.0 (CH), 52.0 (CH3), 33.7 (CH2). 
19F NMR (282 MHz, CDCl3) δ = -62.58 (s). IR (ATR) ν = 2953, 1718, 
1522, 1395, 1335, 1126, 940, 753 cm-1. MS (ESI) m/z (relative intensity): 333 (100) [M+Na]+, 311 (70) 









Methyl 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)benzyl]acrylate (202la): The general procedure K was 
followed using 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]propan-2-ol (168l) (57.6 mg, 0.25 mmol) 
and methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate (201a) (108.1 mg, 0.50 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 4/1) yielded 202la (49.1 mg, 73%) as a 
colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 7.35–7.23 (m, 3H), 7.16 (ddd, J = 7.5, 7.5, 1.2 Hz, 1H), 6.09 (td, J = 1.4, 
0.7 Hz, 1H), 5.91 (s, 1H), 5.20 (td, J = 1.4, 1.4 Hz, 1H), 3.64 (s, 3H), 3.47 (m, 2H), 2.25 (s, 3H), 2.02 (d, 
J = 0.7 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 166.9 (Cq), 148.3 (Cq), 140.2 (Cq), 138.5 (Cq), 138.1 (Cq), 
137.1 (Cq), 130.5 (CH), 128.8 (CH), 128.0 (CH), 127.0 (CH), 126.8 (CH2), 105.1 (CH), 51.8 (CH3), 33.4 
(CH2), 13.6 (CH3), 11.5 (CH3). IR (ATR) ν = 2950, 1719, 1502, 1437, 1204, 1142, 948, 780 cm
-1. MS 
(ESI) m/z (relative intensity): 293 (20) [M+Na]+, 271 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C16H19N2O2 [M+H]
+: 271.1441, found: 271.1450. 
 
 
(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2-[2-(1H-pyrazol-1-yl)benzyl]acrylate (202ab): The 
general procedure K was followed using 2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (50.6 mg, 
0.25 mmol) and (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-{[(tert-butoxycarbonyl)oxy]methyl)} 
acrylate (201b) (136.2 mg, 0.50 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 9/1 → 4/1) yielded 202ab (83.4 mg, 91%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 7.67 (dd, J = 1.9, 0.7 Hz, 1H), 7.56 (dd, J = 2.4, 0.7 Hz, 1H), 7.38–7.25 
(m, 4H), 6.38 (dd, J = 2.4, 1.9 Hz, 1H), 6.12 (td, J = 1.4, 1.3 Hz, 1H), 5.21 (td, J = 1.5, 1.4 Hz, 1H), 4.64 
(td, J = 10.9, 4.4 Hz, 1H), 3.60 (m, 2H), 1.93–1.85 (m, 1H), 1.72–1.53 (m, 3H), 1.50–1.36 (m, 2H), 
1.34–1.25 (m, 1H), 1.07–0.93 (m, 1H), 0.89–082 (m, 4H), 0.79 (d, J = 7.0 Hz, 3H), 0.64 (d, J = 7.0 Hz, 




(CH), 130.6 (CH), 128.4 (CH), 127.2 (CH), 126.5 (CH), 126.2 (CH2), 106.2 (CH), 74.6 (CH), 47.0 (CH), 
40.7 (CH2), 34.2 (CH2), 33.6 (CH2), 31.3 (CH), 26.1 (CH), 23.4 (CH2), 22.0 (CH3), 20.8 (CH3), 16.2 (CH3). 
IR (ATR) ν = 2953, 2924, 2868, 1709, 1517, 1454, 1393, 1252, 1141, 939, 759 cm-1. MS (ESI) m/z 
(relative intensity): 389 (30) [M+Na]+, 367 (100) [M+H]+, 229 (35). HR-MS (ESI) m/z calcd for 
C23H31N2O2 [M+H]
+: 367.2380, found: 367.2377. 
 




A suspension of 2-[2-methyl-6-(1H-pyrazol-1-yl)phenyl]propan-2-ol (203a) (54.1 mg, 0.25 mmol), 
ethynylbenzene (8o) (66.1 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O (1.0 mL) was 
stirred at 120 °C for 16 h under N2. After cooling to ambient temperature, EtOAc (10 mL) was added 
and the mixture was dried over Na2SO4, washed with EtOAc (30 mL) and concentrated in vacuo. 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 204ao (33.9 mg, 
52%) as a colorless oil. 
 
(E)-1-(3-Methyl-2-styrylphenyl)-1H-pyrazole (204ao) 1H NMR (600 MHz, CDCl3) δ = 7.70 (d, J = 1.9 
Hz, 1H), 7.58 (d, J = 2.1 Hz, 1H), 7.36–7.20 (m, 8H), 6.88 (d, J = 16.7 Hz, 1H), 6.36 (dd, J = 2.1, 1.9 Hz, 




137.6 (Cq), 137.1 (Cq), 134.3 (CH), 133.0 (Cq), 131.3 (CH), 130.5 (CH), 128.5 (CH), 127.7 (CH), 127.2 
(CH), 126.3 (CH), 124.5 (CH), 123.1 (CH), 106.3 (CH), 21.2 (CH3). IR (ATR) ν = 3024, 1473, 1393, 1043, 
970, 953, 752 cm-1. MS (ESI) m/z (relative intensity): 363 (10), 283(30) [M+Na]+, 261 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C18H17N2 [M+H]
+: 261.1386, found: 261.1384. 
 
A suspension of 1-(m-tolyl)-1H-pyrazole (20c) (39.6 mg, 0.25 mmol), ethynylbenzene (8o) (66.1 mg, 
0.50 mmol), HOAc (6.0 μL, 40 mol %), [MnBr(CO)5] (13.7 mg, 20.0 mol %) in 1,4-dioxane (1.0 mL) 
was stirred at 100 °C for 16 h under N2. After cooling to ambient temperature, the mixture was 
transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 74co (31.3 mg, 48%) as a 
colorless oil. The data has been reported above. 
 
 
A suspension of 2-[2-methyl-6-(1H-pyrazol-1-yl)phenyl]propan-2-ol (203a) (54.1 mg, 0.25 mmol), 
1-ethynyl-4-methoxybenzene (8q) (66.1 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O 
(1.0 mL) was stirred at 120 °C for 16 h under N2. After cooling to ambient temperature, EtOAc (10 
mL) was added and the mixture was dried over Na2SO4, washed with EtOAc (30 mL) and 
concentrated in vacuo. Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) 
yielded 204aq (43.0 mg, 59%) as a colorless oil. 
 
 
(E)-1-[2-(4-Methoxystyryl)-3-methylphenyl]-1H-pyrazole (204aq) 1H NMR (600 MHz, CDCl3) δ = 
7.70 (dd, J = 1.9, 0.7 Hz, 1H), 7.58 (dd, J = 2.4, 0.7 Hz, 1H), 7.35–7.27 (m, 2H), 7.26–7.20 (m, 3H), 




3.80 (s, 3H), 2.48 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 159.3 (Cq), 140.0 (CH), 139.1 (Cq), 137.5 (Cq), 
133.8 (CH), 133.3 (Cq), 131.3 (CH), 130.4 (CH), 130.0 (Cq), 127.5 (CH), 126.9 (CH), 124.5 (CH), 120.9 
(CH), 114.0 (CH), 106.2 (CH), 55.3 (CH3), 21.3 (CH3). IR (ATR) ν = 2835, 1605, 1509, 1472, 1393, 1247, 
1173, 1031, 752 cm-1. MS (ESI) m/z (relative intensity): 313 (10) [M+Na]+, 291 (100) [M+H]+. HR-MS 
(ESI) m/z calcd for C19H19N2O [M+H]
+: 291.1492, found: 291.1486. 
 
A suspension of 2-[2-methyl-6-(pyridin-2-yl)phenyl]propan-2-ol (203b) (56.8 mg, 0.25 mmol), 
ethynylbenzene (8o) (66.1 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O (1.0 mL) was 
stirred at 120 °C for 16 h under N2. After cooling to ambient temperature, EtOAc (10 mL) was added 
and the mixture was dried over Na2SO4, washed with EtOAc (30 mL) and concentrated in vacuo. 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded 204bo (37.3 mg, 
55%) as a colorless oil. 
 
 
(E)-2-(3-Methyl-2-styrylphenyl)pyridine (204bo) 1H NMR (600 MHz, CDCl3) δ = 8.66 (ddd, J = 4.9, 
1.8, 1.1 Hz, 1H), 7.60 (ddd, J = 7.7, 7.7, 1.8 Hz, 1H), 7.43–7.36 (m, 2H), 7.30–7.23 (m, 6H), 7.22–7.17 
(m, 1H), 7.15 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.10 (d, J = 16.6 Hz, 1H), 6.28 (d, J = 16.6 Hz, 1H), 2.46 (s, 
3H). 13C NMR (125 MHz, CDCl3) δ = 160.1 (Cq), 149.1 (CH), 140.2 (Cq), 137.4 (Cq), 136.6 (Cq), 135.6 
(Cq), 135.5 (CH), 134.9 (CH), 130.4 (CH), 128.4 (CH), 127.9 (CH), 127.3 (CH), 126.9 (CH), 126.7 (CH), 




cm-1. MS (ESI) m/z (relative intensity): 272 (100) [M+H]+. HR-MS (ESI) m/z calcd for C20H18N [M+H]
+: 
272.1434, found: 272.1430. 
 
A suspension of 2-(m-tolyl)pyridine (20d) (42.3 mg, 0.25 mmol), ethynylbenzene (8o) (66.1 mg, 0.50 
mmol), HOAc (9.0 μL, 60 mol %), [MnBr(CO)5] (20.6 mg, 20.0 mol %) in 1,4-dioxane (1.0 mL) was 
stirred at 100 °C for 16 h under N2. After cooling to ambient temperature, the mixture was 
transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by 




(E)-2-(5-Methyl-2-styrylphenyl)pyridine (74do) 1H NMR (400 MHz, CDCl3) δ = 8.77–8.66 (m, 1H), 
7.71 (ddd, J = 7.7, 7.7, 1.6 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.43 (dd, J = 8.0, 1.1 Hz, 1H), 7.38–7.35 (m, 
3H), 7.33–7.15 (m, 6H), 7.00 (d, J = 16.2 Hz, 1H), 2.40 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 158.9 
(Cq), 149.5 (CH), 139.5 (Cq), 137.7 (Cq), 137.6 (Cq), 135.9 (CH), 132.8 (Cq), 130.7 (CH), 129.5 (CH), 
129.2 (CH), 128.6 (CH), 127.4 (CH), 127.3 (CH), 126.5 (CH), 126.2 (CH), 125.1 (CH), 121.8 (CH), 21.2 
(CH3). IR (ATR) ν = 3023, 1585, 1565, 1497, 1462, 964, 750, 693 cm
-1. MS (ESI) m/z (relative 
intensity): 272 [M+H]+. HR-MS (ESI) m/z calcd for C20H18N [M+H]
+: 272.1434, found: 272.1430. 
 
 
A suspension of 2-[2-methyl-6-(pyridin-2-yl)phenyl]propan-2-ol (203b) (56.8 mg, 0.25 mmol), 
methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate (8a) (89.1 mg, 0.50 mmol) and [MnBr(CO)5] 
(6.9 mg, 10.0 mol %) in 1,4-dioxane (1.0 mL) was stirred at 120 °C for 16 h under N2. After cooling to 




and concentrated in vacuo. Purification by column chromatography on silica gel (n-hexane/EtOAc: 
20/1) yielded 204ba (61.4 mg, 71%) as a colorless oil. 
 
 
(E)-2-[2-(1,2-Diphenylvinyl)-3-methylphenyl]pyridine (204ba) 1H NMR (400 MHz, CDCl3) δ = 8.50 
(ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.48 (ddd, J = 7.7, 7.7, 1.8 Hz, 1H), 7.44–7.38 (m, 2H), 7.32 (dd, J = 7.5, 
7.5 Hz, 1H), 7.27 (ddd, J = 7.5, 1.6, 0.7 Hz, 1H), 7.17–7.09 (m, 3H), 7.07–6.94 (m, 8H), 6.49 (s, 1H), 
2.26 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 160.0 (Cq), 148.9 (CH), 142.2 (Cq), 141.2 (Cq), 140.0 (Cq), 
139.6 (Cq), 137.6 (Cq), 137.0 (Cq), 135.1 (CH), 131.9 (CH), 130.4 (CH), 129.9 (CH), 128.9 (CH), 127.9 
(CH), 127.6 (CH), 127.5 (CH), 127.3 (CH), 126.7 (CH), 126.6 (CH), 124.3 (CH), 121.1 (CH), 20.8 (CH3). 
IR (ATR) ν = 3055, 3020, 1586, 1492, 1444, 909, 772, 732, 695 cm-1. MS (ESI) m/z (relative intensity): 
348 (100) [M+H]+. HR-MS (ESI) m/z calcd for C26H22N [M+H]
+: 348.1747, found: 348.1744. 
 
 
A suspension of 2-[2-methyl-6-(1H-pyrazol-1-yl)phenyl]propan-2-ol (203a) (54.1 mg, 0.25 mmol), 
methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate (201a) (108.1 mg, 0.50 mmol), [MnBr(CO)5] 
(6.9 mg, 10.0 mol %) in 1,4-dioxane (1.0 mL) was stirred at 120 °C for 16 h under N2. After cooling to 
ambient temperature, the mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) 
and concentrated in vacuo. Purification by column chromatography on silica gel (n-hexane/EtOAc: 






Methyl 2-[2-methyl-6-(1H-pyrazol-1-yl)benzyl]acrylate (205aa) 1H NMR (600 MHz, CDCl3) δ = 7.63 
(dd, J = 1.8, 0.7 Hz, 1H), 7.45 (dd, J = 2.4, 0.7 Hz, 1H), 7.25–7.21 (m, 2H), 7.18 (dd, J = 6.6, 2.4 Hz, 1H), 
6.33 (dd, J = 2.4, 1.8 Hz, 1H), 6.14 (td, J = 1.8, 0.9 Hz, 1H), 5.04 (td, J = 1.1, 0.9 Hz, 1H), 3.71 (s, 3H), 
3.46 (dd, J = 1.8, 1.1 Hz, 2H), 2.26 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 167.0 (Cq), 140.7 (Cq), 140.2 
(CH), 138.8 (Cq), 138.4 (Cq), 132.7 (Cq), 130.6 (CH), 130.6 (CH), 127.1 (CH), 124.9 (CH2), 124.7 (CH), 
106.0 (CH), 52.0 (CH3), 30.1 (CH2), 19.7 (CH3). IR (ATR) ν = 2950, 1715, 1516, 1394, 1278, 1255, 1135, 
947, 749 cm-1. MS (ESI) m/z (relative intensity): 279 (65) [M+Na]+, 257 (100) [M+H]+, 225 (10). 
HR-MS (ESI) m/z calcd for C15H17N2O2 [M+H]
+: 257.1285, found: 257.1280. 
 
 
A suspension of 2-[2-methyl-6-(1H-pyrazol-1-yl)phenyl]propan-2-ol (203a) (54.0 mg, 0.25 mmol), 
(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-{[(tert-butoxycarbonyl)oxy]methyl)} acrylate (201b) 
(136.2 mg, 0.50 mmol), and [MnBr(CO)5] (6.9 mg, 10.0 mol %) in 1,4-dioxane (1.0 mL) was stirred at 
120 °C for 16 h under N2. After cooling to ambient temperature, the mixture was transferred into a 
round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 




(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2-[2-methyl-6-(1H-pyrazol-1-yl)benzyl]acrylate (205ab) 




(m, 3H), 6.34–6.30 (m, 1H), 6.11 (td, J = 1.7, 1.2 Hz, 1H), 5.02 (td, J = 2.1, 1.2 Hz, 1H), 4.71 (ddd, J = 
10.9, 10.9, 4.4 Hz, 1H), 3.45 (dd, J = 2.1, 1.7 Hz, 2H), 2.28 (s, 3H), 2.01–1.94 (m, 1H), 1.75 (heptd, J = 
6.9, 2.7 Hz, 1H), 1.70–1.61 (m, 2H), 1.48 (tdt, J = 12.0, 6.7, 3.3 Hz, 1H), 1.40–1.34 (m, 1H), 1.10–1.00 
(m, 1H), 0.96 (td, J = 12.1, 10.9 Hz, 1H), 0.88 (d, J = 6.6 Hz, 3H), 0.86–0.84 (m, 4H), 0.72 (d, J = 6.9 Hz, 
3H). 13C NMR (125 MHz, CDCl3) δ = 166.1 (Cq), 140.6 (Cq), 140.1 (CH), 139.1 (Cq), 138.7 (Cq), 133.2 
(Cq), 130.7 (CH), 130.6 (CH), 127.0 (CH), 124.7 (CH), 124.4 (CH2), 105.9 (CH), 74.7 (CH), 47.1 (CH), 
40.8 (CH2), 34.3 (CH2), 31.4 (CH), 30.1 (CH2), 26.5 (CH), 23.6 (CH2), 22.1 (CH3), 20.8 (CH3), 19.7 (CH3), 
16.5 (CH3). IR (ATR) ν = 2953, 2927, 2869, 1708, 1516, 1476, 1393, 1250, 1132, 746 cm
-1. MS (ESI) 
m/z (relative intensity): 783 (58) [2M+Na]+, 403 (60) [M+Na]+, 381 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C24H33N2O2 [M+H]
+: 381.2537, found: 381.2533. 
 
 
A suspension of 2-[2-methyl-6-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (54.1 mg, 0.25 mmol), 
4-vinyl-1,3-dioxolan-2-one (110a) (48.0 μL, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O 
(1.0 mL) was stirred at 120 °C for 16 h under N2. After cooling to ambient temperature, EtOAc (10 
mL) was added and the mixture was dried over Na2SO4, washed with EtOAc (30 mL) and 
concentrated in vacuo. Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1) 







4-[2-Methyl-6-(1H-pyrazol-1-yl)phenyl]but-2-en-1-ol (206) 1H NMR (600 MHz, CDCl3) δ = 7.71–7.69 
(J = 1.9, 0.7 Hz, 0.14H), 7.66 (J = 1.9, 0.7 Hz, 0.86H), 7.57–7.49 (m, 1H), 7.25–7.09 (m, 3H), 6.41 (dd, 
J = 2.1, 1.9 Hz, 0.14H), 6.37 (dd, J = 2.1, 1.9 Hz, 0.86H), 5.64 (dtt, J = 15.4, 6.4, 1.4 Hz, 0.86H), 5.53 
(dtt, J = 15.4, 6.4, 1.4 Hz, 0.14H), 5.40 (dtt, J = 15.4, 6.4, 1.4 Hz, 0.14H), 5.34 (dtt, J = 15.4, 6.4, 1.4 Hz, 
0.86H), 3.97 (dt, J = 5.9, 1.2 Hz, 1.72H), 3.93 (dd, J = 5.9, 1.2 Hz, 0.28H), 3.26 (dd, J = 5.9, 1.5 Hz, 
0.28H), 3.19 (dd, J = 5.9, 1.5 Hz, 1.72H), 2.37 (s, 0.42H), 2.35 (s, 2.58H), 1.92 (brs, 1H). 13C NMR (125 
MHz, CDCl3) Major isomer: δ = 140.1 (Cq), 134.0 (CH), 138.4 (Cq), 134.3 (Cq), 131.0 (CH), 130.7 (CH), 
130.0 (CH), 129.4 (CH), 126.6 (CH), 124.7 (CH), 105.9 (CH), 63.3 (CH2), 30.9 (CH2), 19.9 (CH3). Minor 
isomer: δ = 140.2 (CH), 139.9 (Cq), 138.1 (Cq), 135.2 (Cq), 131.2 (CH), 130.9 (CH), 129.2 (CH), 129.1 
(CH), 126.5 (CH), 124.8 (CH), 106.1 (CH), 58.0 (CH2), 26.9 (CH2), 19.9 (CH3). IR (ATR) ν = 3335, 2856, 
1514, 1475, 1395, 1046, 973, 754 cm-1. MS (ESI) m/z (relative intensity): 251 (60) [M+Na]+, 229 (30) 
[M+H]+, 211 (100). HR-MS (ESI) m/z calcd for C14H17N2O [M+H]
+: 229.1335, found: 229.1333. 
 
A suspension of 1-(m-tolyl)-1H-pyrazole (20c) (39.6 mg, 0.25 mmol), 4-vinyl-1,3-dioxolan-2-one 
(110a) (48.0 μL, 0.50 mmol), HOAc (3.0 μL, 20 mol %), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in 
1,4-dioxane (1.0 mL) was stirred at 100 °C for 16 h under N2. After cooling to ambient temperature, 
the mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in 
vacuo. Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1) yielded 111ca 
(14.3 mg, 25%, E/Z = 5.2/1.0 by 1H NMR) as a colorless oil. 
 





A suspension of 2-[2-(pyridin-2-yl)phenyl]propan-2-ol ([D]1-168j) (53.5 mg, 0.25 mmol), 
1-methyl-1H-pyrrole-2,5-dione (11f) (55.6 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O 
(1.0 mL) was stirred at 120 °C for 16 h under N2. After cooling to ambient temperature, the mixture 
was dried over Na2SO4, washed with EtOAc (30 mL) and concentrated in vacuo. Purification by 
column chromatography on silica gel afforded [D]n-102jf (60.0 mg, 90%). The deuterium 






A suspension of 1-phenyl-1H-pyrazole ([D]5-20b) (37.3 mg, 0.25 mmol), [MnBr(CO)5] (6.9 mg, 10.0 
mol %) in H2O (1.0 mL) was stirred at 120 °C for 16 h under N2. After cooling to ambient 





vacuo. Purification by column chromatography on silica gel afforded [D]n-20b (35.4 mg, 95%). The 





A suspension of 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (108.2 mg, 0.50 mmol), 
1-(3-ethylphenyl)-1H-pyrazole (20e) (86.2 mg, 0.50 mmol), 1-methyl-1H-pyrrole-2,5-dione (11f) 
(55.6 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O (1.0 mL) was stirred at 120 °C for 16 
h under N2. After cooling to ambient temperature, the mixture was dried over Na2SO4, washed with 
EtOAc (30 mL) and concentrated in vacuo. Purification by column chromatography on silica gel 







H/D Exchange Experiments 
 
 
A suspension of 2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (50.6 mg, 0.25 mmol), 
1-methyl-1H-pyrrole-2,5-dione (11f) (55.6 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in D2O 
(1.0 mL) was stirred at 120 °C for 16 h under N2. After cooling to ambient temperature, the mixture 
was dried over Na2SO4, washed with EtOAc (30 mL) and concentrated in vacuo. Purification by 
column chromatography on silica gel afforded [D]n-102af (39.0 mg, 61%). The deuterium 












A suspension of 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol), 
ethynylbenzene (8o) (51.6 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in D2O (1.0 mL) was 
stirred at 140 °C for 16 h under N2. After cooling to ambient temperature, the mixture was dried 
over Na2SO4, washed with EtOAc (30 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel afforded [D]n-74co (35.0 mg, 53%). The deuterium incorporation was 












A suspension of 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol), 
[D]1-ethynylbenzene ([D]1-8o) (51.6 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O (1.0 
mL) was stirred at 140 °C for 16 h under N2. After cooling to ambient temperature, the mixture was 
dried over Na2SO4, washed with EtOAc (30 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel afforded [D]n-74co (39.1 mg, 60%). The deuterium incorporation was 









A suspension of 2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168c) (54.1 mg, 0.25 mmol), 
[D]1-ethynylbenzene ([D]1-8o) (51.6 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in 
1,4-dioxane (1.0 mL) was stirred at 140 °C for 16 h under N2. After cooling to ambient temperature, 
the mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in 
vacuo. Purification by column chromatography on silica gel afforded [D]n-74co (35.9 mg, 55%). The 












A suspension of [D]1-2-[4-methyl-2-(1H-pyrazol-1-yl)phenyl]propan-2-ol ([D]1-168c) (54.1 mg, 0.25 
mmol), ethynylbenzene (8o) (51.6 mg, 0.50 mmol), [MnBr(CO)5] (6.9 mg, 10.0 mol %) in H2O (1.0 mL) 
was stirred at 140 °C for 16 h under N2. After cooling to ambient temperature, the mixture was 
dried over Na2SO4, washed with EtOAc (30 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel afforded [D]n-74co (46.7 mg, 72%). The deuterium incorporation was 
















Preparation of the sample: inside glovebox, an oven dried NMR tube was charged with 
2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (10.2 mg, 0.05 mmol), BnMn(CO)5 (14.3 mg, 0.05 
mmol), 1,3,5-trimethoxybenzene (2.8 mg, 0.017 mmol) and C6D6 (0.6 mL). The tube was transferred 
out of the glove box and the reaction was monitored at 60, 120 and 180 min by 1H NMR at 25, 50 











Synthesis of Complex C′ 
 
A 10 mL oven-dried Schlenk-tube was charged with 2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) 
(70.1 mg, 0.25 mmol), MnBn(CO)5 (71.6 mg, 0.25 mmol) and C6D6 (1.0 mL). The mixture was stirred 
at 70 °C for 18 h under N2 in the glovebox. After cooling to ambient temperature, the solution was 
filtered to through a pipette packed with cotton wool, and removal of solvent under reduced 
pressure yielded a yellow solid (56.6 mg, 73%). Crystals suitable for X-ray diffraction were obtained 
by slow evaporation from n-hexane, providing light yellow crystals 208. 1H NMR (400 MHz, CDCl3) δ 
= 8.11 (d, J = 2.7 Hz, 1H), 7.96–7.91 (m, 1H), 7.71 (d, J = 2.1 Hz, 1H), 7.36–7.09 (m, 3H), 6.51 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ = 219.7 (CO), 214.6 (CO), 211.9 (CO), 157.1 (Cq), 143.5 (Cq), 143.2 (CH), 
142.5 (CH), 126.9 (CH), 126.4 (CH), 124.5 (CH), 111.8 (CH), 109.3 (CH). 
 














A 10 mL oven-dried Schlenk-tube was charged with [5-methoxy-2-(1H-pyrazol- 
1-yl)phenyl](phenyl)methanol (168d’) (280.3 mg, 1.0 mmol), 4-vinyl-1,3-dioxolan-2-one (110a) 
(228.2 mg, 2.0 mmol), MnBr(CO)5 (27.5 mg, 10 mol %). The mixture was connected to a gas 
detection system (GM5-KONT). Subsequently, the reaction was placed in a preheated oil bath at 120 





Order with respect to [MnBr(CO)5] 
The reaction order with respect to [MnBr(CO)5] was examined using the initial rate method.
11 A 
Schlenk-tube was charged with 2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (50.6 mg, 0.25 
mmol), 1-methyl-1H-pyrrole-2,5-dione (11f) (55.6 mg, 0.50 mmol), [MnBr(CO)5] (5.0, 7.5, 10.0, 12.5 
mol %) and 1,3,5-trimethoxybenzene (14.0 mg, 0.083 mmol). H2O (1.0 mL) was added and the 
mixture was stirred at 120 °C. Six parallel reactions with the same amount of MnBr(CO)5 were 
performed. A reaction was stopped every 5 min and cooled to 0 °C immediately. The mixture was 
diluted with EtOAc (1.0 mL), filtered through a short plug of silica gel and analyzed by gas 
chromatography. 
 
MnBr(CO)5 / mol % Δ[102af] Δt
-1/ 10-3 mol L-1 s-1 log(c / mol L-1) log(Δ[102af] Δt-1/ mol L-1 s-1) 
5.0 2.71 -1.90 -2.57 
7.5 3.73 -1.73 -2.43 
10.0 5.53 -1.60 -2.26 






Order with respect to 168a 
The reaction order with respect to 168a was examined using the initial rate method.9 A 
Schlenk-tube was charged with 2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (0.15, 0.20, 0.25, 
0.30 mmol), 1-methyl-1H-pyrrole-2,5-dione (11f) (55.6 mg, 0.5 mmol), [MnBr(CO)5] (6.9 mg, 0.025 
mmol) and 1,3,5-trimethoxybenzene (14.0 mg, 0.083 mmol). H2O (1.0 mL) was added and the 
mixture was stirred at 120 °C. Six parallel reactions with the same amount of 168a were performed. 
A reaction was stopped every 5 min and cooled to 0 °C immediately. The mixture was diluted with 
EtOAc (1.0 mL), filtered through a short plug of silica gel and analyzed by gas chromatography. 
168a / mmol Δ[102af] Δt-1/ 10-3 mol L-1 s-1 log(c / mol L-1) log(Δ[102af] Δt-1/ mol L-1 s-1) 
0.15 2.46 -0.82 -2.46 
0.20 4.80 -0.70 -2.32 
0.25 5.53 -0.60 -2.26 





Order with respect to 11f 
The reaction order with respect to 11f was examined using the initial rate method.9 A Schlenk-tube 
was charged with 2-[2-(1H-pyrazol-1-yl)phenyl]propan-2-ol (168a) (50.6 mg, 0.25 mmol), 
1-methyl-1H-pyrrole-2,5-dione (11f) (1.0, 1.5, 2.0, 2.5, 3.0 equiv), [MnBr(CO)5] (6.9 mg, 0.025 mmol) 
and 1,3,5-trimethoxybenzene (14.0 mg, 0.083 mmol). H2O (1.0 mL) was added and the mixture was 
stirred at 120 °C. Six parallel reactions with the same amount of 11f were performed. A reaction 
was stopped every 5 min and cooled to 0 °C immediately. The mixture was diluted with EtOAc (1.0 
mL), filtered through a short plug of silica gel and analyzed by gas chromatography. 
 
11f / equiv Δ[102af] Δt-1/ 10-3 mol L-1 s-1 log(c / mol L-1) log(Δ[102af] Δt-1/ mol L-1 s-1) 
1.0 5.21 -0.60 -2.28 
1.5 6.00 -0.43 -2.22 
2.0 5.53 -0.30 -2.26 
2.5 6.60 -0.20 -2.18 
3.0 5.81 -0.13 -2.24 
 
 








Removal of Pyrazole Group 
 
To a solution of 74 (1.0 mmol) and TMSCl (217.3 mg, 2.0 mmol) in THF (5.0 mL) was added 
TMPMgCl·LiCl in THF (1.0 M, 4.0 mmol) dropwise, and the mixture was stirred for 36 h at 0 ºC. Then, 
water was added, and the mixture was then extracted with Et2O (3 x 20 mL). The combined organic 
layers were washed with brine, dried over MgSO4, filtered and concentrated. The crude material 
was dissolved in MeOH (30 mL), mixed with aq. HCl 2M (15 mL) and stirred for 1.5 h at 40 ºC. After 
this period, the mixture was neutralized with saturated aq. NaHCO3 (15 mL) and extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered 
and concentrated. Purification by column chromatography on silica gel (n-hexane/EtOAc: 
15/1→20/1) yielded 209. 
 
 
(E)-5-Methyl-2-styrylaniline (209a) (150.5 mg, 72% yield) White solid, M.p. = 79–81 °C 1H NMR 
(400 MHz, CDCl3) δ = 7.49 (d, J = 7.4 Hz, 2H), 7.43–7.28 (m, 3H), 7.27–7.20 (m, 1H), 7.14 (d, J = 16.1 
Hz, 1H), 6.95 (d, J = 16.1 Hz, 1H), 6.63 (d, J = 7.8 Hz, 1H), 6.54 (s, 1H), 3.75 (brs, 2H), 2.28 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ = 143.8 (Cq), 138.7 (Cq), 137.8 (Cq), 129.3 (CH), 128.6 (CH), 127.3 (CH), 
127.1 (CH), 126.3 (CH), 124.2 (CH), 121.1 (Cq), 120.1 (CH), 116.9 (CH), 21.2 (CH3). IR (ATR) ν = 3437, 
3360, 3031, 1609, 1505, 1343, 966, 800, 753, 689 cm-1. MS (ESI) m/z (relative intensity) 210 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C15H16N [M+H]





(E)-2-(4-Bromostyryl)-5-methylaniline (209b) (152.7 mg, 53% yield) Pale yellow solid, M.p. = 124–
125 °C 1H NMR (400 MHz, CDCl3) δ = 7.44 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 7.8 
Hz, 1H), 7.11 (d, J = 16.1 Hz, 1H), 6.86 (d, J = 16.1 Hz, 1H), 6.62 (dd, J = 7.8, 1.7 Hz, 1H), 6.54 (s, 1H), 
3.84 (brs, 2H), 2.26 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 143.7 (Cq), 139.1 (Cq), 136.7 (Cq), 131.7 
(CH), 127.9 (CH), 127.8 (CH), 127.1 (CH), 124.9 (CH), 121.0 (Cq), 120.8 (Cq), 120.3 (CH), 117.1 (CH), 
21.3 (CH3). IR (ATR) ν = 3433, 3357, 1612, 1484, 1268, 1072, 970, 867, 815, 511 cm
-1. MS (ESI) m/z 
(relative intensity) 288 (100) [M+H]+ (79Br), 290 (98) [M+H]+ (81Br). HR-MS (ESI) m/z calcd for 
C15H15
79BrN [M+H]+: 288.0382, found: 288.0384; m/z calcd for C15H15




(E)-2-(1,2-Diphenylvinyl)-5-methylaniline (209c) (168.4 mg, 59% yield) White solid, M.p. = 142–
143 °C. 1H NMR (400 MHz, CDCl3) δ = 7.28–7.22 (m, 5H), 7.19–7.12 (m, 3H), 7.12–7.07 (m, 2H), 7.05 
(d, J = 7.7 Hz, 1H), 6.77 (s, 1H), 6.59 (dd, J = 7.7, 1.7Hz, 1H), 6.50–6.47 (m, 1H), 3.54 (brs, 2H), 2.28 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ = 144.1 (Cq), 140.7 (Cq), 139.9 (Cq), 138.8 (Cq), 137.4 (Cq), 131.0 
(CH), 130.2 (CH), 129.7 (CH), 129.4 (CH), 128.6 (CH), 128.0 (CH), 127.5 (CH), 127.2 (Cq), 126.7 (CH), 
119.2 (CH), 116.6 (CH), 21.2 (CH3). IR (ATR) ν = 3478, 3390, 1613, 1443, 1315, 1257, 1074, 777, 715 
cm-1. MS (ESI) m/z (relative intensity) 286 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H20N [M+H]
+: 
286.1590, found: 286.1590. 
 
Single-Crystal Structure Analysis 
Crystal Data for C13H7MnN2O4 (M =310.15 g/mol): monoclinic, space group P21/c (no. 14), a = 
8.5614(4) Å, b = 6.8901(3) Å, c = 21.4151(11) Å, β = 92.838(2) , V = 1261.70(10) Å3, Z = 4, T = 99.97 K, 
μ(MoKα) = 1.060 mm-1, Dcalc = 1.633 g/cm
3, 18532 reflections measured (6.212 ≤ 2Θ ≤ 60.992), 3828 




2σ(I)) and wR2 was 0.0596 (all data). 
 
Molecular structure of 208 in the crystal. (Anisotropic displacement parameters are depicted at 
the 50 % probability level.) 
 
Crystal data and structure refinement for 208: 
Compound 208 
Empirical formula C13H7MnN2O4 
Identification code 0455_CG_0m 
Empirical formula C13H7MnN2O4 
Formula weight 310.15 
Temperature/K 99.97 
Crystal system monoclinic 
















Crystal size/mm3 0.452 × 0.202 × 0.174 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.212 to 60.992 
Index ranges -11 ≤ h ≤ 12, -9 ≤ k ≤ 9, -30 ≤ l ≤ 30 
Reflections collected 18532 
Independent reflections 3828 [Rint = 0.0179, Rsigma = 0.0147] 
Data/restraints/parameters 3828/0/181 
Goodness-of-fit on F2 1.056 
Final R indexes [I>=2σ (I)] R1 = 0.0213, wR2 = 0.0591 
Final R indexes [all data] R1 = 0.0220, wR2 = 0.0596 
Largest diff. peak/hole / e Å-3 0.44/-0.39 
 
Bond lengths [Å] for 208: 
Atom Atom Length/Å Atom Atom Length/Å 
Mn1 N1 2.0351(8) N1 C1 1.3368(12) 
Mn1 C5 2.0584(9) N2 C3 1.3538(12) 
Mn1 C10 1.8630(10) N2 C4 1.4179(12) 
Mn1 C11 1.8423(10) C1 C2 1.4003(15) 
Mn1 C12 1.8546(11) C2 C3 1.3770(16) 
Mn1 C13 1.8032(10) C4 C5 1.3992(12) 
O1 C10 1.1321(13) C4 C9 1.3889(13) 
O2 C11 1.1408(13) C5 C6 1.3998(13) 
O3 C12 1.1361(13) C6 C7 1.3944(14) 
O4 C13 1.1451(13) C7 C8 1.3889(15) 
N1 N2 1.3588(11) C8 C9 1.3860(15) 
 
Bond angles [°] for 208: 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N1 Mn1 C5 79.10(3) C3 N2 N1 110.99(8) 




C10 Mn1 C5 86.35(4) N1 C1 C2 110.27(9) 
C11 Mn1 N1 92.24(4) C3 C2 C1 105.62(9) 
C11 Mn1 C5 171.34(4) N2 C3 C2 107.11(9) 
C11 Mn1 C10 93.88(4) C5 C4 N2 114.95(8) 
C11 Mn1 C12 95.85(4) C9 C4 N2 121.04(8) 
C12 Mn1 N1 91.87(4) C9 C4 C5 124.01(9) 
C12 Mn1 C5 84.65(4) C4 C5 Mn1 114.01(6) 
C12 Mn1 C10 169.43(4) C4 C5 C6 115.46(8) 
C13 Mn1 N1 172.85(4) C6 C5 Mn1 130.52(7) 
C13 Mn1 C5 93.77(4) C7 C6 C5 121.83(9) 
C13 Mn1 C10 87.16(4) C8 C7 C6 120.42(9) 
C13 Mn1 C11 94.89(4) C9 C8 C7 119.63(9) 
C13 Mn1 C12 87.91(4) C8 C9 C4 118.62(9) 
N2 N1 Mn1 115.76(6) O1 C10 Mn1 175.19(9) 
C1 N1 Mn1 138.22(7) O2 C11 Mn1 178.43(9) 
C1 N1 N2 106.01(8) O3 C12 Mn1 175.27(9) 
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